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Background: Pneumococcal disease is an important cause of hospitalisations and death
in the UK. In addition, antibiotic resistant pneumococci are a problem in several
countries. Data on coverage of pneumococcal polysaccharide vaccine and the factors
associated with its use are poorly understood in the UK. This thesis investigates the
epidemiological characteristics of pneumococcal disease and pneumococcal
polysaccharide vaccination practices in Scotland.
Methods: Laboratory data collected through a national network of diagnostic laboratories
covering the entire population of Scotland was reviewed to examine the epidemiological
characteristics of pneumococcal disease. Cross-sectional surveys were conducted to
explore pneumococcal polysaccharide vaccination practices.
Results: The incidence of invasive pneumococcal disease is highest in young children
aged less than 2 years (44.9/105 persons) and in the elderly aged 65 years and above
(28.4/105 persons). The incidence of pneumococcal meningitis is highest in children aged
less than 2 years (11.8/105 persons). There was a 3-fold increase in the prevalence of
penicillin (from 4.2% to 12.6%) and erythromycin (from 5.6% to 16.3%) non-susceptible
pneumococcal isolates over the study period 1988 to 1999. Regional differences in the
prevalence of antibiotic non-susceptibile pneumococci correlated weakly with the rate of
penicillin prescription, but not with erythromycin prescription. Pneumococci are the
leading cause of invasive non-meningeal bacterial disease and the second leading cause
ix
of bacterial meningitis in Scotland after introduction of Hib conjugate vaccine in the
national vaccination programme.
The formulation of current pneumococcal polysaccharide vaccine covers the serotypes
responsible for the majority of invasive and non-invasive disease in Scotland. Coverage
of invasive and non-invasive serotypes by pneumococcal conjugate vaccines was
substantially higher in younger age groups (5 years and less) than in older age groups. All
polysaccharide and conjugate pneumococcal vaccines cover nearly all serotypes
associated with invasive and non-invasive resistant pneumococcal disease.
General practitioners and hospital doctors have an adequate knowledge of pneumococcal
polysaccharide vaccination. However, coverage of pneumococcal polysaccharide vaccine
was only 13% among the high-risk patients who are currently recommended to receive
this vaccine by the UK Departments of Health. The use of pneumococcal polysaccharide
vaccine has increased over the period 1996 to 1999. The majority of pneumococcal
polysaccharide vaccination was carried out in general practice (94%) and the remainder
were in homes (4%) and in hospital settings (2%).
Recommendation from primary care teams was the principal reason for receipt of the
vaccine. Doctors considered that the most appropriate strategies to increase the coverage
of pneumococcal polysaccharide vaccine were clear national recommendations,
reimbursement policies, computerised systems to identify high-risk patients and
professional education, coupled to a national campaign for vaccination.
x
Conclusions: Pneumococcal disease poses a substantial public health burden in Scotland.
The formulation of current pneumococcal polysaccharide and conjugate vaccines
includes the most prevalent serotypes associated with disease and antibiotic resistance in
young children and adults. Improved strategies such as clear immunisation policies and
financial support for vaccination as identified in this study, could improve the delivery
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INTRODUCTION
The burden of pneumococcal disease
The bacterial pathogen, Streptococcus pneumoniae (the pneumococcus) is an important
cause ofmorbidity and mortality in Scotland and worldwide. It is the most common cause
of bacteraemia, meningitis, pneumonia, otitis media and sinusitis and affects particularly
young children, the elderly and persons with certain underlying conditions, which place
them at increased risk. '>2 xhe pneumococcus has the potential to cause outbreaks or
epidemics in crowded settings.3 In addition, many diseases caused by it could be
considered as endemic throughout the world.4 On a global level, the pneumococcus is
responsible for 1.2 million deaths each year in children under five years of age.^ No
estimated figures are available for death in adults and the elderly.
Despite the use of antimicrobial agents, case-fatality rates of IPD ranged 12-38%."-°
Although penicillin has historically been the antibiotic of choice for treating
pneumococcal disease, pneumococcal resistance to penicillin and other antimicrobial
agents is increasing globally.10 Recent studies have documented that penicillin
resistant invasive pneumococcal strains are associated with adverse medical outcomes.6>8
This has implications for both the choice of antibiotics and the cost of managing
pneumococcal disease, particularly meningitis} 1
These data emphasise the need to prevent pneumococcal disease and minimise the impact
of antibiotic resistance through vaccination.
Prevention of pneumococcal disease
Currently, polysaccharide and conjugate vaccines are available for the prevention of
pneumococcal disease. The 23-valent pneumococcal polysaccharide vaccine (PPV) is
safe, and is effective in preventing 50-80% of invasive pneumococcal disease (IPD) in
older children and adults 1 >12 (section: 1.2). However, its use for the prevention of non-
bacteraemic pneumococcal pneumonia is controversial due to inconclusive evidence from
clinical trials in adults. 12 The vaccine is currently recommended for those aged two years
and above with certain medical conditions (Table 15). However, vaccine coverage is poor
among recommended groups in the UK.13,14 an(j most other developed countries, 15
indicating low acceptance of PPV among clinicians and patients.
PPV is generally ineffective in children under two years, the age group with the highest
risk of pneumococcal disease. This has led to the development of pneumococcal
conjugate vaccines (PCV), which include the 7 to 11 serotypes causing most disease in
young children worldwide. A licensed 7-valent conjugate has been shown to be 97.4%
effective against invasive disease^ and 56-57% against otitis medial7,18 caused by the
vaccine serotypes. The available evidence also indicates that conjugate vaccine has the
potential to reduce the incidence of pneumonia, otitis media and lower and upper
respiratory infections. 16,19 Pneumococcal conjugate vaccines are safe and immunogenic
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in the elderly and those with immunocompromised conditions such as HIV, Hodgkin's
disease, sickle cell disease, compared with the polysaccharide vaccine.20 These data
suggest that PCV raises the very real prospect of preventing pneumococcal disease in
children and high-risk groups. A 7-valent vaccine, known as Prevenar, has now obtained
licensure in the UK and most parts of Europe. This vaccine has already been included in
the routine childhood immunisation schedule in the USA The UK Joint Committee on
Vaccination and Immunisation has now recommended that PCV should be given to
children less than two years of age with certain high-risk conditions.21 A decision on the
inclusion of the vaccine into the UK primary immunisation programme is expected soon.
Other preventive measures include prophylactic antibiotics for persons with
immunocompromised conditions and changes in environmental or life-style factors in
areas with high rates of disease.
Research needs
In Scotland, little is known about the magnitude of the disease burden, the prevalence of
antibiotic resistance, which serotypes are associated with disease and the distribution and
utilisation of the current polysaccharide vaccine. Obtaining these data are vital for
developing and guiding immunisation policy for both polysaccharide and conjugate
vaccines. These data will also be useful in assessing the direct and indirect impact of
conjugate vaccine on pneumococcal disease after its incorporation into the UK primary
immunisation programme.
This thesis investigates the burden and epidemiology of pneumococcal disease and the
characteristics of immunisation practices with PPV in Scotland.
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1. REVIEW OF THE LITERATURE
1.1. Pneumococcal disease epidemiology
1.1.1. The pneumococcus
1.1.1.1. Organism
The pneumococcus is an encapsulated gram-positive bacterium. It has three main surface
layers: plasma membrane, cell wall and capsule.22 The polysaccharide capsule is the
thickest layer of the organism and completely covers the inner components.23 it protects
the bacterium from phagocytosis.24 Ninety serotypes have been identified based on
antigenic differences in the capsular polysaccharide.25 Serotypes with similar chemical
properties are defined as serogroup (e.g. serotypes 9N and 9V in serogroup 9). There are
a total of 45 serogroups. It is generally acknowledged that there is some degree of cross-
protection for serotypes within one serogroup. The extent of invasiveness depends on the
chemical composition of the capsular polysaccharide which differs among
serotypes.26,27 7^ presents a considerable challenge when developing an optimal
pneumococcal vaccine.
The pneumococccus is transmitted from person to person through respiratory droplets or
"autoinoculation" in persons carrying the bacteria in their upper respiratory tract.28
Studies have shown that susceptibility to pneumococcal disease is determined by the
ability of the host to generate specific opsonising antibodies against capsular
1
antigens.29,30 However, the pneumococcus has the ability to escape ingestion and
destroy host phagocytic cells and subsequently cause disease.28 Molecular and cellular
biological studies have demonstrated that the pneumococcus can transfer capsular genes
from one strain to another leading to a change in capsular specificity.31,32 This has
important implications for PCV use in the future.
1.1.1.2. Nasopharyngeal carriage
The mucosal epithelium of the nasopharynx is the primary site of pneumococcal
colonisation.24 Risk factors associated with colonisation include young age,
overcrowding, day care attendance, siblings attending day care, breast-feeding, winter
season, parental smoking, antibiotic treatment and concurrent of upper respiratory
infection.33
The prevalence of nasopharygeal carriage (NPC) is up to 60% in pre-school children, 25-
35% in high school students, 18-29% in adults with children in the household, and 6% in
adults without children in the household.34 The rate of carriage can be as high as 97% in
children who live in institutions or attend day care.35,36 Thus, it appears that children are
likely to be the major source of transmission in the family. Intense and early exposure to
pneumococci is common in children in native populations and developing countries, with
reported carriage rates of 60-89%.37.43 Evidence of simultaneous carriage of three to
five different serotypes has been reported.44.46 r has been suggested that the number of
multiply colonised children is likely to be higher than previous reports because of the
2
lack of a sensitive assay to detect simultaneous carriage of multiple colonisation.46 A
reliable method to detect carriage of multiple serotypes is particularly important when
assessing the impact of PCVs on NPC.
Colonisation commonly occurs at some point during the first two years of life in most
children 47.50 More than 95% of children are sequentially colonised with as many as six
different serotypes during that time.61 Carriage rates gradually increase from 9% to 43%
from two to 24 months of age52 and then decrease between three and five years of
age.35,53,54 The duratjon of nasopharyngeal carriage varies with the age of child^l and
the serotype.35 The median duration of carriage is 30 days in those under one year, 21
days in those between one and four, 13 days in those aged five to six, and 14 to 15 days
in the age group 7 and above.55 However, little is known about the kinetics of acquisition
and the clonal diversity and transmission of pneumococcal isolates in the community and
in children.
Nasopharyngeal colonisation occurs as a result of interaction between pneumococcal
surface proteins and surface cell receptors.56,57 The occurrence of acute otitis media
(OM),36,58 bacteraemia41,59,60 an(j pneumonia61 is associated with nasopharyngeal
colonisation,36,43,62 either by haematogenous spread or direct extension.63 This
suggests that nasopharyngeal colonisation is an important risk factor for disease
development. Studies have also shown that carriage serotypes are comparable to
serotypes responsible for invasive disease and antibiotic resistance60,62,64,65 an(j otitis
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media.58,66,67 The rjsk 0f developing disease from carriage is greatest in the first month
following colonisation with a new serotype,51 with up to 76% of disease occurring
during this period.
1.1.1.3. Serotype distribution
Serotype distribution varies with age, type of specimen, geographical location,
antimicrobial resistance and time.68.70 There have been no observed variations in the
prevalence of common serotypes according to gender or racial group.71 Currently, 5 to 8
and 10 to 11 serotypes are responsible for at least 75% of IPD in children and older
children/adults respectively, worldwide.72 Serotype 1 is more frequently isolated from
blood, serotype 3 from middle ear fluid and serotype 8 from CSF.72 The evidence
suggests that pneumococcal vaccine effectiveness is dependent on the distribution of
vaccine serotypes circulation in the population.69 Therefore, a knowledge of local
serotype distribution is vital in determining vaccination policy.
Serotypes 1, 2, 3, 18C were the most prevalent during 1950s in Europe and the US,
accounting for up to 75% of bacteraemic disease.35,73,74 Serotypes 6, 14, 18 and 19 are
to date the most common cause of invasive and non-invasive disease in the UK,75-77
other European countries72,78 an(j the US.68 An extensive analysis of 70 datasets
worldwide found that serotypes 4, 6, 9, 14, 18, 19 and 23 caused 70-88% of IPD in young
children in Europe, North America and Oceania.72 in addition to these, serotypes 1, 5, 3
and 7 are major causes of IPD in adults in both developed and developing countries.72
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Serotypes 3, 19 and 23 are more commonly isolated from middle ear fluid among young
children in Europe and North America.78
The most common serotypes associated with IPD among children in developing countries
are, in decending order, 6, 14, 8, 5, 1, 19, 9, 23, 18, 15 and 7.69 Serotypes 1 and 5 are the
most prevalent causes of IPD in young children69,72 accounting for 15% to 20% of IPD
in Latin America, Asia and Africa.72 They are also responsible for as much as 25% in
older children and adults in Asia.72 The reasons for the differences in serotype
distribution between countries are not fully understood but may reflect genetic traits and




The acceptance criteria for diagnosing pneumococcal disease vary widely. Isolation of
the pneumococcus from blood, pleural fluid or lung tissue cultures is regarded as definite
pneumococcal disease.79
The detection of pneumococcal antigens in serum or urine by counter immuno-
electrophoresis, latex agglutination or coagglutination80,81 ancj presence of
antibodies to pneumolysin (a protein haemolysin common in all pneumococci) in serum,
are considered as indications of possible pneumococcal infection.82.84 However, these
diagnostic methods are more likely to provide false positive and false negative results as
compared with culture.85.87
The sensitivity for detecting the aetiology of pneumonia is 10% to 20% for blood
culture,70% to 80% for CSF culture^ and 80% to 100% for lung aspirate.89,90 Thus,
the proportion of pneumonias caused by pneumococci is greatly underestimated in studies
that do not use lung aspirate. The absence of rapid, sensitive and specific tests is probably
responsible for widespread use of antibiotics and may contribute to the emergence of
drug resistance in pneumococci.
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1.1.3. Risk factors
Certain factors are associated with an increased risk of and death from IPD (Table 1).1>2
Although the risk of IPD is highest in young children, the elderly and adults with
underlying chronic medical conditions are also at greater risk for IPD and they are more
likely to die from the disease compared with young children in developed countries.91
Table 1. Risk factors for pneumococcal disease
Organism Age
Virulence of colonising serotypes <2 years, >65 years
Chronic medical disease Immunocompromised conditions
Heart disease HIV disease
Pulmonary disease Haematological malignancy
Liver disease Non-haematological malignancy
Renal disease Asplenic dysfunction
Diabetes Sickle cell disease








Residents in long-term care
Winter
Recent viral infections
Exposure to tobacco smoke or smoke in
outside kitchens
Breast-feeding
Studies have shown that the risk of disease increases in adults over 50 years of age and
dramatically increases after 65 years of age.92 US surveillance data have identified that
although only one third of IPD cases are in the elderly, 65 years of age and above, over
7
half of the deaths occur in this age group.93 The reasons for the increased risk of
pneumococcal disease in the elderly are not well defined but may relate to higher
prevalence of chronic medical conditions^ and poor antibody responses to
polysaccharides.95
The increased risk of pneumococcal disease in infants and young children are due to
defective anti-polysaccharide antibody synthesis and low complement activity.96 The
level of Immunoglobulin G2 (IgG2), which acts against bacterial capsules such as those
of pneumococcus, meningococcus and Haemophilus influenzae, is lowest in children
aged between 6 months and 24 months.95 Thus, the risk of IPD is the highest during the
first two years of life.2
Although pneumococcal pneumonia, bacteraemia and otitis media are more common in
males than females,97-103 the rate ofNPC does not differ between sexes.35 The reasons
for this difference are not fully understood but may in part be due to higher prevalence of
smoking, drinking and other risk factors in males.99
An increased incidence and mortality of IPD have been documented in patients with
certain medical conditions.94 Persons with chronic medical conditions have a 2- to 5-fold
increased risk of developing disease 104 ancj a 2- fold risk of dying from it. The annual
estimated incidence of IPD in persons with chronic lung conditions is 503 per 105
persons.'05 The incidence of IPD in different chronic medical conditions is scanty.
8
Splenectomised patients are at considerable risk of the disease, a 12.6-increase compared
with the general population. '06 Additional data would be helpful in correct targeting of
vaccine in persons with chronic medical conditions.
Immunocompromised persons due to disease (e.g. congenital immunodeficiency, human
immunodeficiency virus (HIV) infection, leukaemia, lymphoma, multiple myeloma,
Hodgkins disease, or generalised malignancy) or therapy (e.g. alkylating agents,
antimetabolities, systematic corticosteroids, organ transplant) are at increased risk of
IPD.1>107 Studies have shown that the incidence of pneumococcal bacteraemia in cardiac
transplant patients is extremely high, 3900/105 patients in young children 108 and
3600/105 patients in adults. 109
The pneumococcus is the leading cause of bacterial pneumonia in HIV-infected
persons. 110-113 The risk of disease increases with the progression of
immunodeficiency.! 14 HIV-infected persons have a 6-times higher risk of developing
recurrent IPD than persons who are not HIV-infected. 115 Although the reason for the
increased risk of disease in HIV patients is not clear,! 10-118 high NPC and impaired
mucosal immunity may predispose this group to disease.! 19 The prevalence of carriage
was two-fold higher in children with HIV than non-HlV infected children, 120 hut no
difference in carriage rate was detected in adults. 121
9
Incidence rates of pneumococcal pneumonia or invasive disease in patients with acquired
immunodeficiency syndrome (AIDS) are between 820 and 1,800/105 patients in the
US. 122.126 jhg risk 0f disease is reported to reduce with the use of highly active
antiretroviral therapy (HAART) and co-trimoxazole and azithromycin prophylaxis in
HIV-infected persons. 112,126-128 -p^g US population based surveillance data showed
that the incidence of IPD reduced dramatically from 1060 to 420/105 persons, between
1994 and 1997, the time period for introduction of HAART. 129 ]q0 UK based data are
available for this at-risk group.
It has been suggested that low socio-economic status, poor living conditions or high
prevalence of chronic medical conditions are likely to be important risk factors for IPD in
native populations^, 130 ancj jn African Americans.91 Studies have shown that the risk
of disease remains higher in African Americans even after adjustment for multiple
demographic, medical and socio-economic cofounders. 131-133 Limited data are
available for the risk of disease associated with socio-economic status. Genetic risk
factors for IPD such as sickle cell gene 134,135 may contribute to racial difference in
disease incidence. However, genetic factors influencing the risk of disease are not fully
defined and are difficult to separate from socio-economic factors. 193,133,136,137 Thus,
the increased risk of disease in these groups appears to be due to multiple risk factors.
The occurrence of outbreaks or epidemics of pneumococcal disease has been well
documented in chronic care facilities3,138_ 142 namely a crowded, inadequately
ventilated jail,143 a homeless shelter,144 hospital wards,145,146 ancj a jay care
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centreJ 47 jn nursing home settings, the pneumococcus is reported to be the most
commonly acquired pneumoniaJ 48 7he US data suggest that low vaccine coverage of
less than 10% is a common factor for outbreaks of pneumococcal disease in elderly
residents of long-term care facilities. 141 Studies have shown that day care centre
attendance increases the risk for IPD in children.'49 7he rjsk for ipp> jn children aged
less than 2 years who attend day care centre was 36-fold higher in one Finnish study 150
and 2.3-fold higher in a US study,151 compared with those who do not attend day care.
Nevertheless, no significant difference was noted in those aged 2 years and above. 150
The incidence of pneumococcal disease peaks during influenza and respiratory syncytial
virus (RSV) epidemics,! 52 with a marked increase in hospitalisation and
mortality. 153.155 7jie frequency of IPD7>103,156 and OM51 peaks in midwinter.
Studies have shown that pneumococcal NPC rates are highest in the autumn and winter
among persons living in closed environments.35,47 7he exchange and acquisition of a
new serotype increases dramatically during the winter and early spring, 157 which may
explain the peak of disease in these periods. However, recent studies have failed to
document an obvious seasonal trend in prevalence of carriage.52,158
Higher rates of pneumococcal carriage 121,159 an(j the incidence of IPD 105,133 have
been detected in cigarette smokers. 105,133 us studies have estimated that smoking
contributes to approximately half of IPD in healthy adults.", 105 Although a decline in
IPD has been observed with time, after stopping smoking, former smokers remain at
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high-risk for at least 10 years after stopping. 133 Thus, efforts to promote smoking
cessation and targeting pneumococcal vaccination at those who continue to smoke could
reduce the incidence of disease among smokers.
Numerous studies have found that alcoholism is the most common risk factor for
pneumococcal bacteraemia in adults. 160,161 incidence of IPD is reported to be higher in
heavy alcohol users.99,105 jhe available evidence shows that between 26% and 32% of
adults with IPD are heavy alcohol users. The incidence of IPD is 62/105 persons among
heavy alcohol users. 195
Studies in HIV-infected persons have shown that injecting drug users have an increased
risk of pneumococcal pneumonia compared with those who are not injecting drug
users. 121,126,162 a study in injecting drug users indicates the annual incidence of
bacterial pneumonia to be 9.8% in persons with HIV-infection and 1.4% in those without
HIV-infection.163 Regardless ofHIV status, however, an increased rate of pneumococcal
disease has been reported among injecting drug users. 143
Breast-feeding has been shown to protect against invasive Haemophilus influenzae type b
(Hib) disease 194.167 no^ ipd.150 Although breast-feeding does not reduce the risk
of OM in infants, it reduces the duration of middle ear effusion. 198 Studies have shown
that protein in human milk inhibits the attachment of pneumococci and Hib in human
oropharyngeal cells. 199,170 Since pneumococci colonise the nasopharynx primarily, the
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anti-adhesiveness of breast milk protein may not reach the nasopharynx. This may reduce
the effectiveness of breast-milk against IPD.'50 Therefore, the role of breast-feeding in
prevention of pneumococcal disease remains to be established.
A study in The Gambia found that the risk of pneumococcal disease was higher in infants
from mothers who do not have a personal income.'"71 The increased incidence of IPD in
Afro-Americans may reflect racial differences in socio-economic status. '05,172
However, no difference in the incidence of IPD between races was observed in areas with
similar income.'37
Nearly 80% of paediatric IPD occurs in children less than 2 years of age.'07 The risk of
IPD appears to be low in neonates with an estimated incidence between 4 and 7 per 105
live births.77 Nearly 80% of paediatric IPD occurs in children less than 2 years of
age. 107 The risk of IPD appears to be low in neonates with an estimated incidence
between 4 and 7 per 105 live births.77 Almost every child develops pneumococcal
disease at least once before the age of 5 years, commonly with OM.'07 Furthermore,
children with OM have a higher risk of IPD. It has been reported that children attending
day care centres are at a greater risk of developing OM and thus have a higher risk of
IPD.58 The risk of pneumococcal disease may also be associated with exposure to
cigarette smoking but the relationship has not been clearly demonstrated.
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1.1.4. The burden of disease
Studies have shown that there is significant variation in the frequency of S. pneumoniae
as a cause of community-acquired pneumonia (CAP) in different settings and locations
(Table 2). 173 This may in part result from differences in diagnostic methods used in
these studies. A meta-analysis of 122 reports of CAP between 1966 and 1995 found that
the pneumococcus accounted for 73% of 6,000 cases with defined bacterial
pathogens. 174 jn the UK, pneumococcal disease is estimated to account for 22,000
hospital admissions and 3,000 deaths 175 each year.











UK 36.0 (29.9,42.1) 39 (36.1,41.8) 21.6 (15.9,28.3)
Rest of Europe 8.4 (6.4, 10.8) 19.4 (18.4,20.4) 21.8 (19.4,24.2)
North America - 11.3 (9.5,13.0) -
Australia & New Zealand - 38.4 (33.9,42.9) -
1.1.4.1. Invasive pneumococcal disease
IPD is defined as a positive culture of the pneumococcus from a normally sterile site such
as blood, CSF, or pleural space. More than 90% of IPD cases are bacteraemia. Of the rest,
5% to 10% are meningitis and less than 2% pericarditis, septic arthritis, osteomylelitis or
peritonitis. 176 Bacteraemia is considered when patients have a positive blood cuture and
no clinical focus. The reported incidence of IPD varies among surveillance reports
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(Tables 3 & 4). This is likely to be due to factors related to case ascertainment rather than
the true difference in incidence. These factors include variations in protocols for blood
culture collection and processing in patients with febrile illness, the practice of antibiotic
administration before blood culture, differences in surveillance systems and inherent
differences in risk factors for the population under surveillance.92,132,137
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Sweden 15.3 < 5 y 1981-95 177
Germany 18.9 < iy 1997-98 178
UK 33.2-48.1 < iy 1995-99 77** 103,179
Denmark 39.4 < iy 1981-99 180
Finland 45.3 <2y 1985-89 181
Canada 55.3 < 5 y 1996 182* * *
Australia 71 <2y 1992-2000 183
Chile 90.6 <ly 1989-93 184
Australia 96.4 < i y 1997-99 185*
Israel 104 < iy 1988-90 100
New Zealand 110 <2y 1984-92 186
US 145-183 <2y 1992-98 94*187,188*
The Gambia 224-554 < iy 1989-95 101 189
Bacteraemia
US (South California) 143 < 2 y 1992-95 187
US (South Carolina) 162 < 2 y 1986-87 172
US (New York) 175.5 < i y 1985-89 190
Finland 24.2 < 5 y 1985-89 181
Sweden 13.8 < iy 1970-80 99
Switzerland 3.6 < 2 y 1985-94 191
UK 19.4-35 < i y 1993-95 7 77**•>
Meningitis
Finland 4.7 V 1985-89 181
Switzerland 5.6 <2y 1985-94 191
US 6.6-10 <2y 1992-95 187 188*9
UK 9.4-15.7 < iy 1993-99 7,77**^179
Germany 9.7 < iy 1997-98 178
Israel 11.1 <2y 1988-90 100
Sweden 12 < iy 1970-80 99
Australia 17 <2y 1992-2000 183
Denmark 17.4 < iy 1981-99 180
New Zealand 23 <2y 1984-92 186
Chile 26.7 < iy 1989-93 184
The Gambia 34 < ly 1993-95 189
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Niger 149.6 < ly 1981-96 192
y = year(s), * Active surveillance, ** Enhanced surveillance, *** Sentinel surveillance,
The remainder were based on passive surveillance or did not indicate the type of
surveillance
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France 17.8 >65 y 1994-98 193
Sweden 20.4-37 >65 y 1981-95 177
UK 21.2-44.7 >65 y 1995-99 77** 103
Australia 25-100 >65 y 1997-99 185*
Finland 27.1 >65 y 1985-89 181
Israel 55 >65 y 1994-96 102
US 55.9-59.7 >60 y 1995-98 94*188*
Bacteraemia
Sweden 10.4 >65 y 1970-80 99
UK 23.6 >65 y 1993-95 7
US (South California) 31 >65 y 1992-95 187
Canada 46 >65y 1996 182* * *
US (South Carolina) 52.8 >65y 1986-87 172
US (New York) 56.3 >65 y 1985-89 190
UK 78 >80 y 1993-95 194
US (Dallas) 80 >65 y 1995 105*
Meningitis
UK 0.85-1.2 >65 y 1995-99 77**
US (South California) <1 >65 y 1992-95 187
Sweden 1.2-3.7 >60 y 1970-95 99 1779
US 1.9 >60 y 1995 188*
y = year(s), * Active surveillance, ** Enhanced surveillance, *** Sentinel surveillance,
The remainder were based on passive surveillance or did not indicate the type of
surveillance
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The overall annual incidence of 1PD for all ages is 6.6 to 10.3/103 population in the
UK.7>77,103 incidence of 1PD is greatest in young children, the elderly and persons
with certain underlying medical conditionsJ The estimated incidence of IPD is 33.2 to
48.1/105 infants aged less than one year in the UK,77,103 which is much lower than cited
for the US, 140 to 167/105 in children aged less than two years6>94,105,172,187,195 in
those aged 65 years and above, reported rates of IPD per lO"1 persons range from 25 to 90
cases in Europe and North America.92 Several US studies have highlighted a higher rate
of IPD for African Americans than white Americans.94,132,188 jhe highest reported
rates of IPD are in The Gambia and native populations in the US, New Zealand, and
Australia (Table 5). The estimated case-fatality rate for bacteraemic pneumococcal
disease is 4.5% in children, 196 20% in young adults, 30% to 55% in the elderly74,197
and 76% in those who required Intensive Care Unit support. 198 Although there are wide
geographical variations in rates for IPD, the incidence of pneumococcal meningitis is
comparable in Europe and North America. This suggests that the observed differences in
IPD may be largely due to variations in blood culture sampling.
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Table 5. Incidence of invasive pneumococcal disease in native populations





Aboriginal ** 297-326 183
Aboriginal ** 754 199
Aboriginal *** 935 200
Navajo* 664 201
Alaska ** 624 202
Alaska ** 1235 203







* Children aged less than I year, ** Children aged less than 2 years, *** Children aged
less than 5 years
1
Elderly aged 65 years and above, 2 Elderly aged 60 years and above
§ Based on passive surveillance or did not indicate the type ofsurveillance
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In the UK, the pneumococcus became the second most common cause of bacterial
meningitis in young children after the implementation of Hib conjugate vaccine into the
primary immunisation programme in 1992.205 pneumococcus is the most common
aetiological agent of bacterial meningitis in adults206 ancj the elderly. 188,207 The overall
annual incidence of pneumococcal meningitis for all ages is estimated to be 0.4 to 0.8/105
population, with the highest incidence of 9 to 15/103 in infants aged less than one year in
the UK.7'77 Case-fatality rates range from 7% to 30% in children aged less than 5 years
and reaches 50% in the elderly.207-210 of those who survive, 25% have neurological
sequelae and 32% have hearing loss.2'0 \ recent UK study in 1717 children aged 5 years
or under with bacterial meningitis found that the risk of disability was higher in children
with pneumococcal meningitis than H. influenzae or meningococcal meningitis.2' 1 In
addition, the rapidly spreading antimicrobial resistance has an important impact on
pneumococcal meningitis, making antibiotic treatment more difficult and costly.
1.1.4.2. Non-invasive pneumococcal disease
Non-invasive pneumococcal disease (NIPD) includes pneumonia, otitis media, sinusitis
and other upper and lower respiratory infections when the pneumococcus is recovered
from sputum, nasopharynx and other superficial sites. It is considered to be more difficult
to diagnose NIPD due to the empirical and widespread use of antibiotics, relatively
common nasopharygeal colonisation and the need for tympanocentesis. As a result, an
accurate figure for the incidence ofNIPD in the UK remains unknown.
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Nevertheless, the pneumococcus is considered to be the most common cause of upper and
lower respiratory infections and OM in the UK.212 An estimated incidence of
pneumococcal pneumonia per 100,000 persons is 100 in all ages,212 500 in children aged
less than five years213 an(j 200 to 400 in the elderly. 123,214
OM is one of the most common diseases of childhood and is caused by three key
pathogens: the pneumococcus, Haemophilus influenzae and Moraxella
catarrhalis?\5>H6 Data from 13 published studies on bacteriology of OM in 4157
children show that the pneumococcus accounts for 20% to 37% of cases, followed by H.
influenzae (20%), Moraxella catarrhalis (6%), Streptococcus pyogenes (2%),
Staphylococcus aureus (2%) and others (6%).217 Similar pathogens were responsible for
acute OM in adults.218 An international study, conducted in Eastern and Central Europe,
Israel and the US, showed that the pneumococcus is the most frequent cause of OM
pathogen in Europe.2'6 -p^g distribution of causative pathogens in bacterial sinusitis is
comparable to those in OM.219
Acute OM occurs in 7 out of every 10 children.2'7 of these, repeated episodes develop
in 30% and chronic OM with effusion in 5% to 10% of cases. Recurrent OM can affect
hearing, language acquisition and achievement in school220,221 jn 20% of cases.222 p^g
peak incidence ofOM occurs at six to 18 months of age.215,223,224 pp,e annuai estimate
for episodes of pneumococcal OM for children aged less than two years in the UK is
between 180,000 and 540,000.
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Acute OM is the most common reason for antibiotic prescription in Europe and the
US.225.227 jn the UK, 97% of children with OM receive an antibiotic prescription when
they see their general practitioners (GPs).225 jhe widespread use of antibiotics for acute
OM is associated with an increase in rates of drug resistant bacterial pathogens.228,229
Children with frequent OM episodes are more likely to carry multi-drug resistant
pneumococci.230
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1.1.5. Antibiotic resistant pneumococci
Pneumococcal resistance to a particular antimicrobial agent is variable and is measured
by the minimum inhibitory concentrations (MIC). Isolates with MICs for penicillin <
0.06 pg/ml, between 0.12 to 1.0 pg/ml and > 2 pg/ml are considered sensitive,
intermediately resistant and high-level resistant respectively.231 Multidrug resistance is
defined as resistance to three or more antimicrobial agents.232,233
The prevalence of pneumococcal resistance to penicillin and other antibiotics is
increasing in the UK and other countries.234 jn England and Wales, the proportion of
penicillin resistant (PR) pneumococcal isolates has increased from 1.5% in 1990 to 3.9%
in 1995235 an(j 3.6-7.4% in 1997/1998.236 yhe proportion of erythromycin resistance
has also increased, from 2.8% in 1990 to 8.6% in 1995235 ancj to 11% in 1997/1998.236
The prevalence of resistance to penicillin and erythromycin was low in Scotland but an
increase of 1.5% to 2.3% and 1.4% to 4.5%, respectively, was documented between 1992
and 1995.20 Geographic variations in prevalence of antibiotic resistant pneumococci
have been observed both between and within countries (Table 6).237_239 yhe highest
resistance has been reported in some parts of Europe240,241 Asia242 ancj the US.243 in
Europe, much higher rates of PR pneumococci have been detected in Hungary,240
Spain,241 France244 ancj Portugal.245
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Although rates of PR pneumococci are highest in young children, 149 ,jata from the US
indicate an increased rate of penicillin resistance in pneumococci in the elderly.246,247
In some parts of the US up to 40% of invasive isolates have shown reduced susceptibility
to penicillin in the elderly.247 An outbreak'40 ancj a cluster of (multi) antibiotic resistant
pneumococcal disease248 have been reported among institutionalised elderly with low
vaccine coverage in the US, suggesting the need for pneumococcal polysaccharide
vaccination in residents of nursing facilities. Specific data on the prevalence of antibiotic
resistant pneumococci in the elderly and persons in long-term care facilities in the UK
have not yet been reported.
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Table 6. Penicillin non-susceptibility in pneumococci in selected countries by
continent
Region Year Resistance % Reference
Europe
UK 1990-1998 <1 - 7.4 236
UK 1995 2.9 7
UK 1995-99 4.6 77
Germany 1998 6.7 244,249
Poland 1997 14.4 250
Iceland 1998 32.8 244
Hungary 1997 43 251
France 1998 53.3 244
Spain 1999 60.1 252
North America
Canada 1997-98 21.2 253
US 1997 49.7 254
Canada 1994 54.9 255
Latin America & Caribbean
Colombia 1994-96 15.6 256
Seven countries* 1997 23.6 257
Six countries** 1993-99 28.6 (20.7-33) 258
Oceania
New Zealand 1997 17 259
Australia 1997 25.4 260
Asia
India 1996-97 3.8 242
China 1996-97 9.8 242
Bangladesh 1993-97 12.7 261
Japan 1998 30.9 244
Thailand 1992-94 37.2 262
Hong Kong 1999-2000 58 263
Singapore 1997-99 63.3 264
Vietnam 1996-97 60.8 242
Taiwan 1998-99 76 265
Korea 1996-97 79.7 242
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Africa
Kenya 1992-96 22.6 266
South Africa 1998 43.8 244
* Argentina, Brazil, Chile, Mexico, Panama, Venezuela, and West Indies
** Mexico, Brazil, Argentina, Chile, Colombia, Uruguay
Non-susceptible included intermediate and resistant isolates (MIC level > 1.02 (ag/ml)
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Worldwide data indicate six serotypes (6B, 9V, 14, 19A, 19F and 23F) to be the most
frequent causes of antibiotic resistant pneumococcal disease.267 These serotypes are also
mostly associated with multidrug resistance,268 particularly, serotypes 6B and
23F. 195,269 ]\|pc with these strains is common in children,33,267 suggesting that young
children may play a major role in the spread of resistant pneumococcal strains in the
community.270
The molecular epidemiology of penicillin resistant pneumococci in 15 countries found
that serotypes 23F and 9V clones are responsible for the global spread of antibiotic
resistant pneumococcal isolates.271 The most prevalent penicillin resistant serotypes are
23, 6 and 9 in the UK.272.275 Several studies have reported that serotypes 6B, 9V, 14,
19A (19F), and 23F are the most frequent cause of outbreaks of antibiotic resistant
pneumococcal disease in paediatric hospitals276,277 jay care centres 147,230,278,279
and nursing homes. 140 All these serotypes associated with antibiotic resistance are
included in the formulations of PPV and PCV.
A relationship between antibiotic use and an increase in rates of antibiotic resistant
pneumococci has been demonstrated in some parts of Europe,226,280.284
Canada,285,286 the US 140,226,268,287,288 an(j Australia,289 hut not in Scotland. US
studies have documented an association between antibiotic resistant pneumococci and
socio-economic or racial status. 137,195,290 Although the incidence of invasive disease is
at least 3-fold higher in African Americans than White Americans, the latter are at greater
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risk for antibiotic resistant pneumococcal disease, suggesting greater use of antimicrobial
agents, perhaps through increased access to health care. 137,291,195 other major risk
factors for carriage or infection with penicillin non-susceptible pneumococci are young
age, day care centre attendance, otitis-prone conditions and prior hospitalisation. '49
The emergence of antibiotic resistance is likely to have an impact on the choice of
treatment regimen.210 Pneumococci with high-level resistance to penicillin and other
antibiotics would have serious implications for patients with invasive disease, particularly
meningitis. ^'292 Treatment failures and fatal outcomes in patients with meningitis
caused by beta-lactam resistant pneumococci have been documented.293.296 Although it
has not been consistently documented in the US studies,297,298 there is also strong
evidence that penicillin resistant pneumococcal strains are associated with increased
adverse medical outcomes*^,299,300 such as high mortality (MIC> 2.0 mg/ml)8 and
longer hospitalisation (3.7 days) (MIC> lmg/ml)^ than patients with penicillin
susceptible pneumococcal disease.
Key strategies to control the spread of antibiotic resistant pneumococci include improved
antibiotic resistance surveillance, the promotion of judicious antibiotic use and improved
use of pneumococcal vaccine. 149,288,301 Interventions targeting patients and health care
providers are also an essential part of reducing unnecessary use of antimicrobial
agents.288 Accurate population-based data on the overall prevalence and the distribution
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of serotypes associated with antimicrobial resistance in pneumococci are necessary in
order to implement effective public health measures in Scotland.
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1.1.6. Economic impact of pneumococcal disease
The total health care cost of pneumococcal disease has not been determined in the UK.
However, the annual cost of treating CAP is estimated at £440 million (1992/93
prices).302 y^g available data show that respiratory infections are the most common
reason for general practice medical consultations, accounting for about 30 million
antibiotic prescriptions and over 3 million sickness prescriptions annually in the UK.212
The average cost is £389 for myringotomy and £303 for grommet insertion, which results
in nearly £30 million per year for surgical treatment of glue ear in England and
Wales.303 At present, data are lacking on the economic impact of pneumococcal disease
in the UK and studies on economic evaluation in this area are required. These data are an
essential component of calculating the cost-effectiveness of introducing pneumococcal
vaccines and prioritising treatments and preventive measures in order to manage the
escalating costs of health care.
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1.2. Prevention of pneumococcal disease
1.2.1. Immunity against the pneumococcus
1.2.1.1. Natural immunity
Defence against pneumococcal disease includes the activity of type-specific antibodies,
opsonisation and efficient phagocytosis and killing by neutrophils.29 The development of
antibodies against the polysaccharide capsule occurs following pneumococcal disease or
exposure to pneumococci.304.307 Serotype-specific antibodies directed to capsular
polysaccharides are protective against pneumococcal disease.308 The development of
natural immunity309 appears to relate to the induction of mucosal IgA with NPC^IO ancj
serum IgG to pneumococcal surface protein A (Psa A), pneumococcal surface adhesin A
(Psa A) and pneumolysin.311 The immune response to pneumococcal polysaccharides is
influenced by genetic factors.312,313 However, the molecular basis of the natural
immune response to pneumococci is poorly understood.
1.2.1.2. Vaccine induced immunity
Vaccines based on pneumococcal capsular polysaccharides induce serotype-specific
antibodies.308,314-316 Currently, the exact antibody level that is "protective" is
unknown. However, certain levels of antibody after vaccination or infection are
considered to be associated with protection.317 The level of 0.15 pg ml"1 and 1.0 pg ml"'
are considered as surrogates for short-term and long-term protection respectively.318 ^ js
32
generally assumed that vaccines containing serotypes 6B and 19F induce cross-reactive
antibodies to serotypes 6A and 19A.319 However, studies have shown that vaccine
serotypes 6B and 19F do not always provide functional antibody to cross-reactive
serotypes 6A and 19A.320.322 Current clinical trials of pneumococcal vaccines should
determine the presence of the cross-reactive protection within vaccine serotypes.
1.2.1.2.1. Pneumococcal polysaccharide vaccines
A 14-valent PPV containing serotypes 1, 2, 3, 4, 6A, 7F, 8, 9N, 12F, 14, 18C, 19F, 23F
and 25319 was replaced with a 23-valent PPV in 1989 in the UK, 15 the latter including
additional serotypes, 5, 6B, 9V, 10A, 11 A, 15B, 17F, 19A and 33F.323 Overall, the
current vaccine covers between 88% and 90% of IPD causing serotypes in adults and
85% in older children in the UK, other parts of Europe and North
America.76'77,319,323,324 -phe evidence indicates that the level of PPV-induced
antibodies is lower in patients with chronic obstructive pulmonary disease,525
immunocompromised conditions,526,327 the elderly528_330 ancj young children551
compared with healthy adults.
There are two major study designs that have been used to evaluate the efficacy and
effectiveness of pneumococcal vaccines. These include experimental studies (randomised
controlled trials, RCT) and observational studies (cohort, case-control and indirect cohort
studies).532 Although RCTs are regarded as the most rigorous method of assessing
vaccine efficacy, they are sometimes impractical due to ethical, financial and logistical
factors. 12,332,333 jn addition, lack of sufficiently sensitive and specific diagnostic
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methods and the relatively low incidence of 1PD represent major obstacles in determining
efficacy of PPV.334
In contrast, case-control and indirect cohort studies have advantages in rapid gathering of
data and higher statistical power to evaluate vaccine effectivenesses an(j jn certain
circumstances are a more pragmatic approach for evaluating the impact of vaccine under
normal clinical practice.335 Nevertheless, these studies are more likely to be associated
with bias.336 Berth case-control and indirect studies require positive pneumococcal
isolates from a sterile body site, accurate records of vaccination status and a study
population with vaccine coverage of at least 15%. In the past, the US was the only
country where vaccine coverage was adequate to permit the use of these research designs.
However, surveys in Europe show that coverage of PPV is 15% in the UK '4 and 20% in
Belgium337 jn 1998. Thus, these methodologies could be used in some Western
European countries to confirm the earlier results of US studies.
There are five systematic reviews or meta-analyses of RCTs, which evaluate PPV
effectiveness (Table 7).338.342 Unfortunately, these papers have reached differing
conclusions highlighting problems with meta-analysis, which have been subject to debate
in the journals.343 Although the methodology used in these reviews differs, no studies
assess vaccine efficacy by the type of vaccine and its outcome measures and patient
population. None of these studies have clearly concluded that PPV is effective against
non-bacteraemic pneumonia in industrialised populations. It was not surprising that
Moore et al341 failed to show the efficacy of the vaccine, since they did not include three
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large RCTs, which concluded the vaccine was protective. The recent systematic
review339 concluded that PPV has protective effects for mortality and all causes of
pneumonia in non-industrial populations. These clinical outcomes were not demonstrated
in industrialised populations with the exception of pneumococcal bacteraemia. However,
a reduction in bacteraemia did not show any statistical significance. As the authors stated,
the small sample size in most of the trials carried out in industrialised countries is likely
to be the major reason for not demonstrating a clear benefit of vaccine in older patients.
The other three meta-analyses338,340,342 included RCTs found that the vaccine was
effective in preventing invasive pneumococcal disease caused by vaccine serotypes in
immunocompetent adults. However, two of these studies338,342 representing 40,431-
48,837 patients, found lack of benefits in older patients or persons with high-risk
conditions (e.g. immunosuppression or chronic organ dysfunction). In contrast, the
Canadian study340 consisting ofmore than 65,000 patients suggests no evidence of lower
effectiveness of vaccine in the elderly, institutionalised patients or persons with chronic
disease for systematic pneumococcal disease due to all pneumococci. Thus, it appears
that the sample size is critical in demonstrating the protective benefits of PPV in specific
target groups as in individual clinical trials.
However, the Canadian study did not find statistically significant benefit for any outcome
measure in patients with chronic organ dysfunction and the elderly, if the open
randomised trial published in 1947 was removed from the analysis. The conclusion from
these meta-analyses suggest that PPV may not offer any benefits for the elderly and
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patients with immunocompromised conditions but the validity of the meta-analyses
which gathered the results of studies with different outcome measures, inadequate
samples or limitations in methodology has been highlighted.344
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Table7.Conclusionsoff rsystematicreviewmeta-an ly ispneum coc alpolysac haridev c ineffi cy ReferenceTypeofreviewConclusion FineMJ,etMeta-analysisof9tri publishedpto1991Pneumococcalvaccinationappearseffi acioui reducingbact r micpneumoco caleum ialow- riskadults.However,evidencefromRCTtdemonstrataccinefficacypneumo occal infection-relatedrothermedicalutcom sthh erogen ousg pfsubj ctcurr ntlylab las highrisk. HutchisonBG,etMeta-analysisof13tri l publishedptoNovemb r 1996Vaccinationwi hPPVnbeexpectedtoreducehiskfsystemicinf c idupn umococcalty s includedthvaccineby83%nsystemici fec iondollpneum cocci7 .Nevid ewas foundthatevaccinew slesseffi ciousorld rly,institutionali dpeople,ithchr ic disease. MooreRA,et'Systematicr viewof9t ials publishedpto1999Theweightofevidenceist aPPVshaveybhownrknt pp plgivt m industrialisedcountri s.Th lyreaev dencet tomfrwoimprop rlyrandomis d studiesfromth1940s. WatsonL,etSystematicr viewandmeta¬ analysisof16tri l publishedptoMarch1999Forstudiescarri doutinthWest,rwaoprotectiveeffectfounmo tality,lpne monia pneumococcaleumonia,alth ughth rewasprote tiver ndfoneumoc calbact r emi , surrogateo tc me.Inthirdw rldtudiesasignific ntprotectiveff ctafocli i al outcomes. Cornu,etMeta-analysisof14tri publishedbetween1966and 1999Vaccinationiseffectivepr venting71%def itepneumococcaln umon a,40r sumptive pneumococcaleum niaand32%morta ityduetiimmunoc petentdul s.Nprote io isobservedf all-causepneumoniadeath.Vac ineff cacyotapp r nttheld rly,>55y rsf age,mainlyduetolowstatisticalp wer.
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PPV has been shown to be between 76% and 92% efficacious against pneumococcal
pneumonia and pneumococcal bacteraemia in RCTs conducted in military recruits,345
South African gold miners^46,347 an(j adults in Papua New Guinea (Table 8).348
However, the results of 7 RCTs'36,349,350.355 an(j two prospective intervention studies
in which PPV was administered with or without influenza vaccine353,356 jn the elderly
population are contradictory (Table 8). Indeed, surprisingly, an increased number of
pneumococcal disease events was even observed for vaccine recipients among HIV-1
infected adults in Uganda.355 Differences in study populations and methods such as
whether a placebo was used and the choice of placebo, make these results difficult to
compare.334 [n contrast to the results from Finland and Sweden, the additive health and
economic benefits of pneumococcal and influenza vaccination have been demonstrated in
the elderly with chronic lung disease in the US.357 One prospective study in Canada also
showed that pneumonia and other respiratory infections were more likely to occur in
unvaccinated elderly residents in long-term care facilities.358 Differences in individuals
responses to polysaccharide vaccine and against pneumococci suggesting that the
effectiveness of PPV is likely to be varied among patients with different at-risk
conditions.359 However, very few clinical trials have assessed the efficacy of PPV
vaccine by separating subgroups of patients. A small randomised trial, which assessed the
immunogenicity of 14- to 17-valent PPV in patients with chronic obstrtuctive pulmonary
disease (COPD) or bronchogenic carcinoma observed that PPV was immunogenic in
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these patients325,360,361 a rapid decline of antibody after vaccination was noted in
one study.325
Five case-control and four indirect cohort studies have been conducted to assess the
effectiveness of PPV in high-risk groups (Table 9). With the exception of one study,362
PPV was estimated to be 48% to 81% effective against 1PD in immunocompetent elderly
persons and persons with underlying medical conditions. However, protection was lower
in those with sickle cell disease, haematological malignancies363 amj recurrent otitis
media.364 -p^e one study, which failed to demonstrate vaccine effectiveness, is thought to
be due to incomplete ascertainment of vaccination status of the study subjects and
possible bias in the selection of controls.365,366
Early data from RCTs in Papua New Guinea showed that PPV was 50% efficacious in
reducing death from acute lower respiratory tract infections in children aged between four
months and two years.367,368 n0 effectiveness was noted for respiratory and otitic
complaints in studies in Australia.369,370 ppy has been shown to reduce the incidence
of OM caused by vaccine serotypes associated with good antibody responses in young
children in the US371,372 ancj Finland364 huj not jn other US studies.373 Although one
US study noted a 50% decrease in the incidence of subsequent ear infections in African
Caribbean American children aged between 6 and 11 months, there was no reduction in
White American children.374 a recent US retrospective study in children aged two to
five years found that the vaccine effectiveness was 63% for all children and 62% for
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children with sickle cell disease.375 Studies that failed to show evidence of the benefits
of vaccination in young children are probably due to poor humoral response in this age
group. Conflicting results may also relate to genetic factors, differences in measurement
of antibodies and age of study population and the prevalence of non-vaccine serotypes or
adult serotypes.
Based on these data, the evidence of PPV is restricted to the prevention of IPD in
immunocompetent older children and adults and the elderly, many of whom have high-
risk conditions.376 Its effectiveness in high-risk patients against pneumonia (in the
absence of bacteraemia) is not certain. At present, insufficient data are available to
support the effectiveness of PPV in preventing non-bacteraemic pneumonia in the elderly
and otitis media and other non-invasive pneumococcal disease in young children.
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63(8,85)Allchildren 62(-294,98)ChildrenwithSCD 84(40,96)ChildrenwithoutSCD 93(45,100)****AIIchildren
CDC,US(isolatesco lectedthrough hospitallab ratory-based surveillance)
145/173 39/46 106/127 19/47
' caseontrolstudy,indirecthortCDC=entrfoDisetraPr ve i nSCDsickl -celldis43 *Allconditions **lVithunderlyingmedicalcon i ions(chroniclu g,heartivre adiab t sllitua dlcoh li m) ***Immunocompromisedconditions(splenicdis r er ,sicklleas ,haemat log calmalig anci s,trans l tndsystematiclu uerythe tosus) ****Effectivenessforthserotypen tinclud d7-valentonjuga ev cci
Current evidence suggests that PPV is safe and does not cause serious adverse
events.338,384 a review of 1099 elderly receiving two doses of PPV found that
revaccination does not cause adverse events requiring hospitalisation.385 fhere are no
reports to date of severe febrile reactions or anaphylactic reactions after initial
vaccination or revaccination.376 Simultaneous administration of influenza and
pneumococcal vaccines has been shown to produce a satisfactory antibody response
without increased adverse reactions.386 The incidence and severity of adverse reactions
after more than two doses of PPV are not known.
PPV is poorly immunogenic in children aged less than two years,387 the age group with
the highest incidence of invasive and mucosal infection. As a consequence, it is not
recommended for them. Since polysaccharide antigens are T-cell independent, the
vaccine is unable to induce immunological memory and does not reduce carriage.316 An
immune response of capsular polysaccharide is relatively short-lived in older adults and
persons with underlying diseases.388,389 jn addition, it does not protect against non¬
invasive disease such as pneumonia or otitis medial Thus, conjugate vaccines have been
developed in response to these problems. Linking polysaccharides to protein carriers
converts the polysaccharide from T-cell-independent antigens to T-cell-dependent
antigens.390 This results in induction of immunological memory, maturation of immune
response in infants, the elderly and those with immunocompromised conditions.4391
Conjugate vaccines have proven highly successsful in reducing invasive H. influenzae
type b392 an(j group C meningococcal disease.393
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1.2.1.2.2. Pneumococcal conjugate vaccines
Current PCV formulations include the 7 to 11 serotypes causing the majority of
pneumococcal disease in children (Table 10)72,316 All p^y formulations also include
serotypes 6, 14, 19 and 23, which in polysaccharide vaccines are less immunogenic in
children331,394 an(] strains currently resistant to antimicrobial agents worldwide.267 The
7-, 9- and 11-valent conjugate vaccine serotypes cover 75%, 80% and 87% of IPD
respectively in children less than 5 years of age in the UK.'7 The coverage of IPD with
these vaccines decreases in older children and the elderly in the UK and US.77,363 The
serotypes in the 9- and 11-valent conjugate vaccine are responsible for 76-93% of IPD in
Europe and the US.376 Coverage of non-invasive pneumococcal isolates in young
children was 65% in the US with 7-valent conjugate vaccine.68 Data on coverage of
conjugate vaccines for non-invasive disease have not yet been reported in the UK.
Serotypes included in the 9-valent and 11-valent conjugate vaccines covered over 60% of
all pneumococcal isolates worldwide (except CSF isolates in Asia where coverage of
both vaccines was only 40% and above) from pneumonia patients, both young children
and adults.78
PCVs are safe and immunogenic in infants,20 the elderly and persons with
immunocompromised disorders (HIV, Hodgkin's and sickle cell diseases),395,396.398
recurrent respiratory infections,399,400 natiVe American Indian^Ol African and Asian
descents.^ 16,402.407
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the US * and Europe




Phase I I/I 11
8-valent (3 with 7-valent vaccine Diphtheria toxoid Pasteur Merieux Phase 1/11
serotypes) Connaught
8-valent (3 with 7-valent vaccine Tetanus toxoid Pasteur Merieux Phase I/1I
serotypes) Connaught
9-valent (1,5 with 7-valent vaccine CRM 197 mutant Wyeth Lederle Phase III
serotypes) diphtheria protein vaccine
11 -valent (1, 5, 3, 7F with 7-valent Diphtheria toxoid Pasteur Merieux Phase 1/11
vaccine serotypes) or tetanus toxoid Connaught
* Included in the routine childhood immunisation programme
Antibody responses to PCVs vary according to serotype and vaccine formulation.408
Studies in developed and developing countries have reported that PCVs are immunogenic
in infants aged six to eight weeks.316,409 After three doses with PCVs, anticapsular
antibody levels are raised 3.5 to 20 fold compared with pre-immunisation levels.410-413
The level of antibody at seven months of age after a series of three doses ranges from 0.5
to 4.29 pg/ml for poorly immunogenic serotypes and to 1.13 to 14.09 pg/ml for the most
immunogenic serotypes.316 Serotypes 6B, 18C and 23F are less immunogenic than
serotypes 4, 9V, 14 and 19F414 an(j require a second dose of vaccine to elicit protective
antibody levels.415,416 correlation between vaccine-induced efficacy and
anticapsular antibody as measured by radio immuno-assay (RIA), enzyme-linked
immunosorbent assay (ELISA) and functional assay (opsonophagocytic) has not been
evaluated.
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At present, there are limited data on PCVs in adults and the elderly. Of the eight studies
of PCVs in adults and the elderly,417 sjx studies showed that PCVs elicited higher
antibody responses than PPV in younger adults.391,396,418.421 jn contrast, two other
studies in persons aged 50 years above did not show significant advantages in antibody
responses over polysaccharide with the conjugate vaccines.391,421 Although there is no
clear explanation, low baseline immunity to diphtheria protein (prevaccination anti-
diphtheria antibody level <0.55 IU/ml) may contribute to the lower antibody responses to
conjugate vaccines in older adults.422 The immunogenicity and the effect on NPC by
PCVs in high-risk adults and the elderly require further investigation.
The results of a 7-valent CRM197 (cross-reactive material, nontoxic variant of diphtheria
toxin isolated from cultures of Corynebacterium diphtheriae strain C7 ((3197)) PCV trials
in North California and the native American population in Arizona show that the vaccine
is very effective in infants, who were immunised at 2, 4, 6 and 12-15 months of age
(Table 11). Serotype specific efficacy differs among vaccine serotypes. In the California
trial, the immunity for serotypes 9V, 14, 18C and 23F was superior to other vaccine
serotypes. The failure to detect significant protection for vaccine serotypes 4, 6B, and
19F may be due to the small number of cases in the control group (48 cases) and in the
PCV group (3 cases). Although an increase in non-vaccine serotypes was detected in the
Navajo study (but not in the California study), the number of cases of IPD caused by non-
vaccine serotypes did not increase in either study. In the California trial, 95% of PCV
recipients achieved an antibody level of 0.5 pg/ml.16 Thus, this level is likely to confer
protection against IPD in the population and could be used as a surrogate marker for the
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efficacy of conjugate vaccines. A recently completed clinical trial in 9480 HIV-infected
children in South Africa showed that the efficacy of 9-valent PCV is 50% for bacteraemia
and 80% for meningitis in these high-risk children.423 All the clinical trials are well
designed and have an adequate statistical power to detect the outcome in question.
Table 11. Efficacy of 7-vaIent pneumococcal conjugate vaccine against invasive
disease, as reported from randomised trials in the US
Invasive disease Efficacy % (95%CI)






Vaccine serotypes (cases: controls) 16
4 (0:0) -
6B (7:1) 85.7 (-11.2, 99.7)
9V (3:0) 100 (-142, 100)
14(11:0) 100 (60.2, 100)
18C (9:0) 100 (49.3, 100)
19F (13:2) 84.6 (32, 98.4)
23F (6:0) 100(15.1, 100)
Three studies have reported the efficacy of 7-valent PCV against otitis media (Tables
12a-b). 16,17,425 jn Finnish otitis media trials, the 7-valent PCV prevents 56% to
57% of serotype-specific culture confirmed acute OM and 25% to 34% of any
serotypes. 17,18 Cross-reactive immunity was detected for serotype 6A only, not other
serotypes belonging to the same serotype in the vaccine. The efficacy of vaccine
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increases along with the severity of disease, from 6% against all clinical episodes to 20%
against ventilatory tube replacement16 and between 61% and 69% against severe forms
of ear disease such as spontaneous perforation or bulging tympanic membrane, caused by
vaccine serotypes425 a 9-valent CRM 197 PCV has also been shown to reduce otitis
media episodes by 17% in toddlers aged 12 to 35 months in a day care centre in Israel.!"
Table 12a. Efficacy of 7-valent pneumococcal conjugate vaccine against otitis media
of any aetiology
Otitis media Efficacy % (95%CI)
US study16'426 Israeli study 19 Finnish study12
Visits 8.9 (5.8, 11.8) - -
Episodes 7.0(4.1,9.7) 17* -
Frequent otitis media 4/5 11.9(1.6,21.1) - -
Ventilatory tube replacement 20(1.5,35.2) - -
AOM of any aetiology 6 (-4, 16) - 6 (-4, 16)
* 95% CI not available
Table 12b. Efficacy of 7-valent pneumococcal conjugate vaccine against
pneumococcal otitis media
Otitis media Efficacy % (95%CI)
Finnish studies
Study 112 Study 2^'426
Vaccine serotypes 57 (44, 67) 56(44, 66)
Vaccine serotypes (spontaneous perforation) - 69 (5, 90)
Vaccine serotypes (sponatanous perforation and 61 (44,73)
bulging tympanic membrane) -
Vaccine serogroups 51 (27, 67) -
Culture-confirmed pneumococci 34(21,45) 25 (11,57)
The California trial suggests that PCV appears to be effective in preventing pneumonia in
infants and young children. 16 The reported vaccine efficacy was 11.4% (95%CI: 1.3,
20.5) for clinical pneumonia, 33% (95%CI: 7.3, 51.5) for X-ray-confirmed pneumonia,
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73.1% (95%CI: 38, 88.3) for consolidation (>2.5cm on X-ray) and 85% for bacteraemic
pneumonia (Table 13). The 9-valent PCV has been shown to reduce the occurrence of
respiratory infections by 15% to 16% in young children attending day care in Israel'9
and pneumonia by 17% in HIV-infected children in South Africa.423
Evaluation of efficacy of PCVs against acute pneumococcal OM and non-invasive
disease needs further determination. In addition, the development of standard diagnostic
criteria for pneumonia is essential in generating comparable data for the impact of PCVs
on culture-negative pneumonia.
Table 13. Efficacy of 7-valent pneumococcal conjugate vaccine against pneumonia
and other respiratory infections
Basic for diagnosis Efficacy % (95% CI)
US study426
Clinical diagnosis 10.7 (-0.7, 20.8)
Chest X-ray confirmed 35.0 (5.5, 55.8)
Consolidation on chest X-ray (>2cm) 62.7(11.3, 84.3)
Israeli study '9
Upper respiratory infection 15
Lower respiratory infection 16
PCVs have been shown to reduce the carriage rate for vaccine serotypes, particularly
antibiotic resistant serotypes (6B, 9V, 14, 19A (19F), 23F)50,406 in vaccinated children
and their contacts.422 a trial in South Africa reported a 50% reduction in penicillin
resistant pneumococci, 21% carriage in immunised infants compared with 41% in
controls.4^6 jn addition, PCV has been reported to reduce antibiotic use, a 5.3% in the
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California trial 16 and antibiotic days, a 17% in day care attendees in Israel. 19 Therefore,
PCVs have the potential to reduce the prevalence of resistant strains and antibiotic use.
Studies in the US428s Israel,410 South Africa^Ob and The Gambia'^ have shown that
PCVs reduce the acquisition of NPC of vaccine serotypes in immunised children
although an increase in colonisation with non-vaccine serotypes has also been
detected. 17,79,406,428,430 jn jhe Gambia trial, non-vaccine serotypes were 79% in the
7-vaIent PCV recipients compared with 42.5% in controls.429 \ trial of 9-valent
conjugate vaccine found that carriage of non-vaccine serotypes was 39% in immunised
children and 21% in the controls in Israel, with a significant increase in serotypes 7 and
15,406 which are known to be important cause of IPD.309
The Finnish otitis media trial also detected a 33% increase in disease caused by non-
vaccine serotypes in the 7-valent PCV recipients. 17 It is uncertain whether these data
indicate true serotype replacement, or the "unmasking" of less prevalent serotypes due to
elimination of predominant serotypes by conjugate vaccine. However, a community-
randomised trial in Native American Indian428 ancj mathematical modelling data431.433
suggest that conjugate vaccination results in true replacement of carriage of non-vaccine
serotypes. Although replacement in carriage of non-vaccine serotypes and an increase in
culture confirmed OM caused by non-vaccine serotypes occurred in vaccinated infants,
there was no evidence of an increase in 1PD caused by non-vaccine serotypes. 16 These
data highlight uncertainty in the long-term effectiveness of PCVs and the need to develop
effective and affordable pneumococcal vaccines.
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The results from clinical trials suggest that PCV provides at least 4 years immunity^ but
the duration of protective immunity remains to be determined. Data from Hib conjugate
vaccine indicates that conjugate vaccines could provide long-term immunity.392
Continuous surveillance following widespread use of PCV in infants and long-term
follow-up of vaccinated adults with high-risk conditions are necessary to determine the
duration of its effectiveness.
In the US^ and Canada,21 the recommended schedule for newborns is four doses,
administered at 2, 4, 6 and 12 to 15 months of age. Depending on the age, one or more
dose of vaccine are also recommended for children between the ages of 24 months and 59
months with high-risk conditions. In the UK, PCV is recommended in children less than
two years of age with certain high-risk conditions, one each at 2, 3, and 4 months of age
or two doses at least a month apart if aged 5 to 24 months.21 Further studies are required
to determine the optimal schedule for newborns and among persons above 2 years of age,
the effectiveness of fewer doses, the requirement for periodic boosting with conjugate or
polysaccharide vaccine, the benefits of sequential vaccination with PCV and PPV and the
identification of immune markers that correlate with clinical protection.
1.2.1.2.3. Protein pneumococcal vaccines
Five antigens of pneumococcal proteins, neuraminidase, autolysin, pneumolysin,
pneumococcal surface protein A (PspA) and pneumococcal surface adhesin A (PsaA or
37-kDa) are considered as potential candidate vaccines.434 jn addition to protection
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against all pneumococcal serotypes, these protein antigens appear to elicit a T-cell-
dependence with immunological memory.435,436 jn animal models immunisation with
pneumolysin and PspA have been shown to protect against pneumococcal
disease.437.439 Conjugation of these proteins to capsular polysaccharide could also
enhance the immunogenicity and efficacy of the vaccine in high-risk adults and the
elderly.434 Current data indicate that PspA appears to protect against IPD436 an(j psaA
protects against carriage.440 Therefore, both proteins can be recommended for inclusion
in the formulation of protein vaccine.436 since these vaccines are more likely to be
affordable for widespread use in developing countries, their development should be
encouraged. Further studies are also required to determine the ability of these proteins to
combat a variety of existing pneumococcal serotypes that cause the various clinical
syndromes.
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1.2.2. Cost-effectiveness of pneumococcal vaccination
1.2.2.1. Pneumococcal polysaccharide vaccine
Studies in North America and Europe show that pneumococcal polysaccharide
vaccination is cost-effective in preventing pneumococcal pneumonia or IPD or penicillin
resistant pneumococcal infection, particularly in the elderly (Table 14). A recent study in
five European countries, including Scotland, Belgium, France, Spain and Sweden, found
that pneumococcal vaccination in all persons 65 years of age and above is cost-effective
for preventing IPD.441 Under certain assumptions vaccination is cost saving.442 Most
studies have used the following basic assumptions for determining cost-effectiveness: (a)
15% to 50% of pneumonia are caused by the pneumococcus (b) 75% to 80% of cases of
pneumococcal pneumonia are caused by organisms of serotypes included in the vaccine,
(c) 50% to 80% vaccine efficacy (assuming vaccine is effective in preventing both
bacteraemia and non-bacteraemic serious pneumococcal disease), (d) 3 to 8 years of
immunity, (e) $15 for a vaccine (1983 cost).443 However, it is important to acknowledge
that current evidence on the clinical effectiveness of pneumococcal polysaccharide
vaccination is limited to the prevention of pneumococcal bacteraemia. In the absence of
direct evidence on preventing non-bacteraemic pneumonia, the validity of these cost-
effectiveness studies remains uncertain.
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Table 14. Economic studies of pneumococcal polysaccharide vaccine
Investigator Year Vaccine Location Risk group Outcome measure Cost-
effective3
'OTA444 1979 14-valent US Elderly Pneumococcal
pneumonia*
Yes
Willems et al443 1980 14-valent US Elderly Pneumococcal
pneumonia*
Yes
Sisk & Riegelman44^ 1986 23-valent US Elderly Pneumococcal
pneumonia*
Yes
Gable et al442 1990 23-valent us Elderly Pneumococcal
pneumonia*
Yes
Holzer et al448 1993 23-valent us Elderly Pneumococcal
pneumonia*
Yes
Plans et al44" 1995 23-valent Spain Elderly Pneumococcal
pneumonia*
Yes
Jimenez & Gullar43" 1996 23-valent Spain Elderly Pneumococcal
pneumonia*
Yes
Baltussen et al43' 1997 23-valent Netherlands Elderly Pneumococcal
pneumonia*
Yes
Sisk et al442 1997 23-valent us Elderly Invasive disease*** Yes
Gable et al432 1997 23-valent US Elderly Pneumococcal
pneumonia*
Yes
Herman et al442 1998 23-valent US Elderly Penicillin resistance
pneumococcal infection
Yes










Pepper et al434 2000 23-valent US Marine corps Pneumococcal
pneumonia*
Yes
Ament et al441 2000 23-valent Five European
regions **
Elderly Invasive disease*** Yes





COPD = chronic obstructive pulmonary disease
* Pneumococcal pneumonia (bacteraemic and non-bacteraemic pneumococcal pneumonia)
** Europe (including Scotland)
*** Invasive disease (pneumococcal bacteraemia and meningitis)
**** ajso receiveci influenza vaccine
1 US Congressional Office ofTechnology Assessment (OTA)
2 CMC (chronic medical conditions)
3 Cost-effectiveness varied according to outcome measures used. These included direct and indirect medical costs, societal costs or
both medical and societal costs and also the value of costs per life-year saved/gained among countries
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1.2.2.2. Pneumococcal conjugate vaccine
Two US economic studies have suggested that routine use of PCV in infants and young
children is likely to be cost-effective 456,457 Qne study concluded that the prevention of
IPD alone has been estimated to gain net direct costs of $0.08 to $2.42 per child.456
Vaccination against invasive and non-invasive pneumococcal disease with a vaccine
price of $58 per dose has been estimated to cost society $80,000 per life-year saved, $160
per otitis media episode, $3200 per pneumonia case, $15,000 per bacteraemia case and
$280,000 per meningitis case prevented.457 The investigators conclude that if the
vaccine price was lower, it could even be cost saving.457 However, these data cannot be
extrapolated to countries with different health care systems such as the UK. Economic
analysis of pneumococcal conjugate vaccination programme in the UK has not yet been
established. The results of the analysis can provide a rationale and justification for
introducing PCV into the UK primary immunisation programme.
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1.2.3. Issues in relation to use of polysaccharide vaccine
In the UK, a single dose of PPV is currently recommended for individuals aged two years
and above with certain chronic medical conditions (Table 15). The vaccine is not yet
recommended for all elderly and residents in long stay facilities as in the US .1 So far,
little is known about the factors associated with adherence to vaccination guidelines,
views on vaccine indications and responsibilities among clinicians in the UK.




Chronic liver disease (including cirrhosis)
Chronic renal disease (including nephrotic syndrome)
Diabetes mellitus
Hyposplenism (including homozygous sickle cell disease)
Immunodeficiency states (including HIV infection)
US (additional indications) 1
Aged 65 years and above
All residents of nursing homes, homes for the aged, chronic care facilities or wards
Alcoholism
Surveys from England showed that coverage of vaccine is low but it is increasing, from
4% in 199513 to 15% in 199814 among persons with vaccine indications. This indicates
that the acceptance of the vaccine among health care professionals and patients is poor in
the UK. Data on the number of doses of PPV distributed in the UK and other parts of
Europe have reported to be increasing. 1 ^ These increases may be associated with changes
in recommendations for pneumococcal vaccination policies in these countries, 13
suggesting that a national guideline is influential in improving vaccine coverage. The
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monitoring of the numbers of vaccine doses used and distributed are required to identify
the areas in need of improvement in vaccine delivery and utilisation in primary care and
hospital care settings in Scotland.
Lack of awareness of vaccine availability and its benefits are reported to be the major
reasons for not being vaccinated in 73% of patients with indications for PPV in the
UK.14 Similarly, 57% of the elderly aged 65 years and above reported "not knowing
vaccination was needed" as the most common reason for not receiving the vaccine in the
US national survey.4^ Other reasons for not receiving the vaccine may partly relate to
controversy regarding its side effects, efficacy, duration of protection and failure to
consider vaccination during patient appointments.4"®-4"^ Since knowledge, attitudes and
practice of health care professionals and patients are known to affect the acceptance of
vaccine,4^3 studies in these areas and the reasons for receipt and non-receipts of vaccine
in high-risk patients are required in Scotland.
A UK study reported that 85% of PPV recipients received vaccine on the basis of advice
from their GPs,l4 indicating the pivotal influence of the primary care team in
determining vaccine coverage. Organised education and vaccination programmes for
PPV in England have been shown to increase vaccine coverage from 4% to 33%. 13
Similar strategies are reported to improve the rate of pneumococcal polysaccharide
vaccination in the US4®4-4^ and Belgium.337
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Currently, no financial support is available for GPs to use PPV in Scotland. The presence
of reimbursement and the adoption of age-based policies analogous to influenza
vaccination468 COuld enhance coverage of PPV. Studies in the US show that the use of
computer, chart, letter and label to identify vaccine eligible patients, standing orders for
nurses, information leaflets on disease and the benefits and side effects of vaccination,
can improve coverage of vaccine in high-risk patients.469,470
The evidence indicates that about 70% of patients admitted to hospital with
pneumococcal pneumonia or bacteraemia had previous hospital admissions.^? 1-474 yhjs
suggests that previous hospital care could be used to identify persons at increased risk for
pneumococcal disease.475,476 yhe organised hospital based programmes in outpatient,
emergency departments and geriatric units have been shown to improve coverage of PPV
among high-risk patients.4??-484 However, only 0.5% of patients with indications for
PPV vaccine had received the vaccine in a hospital care setting in the UK. 14 yhus,
research on factors influencing PPV use and the presence of vaccination policies in
clinical settings is required to modify any problems in the delivery of vaccine to high-risk
patients.
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2. AIMS OF THE STUDY
The aim of the thesis was to determine the burden and epidemiology of pneumococcal
disease and the characteristics of pneumococcal polysaccharide vaccination practices in
Scotland. This should inform future public health policy decisions on preventing
pneumococcal disease in Scotland, in particular in relation to the role of pneumococcal
polysaccharide and conjugate vaccines.
The specific objectives were:
1. Burden of invasive pneumococcal disease
• To determine the incidence of invasive pneumococcal disease in children, the
elderly and other age groups;
• To assess the prevalence of penicillin and erythromycin non-susceptibility of
invasive isolates;
• To evaluate the relative contribution of the pneumococccus to bacterial meningitis
and invasive non-meningitic bacterial disease (INMD), compared with the
meningococcus, Haemophilus influenzae, group B streptococcus and Listeria
monocytogenes before and after the implementation of Hib conjugate vaccine into
the primary childhood immunisation programme.
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2. To estimate coverage of pneumococcal vaccine for serotypes associated with
disease and antibiotic non-susceptibility
• To analyse the distribution of serotypes among all invasive and non-invasive
pneumococcal isolates and among those shown antibiotic resistance;
• To estimate the coverage of 23-valent and previous 14-valent polysaccharide and
7-, 9- and 11-valent conjugate pneumococcal vaccines for serotypes associated
with disease (in order to predict the likely impact on incidence of invasive and
non-invasive pneumococcal disease);
• To estimate the coverage of 23-valent and previous 14-valent polysaccharide and
7-, 9- and 11-valent conjugate pneumococcal vaccines for serotypes associated
with antibiotic non-susceptibility (in order to predict the likely impact on
prevalence of antibiotic resistance in pneumococci).
3. Pneumococcal polysaccharide vaccination practices in Scotland
• To examine knowledge, attitudes and practice of pneumococcal polysaccharide
vaccination in general practitioners and hospital doctors;
• To determine pneumococcal polysaccharide vaccine distribution and use in
primary care, hospital settings and nursing homes;






For health administration purposes, Scotland is divided into 15 National Health Service
boards (HB). These include Argyll and Clyde, Ayrshire and Arran, Borders, Dumfries
and Galloway, Fife, Forth Valley, Greater Glasgow, Grampian, Highland, Lanarkshire,
Lothian, Orkney, Shetland, Tayside and Western Isles. Scotland has an estimated
population of 5.1 million, which represents 8.6% of the UK population. The monitoring
and surveillance of pneumococcal disease in Scotland is carried out by the Scottish
Centre for Infection and Environmental Health (SCIEH) and the Scottish Meningococcus
and Pneumococcus Reference Laboratory (SMPRL), both located in Glasgow.
3.1.2. SCIEH and SMPRL
SCIEH operates as a national surveillance centre for monitoring infectious diseases and
environmental hazards. Reports from laboratories throughout Scotland are received
weekly at SCIEH. Before entering into an electronic dataset, these data are reviewed by a
consultant epidemiologist to ensure the accuracy of records. Laboratory reports of
pneumococcal disease from 1983 onwards are available in electronic format at SCIEH.
SMPRL has been established to provide an enhanced diagnostic and national surveillance
for pneumococcal diseases in 1992. It serves as the national reference laboratory for
pneumococcal disease, providing organism confirmation, serotyping and antibiotic
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susceptibility testing of pneumococcal isolates. All diagnostic laboratories are
encouraged to submit isolates from body fluids of patients with suspected pneumococcal
disease. However, it is likely that some laboratories only refer isolates thought to be
antibiotic resistant. To address this potential bias enhanced active pneumococcal
surveillance was established in Scotland in April 1999.
There were 29 to 33 laboratories which reported pneumococcal disease to SC1EH and
SMPRL between 1983 and 1999. An increase of 4 reporting laboratories occurred after
1994.
3.2. Population-based laboratory surveillance data
3.2.1. Laboratory records of pneumococcal isolates reported to SCIEH between 1988 and
1999 and the pneumococcal isolates submitted routinely to SMPRL between 1993 and
1999 from all diagnostic laboratories in Scotland have been combined in a single
database. Duplicate records of the same patients in SCIEH and SMPRL datasets were
identified by matching surname, date of birth, date of specimen, sex, and health board
(HB). They were excluded from the study. This dataset was used to examine the serotype
distribution in terms of disease presentation, susceptibility for penicillin and
erythromycin and the coverage of 23-valent and previous 14-vaient polysaccharide and 7-
, 9-, and 11 -valent conjugate vaccines for both invasive and non-invasive isolates
associated with disease and antimicrobial non-susceptibility. Because of the difficulty in
determining case ascertainment of non-invasive pneumococcal disease by current
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laboratory methods, the incidence of disease and the prevalence of penicillin and
erythromycin susceptibility were determined only for invasive isolates.
Recurrent disease was considered to be present if the pneumococcus was isolated from
the same patient more than 7 days after the initial episode 94,129 Demographic
information on age, sex, site of specimen with date were available in all laboratory
records but only limited data for clinical syndrome and outcome of illness.
Laboratory records of invasive pneumococcal, meningococcal, Haemophilus influenzae,
group B streptococcus (GBS) and Listeria monocytogenes isolates reported to SCIEH
only between 1983 and 1999 were also reviewed to determine the predominant pathogens
responsible for bacterial meningitis and INMD over the period 1983-99. We then
compared the data from the two periods, 1983-91 and 1992-99, before and after routine
use of Hib conjugate vaccine in October 1992 in Scotland.
The number of laboratories reporting cases of these five pathogens to SCIEH increased in
1983-99; from 29 to 33 for the pneumococcus and meningococcus, from 25 to 28 for
GBS and H. influenzae and from 15 to 22 for L. monocytogenes.
3.2.2. Case definitions
Isolation of pneumococci from a sterile body site was regarded as invasive disease. This
included blood, cerebrospinal fluid (CSF), joint or pleural fluid, bone marrow, lung
aspirate, pericardial fluid and bronchial aspirate. Bacterial meningitis was defined by the
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isolation of bacteria from CSF or blood and CSF. Isolates from blood or other normally
sterile site but not from CSF were regarded as INMD. Pneumococcal isolates from
sputum, nasopharynx, ear, eye, urine and other non-sterile sites were considered as non¬
invasive disease.
3.2.3. Culture technique used at SMPRL
The identification of pneumococci was performed by latex aggulutination.485
Pneumococcal isolates were serogrouped/typed by coagglutination testing,485 using
commercially available antisera from the Statens Serum Institut, Copenhagen, Denmark.
Additional factor serum was used to classify serotypes of certain serogroups. The Danish
system of nomenclature was used to classify serotypes.
Susceptibility testing was started for penicillin in 1992 and for erythromycin in 1994.
Minimal Inhibitory Concentrations (MICs) were determined by a standard agar dilution
method (incorporating the antibiotic into agar) from 1992 to 1993. The E-test (Cambridge
Diagnostics, Cambridge UK) was used from 1994 onwards. The breakpoints for
penicillin susceptibility were defined in accordance with the National Committee for
Clinical Laboratory Standards (NCCLS).231 Penicillin sensitivity, intermediate
resistance and high-level resistance were defined if isolates had an MIC of <0.06 pg/ml,
between 0.1 and 1 pg/ml and >2 pg/ml respectively. Isolates in the intermediate and
resistant categories were considered non-susceptible to penicillin. A single breakpoint
concentration (1 pg/ml) was used to classify susceptible and non-susceptible isolates for
erythromycin.
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3.2.4. Calculation of incidence of disease and antibiotic non-susceptibility
The appropriate denominators for calculation of all rates for disease and susceptibility for
penicillin and erythromycin of invasive isolates were obtained from the Office for
National Statistics (ONS) population projections, UK (http://www.statistics.gov.uk). The
midpoint year, 1993, was used for calculating the mean age and sex specific rates of
disease and antimicrobial non-susceptibility, for a combined pneumococcal dataset from
SCIEH and SMPRL between 1988 and 1999.
To calculate the age specific incidence of pneumococcal, meningococcal, H. influenzae,
GBS and L. monocytogenes cases in the SCIEH dataset, the two midpoint years, 1987 and
1996, were used for two time periods (1983-91) and (1992-99) before and after the
routine use ofHib vaccine.
3.2.5. Antibiotic prescription
Prescription data for penicillin, erythromycin and all other antimicrobial agents in
Scotland between 1992 and 1999 were collected from the Primary Care Unit, Information
and Statistics Division (ISD) of the Common Services Agency of the NHS in Scotland.
Rates for antibiotic prescribing were calculated per 100,000 population. The association
between the prevalence of antimicrobial non-susceptibility and antibiotic prescription rate
was examined in 15 HBs.
3.2.6. Statistical analysis
66
Study data were entered into "DataEase version 4.5" and exported to SPSS version 10
(SPSS Inc, Chicago, Illinois, US). Data analysis for serotypes distribution and their
relationships to disease and antimicrobial non-susceptibility was performed in SPSS. 95%
confidence intervals for coverage of polysaccharide and conjugate vaccines for invasive
disease causing serotypes in different age groups between 1993 and 1999 were calculated
in Stata (Stata Corporation, version 6.0, 1999, College Station, Texas). It was assumed
that serotypes in a serogroup were potentially cross-reactive (e.g. 6B vs. 6A). Analyses
are for complete years 1988-1999, with the exception of serotypes distribution for
invasive isolates, which is until August 1999 only.
Relative risk of disease incidence according to sex and corresponding 95% confidence
intervals were calculated using the CIA programme (Gardner SB, Winter PD, Gardner
MJ: London, 1991). Using SPSS, x2 test for trend and Pearson correlation coefficients
were used to determine associations between variables, including (1) the annual antibiotic
prescription rates for penicillin and erythromycin and their annual prevalence (2) overall
antibiotic prescription rates for penicillin and erythromycin and the prevalence of non-
susceptibility in HBs, and (3) the annual prescription rate of penicillin, erythromycin, all
antibiotics and the prevalence of penicillin non-susceptibility in age groups less than 5
years, 5-64 years and 65 years and above. P< 0.05 was regarded as statistically
significant.
3.2.7. Data protection issues
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Laboratory reports for patients who had invasive bacterial disease due to pneumococcal
or the other four pathogens were accessed by the author for the purpose of data analyses
only. These data were maintained in accordance with guidelines for patient
confidentiality at SCIEH and the Data Protection Act throughout the study period.
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3.3. Questionnaire surveys on the epidemiology of pneumococcal vaccination
practices
Pneumococcal polysaccharide vaccine is currently recommended for persons with certain
underlying medical conditions in the UK. Information on distribution and actual use of
pneumococcal vaccine in primary and hospital care settings is not clearly established in
Scotland. Little is known about vaccine indications, barriers for vaccine use, policies and
responsibilities for vaccination among clinicians. In addition, few data are available on
the reasons for receipt and non-receipt of vaccine among high-risk patients. A total of
four questionnaire surveys have been conducted to assess the epidemiological features of
pneumococcal polysaccharide vaccination in Scotland. The specific surveys were:
Survey 1. Opinions of general practitioners and hospital doctors on pneumococcal
polysaccharide vaccination;
Survey 2. Pneumococcal polysaccharide vaccine distribution and use along with
practices and policies in primary care and hospital settings;
Survey 3. Pneumococcal polysaccharide vaccine coverage, policies and reasons for
receipt and non-receipt of vaccine in nursing homes;
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Survey 4. Pneumococcal polysaccharide vaccine coverage and antibiotic prophylaxis
together with meningococcal polysaccharide vaccine, Hib conjugate vaccine and annual
influenza vaccine (1997, 1998, 1999 and 2000 years) in splenectomised patients;
3.3.1. Ethical approval and co-operation
Surveys 1, 2 and 3 did not require ethical approval. Nevertheless, permission was sought
from:
Survey 1: Clinical Medical Directors of hospitals, HDs and GPs.
Survey 2: The ISD Privacy Advisory Committee, Edinburgh, which decided that the
selection of 10 high-risk patients per CMR practice does not require
ethical approval, since the CMR system does not identify the names of
these patients.
Survey 3: The nurse in charge or care manager of nursing homes.
Survey 4: Permission was sought from the Director of Public Health in the 15 HBs to
access details of splenectomised patients in their area who were registered
at ISD (Appendix a). Agreement was obtained from 11 HBs. Approval




This survey included 800 current practising GPs and hospital doctors (HDs) who were
chosen to be representative of Scotland.486 fhe selection and identification of study
participants were carried out in September 1999. The names of 400 GPs along with their
demographical details were selected from a national database at the ISD of the Common
Services Agency, Edinburgh, using computerised random sampling (detail in Appendix
b).
Thirty National Health Service (NHS) hospitals were chosen systematically from the
NHS hospital directory based on their geographical locations to be representative of
Scotland. They were requested to supply details of 25 HDs including names, specialties,
grades or positions and corresponding addresses by sampling personnel records. A simple
random sample was performed using SPSS random function to select four hundred
doctors from 16 hospitals for the survey.
The study questionnaire was based on that of Berk and colleagues.487 A pilot study was
tested on 12 GPs and 12 HDs in October 1999. The questionnaire was then revised. In
November 1999, the modified questionnaire was sent to the 800 GPs and HDs. Non-
respondents received a reminder questionnaire after six weeks. They were requested to
give their views on a number of related issues: the target groups for vaccination, vaccine
safety and effectiveness, practice and policies, the source of their knowledge, and any
initiatives in place to enhance the use of PPV in their setting (Appendix c).
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3.3.3. Survey 2
The distribution of the number of doses of PPV used was reviewed for the whole of
Scotland between 1983 and 1999 and for general practices included in the "Continuous
Morbidity Recording" (CMR) system between 1993 and 1999. These data were obtained
from ISD.
The CMR practices included 53 general practices covering 5% of the population of
Scotland. The CMR system requires at least one diagnosis to be recorded at each face-to-
face contact between a GP and patient. The diagnoses are Read coded and all data are
internally linked to build up a continuous record for each patient. Information collected
through CMR system is considered to be representative of the Scottish population in
terms of sex, age, deprivation and rural/urban mix and geographic locations.486 Qn 1
April 1998, the CMR data became part of the national "core data set". Specific diagnostic
codes for chronic medical conditions were used to search for the number of at-risk
patients registered in the CMR practices. To avoid counting more than once for high-risk
patients, the identification of these patients was based on persons not GP consultations. A
questionnaire was sent to GPs in the CMR practices, which asked for the information
related to use of PPV.
For the survey, ten high-risk patients per CMR practice were selected and identified by
ISD similar to survey one (Appendix b). Since the CMR system is completely
anonymous, the names of the patients were not known. Nevertheless, the date of birth,
sex and postcode of these patients were available. This information allowed GPs to
72
identify them and their medical records. A pilot study, including 20 patients in two CMR
practices, was carried for the validity and suitability for the study design and
questionnaire. To compensate the time needed for reviewing and establishing the
vaccination status of high-risk patients, a set fee was offered to each GP. They were
asked to review the medical records to identify vaccination status, place of vaccination,
their views on vaccine indications, policies and responsibilities for vaccination
programme (Appendix d).
As in the previous report, '5 the number of doses of PPV dispensed per 10,000 population
was used to estimate the use of vaccine. The total number of persons recommended for
vaccination in Scotland was also estimated based on the number of registered high-risk
patients in the CMR practices. These figures made it possible to estimate the rate of
vaccination per 10,000 population for the whole Scotland and the coverage of vaccine in
the CMR practices. Data from the survey and vaccine distribution statistics also gave an
opportunity to check what proportion of distributed vaccines was actually used in
recommended patients in the CMR practices.
The Carstairs Deprivation Score^SS was usecj tQ determine the influence of deprivation
category of the patient's area of residence on the coverage of vaccine. The level of
deprivation was based on the postcode sector, which was categorised into 1 to 7, 1 being
the most affluent and 7 being the most deprived.
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3.3.4. Survey 3
ISD supplied the directory of all nursing homes in Scotland, which included home name,
the corresponding address and bed complement. There were a total of 550 licensed
nursing homes in the whole of Scotland in 2001 providing nursing care primarily to the
elderly. The questionnaire was piloted to 12 nursing homes and was amended as
necessary. All nursing homes were sent a reply-paid questionnaire on 12 June 2001 and
were requested to be completed by the nurse in charge or care manager. A reminder was
posted to those who did not respond to the initial questionnaire.
The questionnaire requested information on the number of residents, the number of
general practices looking after residents, the existence of immunisation records, coverage
of vaccine in residents, vaccination policies, the factors influencing coverage of vaccine,
and the reasons for receipt and non-receipt of vaccine (Appendix e). The latter two were
selected from a number of key reasons defined in a pilot study. Since information was
requested in an aggregated format, it was completely anonymous and did not permit the
identification of elderly individuals living in each nursing home.
3.3.5. Survey 4
Patients who underwent splenectomy between 1 January 1988 and 31 December 1998
were identified using the Scottish Morbidity Record (SMR01), which is recorded on
discharge from hospital for all episodes of inpatient or day-case care. It collects
information on demography and the clinical details of patients receiving hospital care.
These SMR01 records were linked to the Register General Office, Scotland, for death
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registrations, using probability matching as described in the previous report,489 to
identify the patients who had died.
GPs of all living patients were identified from Practitioner Services, which provide
administrative support and process payments to all Primary Care Practitioners on behalf
of Primary Care Trusts and Island Health Boards in Scotland. Since medical records of
deceased patients would not be available to GPs, they were excluded from the survey. A
pilot study was performed on GPs of 12 splenectomised patients to determine the
feasibility and validity of study design and questionnaire.
The appropriate changes were made before sending a questionnaire to GPs of all living
splenectomised patients. The questionnaire asked for the information on whether
splenectomy was performed as an elective or emergency, the status of antibiotic
prophylaxis and vaccination against pneumococcus, meningococcus, Hib and influenza
(Appendix f). A reminder was sent to those who did not respond after 6 weeks.
3.3.6. Data analysis
The chi-squared test was used to identify the significance of association between the
variables for pneumococcal polysaccharide vaccination in GPs and HDs. The Carstairs
Deprivation Score488 was usecj determine the deprivation index values of the patients'
area of residence relation to PPV coverage in at-risk patients in the CMR practices and
the coverage of vaccines and antibiotic prophylaxis in splenectomised patients.
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Since the data are non-Normally distributed, nonparametric tests were applied to the
survey of PPV coverage in elderly nursing home residents. In addition, Mann-Whitney
tests were used to compare median coverage where the covariate was binary and Kruskal-
Wallis tests were used when the covariate had more than two levels. P-value < 0.05 was





There were 6007 reports of invasive pneumococcal disease from a sterile body site
(see in section 3.2.2. for case definition) in the study period from 1988 to 1999. 2657
(44.2%) from the age group 65 years and above, 2186 (36.4%), 6-64 years, 734
(12.2%) <5 years and 430 (7.2%) of unknown age. The age of patients ranged from 0
to 99 years, with a median age of 54 years. 5456 (90.8%) were from blood, 467
(7.8%) from CSF and 84 (1.4%) from other sterile sites (joint or pleural fluid, bone
marrow, lung aspirate, pericardial fluid and bronchial aspirate). 3077 (51.2%) were
from males, 2758 (45.9%) females and 172 (2.9%) of unknown sex. Antibiotic
susceptibility testing against penicillin and erythromycin was performed in only
20.8% and 18.7% respectively.
4.1.2. Incidence of IPD
The overall mean annual incidence of IPD was 9.8/105 population between 1988 and
1999, with an increasing trend from 5.8 in 1988 to 12.6 in 1998 and to 10.8/103
population in 1999 (Figure la). The incidence of IPD has been relatively stable in the
last six years. The observed increase in the incidence of IPD was due to an increased
frequency of blood culture over this period, which increased from 248 isolates in 1988
to 510 isolates in 1999. The overall pattern of ratio of blood and CSF isolates also
increased over three-fold in the study period, from 5:1 in 1988 to 18:1 in 1999. No
increase was observed for CSF isolates (Figure lb).
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Figure la. Number of blood and all invasive isolates and incidence of invasive
pneumococcal disease in Scotland, 1988-99
1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998
Year






Figure lb. Number of invasive pneumococcal isolates (blood, CSF and all
invasive isolates) in Scotland, 1988-99
4.1.2.1. Relative importance of the pneumococcus to other pathogens
There were a total of 12108 cases of invasive bacterial disease caused by the
pneumococcus, meningococcus, H. influenzae, GBS and L. moncytogenes in the study
period, 1983-99. Of these, 2514(20.8%) were from CSF. The annual relative
contribution of meningitis and INMD due to these five pathogens from 1983 to 1999
is presented in Figures 2a and 2b. The proportion and incidence of meningitis and
INMD caused by these five pathogens between 1983-91 and 1992-99 are shown in
Table 16.
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Figure 2a. Proportion of bacterial meningitis caused by the five pathogens in
1983-99
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4.1.2.1.1. Age-specific incidence of invasive bacterial disease by pathogen
The age-specific incidence rates for meningitis and INMD varied with pathogens in
1983-91 and 1992-99 (Tables 17a-b). There was a 50% decrease (from 3.8 to 1.9 per
100,000 population) in the incidence of bacterial meningitis and a 30% increase (from
9.7 to 12.6 per 100,000 population) in the INMD in 1983-91 and 1992-99 caused by
these five pathogens. The pneumococcus was the most common cause of INMD and
the second most common cause of meningitis between 1983-91 and 1992-99. During
these two periods, the incidence decreased 12.5% (0.8 to 0.7 per 100,000 population)
for meningitis and increased 56% (5.5 to 8.6 per 100,000 population) for INMD
caused by the pneumococcus.
Those under the age of 5 years showed the greatest increase in the proportion of cases
of meningitis and INMD due to the pneumococcus between the periods 1983-91 and
1992-99. An increase of 2 to 3-fold in the proportion of bacterial meningitis due to the
pneumococcus was noted in age groups, less than 1 year and 1-4 years. The
proportion of INMD disease caused by the pneumococcus also increased in all age
groups except for the 5-24 years age group. A substantial proportion of bacterial
meningitis in each period (63.6% and 82.8% respectively) and (78% in the second
period) and INMD was caused by the pneumococcus in the elderly, (67% in the first
period and 78% in the second) respectively.
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The incidence of IPD (bacteraemia and meningitis) was higher in males than females.
The overall incidence for bacteraemia was 9.4/105 in males and 8.1/105 population in
females (male:female = 1.2:1) (RR = 1.17, 95%CI 1.11, 1.24) for bacteraemia. The
overall incidence for meningitis in males and females was 0.9/105 and 0.6/103
population (male:female = 1.5:1) (RR = 1.41, 95%CI 1.18, 1.70). There was a higher
incidence of bacteraemia in males than females for all age groups except 10-14 years
(Figure 3a). The incidence of pneumococcal meningitis was also higher in males than
females for all age groups except in adults 35-44 years, 55-74 years and 85 years and
above (Figure 3b). The annual incidences of bacteraemia and meningitis were also
higher in males than females between 1988 to 1999 (except for years 1993 and 1996
for meningitis and 1994 for bacteraemia).
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Figure 3a. Incidence of pneumococcal bacteraemia by age group in Scotland,
1988-99
5 20
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Age group (Year) □ Males
□ Females
Figure 3b. Incidence of pneumococcal meningitis by age group in Scotland,
1988-99
2-4 5-9 1 0-14 1 5-24 25-34 35-44 45-54 55-64 65-74 75-84 >_ 8 5




The highest incidence of IPD occurred in infants aged less than two years, 44.9/105
persons and the elderly aged 65 years and above, 28.4/105 persons (Figure 4). The
incidence for bacteraemia was 9/105 population in all ages but increased to 33.1/105
persons infants aged less than two years and to 27.5/105 persons in the elderly, 65
years and above. Marked increases in bacteraemia were observed in infants, from 16.9
in 1988 to 47.4/105 persons in 1999, and the elderly, from 14.5 in 1988 to 31.2/105
persons in 1999.
The number of blood isolates increased in different age groups from 1988 to 1999;
from 20 to 56 in less than 2 years, from 26 to 66 in 5 years and less, from 99 to 192 in
5-64 years, and from 114 to 245 in 65 years and above. An overall trend towards on
increased ratio for blood to CSF isolates was also observed from 1988 to 1999 for
these age groups, with the corresponding figures of from 2.2:1 to 2.8:1, from 2.9:1 to
3:1, from 3.7:1 to 10.7:1 and from 12.7:1 to 28.7:1. However, there was no increase in
the number of CSF isolates in age groups, less than 2 years, less than 5 years, 5-64
years and 65 years and above in the study period.
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The incidence ofmeningitis was 0.8/105 population at all ages. The highest incidence
was noted in children aged less than two years, 11.8/105 persons, but decreased
substantially to 0.4/105 persons in age group, two to four years. The incidence of
meningitis ranged from 0.4 to 1.2/103 persons in aged 65 years and above.
4.1.5. Seasonal variation
A seasonal trend in the occurrence of IPD was observed. Data aggregated in three-
month periods over the study period showed that the number of cases consistently
peaked in the first three months of the year. This pattern coincided with the clear
seasonal pattern of influenza activity reported to SCIEH by laboratory records (Figure
5).
88
Figure 5. Seasonal pattern of laboratory reports of influenza and invasive
pneumococcal isolates by 3-month period, Scotland, 1988-99
800





The overall proportion of non-susceptibility was 8.6% for penicillin in 1992-99 and
9.6% for erythromycin in 1994-99 among invasive isolates tested for antibiotic
susceptibility. Penicillin non-susceptible isolates increased from 1 (4.2%) in 1992 to
21(12.6%) in 1999 (p = 0.0004) and erythromycin resistant isolates from 7 (5.6%) in
1994 to 27 (16.3%) in 1999 (p = 0.0015) (Figure 6). Only 2 cases of penicillin-
resistant pneumococci were reported (in 1998).
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Figure 6. Proportion of penicillin (1992-99) and erythromycin (1994-99) non-
susceptible isolates among all invasive pneumococcal isolates
4.1.7. Age-specific antibiotic susceptibility
There was an inconsistent increase in the proportion of penicillin non-susceptible
invasive isolates in age groups, less than 5 years, 5-64 years and 65 years and above
between 1992 and 1995 but an increase trend was observed from 1996 onwards in
these three age groups (Figures 7a-c). The overall prevalence of penicillin non-
susceptible isolates was 3.7% in age group less than 5 years, 7.3% in age group 5-64
years and 8.6% in age group 65 years and above.
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Figure 7a. Prevalence of penicillin non-susceptible pneumococcal isolates in age
group less than 5 years, 1992-99
3.5
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Figure 7b. Prevalence of penicillin non-susceptible pneumococcal isolates in age
group 5-64 years, 1992-99





Figure 7c. Prevalence of penicillin non-susceptible pneumococcal isolates in age
group 65 years and above, 1992-99
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4.1.8. Antibiotic susceptibility and antibiotic prescribing
Geographical variations in the proportion of penicillin non-susceptibility correlated
marginally with penicillin prescribing rates in each health board (Pearson correlation,
r = 0.52, p = 0.05). No correlation was documented for erythromycin prescription rate
and the incidence of erythromycin non-susceptible isolates (r = 0.385, p = 0.16)
(Table 18). A scatter plot was constructed before the assessment for these
correlations.
A statistically significant correlation was noted between the prevalence of pencillin
non-susceptible isolates and the annual rates of penicillin, erythromycin and all
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antibiotics dispensed in Scotland in 1992-1999 for age groups less than 5 years (p =
0.004, 0.002 and 0.009, respectively) and 65 years and above (p= 0.021, 0.026 and
0.013 respectively). However, in the age group 5-64 years, a correlation was
documented between the prevalence of penicillin non-susceptibility and the rate of
erythromycin prescription (p= 0.013), but not for pencillin (p = 0.153) and all
antibiotics prescription (p = 0.056).
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4.2. Pneumococcal polysaccharide vaccination surveys
Although PPV has been available for use in the UK since 1979, the UK Joint
Committee on Vaccination and Immunisation (JCV1) did not recommend its use in
high-risk groups until 1992. This section presents the data on the epidemiological
characteristcs of PPV distribution and use in Scotland based on the four questionnaire
surveys. These involve:
4.2.1. Survey 1: Opinion of general practitioners (GPs) and hospital doctors
(HDs)
This survey was conducted to determine GPs and HDs knowledge, attitudes and
practices in relation to pneumococcal polysaccharide vaccination in order to identify
the barriers that may affect vaccine use.
Of the 800 questionnaires sent out, 504 (63%) were returned. Of these, 20 were
unanswered because the intended recipient had moved or did not want to participate.
Of the 484 (60%) completed questionnaires, 286 (59%) were from GPs and 198
(41%) from HDs. The characteristics of respondents by healthcare setting are shown
in Table 19.
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Table 19. Characteristics of questionnaire respondents
General practitioners (n=286) Number (%)
Patient population
Mean number of patients per practice 5127


























4.2.1.1. Target groups and knowledge of vaccine
The respondents' views on pneumococcal vaccination in various high-risk conditions
are shown in Table 20. Splenic dysfunction and older age were considered to be the
most and the least important indication for vaccination, respectively.
Table 20. Views of respondents on indications for pneumococcal polysaccharide
vaccination in various high-risk patient groups, by level of agreement
General practitioners (GPs) (n= 286)
Hospital doctors (HDs) (n=198)
Risk conditions Respondents Strongly Agree Disagree Strongly Don't Not
agree % % % disagree know Reported
% % %
Splenic dysfunction* GPs 80 19 0 1 0 0
HDs 67 14 2 1 16 0
Chronic pulmonary GPs 59 36 1 I 2 1
disease*
HDs 34 40 5 1 20 0
Immunocompromised* GPs 51 33 5 1 8 2
HDs 36 32 6 22 1
Chronic heart disease* GPs 39 39 11 1 9 1
HDs 21 40 11 1 27 0
Chronic renal disease* GPs 36 40 10 1 13 0
HDs 20 35 10 1 33 1
Diabetes mellitus* GPs 36 40 10 1 13 0
HDs 14 38 15 1 32 0
Chronic liver disease* GPs 30 39 13 1 16 1
HDs 17 39 11 1 31 1
Elderly (>65 years) GPs 15 34 28 5 16 2
(residents of long stay
facility)
HDs 13 39 18 3 25 2
All elderly >65 years GPs 16 31 32 8 12 1
HDs 10 36 22 4 27 1
* Currently recommended by the UKDepartments ofHealth
HDs were less likely than GPs to agree on the need for vaccination in the high-risk
conditions currently recommended by the Department of Health (DoH). They were
also more likely to be uncertain whether the risk condition cited was an indication for
vaccine recommendation.
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Knowledge of vaccine safety and effectiveness for the patient categories given was
suboptimal among respondents (Table 21).
Table 21. Views of respondents on pneumococcal polysaccharide vaccine safety
and effectiveness in preventing invasive pneumococcal disease, by patient group,
by level of agreement
General practitioners (GPs) (n = 286)


















GPs 28 46 5 2 18 1
HDs 17 38 4 1 38 2
Adults with chronic GPs 25 60 3 1 11 0
heart/pu 1monary/renal/
liver/diabetic disease
HDs 13 40 4 1 42 0














Young adults GPs 22 39 7 4 28 0
HDs 16 34 7 3 40 0
4.2.1.2. Usage
A majority of HDs (79%) had never used the vaccine compared with only 17% of GPs
(Figure 8). There was no difference in use of vaccine between specialities or grades of
HDs.
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Frequency of vaccine use
Number of respondents: GPs = 282. HDs =196
□General practitioners (GPs)
■Hospital doctors JHDs)
Although statistically not significant, GPs in rural areas and in group practices used
more vaccines than single practices and GPs in urban areas (rural = 35/40 (88%) vs
urban = 199/242 (82%), p = 0.55) (group practices = 199/235 (85%) vs single
practices = 35/47 (74%), p = 0.09).
4.2.1.3. Attitudes and practices
A total of 53% of GPs and 41% of HDs indicated that they would use both influenza
and pneumococcal polysaccharide vaccines if an elderly person requested a vaccine
against pneumonia (Figure 9). Although influenza vaccine alone would be
recommended by 36-40% of GPs and HDs, less than 10% would agree to give PPV
alone. GPs in urban areas were more likely to offer both pneumococcal
polysaccharide and influenza vaccines (rural = 21/117 (18%) vs urban = 125/141
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(89%), p = 0.0001) and those in rural areas were more likely to use influenza vaccine
alone (rural = 96/117 (82%) vs urban = 16/141 (11%), p = 0.0001).








Number of respondents: GPs =277, HDs =172
□ General practitioners (GPs)
0 Hospital doctors (HDs)
Although not statistically significant, use of vaccine varied with practice type. GPs in
group practices were more likely to recommend influenza vaccine alone (group
practices = 99/216 (46%) vs single practice = 13/42 (31%), p = 0.08) or both
pneumococcal polysaccharide and influenza vaccines (group practices = 117/216
(54%) vs single practices = 29/42 (69%), p = 0.08) than those in single practices.
Usage of vaccine among HDs did not vary with their grade and specialty.
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4.2.1.4. Policies and responsibilities
The presence of policies for pneumococcal vaccination in the respondent's setting is
presented in Figure 10. A majority of respondents indicated no pneumococcal
vaccination policy in the clinical setting. Only 3% of GPs had a policy, which
included a set target.
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No policy Do not know
Number of respondents: GPs =276, HDs = 165
□ General practitioners (GPs)
@ Hospital doctors (HDs)
Policies for pneumococcal vaccination were associated with general practice type and
location with GPs in urban areas (rural = 25/41 (61%) vs urban = 113/226 (50%), p =
0.19) and group practices (group practices = 124/229 (54%) vs single practices =
23/47 (49%), p = 0.51) more likely to have some form of pneumococcal vaccination
policy than those in rural and single practices.
Views on the primary responsibility for pneumococcal vaccination among
respondents are displayed in Figure 11. The majority (over 70%) of GPs and HDs felt
that the primary responsibility for pneumococcal vaccination should be placed with
GPs, followed by the DoH and the HBs.
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Figure 11. Views on the primary responsibility for pneumococcal polysaccharide
vaccination
90
GPs Department Health Hospital Patients Do not know
of Health Boards doctors
Primary responsibility of :
Number of respondents: GPs = 478, HDs = 356
□ General practitoners (GPs)
|g] Hospital doctors (HDs)
4.2.1.5. Source of knowledge and strategies for improving vaccine coverage
Discussion with colleagues, personal review ofmedical literature, past experience and
the DoH constituted the most frequently stated main sources of information on PPV
both among GPs and HDs (Table 22). Consultants and specialist registrars mostly
acquired knowledge of PPV from past experience and further education whereas HDs
in other grades gained from other categories.
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Table 22. Sources of knowledge about pneumococcal polysaccharide vaccine







Discussion with colleagues 43 27
Own review of medical literature 38 33
Past experience 27 26
Department of Health 27 32
Health Boards 22 27
Further medical education 22 28
Advice from manufacturer 14 5
Do not know 5 7
* Can answer more than one category
Most GPs and HDs (80%) considered a clear immunisation policy to be a key strategy
for improving vaccine coverage in high-risk patients, followed by financial support
for vaccination, promoting public health pneumococcal vaccination campaigns and a
computerised system to identify persons with definite indications for the vaccine
(Table 23).
Table 23. Strategies to improve pneumococcal polysaccharide vaccine coverage:







A clear immunisation policy 87 80
Financial support for vaccination 72 54
Computerised systems to identify high-risk patients 49 47
Vaccine awareness public health campaign 46 46
Further education on immunisation 32 44
Conclusive evidence of vaccine efficacy 22 30
Nurse assistant 18 16
Do not know 5 3
* Can answer more than one category
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4.2.2. Survey 2: Pneumococcal polysaccharide vaccine distribution and use in
primary care and hospital care settings
Currently PPV is recommended for patients aged two years and above with with
splenic dysfunction, chronic heart, lung, liver and renal diseases, diabetes and
immunocompromised conditions in the UK.458 surVey was carried out to
examine the distribution patterns and actual use of PPV among high-risk patients in
primary care and hospital care settings. In addition, views on vaccine indications,
policies and responsibilities for pneumococcal polysaccharide vaccination among GPs
in the CMR practices were examined.
There was a significant increase in the annual distribution of PPV in Scotland in
1984-99 (Figure 12) and in the CMR practices in 1993-99 (Figure 13). Of the 53
questionnaires posted to GPs within the CMR practices, the completed questionnaire
was returned by 84.9% (45/53) of GPs. The selected high-risk patients included in the
questionnaire survey divided into 8 groups (Table 24).
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Figure 12. Annual number of pneumococcal polysaccharide vaccine doses
distributed per 10,000 population in Scotland, 1984-99
Year
Vaccine prescription data obtained from the Information and Statistics Division of the Common
Services Agency, Edinburgh, Scotland
Figure 13. Number of doses of pneumococcal polysaccharide vaccine dispensed
in the 53 CMR practices, 1993-99
1993 1994 1995 1996 1997 1998 1999
Year
i i Dose distributed per 10,000 population
—♦— Num ber of doses dispensed
Vaccine prescription data obtained from the Information and Statistics Division of the Common
Services Agency, Edinburgh, Scotland
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4.2.2.1. Distribution and vaccine coverage
No vaccine distribution occurred until 1991. Rates of annual vaccine distribution
increased from 0- to 63-doses/104 population during the period 1991-99 for the whole
of Scotland (Figure 12). Only 1 to 7 doses/104 population were dispensed during the
period 1992-1996. There was a substantial growth after 1996, from 30 in 1997 to 63
doses/104 population in 1999, following with the publication of the DoH
recommendations for pneumococcal polysaccharide vaccination in 1996. Rates of
vaccine distribution also rose from 1.9 in 1993 and to 68.1 in 1998 and to 50.1 in
1999 doses/104 population in the CMR practices (Figure 13).
Vaccine coverage reported in the questionnaire was 13% among patients
recommended for the vaccine by the DoH. Variations in coverage of vaccine were
noted in the eight risk categories, with lower coverage in patients with chronic renal
disease and chronic pulmonary disease and higher coverage in the elderly (Table 24).
4.2.2.2. Views on vaccine indications
Views on vaccine indications among GPs are shown in Figure 14. Most GPs
considered asplenic conditions (76%) and chronic pulmonary disease (70%) as the
most important indications for vaccination. However, the elderly (including those
living in long -term care facilities) were stated to be an indication for vaccination by
only 13% ofGPs.
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Figure 14. Views on pneumococcal polysaccharide vaccine indications
80
Indications for vaccine
4.2.2.3. Vaccination responsibility and policies
The groups with primary responsibility for vaccination as reported by questionnaire
respondents are presented in Figure 15. A higher proportion of GPs (55%) believed
that the responsibility for vaccination should lie with GPs. Vaccine use was not
significantly related to views concerning the group with primary responsibility for
vaccination (28/263 (11%) vs 24/151 (16%), p = 0.126).
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The existence of vaccination policies among GPs is shown in Figure 16. Only 11% of
GPs reported that they had a pneumococcal vaccination policy with or without a set
target. Many GPs (45%) reported that they had verbal agreement on its use among
partners.
Figure 16. Policies for pneumococcal polysaccharide vaccination
W ritten policies





N o po licy
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4.2.2.4. Estimated high-risk patients and required immunisations
Table 25a shows the total numbers of high-risk patients in the 53 CMR practices.
Using these data and vaccine prescription statistics, the cumulative vaccine coverage
in 1993-99 was calculated only for the CMR practices. Coverage of PPV was 23.4%
(5889/25120) among persons with high-risk conditions recommended by the DoH and
8.3% (5889/70615) among all high-risk conditions (including all elderly aged 65
years and above).
Table 25a. Number of patients with indications for pneumococcal polysaccharide
vaccination in the CMR practices and estimated number of required
vaccinations in Scotland






for the whole of Scotland
Chronic liver disease 265
Chronic pulmonary disease 13,696
Chronic renal disease 318
Diabetes 3,991 418,646
Chronic heart disease 6,684
Immunosuppression/immunodeficiency 41
Asplenia 125
Table 25b. Estimated vaccine coverage in the elderly in the CMR practices and
the whole of Scotland
Number of required pneumococcal
polysaccharide vaccinations for the
elderly
CMR practices only The whole of Scotland
Elderly 65 years of age and above





* DoH recommendations for pneumococcal polysaccharide vaccination include all listed high-risk
conditions except the elderly
** Patients are based on person (patients with two high-risk conditions = 1374, three high-risk
conditions = 78 andfour high-risk conditions = 2)
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The estimated total numbers of high-risk patients (with and without the elderly) or
required pneumococcal immunisations for the whole of Scotland was also projected
based on the total of high-risk patients registered in the CMR practices (Table 25a/b).
4.2.2.5. Place of vaccination
The majority of pneumococcal vaccination (94.2%) took place in general practice.
Very few patients (3.8%) had received pneumococcal vaccination at home. Only 2%
of pneumococcal vaccination occurred in hospital care settings.
4.2.2.6. Socio-economic status in relation to vaccine coverage
The coverage of pneumococcal vaccination differed by deprivation status categories
of residence of patients (Table 26). A statistically significant association between
deprivation category and vaccination was noted (p = 0.01, yf for trend = 6.5) but
trend not easy to interpret.
Table 26. Level of pneumococcal polysaccharide vaccine coverage in relation to
deprivation category
Deprivation Pneumococcal vaccine
Category* No (%) Yes (%)
1 15 (4.3) 4 (8) 19
2 43 (12.3) 7 (14) 50
3 90 (25.6) 22 (44) 112
4 132 (37.6) 13 (26) 145
5 24 (6.8) 2 (4) 26
6 38 (10.8) 2 (4) 40
7 9 (2.6) (0) 9
P = 0.01, x2for trend = 6.5) 351 (100) 50 (100) 401
Carsiairs deprivation index which is based at postcode sector ofpatients' area ofresidence.lt is the
most common type ofdeprivation indicator used in the Scottish Health Service. * 1 being the most
affluent and 7 being the most deprived
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4.2.3. Survey 3: Characteristics of pneumococcal polysaccharide vaccination in
nursing homes
Although influenza vaccine is recommended for all elderly aged 65 years and above
and persons in long-term care facilities, PPV is not yet recommended for these
vulnerable groups in the UK. There are limited data on coverage and policies of
pneumococcal polysaccharide vaccination in UK nursing homes. The reasons for
receipt and non-receipt of vaccine in the elderly home residents are poorly
understood. This survey was conducted to determine PPV coverage, policies and the
factors associated with use and receipt of vaccine in Scottish nursing homes.
Of the 550 nursing homes surveyed, 394 homes (72%) responded to the questionnaire.
The mean size of home was 46 residents. The number of general practices looking
after residents ranged from 1 to 24 practices, with a mean of 5 practices. The presence
of systematic immunisation records, defined as completed documentation of
immunisation history, was reported by 6% (23/394) of nursing homes.
There were no significant differences in median pneumococcal vaccination rates for
the following covariates: areas of Scotland by Health Boards (p=0.37, Kruskal-Wallis
test), the presence of systematic immunisation record (p=0.55), the number of GPs per
home (<5 GPs=0% vs. >5 GPs=0%, p=0.10 respectively).
No significant association between the number of residents and the median
vaccination rates was found for PPV (<30 residents vs 31-50 residents vs >51
residents, P=0.71, Kruskal-Wallis test). There was a significantly higher median
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coverage of PPV in nursing homes with a pneumococcal vaccine policy compared
with those who did not have one (P=0.007).
4.2.3.1. Vaccine coverage
Of the 394 homes returning the questionnaire, information on vaccine coverage of
pneumococcal vaccination was provided by only 142 homes. Thus, vaccine coverage
was calculated based on the appropriate denominators (homes reporting data on
vaccine coverage). Overall, vaccine coverage was 11 % for PPV in the last five years
among 13,700 residents. Less than 5% PPV coverage among residents was
documented in 74% of nursing homes (Table 27).
Table 27. Pneumococcal polysaccharide vaccine coverage among nursing homes,
which provided information on vaccination
Percentage of residents received
pneumococcal polysaccharide vaccine








4.2.3.2. Strategies for improving vaccine coverage
The most frequently reported strategies for having improved coverage of PPV were a
clear immunisation policy (76%), awareness and education of staff and residents
(68%) and consent on behalf ofmentally incompetent residents (66%) (Figure 17).
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Figure 17. Factors considered important for improving pneumococcal
polysaccharide vaccine in nursing homes
4.2.3.3. Vaccination policies
Of the 394 responding homes, 42 (10%) nursing homes had a vaccination policy for
PPV in one form or another including verbal agreement (3%), written policies with set
target (5%) and written policies without set target (2%) (Figure 18).
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Figure 18. Policies on pneumococcal polysaccharide vaccination in nursing
homes*
Verbal agreement Written policies No policy Written policies Others
among partners with set target without set target
Policies
* Percentages do not add up to 100% because respondent rate for this question was
25%
4.2.3.4. Main reasons for receipt and non-receipt of pneumococcal
polysaccharide vaccine
The most common reasons for receipt of PPV were advice from community doctors
and nurses (20%), nursing home policies and guidelines (12%) and efficacy against
respiratory infection (13%) (Figure 19).
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The main reasons for non-receipt of PPV were that it was not recommended by their
GPs (19%) and refusals by residents (15%) (Figure 20).






4.2.4. Survey 4: Vaccination in splenectomised patients
This survey identified the coverage of preventive measures in splenectomised patients
in Scotland from 1988 to 1998. These include antibiotics, polysaccharide
pneumococcal, meningococcal and conjugate Hib vaccines.
Of the 1648 patients who underwent splenectomy during the study period 1988-1998,
974 were alive in 2001. Of these alive patients, information on vaccination status was
available for 708 (73%) of patients. There was a higher coverage of PPV (622/708,
88%) and Hib conjugate vaccine (468/664, 70%) than meningococcal polysaccharide
vaccine (317/619, 51%) in these patients (Table 28).
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All cases (pre- or post-operation)
Two weeks prior to elective operation
622/708 (88)
153/541 (28)
Hib vaccine only All cases (pre- or post-operation)





All cases (pre- or post-operation)
Two weeks prior to elective operation
317/619 (51)
48/335 (14)














All cases (pre- or post-operation)





All cases (pre- or post-operation)





All cases (pre- or post-operation)






All cases (pre- or post-operation)






All cases (pre- and post-operation) for







All cases (pre- and post-operation) for
vaccines and post-operation for antibiotic
prophylaxis
201/571 (35)
* Main Department of Health (DoH)^^° and British Committee for Standards in Haematology
(BCSH)613 recommendations includepneumococcal and Hib vaccine and antibioticprophylaxis
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All three vaccines were received by (269/576, 47%) of the patients. Vaccination status
prior to elective splenectomy was recorded for 541 (56%) of the patients. Coverage of
PPV (153/541, 28%) was higher than that of Hib (83/435, 19%) or meningococcal
polysaccharide vaccine (48/335, 14%) for elective splenectomy. All three vaccines
were received by 13% (38/291) of the patients.
There was an increasing trend in coverage of influenza vaccine between 1997 and
2000, from 76% in 1997-1998 season to 96% in 2000-2001 season. Of the 770 (79%)
patients in whom antibiotic status was recorded, 518 (67%) received antibiotic
prophylaxis. Coverage was 35% (201/571) for all three vaccines and antibiotic
prophylaxis and 52% (333/634) for pneumococcal and Hib and antibiotic prophylaxis.
4.2.4.1. Preventive measures in relation to deprivation status category of
residence of patients
There were no significant trends in the deprivation status category values for coverage
of vaccine with (p=0.12) or without antibiotic prophylaxis for combination of
pneumococcal and Hib vaccine (p=0.14). Similar findings were recorded for
combination of pneumococcal, meningococcal and Hib vaccine with (p=0.07) or
without antibiotic prophylaxis (p=0.08). Nor did influenza vaccine coverage relate to
the deprivation index (Fisher's exact test, p= 0.46).
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4.3. To estimate coverage of pneumococcal vaccine for serotypes associated with
disease and antibiotic non-susceptibility
4.3.1. Invasive serotypes distribution
Serotype information was available for 1531 isolates. 1426 (93.1%) had their serotype
recorded between 1993-99, following the establishment of the SMPRL in 1992/93. Of
the invasive isolates with serotypes information, 14.2% were from those under two
years of age, 16.1% from aged five and less, 32.7% from age group 5-64 and 37.4%
from aged 65 and above. Antibiotic susceptibility was tested on 1248/1531 (81.5%) of
isolates for penicillin and on 1125/1531 (73.5%) of isolates for erythromycin.
The distribution among the 15 HBs in Scotland of isolates whose serotypes/groups
were determined was as follows: Greater Glasgow, 428; Lothian, 400; Lanarkshire,
235; Grampian, 120; Ayrshire and Arran, 88; Argyll and Clyde, 60; Forth Valley, 53;
Tayside, 51; Highland, 44; Borders, 20; Fife, 13; Dumfries and Galloway, 12;
Western Isles, 4; Orkney and Shetland, 0; and unknown area, 3.
4.3.1.1. IPD related serotypes
The most common serotypes were 14, 6, 19, 23, 9, 18, 7, 4, 3, 1 and 8 but varied in
their orders among different age groups (Table 29). These serotypes were responsible
for over 80% of all invasive pneumococcal isolates in all ages. Overall, type 14 was
the most prevalent serotype, accounting for 10-32% of invasive isolates in all age
groups except for the 5-64 years age group. Serotype 1 was the most prevalent in age
group 5-64 years and caused 13% of invasive isolates.
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The prevalence of most common serotypes varied year to year of the period 1993-99
(Table 30). Notably, there has been an increase in the proportion of serotype 14 over
the study period.
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Table 30. Most prevalent (11) serotypes: annual variation, 1993-99
Number of isolates
Serotypes 1993 1994 1995 1996 1997 1998 1999 Total
1 15 22 16 23 11 11 7 105
3 11 16 15 14 20 9 6 91
4 13 9 20 12 10 10 11 85
6 22 17 17 24 13 18 17 128
7 8 12 14 4 13 9 3 63
8 10 12 6 6 11 7 8 60
9 19 11 19 21 12 30 24 136
14 21 31 26 35 29 52 50 244
18 4 10 5 3 3 8 1 34
19 21 20 18 15 15 23 20 132
23 14 23 13 17 14 13 26 120
Others 30 46 32 32 30 27 31 228
Total§ 158 183 169 174 151 190 173 1198
Total* 188 229 201 206 181 217 204 1426
* = All total serotypes in each year, § = A total oftop 11 serotypes in each year
4.3.1.2. Penicillin/erythromycin non-susceptibility related serotypes
The distribution of penicillin and erythromycin susceptible and non-susceptible
serotypes is shown in Table 31. Serotype 14 was reported in two high-level penicillin
resistant blood isolates. It also accounted for 20.6% of all penicillin non-susceptible
isolates and 75% of all erythromycin non-susceptible isolates. Serotypes 6, 9, 14, 19
and 23 were responsible for 94.3% penicillin non-susceptibility and for 99.1%
erythromycin non-susceptibility.
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MIC ST CSF Blood Others Total MIC ST CSF Blood Others Total
1 3 90 4 97 1 2 74 5 81
2 - 6 - 6 2 - 6 - 6
3 7 67 6 80 3 8 56 5 69
4 7 69 3 79 4 6 53 3 62
5 - 1 - 1 5 - 2 - 2
6 17 66 3 86 6 13 63 4 80
7 5 51 1 57 7 5 43 1 49
8 8 45 1 54 8 7 38 1 46
S 9 8 83 1 92 S 9 7 88 81 176
10 - 9 1 10 10 - 8 - 8
11 3 23 1 27 11 2 20 - 22
12 5 24 - 29 12 4 21 - 25
13 - 2 - 2 13 - 1 - 1
14 25 151 9 185 14 5 83 8 96
15 1 14 1 16 15 1 12 - 13
16 1 5 - 6 16 1 4 - 5
17 1 3 - 4 17 1 3 - 4
18 10 23 - 33 18 7 18 - 25
19 11 89 3 103 19 9 79 5 93
20 - 15 - 15 20 - 14 - 14
21 - 1 - 1 21 - 1 - 1
22 5 28 - 33 22 5 22 - 27
23 14 65 5 84 23 10 62 6 78
24 2 3 - 5 24 1 3 - 4
27 - - 1 1 27 - - 1 1
29 - 4 - 4 29 - 4 - 4
31 1 6 - 7 31 1 5 - 6
38 1 9 - 10 38 1 6 - 7
34 - 3 1 4 34 - 3 1 4
35 - 3 - 3 35 - 2 - 2
38 - 5 - 5 38 - 4 - 4
41 - 1 - 1 41 - 1 - 1
42 - 1 - 1 42 - 1 - 1
Total 135 965 41 1141 96 800 121 1017
1 - - 1 1 1 - - - -
3 1 1 1 3 3 - - - -
4 - - - - 4 - 1 1
5 - 1 - 1 5 - - -
6 - 19 3 22 6 - 10 2 12
I 8 - 1 - 1 R 8 - - - -
9 1 23 9 33 9 - 3 2 5
14 - 18 2 20 14 16 63 2 81
15 - 1 - 1 15 - - - -
19 - 8 2 10 19 1 4 - 5
23 - 9 3 12 23 - 3 1 4
29 1 - 1 29 - - - -
Total 2 82 21 105
R 14 - 2 - 2
Total - 2 - 2 Total 17 | 84 7 108
S = sensitive isolates, I = intermediate isolates, R = resistant isolates= non-susceptible = intermediate
and resistant, ST = serotypes
MIC = minimum inhibitory concentration
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4.3.2. Potential coverage of vaccine for invasive isolates
4.3.2.1. By age group
The 14- and 23-valent PPV covered more than 88.4% and 96.4% of invasive isolates,
respectively, in all ages. Serotypes in the 7 to 11-valent PCV caused between 82%
and 93% of invasive disease in age group 5 years and less but a lower percentage in
the older age groups (Table 32). The marked annual variation in coverage ofPCV was
noted in different age groups in 1993-99 (Table 33).
Table 32. Vaccine coverage of pneumococcal serotypes in different age groups
Number of vaccine related isolates (%)
Vaccine <2 vears <5 years 5-64years >65years All ages
No. (%) No. (%) No. (%) No. (%) No. (%)
23§ N/A N/A 244 (99.2) 475 (95) 550 (96) 1476 (96.4)
14+ N/A N/A 232 (94.3) 427 (85.4) 481 (83.9) 1354 (88.4)
lit 201 (92.6) 226 (91.9) 379 (75.8) 440 (76.8) 1221 (79.8)
911 187 (86.2) 210 (85.4) 313 (62.6) 366 (63.9) 1047 (68.4)
7± 182 (83.9) 201 (81.7) 247 (49.4) 331 (57.8) 931 (60.8)
Total 217 (100) 246 (100) 500 (100) 573 (100) 1531 (100)
§ 23-valentpolysaccharide vaccine, t 14-valent vaccine (not in use), J 11-valent conjugate vaccine,
1 9-valent conjugate vaccine, ±7-valent conjugate vaccine
N/A = not applicable (polysaccharide vaccines are not recommend for children under two years of
age)
4, 6B, 9V, 14, 18C, 19F, 23F
1, 4, 5, 6B, 9V, 14, 18C, 19F and 23F







1, 2, 3, 4, 6A, 7F, 8, 9N, 12F, 14, 18C, 19F, 23F and 25
1,2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F,
19A, 19F, 20, 22F, 23F and 33F
8C,
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4.3.2.2. By antibiotic susceptibility
The 14- and 23-valent PPV serotypes covered over 86% of penicillin and
erythromycin susceptible isolates respectively (Table 34). Both polysaccharide
vaccines covered over 98% penicillin and erythromycin non-susceptible isolates. The
7, 9- and 11-valent PCVs included 57 to 79% of penicillin and erythromycin
susceptible isolates. Above 94% coverage with all conjugate vaccines was noted for
penicillin and erythromycin non-susceptible isolates.
Table 34. Penicillin and erythromycin susceptible and non-susceptible



















*»§ 1100 (97.3) 104 (99.0) 2 (100) 1206 (96.6) 910 (96.3) 108 (100) 1018 (96.7)
14+ 985 (86.3) 103 (98.1) 2 (100) 1090 (87.3) 813 (86.0) 108 (100) 921 (87.5)
lit 897 (78.6) 102 (97.1) 2 (100) 1001 (80.2) 738 (78.1) 108 (100) 846 (80.3)
91 760 (66.6) 99 (94.3) 2 (100) 861 (69) 620 (65.6) 108 (100) 728 (69.1)
7± 662 (58.0) 97 (97.4) 2 (100) 761 (61) 537 (56.8) 108 (100) 645 (61.3)
Non-susceptible = intermediate and resistant
§ 23-valentpolysaccharide vaccine, t 14-valent vaccine (not in use), } 11-valent conjugate vaccine,
*[ 9-valent conjugate vaccine, ±7-valent conjugate vaccine
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4.3.3. Non-invasive serotype distribution
There were 4491 non-invasive isolates in 1988-99, comprising 3988 (88.8%), 79
(1.8%) and 424 (9.4%) from sputum, nasopharynx and other superficial sites
respectively. Serological information was available for 1011 (22.5%) isolates, in
which 524 had specific serotype information and 833 had serotype information (Table
35). Of these serotyped isolates, 654 (64.7%) isolates were from sputum, 79 (7.8%)
from the nasopharynx and 278 (27.5%) from other non-invasive sites. Susceptibility
to penicillin and erythromycin was tested in 60.4% (611/1011) and 50% (505/1011) of
all isolates which were serotyped. The prevalence of non-susceptible isolates was
373/611 (61%) for penicillin in 1992-99 and of 70/505 (14%) for erythromycin in
1994-99 for the isolates for which there was serotype information.
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Table 35. Distribution of non-invasive pneumococcal serotypes
Serogroups Serotypes Serogroups/types
Groups Number Percent Groups Number Percent Groups Number Percent
(%) (%) ("%>)
23 224 26.9 23F 77 14.7 23 224 22.2
23A 12 2.3
9 166 19.9 19F 57 10.9 9 166 16.4
19A 18 3.4
6 150 18 14 69 13.2 6 150 14.8
19 138 16.6 6A 32 6.1 19 138 13.6
6B 30 5.7
15 36 4.3 9V 36 6.9 14 69 6.8
9N 13 2.5




33 18 2.2 11A 33 6.3 15 36 3.6
11C 1 0.2
7 15 1.8 33F 16 3.1 11 35 3.5
10 15 1.8 10A 14 2.7 33 18 1.8
18 13 1.6 8 13 2.5 7 15 1.5
17 6 0.7 1 12 2.3 10 15 1.5
12 5 0.6 18C 12 2.3 8 13 1.3
16 5 0.6 7F 9 1.7 18 13 1.3
7C 1 0.2
22 3 0.4 35 7 1.3 1 12 1.2
24 3 0.4 17F 6 1.1 35 9 0.9
41 1 0.1 31 5 1 17 6 0.6
12F 3 0.6 12 5 0.5
27 3 0.6 16 5 0.5
29 3 0.6 31 5 0.5
4 2 0.4 22 3 0.3
20 2 0.4 24 3 0.3
22A 2 0.4 27 3 0.3
34 2 0.4 29 3 0.3
42 2 0.4 4 2 0.2
5 1 0.2 20 2 0.2
16F 1 0.2 34 2 0.2
24F 1 0.2 42 2 0.2
37 1 0.2 5 1 0.1
37 1 0.1
41 1 0.1
Total 833 100 Total 524 100 Total 1011 100
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4.3.3.1. Non-invasive pneumococcal disease related serotypes
The eight most prevalent pneumococcal serotypes (in descending rank order) were 23,
9, 6, 19, 14, 3 15, and 11. These eight serotypes were responsible for over 86.3% of
non-invasive disease regardless of specimen type (Table 35). The frequency of
serotypes associated with NIPD, by age group, is shown in Table 36. Serotypes 23, 9,
6, 19 and 14 accounted for the majority of penicillin and erythromycin non-
susceptibility (Table 37).
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Table 36. Serotype distribution of non-invasive pneumococcal isolates by age
group, 1988-99
< 2 vears < 5 vears 5-64 vears > 65 vears
ST No. % ST No. % ST No. % ST No. %
23 52 (28.0) 23 55 (26.3) 23 67 (20.8) 23 82 (21.9)
6 45 (24.2) 6 49 (23.4) 6 47 (14.6) 9 67 (17.9)
19 30 (16.1) 19 32 (15.3) 9 46 (14.3) 19 52 (13.9)
9 22 (11.8) 9 26 (12.4) 19 41 (12.7) 6 42 (11.2)
3 12 (6.5) 3 15 (7.2) 3 18 (5.6) 14 32 (8.5)
14 11 (5.9) 14 14 (6.7) 11 14 (4.3) 15 19 (5.1)
11 4 (2.2) 11 6 (2.9) 14 13 (4.0) 3 17 (4.5)
10 2 (1.1) 15 3 (1.4) 15 13 (4.0) 33 12 (3.2)
15 2 (1.1) 10 2 (1.0) 18 10 (3.1) 11 10 (2.7)
24 2 (1.1) 1 1 (0.5) 8 8 (2.5) 7 8 (2.1)
7 1 (0.5) 4 1 (0.5) 10 5 (1.6) 10 7 (1.9)
1 1 (0.5) 7 1 (0.5) 7 5 (1.6) 8 4 (1.1)
4 1 (0.5) 17 1 (0.5) 1 5 (1.6) 17 4 (1.1)
20 1 (0.5) 20 1 (0.5) 12 4 (1.2) 35 4 (1.1)
24 2 (1.0) 4 1 (0.3) 18 3 (0.8)
16 4 (1.2) 29 3 (0.8)
33 4 (1.2) 27 2 (0.5)
35 4 (1.2) 31 2 (0.5)
17 2 (0.6) 12 1 (0.3)
22 2 (0.6) 16 1 (0.3)
31 2 (0.6) 22 1 (0.3)
34 2 (0.6) 24 1 (0.3)





Total 186 100.0 209 100.0 322 (100.0) 375 100.0
ST = serotype
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Table 37. Penicillin and erythromycin susceptible and non-susceptible
pneumococcal serotypes associated with non-invasive isolates
Number (%) of isolates
Penicillin Erythromycin
Serotypes Sensitive Intermediate Resistant Total Sensitive Resistant Total
23 72 78 5 155 110 24 134
9 14 115 4 133 113 5 118
6 24 61 0 85 53 19 72
19 35 45 0 80 55 8 63
14 12 46 1 59 43 11 54
Others* 81 18 0 99 61 3 64
Total § 157(66) 345(95) 10(100) 512(83.8) 374(86) 67(95.7) 441(87.3)
Total §§ 238(100) 363(100) 10(100) 611(100) 435(100) 70(100) 505(100)
Non-susceptible isolates = intermediate and resistant, § Total isolates for serotypes (23, 9, 6, 19, 14),
§§ Overall total isolates
*Others (sensitive = serotypes 11, 15, 1,7, 10, 31, 33,16, 4, 5, 22, 24, 29, 34, 35, 42) (intermediate =
serotypes 8, 15, 7, 29, 1,4, 18, 35) in descending order for penicillin
*Others (sensitive = serotypes 8, 15, 1, 7, 29, 31, 16, 4, 5, 18, 22,24, 33, 34,35, 42) (resistant =
serotypes 4, 11, 15) in descending order for erythromycin
4.3.4. Potential vaccine coverage for non-invasive isolates
4.3.4.1. By age groups
The coverage of 14- and 23-valent PPV and 7- to 11-valent PCV varied for sputum,
nasopharynx and other non-invasive sites in different age groups (Table 38). The 14-
and 23-valent vaccine serotypes would cover over 91% of these non-invasive isolates
in age group less than 2 years, over 88% in age group 5 years and less, 75-96% in age
group 65 years and above and 82-99% in all ages. The 7, 9, and 11-valent conjugate
vaccine in these age groups covers for 80-100%, 76-100%, 25-82% and 70-88% of
non-invasive isolates respectively.
Overall, coverage of 7- to 11-valent conjugate vaccine serotypes for total non¬
invasive isolates was between 85% and 94% for age groups less than 2 years and 5
years and less but their coverage reduced to 74-84% in age groups 65 years and above
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and all ages. Overall, serotypes in the 14- and 23-valent polysaccharide vaccine
caused 82-94% and 96-99% of total non-invasive disease, respectively in all age
groups.
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4.3.4.2. By antibiotic susceptibility
The coverage of 7, 9, and 11-valent conjugate ranged from 74% to 94% of non¬
invasive isolates. The 23-valent PPV and all PCVs covered 94% and above of
penicillin and erythromycin non-susceptible both invasive and non-invasive isolates
(Table 39).
Table 39. Coverage of pneumococcal vaccines for penicillin and erythromycin
susceptible and non-susceptible isolates
Vaccine Sensitive
Peni














23§ 228 (95.8) 360 (99.2) 10 (100) 598 (97.9) 423 (97.2) 70 (100) 493 (97.6)
lit 194 (81.5) 353 (97.2) 10 (100) 557 (91.2) 405 (93.1) 68 (97.1) 473 (93.7)
91 166 (69.7) 348 (95.9) 10 (100) 524 (85.8) 382 (87.8) 68 (97.1) 450 (89.1)
7± 158 (66.4) 347 (95.6) 10 (100) 515 (84.3) 376 (86.4) 68 (97.1) 444 (87.9)
Overall 238 (100) 363 (100) 10 (100) 611 (100) 435 (100) 70 (100) 505 (100)
Non-susceptible = intermediate and resistant
§ 23-valent polysaccharide vaccine, J 11-valent conjugate vaccine, 1 9-valent conjugate vaccine,
± 7 valent conjugate vaccine
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5. DISCUSSION
5.1. Limitations of study methods and data
The present study provides data on the burden of IPD, the use of PPV and some of the
limitations to the use of PPV in Scotland. The data presented in the study may be
subject to the following potential biases and limitations. These should be borne in
mind in interpretation of these data.
5.1.1. Laboratory data
5.1.1.1. Reporting
Laboratory reports on pneumococcal disease are based on passive surveillance; the
voluntary reporting of cases from diagnostic laboratories. Therefore, it is likely that
not all cases of IPD are reported to SCIEH and SMPRL, underestimating the true
number of cases and thus underestimating the true incidence of disease. In addition,
estimates of disease incidence were based on isolates from sterile body sites only,
thus, these data do not reflect the true overall burden of pneumococcal disease in
Scotland.
Nevertheless, an audit carried out by SCIEH and SMPRL showed over 90%
completeness for referred pneumococci and reports of IPD in Scotland over the period
1994-99 (unpublished data, P Christie). In addition, the study results are supported by
data from enhanced pneumococcal surveillance in Oxford between 1995 and 1999,^7
which reported similar data on age-specific incidence of IPD. To ensure the accuracy
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of study data, duplicate records for the same patient existing in SCIEH and SMPRL
datasets were removed to avoid accounting more than once for the same patient. In
addition, a consultant epidemiologist was responsible for reviewing these laboratory
data every week for the completeness of case ascertainment and reliability. These
measures strengthen the validity of the study results.
The observed increase in the number of cases of pneumococcal disease after 1992 is
probably due to the establishment of SMPRL, which encourages all diagnostic
laboratories to send isolates from body fluids of patients with suspected
pneumococcal disease. Moreover, improved awareness of the disease among
clinicians and the public may also play a role in the increase in incidence of IPD in the
recent years.
5.1.1.2. Number of participating laboratories
The number of laboratories reporting cases of pneumococcal disease to SCIEH or
SMPRL increased from 29 to 33 between 1988 and 1999. The four additional
laboratories began reporting after 1994. It is possible that this affected the study
results. The total number of cases of IPD ranged from 296 to 536 in 1988-93 and from
552 to 646 in 1994-99. However, a clear increase in the incidence of IPD was
observed prior to 1994 (Figure la), suggesting that the participation of four additional
laboratories is unlikely to explain most of the observed increase in the incidence of
IPD.
Between 1983 and 1999, the number of laboratories reporting to SCIEH has increased
for the five pathogens causing invasive bacterial disease; from 29 to 33 for
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pneumococci and meningococci, from 25 to 28 for GBS and H. influenzae and from
15 to 22 for L. monocytogenes. This may have affected the data on the relative
importance of these pathogens. However, the increase in the number of reporting
laboratories for the major pathogens, namely pneumococci, meningococci, GBS and
H. influenzae was relatively small. Although an additional seven laboratories reported
L. monocytogenes, the number of cases due to this pathogen was small. In addition,
cases of L. monocytogenes decreased over the study period, 1983-1999. These data
suggest that the increase in the number of laboratories reporting to SCIEH during the
study period is unlikely to represent the primary explanation for the reported findings.
5.1.1.3. Case definition
Only cases with isolation of pneumococci, meningococci, GBS, H. influenzae and L.
monocytogenes from CSF isolates were considered as meningitis in the study. Thus,
cases without CSF cultures, which were blood culture positive, but with a clinical
diagnosis of meningitis, were classified as INMD. In the study of invasive bacterial
disease some pathogens are not included in this review, which can also cause bacterial
meningitis or INMD. However, based on the previous studies, meningitis is less
commonly associated with other bacterial pathogens (less than 15% in the US^90 and
between 5% and 9% in the and thus may not have a significant impact on the
study results of bacterial meningitis. However, this was not known for INMD due to
other bacterial pathogens.
5.1.1.4. Serological testing and antibiotic susceptibility
Although antibiotic susceptibility and serotyping was performed on all isolates
submitted to SMPRL, they represent less than 25% of total isolates included in the
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study. Information on serological and antibiotic susceptibility was presented in less
than 5% of cases of pneumococcal disease reported to SCIEH. The establishment of
SMPRL in 1992 has improved the data on pneumococcal disease, particularly for
serotype distribution and antibiotic susceptibility. The formation of the combined
database provides high quality data on pneumococcal disease across Scotland.
Nevertheless, 35% and 33% of total invasive and non-invasive isolates, respectively,
had serotype information in 1993-99. Data on antibiotic susceptibility ranged from
23% to 44% for penicillin and from 20% to 45% for erythromycin of toal invasive
isolates in 1993-99.
The data for resistant isolates may also be over-represented as a result of selectively
higher referral by diagnostic laboratories since it is possible that laboratories were
more likely to submit antibiotic non-susceptible pneumococcal isolates to SMPRL for
confirmation of antibiotic resistance and determination of serotyping. Of the total
isolates with serotype information, penicillin and erythromycin susceptibility were
tested in 60% and 50% of non-invasive isolates respectively and in 82% and 73% of
invasive isolates respectively.
In addition, non-susceptible pneumococcal isolates may have been more likely to be
submitted if they were from patients with treatment failure. This may bias the
estimates of prevalence of antibiotic non-susceptibility and the distribution of
serotypes observed. Thus, the data presented may be unrepresentative of the general
picture in Scotland. However, there was no geographical variation in serotype
distribution or testing for antibiotic susceptibility across the 15 HBs.
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The size of the effect due to these potential biases on the study is not clear.
Nevertheless, the annual prevalence of antibiotic non-susceptibility was inconsistent
in the study period, suggesting that the increase in antibiotic resistant pneumococci
may partially relate to these suggested biases. However, this could equally represent a
true temporal variation (Figure 6).
5.1.1.5. Diagnostic methods
The rise in the use of non-cultural diagnostic methods, including latex agglutination,
co-agglutination, polymerase chain reaction (PCR) and antigen detection for
pneumococci and meningococci in the late 1990s may contribute to the increase in
incidence of disease to some extent. For example, a Scottish study showed that cases
of meningococcal disease diagnosed by outer membrane protein antibody increased
significantly from 7.2% in 1994 to 16.5% in 1999.49' However, the increase in use of
non-culture diagnostic methods may also have led to a decrease in lumbar punctures
and thus biased the data on meningitis. Nevertheless, PCR or antibody detection tests
would offer an increased likelihood of establishing a positive diagnosis in those who
received prior antibiotics.
5.1.1.6. Clinical practices
Changing practices of blood culture and antibiotic administration prior to blood
culture may have influenced study results. The implications of these issues on the
results of study will be discussed in greater detail in section 5.2.1. No information is
available on the changes in clinical practices of blood culture collection and
processing procedures for febrile patients in hospitals in Scotland. Similarly, a study
in England also reported lack of these data.'03
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5.1.1.7. Vaccine serotypes
Data on coverage of PPVs and PCVs were based on serotypes, assuming that vaccine
serotype antigens have cross-reactive protection to other types within that serogroup.
Thus, vaccine coverage data may be overestimated.-^^ 1,322 Although it is not
definitely established, it is generally considered that there is likely to be some degree
of cross-protection by vaccine serotype antigens for other types within that
serotype.319 Recent data from the 7-valent PCV trials in US'6 and Finland^
indicate the possible protection against the 7-valent vaccine-related serotypes within
that serotype for both IPD and otitis media.
Data on 14-valent polysaccharide vaccine may seem less relevalent since this vaccine
is not in use the UK and most other countries. Nevertheless, data on coverage of this
vaccine will be useful for developing conjugate vaccines in the elderly and adults at-
risk. At the current time, PCV can be composed of up to 13 serotypes. It is likely
therefore that a 14-valent conjugate vaccine may be developed in the future. Thus,
data on a 14-valent vaccine is important for developing and guiding policy for high-
risk adults.
5.1.1.8. Population estimates
The aggregated population under surveillance for pneumococci and other pathogens
was relatively stable in the study period and ranged from 5,100,000 to 5,120,000
approximately. However, there was a decrease in the population under five years of
age, from 317,900 in 1983 to 323,000 in 1988 and to 300,817 in 1999 and an increase
in the elderly population from 739,800 in 1983 to 757,700 in 1988 and to 784,141 in
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1999. The total number of persons with chronic medical conditions such as chronic
lung or heart disease also increased in Scotland in the study period.486 it is likely that
population changes, either in age distribution or numbers of people with chronic
medical conditions, may affect the study results. Nevertheless, it is difficult to know
to what extent the increase in incidence of IPD is due to the increase in the size of
these high-risk populations. The incidence of IPD by year and age group was
calculated based on the correct population denominators. However, changes in the
population with chronic medical conditions were unable to be accounted for in the
calculation.
5.1.1.9. Vaccine effect
The present data do not account for the possible effects of pneumococcal and
meningococcal polysaccharide vaccines and Hib conjugate vaccine on the incidence
of disease. No information is available either on vaccination status or vaccine failures
for the study cases. However, from the study survey, the estimated coverage of PPV
was 13% among patients with an indication for the vaccine in Scotland. This limited
use of PPV among high-risk patients suggests that unknown PPV status and possible
vaccine failures among study cases would have little impact on the study results.
There is no information on the coverage of meningococcal polysaccharide vaccine in
the recommended groups in Scotland but the use of this vaccine appears to be low
based on vaccine prescription data and thus may have little effect on the incidence of
disease.
Although it is not known individually for the study cases, the coverage of Hib vaccine
was over 95% in target groups in Scotland (with known effectiveness of over
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90%).392 xhis finding is consistent with the results from the present study, which has
shown a greater than 90% reduction in meningitis caused by H. influenzae.
5.1.1.10. Clinical and other relevant information
No information is available with which to assess the prevalence of specific clinical
presentations, underlying medical conditions, life-styles and socio-economic statuses,
case-fatality rates and other related outcomes of illness among patients with antibiotic
susceptible and non-susceptible IPD. However, these issues are currently being
investigated in an ongoing Scottish study (Appendix g).^92
5.1.2. Survey data
The reliance on self-reported data from respondents is a major limitation of the
surveys on PPV. It is possible that rates of PPV coverage in non-respondents may
have been lower than those who responded to the surveys. Thus, the study results
should be interpreted with some caution.
In survey 1, the HDs were chosen from the hospitals which were selected non-
systematically from the NHS in Scotland Directory to be representative of all HDs
throughout Scotland. In addition, they were selected non-systematically from personal
records. Thus, the data provided by HDs may have a selection bias. Nevertheless,
HDs were selected equally from urban and rural hospitals, specialities and grades.
This, together with a fair response rate, indicates that the information provided by
HDs may be generalisable to all HDs in Scotland.
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In survey 2, it is possible that vaccination practices of GPs in the CMR practices may
differ from other GPs. However, data on coverage of childhood vaccines were similar
in the CMR practices and other general practices in Scotland. This suggests that the
results from the CMR survey should be reasonably representative of Scotland as a
whole. In addition, data from CMR practices are considered to be correspond to those
for the whole of Scotland (section: 3.3.3). The response rate of 85% in this survey
also suggests that the results are unlikely to be influenced by respondent-
nonrespondent bias. In addition, the response rate in this survey and the survey 1
(60%) were also comparable to the surveys of physician barriers to use PPV in the
US, for which response rates were between 52% and 77%.487,493,494
In survey 3, the response rate was 72%, similar to a previous UK survey, which
determined the use of influenza vaccine in nursing homes.495 However, only 26% of
all nursing homes provided the data on vaccine coverage in the survey. It is therefore
possible that vaccine coverage may vary between nursing homes that provided
vaccine coverage data and those that did not. There was no difference in vaccine
coverage among nursing homes providing vaccine coverage data even when the
average number of residents and the presence of immunisation policies were taken
into considerations.
In survey 4, coverage for vaccines and antibiotic prophylaxis was determined only for
splenectomised patients who are alive. Coverage of these preventive measures may be
lower in deceased splenectomised and thus the results may be an overestimate.
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5.2. The public health impact of invasive pneumococcal disease
5.2.1. Incidence of invasive disease
A detailed understanding of the local burden of disease is important for informing
decisions on the adoption of new vaccines or for prioritising a vaccination
programme.496 This population-based study, with data collected through a national
network of diagnostic laboratories covering the entire population of Scotland,
demonstrates the burden of IPD in Scotland. These data are necessary to predict the
impact of PCV following its inclusion in the UK childhood immunisation programme
and to devise effective strategies to increase coverage of PPV in high-risk persons
aged 2 years and above.
The mean annual incidence of IPD in Scotland is 9.7/105 population in all ages in the
study period. This is similar to the population-based data in England and Wales (9 to
lO/lO3 population),03 Netherlands (8/105 population)497 an(j Finland (9.1/105
population).498 incidence of IPD is lower than that reported from Denmark
(19/105 population),75 Australia (non-Aboriginal) (14/105 population), 185 Canada
(15/103 population)' 82 an(j us (22 to 23/105 population).94,105 p)ata from Sweden
have yielded differing estimates which show wide variation in incidence of invasive
disease ranging from 5 to 15/105 population respectively.99,499,500 js important to
emphasise that these studies differed in their surveillance of IPD that is whether they
were passive, active or enhanced surveillance. This should be considered when
comparing disease incidence in different countries. Only US94,105 ancj Australian' 85
studies were based on active laboratory-based surveillance of IPD, which ensures the
complete collection of cases of IPD.
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There was an increase in the incidence of 1PD in Scotland between 1988 and 1999.
This finding is consistent with the results of studies from the US in 1978-97,196
Sweden in 1988-96,500 Denmark in 1989-9475 and England and Wales in 1982-
92.501 jn contrast, data from Finland498 showed no increase in 1PD. A correlation
between blood culture and the incidence of IPD has been previously documented in
one UK study. 103 In the study period, there was a 3-fold increased trend in both the
total number of blood cultures and the ratio of positive blood to CSF cultures. This
increase in blood cultures during the study period is likely to be the cause for an
increase in incidence of bacteraemia. This figure also reflects an approximate two¬
fold increase in the overall incidence of IPD in the study period. Nevertheless, data
from Sweden showed that there was a substantial increase in the incidence of IPD
without an increase in the number of blood cultures.502
It has been postulated that less frequently obtained blood cultures from cases with
mild disease may largely relate to under reporting of IPD.503 jhis assumption is
supported by surveillance data from Chile where blood cultures were usually taken
from children with febrile illness, resulting in a two-fold increase in the incidence of
IPD.504 Studies in Europe75,505 ancj US^2 observed that the increase in the
incidence of IPD was related to an increase in the number of positive pneumococcal
isolates from blood cultures. The introduction of a new blood culture system such as
BacTAlert in 1996 or automated microbiological procedures for culturing blood may
also have some influence on this increase. Other additional factors, which may
influence the incidence of bacteraemia, are changes in laboratory and clinicians'
diagnostic practices as stated in section 5.1.1. The variation in reported incidence
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nationally is difficult to interpret whether there is true geographical variation in the
incidence of 1PD in different locations. In order to understand geographic differences
in disease incidence, the establishment of sentinel surveillance systems is required to
allow valid comparisons to be made.
It is also possible that the increase in the incidence of IPD over time may relate to the
emergence of virulent capsular serotypes in Scotland. It had been suggested that the
increase in cases of bacteraemia in Sweden in recent years was due to the newly
introduced virulent serotype 14.506 Valid molecular typing procedures507 such as
multilocus sequence typing (MLST) and multilocus enzyme electrophoresis (MLEE)
are required to test this hypothesis.
The peak incidence of IPD was found in young children and the elderly. This
confirms the important disease burden of IPD in persons at the extremes of age. IPD
has been reported to occur without known high-risk conditions in these two age
groups 177 but this remains to be proven in young children.88 IPD is less common in
those aged 2-64 years. The incidence of IPD in young children and the elderly in
Scotland is comparable to other developed countries although incidences vary
substantially among countries (Tables 3 and 4). Eleavy nasopharyngeal colonisation
and frequent viral infections in young children may contribute to higher incidence of
invasive diseaseJ 52 y^g presence of chronic medical conditions and waning
immunity may relate to increased susceptibility to and mortality from pneumococcal
disease in the elderly.508 jn keeping with other studies,02 the incidence of IPD was
found to increase with advancing age, from 27.5/105 persons in aged 65 years and
above to 51.5/105 persons in aged 85 years and above. Based on this data, each year,
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there are at least 215 cases of pneumococcal bacteraemia and meningitis in Scotland
and 1420 cases for the whole of UK among the elderly aged 65 years and above. In
addition, nearly half of the cases of IPD occurred in this age group in the study
although they accounted for only approximately 13-15% of the population.
Although it is not included in the present work, a recent Scottish study has shown that
the majority of patients with IPD have underlying medical conditions.492 The leading
high-risk conditions for IPD were coronary artery disease/chronic heart disease,
chronic pulmonary disease, non-haematological malignancy, central nervous system
disorder and diabetes. A higher case-fatality rate was noted in coronary artery
disease/chronic heart disease, hepatic/alcohol abuse and renal disease (Appendix g) as
shown in recent data from the US.94 The overall case-fatality rate of IPD in adults
aged 18 to 64 years was 12% in patients with high-risk conditions and 5% in those
without high-risk conditions.94 Case-fatality rate was lowest among children under
two years of age (2%) and highest in the elderly 85 years of age and above (40%).246
It has been documented that more than 62% of deaths due to IPD occurred in persons
aged 65 years and above in Scotland in 2000.492 These data highlight that elderly
persons have the highest risk for developing IPD and resultant death. In the future, the
public health importance of pneumococcal disease will be significantly greater as the
population of elderly people aged 65 years and above is expected to rise in numbers.
At present, population based data on the prevalence of underlying medical conditions
associated with IPD and their case-fatality rates are lacking in the UK. Such data are
essential in deciding correct vaccination policies and systems to provide such data
were introduced in Scotland in 2000 (Appendix g).
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In common with other studies in the UK,7 US, 129 Europe99,498 and Australia (non-
indigenous),^^ a higher incidence of IPD was observed in males (9.4/105) than
females (8.1/105). This difference was noted in both adults and young
children. 1 ^0,177,181 Although it is not clearly understood, both genetic and
behavioural factors may account for these differences in adults. Studies, which
adjusted for life-style factors found that the difference between sexes was smaller but
a gap remains.27,204,498,510 j^e predominant disease related serotypes among
males might contribute to this difference but no statistical association between sex and
serotype was documented.511 It has been shown that antibody responses to PPV were
lower in males than females,^ 12 suggesting that females may have greater resistance
to disease than males.
The population in Scotland is predominantly Caucasian people. The study data did not
provide information on ethnic origin of patients. Nevertheless, the risk of IPD has
been documented to be significantly higher in disadvantaged populations such as
native (Table 5) or black population compared with white population. This difference
may relate to genetic factors and/or poor socio-economic status. However, no
deprivation related difference in the incidence of IPD has been seen in Scotland
(Appendix g)492 jn contrast to some US studies.105,132,137 Differences in health
care systems may contribute to the conflicting findings on socio-economic status and
the risk of IPD. At present, limited data are available on the genetic influence on the
development of pneumococcal disease.213 Further studies are required to elucidate its
role in relation to IPD.
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The overall incidence of pneumococcal bacteraemia and meningitis was 9/105
population and 0.8/105 population respectively in the study period. The highest
incidence of pneumococcal bacteraemia was found in young children less than 2 years
of age (33.1/105 persons) and in the elderly age groups, 65 years of age and above
(27.5/105 persons) and 85 years and above (51.1/105 persons). Previous studies have
shown that the incidence of pneumococcal bacteraemia in young children was 19 to
35/105 persons in the UK, 4 to 24/105 persons in other parts of Europe and 143 to
176/105 persons in the US (Table 3). Incidences of pneumococcal bacteraemia in the
elderly ranged from 10 to 80/105 persons in developed countries (Table 4). The
factors, which may influence these differences, have been previously discussed
(section: 5.1.1). In the study period, the incidence of IPD increased substantially in the
elderly (aged 65 years and above) and young children (aged less than 5 years, or less
than 2 years) in Scotland. However, a study from Sweden reported that a significant
increase in the incidence of pneumococcal bacteraemia occurred in those aged above
60 years but not in children aged less than two years between 1981 and 1995.17*7 The
overall pattern of both blood cutures and the ratio of blood and CSF cultures increased
during the study period in age groups, 65 years and above, less than 2 years or less
than 5 years. Thus, it appears that the increase in the incidence of IPD in young
children and the elderly is likely to be due to the increased blood culture sampling.
It has been proposed that the increase in the incidence of IPD in children may relate to
the disappearance of Hib disease due to the wide spread use of Hib conjugate
vaccine.^ 14 However, no change in the prevalence of carriage^ ^ and the incidence
oflPD516 was observed among Hib vaccine recipients. There were also no reports on
the emergence of epidemic serotypes in Scotland in the study period as noted in
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Iceland in 1988-91.517 Nevertheless this observed increase in the incidence of IPD in
young children and the elderly highlights the need for effective pneumococcal
vaccines for these two age groups.
Although individuals of all ages can be affected, infants and young children have a
higher risk of pneumococcal meningitis. Since the introduction of Hib conjugate
vaccine, the pneumococcus has become the leading or second leading cause of
bacterial meningitis in children in the UK^IS and US.'88 Consistent with other
studies, 177,500,519 the incidence of pneumococcal meningitis remained stable during
the study period. The annual incidence of pneumococcal meningitis is greater in
young children less than 2 years of age (11.8/10 persons) than in older age groups, 2
years and above (< 1/105 persons) in the present study. No increase in the incidence of
pneumococcal meningitis was found in the elderly in contrast to bacteraemia.
Incidences of pneumococcal meningitis ranged from 2 to 23/103 persons in young
children and 0.4 to 3.6 per 105 persons in the elderly in population based surveillance
in a number of countries (Tables 3 & 4). Differences in the incidence of
pneumococcal meningitis are likely to reflect true geographical variation. This is
because the completeness of case ascertainment for meningitis is higher since patients
with bacterial meningitis require both hospitalisation and positive CSF cultures for
diagnosis ofmeningitis.
The data in this study may still represent underestimates since many febrile patients
may not be routinely tested by blood culture. In addition, some cases may be treated
in the community or left untreated as previously reported.520 One US study reported
that the risk of occult bacteraemia in febrile children less than 3 years of age who, did
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not present localising signs, was between 3% and 11%.521 Blood cultures have been
shown to have poor sensitivity for diagnosing pneumococcal pneumonia^22 Studies
have shown that 8% to 26% of blood cultures are positive for
pneumococci. 1,523-525 However, between 15% and 30% of cases of
pneumococcal pneumonia have bacteraemia.92 In addition, patients with pneumonia
may not have bacteraemia at the time they present for treatment or when blood
cultures are taken. Thus, the true burden of disease due to pneumococci is clearly
underestimated in the present study.
Although lung aspiration yields higher sensitivity than blood culture, it is not suitable
for routine use89 and may cause adverse effects.40,525 The detection of
pneumococcal DNA in blood with use of a PCR method can improve the diagnosis of
bacteraemic pneumococcal disease^ but the validity of this method has been
questioned.87 Thus, the lack of a reliable diagnostic method is the major barrier to
determine the true burden of pneumococcal disease.89,526,527 jn order to understand
the disease burden, some investigators have suggested that studies of hospitalised
adults with CAP would provide a good estimate of the burden of disease caused by
pneumococci,92 particularly in relation to health service utilisation. Although there
were differences in selection criteria and diagnostic methods for pneumonia, the
pneumococcus was the first or the second common cause of pneumonia in these
studies.92 Data from current clinical trials of PCVs would also provide an indirect
method for estimating the burden of disease, in particular for culture-negative
"hidden" IPD. However, this approach relies on vaccine efficacy and could lead to an
underestimate if the vaccine has a low efficacy.
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In the present study, there is no information on whether patients received prior
antibiotic treatment before cultures have been drawn. One study demonstrated that 5%
of blood cultures were positive in those who had prior antibiotic compared with 19%
in those who did not receive prior antibiotic treatment.528 Therefore, these data
almost certainly represent an underestimate of the true burden of IPD in Scotland. The
development of non-invasive and more sensitive methods of diagnosing
pneumococcal disease and the education of health care professionals to carry out
blood cultures on febrile patients are essential to document the true impact of the
disease.
The prevalence of IPD was clearly related to season in the present study with the
highest reported cases in January-March each year, coinciding with the period of peak
influenza activity, the period during which it has been shown that pneumococci are
isolated more frequently in children.35,51,156 The seasonal increase in IPD may
relate to the concurrent circulation of respiratory viruses in the winter period.'52
Increased activity of respiratory virus activity in winter periods has also been noted as
a risk factor for developing pneumococcal pneumonia.529,530 About 50-80% of
pneumococcal pneumonia is thought to be associated with prior occurrence of some
form of viral respiratory illness.529 Viral infections might play a role in facilitating
bacterial colonisation and adherence on the epithelial cells, thereby increasing the
opportunity for developing bacterial disease.'52
An additional factor associated with seasonal variation could be related to socio¬
economic factors among subgroups of susceptible individuals such as the homeless
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and alcoholics. 156 The present study was unable to assess these life style factors,
which have been shown to be associated with the increased risk of disease. 181 This
peaked seasonal pattern of IPD could also be indicative of non-invasive
pneumococcal pneumonia both in hospitals and in consultations in primary care.531
The increase in IPD during the winter period emphasises the importance of
pneumococcal polysaccharide vaccination as part of the preventive strategy for
influenza. This could prevent high-risk patients, particularly the elderly from being
admitted to hospital thereby reducing the winter pressure on the NHS.
Since the incidence of pneumococcal bacteraemia and meningitis represent a
considerable health problem in Scotland and other countries, an effective strategy to
prevent pneumococcal disease, particularly in young children, the elderly and those
with underlying medical conditions deserves high public health priority. PPV and
PCV are available for the prevention of disease and would offer benefits to these
high-risk groups. At present the recommendations for these vaccines are restricted to
certain high-risk groups.
Although PPV does not provide protection in children less than two years of age, a
new 7-valent PCV is reported to be highly effective in preventing IPD when given
along with other childhood vaccines in the US.532 However, it is not yet included in
the routine childhood immunisation programme and is only recommended for
children less than two years of age with certain underlying medical conditions in the
UK.21 Although the current recommendations offer benefits to children at highest
risk, the universal vaccination of all children less than two years would substantially
reduce the overall burden of pneumococcal disease in this age group in the UK.
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The current recommendations for PPV are limited to persons aged two years and
above, with certain underlying medical conditions, and is not recommended for
routine use in the elderly outside these groups.458 The elderly are the largest single
high-risk group for the disease. The use of PPV in the elderly and high-risk patients is
not universally accepted,341 but the WHO, US, Canada and some countries in Europe
recommend the routine use of PPV in those aged 65 years and above based on its
proven safety, clinical effectiveness (from case-control and indirect cohort studies)
and cost-benefit. 1 ^ Although the goal of pneumococcal vaccination is to prevent both
bacteraemic and non-bacteraemic pneumococcal disease, its effectiveness in the
prevention of bacteraemia alone justifies establishing a policy for the routine use of
PPV in the elderly.533 Thus, the role of PPV in the elderly should be re-evaulated in
the UK.
The signficant public health impact of pneumococcal disease described in the present
study suggests that utilisation of antibiotics alone cannot reduce the burden of disease
in Scotland. Thus, pneumococcal vaccines should be a crucial part of the strategies for
prevention of disease in high-risk groups.
5.2.2. Prevalence of antibiotic non-susceptibility
There was an increase in the overall prevalence of penicillin non-susceptible
pneumococci in Scotland. It is not consistent in the study period; the prevalence of
penicillin non-susceptible pneumococci also increased in different age groups, less
than 5 years, 5-64 years and 65 years and above after 1996. Although the study results
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may have biases to some extent, local knowledge of the prevalence of antibiotic non-
susceptible pneumococci is useful for managing pneumococcal disease, minimising
the impact of antibiotic use to limit the spread of antibiotic resistance and tracking the
impact of intervention outcomes such as programmes increasing PPV coverage and
reducing inappropriate antibiotic use.
The prevalence of antibiotic non-susceptible pneumococci is highest among preschool
aged children,-46,534 relating to possible excessive antibiotic use, day care
attendance and otitis prone condition. 149 jn contrast, the level of penicillin non-
susceptible isolates was lower in children less than 5 years of age than in the elderly
65 years of age and above in the present study. This suggests that the reporting of
invasive isolates may be affected by age. Thus, these data should be interpreted with
caution. Nevertheless, the data provide some evidence of the extent of antibiotic non-
susceptible pneumococcal disease in Scotland and have been shown to be useful in
guiding patient care.535
The increase in the prevalence of penicillin and erythromycin non-susceptible
pneumococcal isolates in Scotland is of concern since most penicillin non-susceptible
isolates are more likely to be multiresistant.536 In addition, erythromycin non-
susceptible isolates have been found to have resistance to other macrolides such as
clarithromycin and azithromycin.537 Thus, choosing the correct antibiotic for treating
patients with antibiotic non-susceptible pneumococcal disease becomes challenging.
Treatments for invasive and non-invasive pneumococcal disease remain empirical due
to the lack of rapid, sensitive and specific diagnostic tests. Decision on antibiotic
therapy must be made before diagnostic results are available. Thus, guidelines for
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empiric therapy decisions in the management of pneumonia^ 73,538 ancj otitis
medians are recommended to take into account the local pattern of antibiotic
resistant pneumococci.
Although the prevalence of antibiotic resistant isolates varied with geographical
location (Table 6), there was a steady increase in the prevalence of pneumococci
resistant to antibiotics worldwide.238,239 There was a 3-fold increase in the
proportion of invasive penicillin and erythromycin non-susceptible isolates in the
study period. Surveillance data from England and Wales noted a similar increase in
penicillin and erythromycin resistant isolates between 1990 and 1998.-36 \
substantial increase in penicillin resistant pneumococci was observed in France (a 43-
fold increase from 1986 to 1996), in Japan (a 28-fold increase from 1974 to 1991),
and in the US (a 10-fold increase from 1986 to 1997).539 Improved diagnostic
methods in detection of resistant isolates and greater awareness of IPD may in part
relate to this increase. However, it is important to note that the determination of the
prevalence of resistant pneumococci based on sterile isolates may be biased since
isolates obtained from blood or CSF are taken from individuals attending hospital
settings. Therefore, nasopharyngeal isolates collected directly from the site associated
with person-to-person transmission may be more reliable in detecting the prevalence
of pneumococcal resistance in the community.^
The prevalence of antibiotic non-susceptible pneumococcal isolates varied among
regions in Scotland, ranging from 0% to 27% for penicillin between 1992 and 1999
and from 0% to 55% for erythromycin between 1994 and 1999. The present study
indicates that the national prevalence of antibiotic non-susceptibility in pneumococci
158
may not accurately reflect the prevalence of antibiotic resistance within specific
regions in Scotland. Thus, specific regional preventive strategies may be required for
preventing the spread of antibiotic resistance. Geographical variations in the
prevalence of antibiotic non-susceptible isolates are not known but may relate to
spread of resistant clones due to the movement of populations.243,536,540
Differences in populations and study and surveillance methods may also influence the
reported variation in the prevalence of antibiotic resistant pneumococci, but these
factors are unlikely to explain the regional differences in Scotland. Understanding the
factors, which influence these geographical differences in the distribution of
pneumococcal resistance could provide clues to prevent the spread of antibiotic
resistance.
In the US, the prevalence of antibiotic non-susceptible pneumococci ranged from 7%
to 25% for penicillin and from 6% to 15% for erythromycin between 1991 and
1998.6,195,269,536 jn some locations in the US,541 Up to 60% of pneumococcal
isolates were resistance to antibiotics. This suggests that the prevalence of resistant
pneumococcal isolates may increase steadily once resistant isolates become
established in one location. Since a rapid increase in the prevalence of antibiotic
resistant pneumococci can occur in a given geographical region, accurate data on
antibiotic susceptibility are necessary for timely interventions.
Antibiotic use is generally considered to be directly related to the level of
pneumococcal resistance 149 and may influence the difference in rates of resistant
pneumococci among different locations.226 The relationship between antibiotic use
and the frequency of resistant pneumococci in the community has been
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documented.286,542 -p^g prevalence of antibiotic resistance was lower in Northern
than Southern Europe^^ with the reported prevalence of 0% to 5% in Denmark, '80
1.5% to 3.4% in Sweden502 ancj \<y0 jn p^g Netherlands.544 An analysis of antibiotic
prescription rate per 1000 persons in 13 European countries showed a low utilisation
of antibiotics in these countries.545
In Scotland, the pattern of antibiotic prescription varied among 15 HBs. Although
there was a borderline statistically significant correlation between rates of penicillin
prescription and the prevalences of penicillin non-susceptible pneumococci in each
HB, this was not observed for erythromycin prescription and the prevalences of
erythromycin non-susceptible pneumococci. In addition, the prevalence of penicillin
non-susceptible pneumococci was found to correlate with the rate of penicillin (and
also erythromycin and all antibiotics) dispensed in Scotland between 1992 and 1999
for age groups less than 5 years and 65 years and above, but not in the age group 5-64
years (although a correlation was noted for erythromycin). Thus, the observed
development in the proportion of penicillin and erythromycin non-susceptible isolates
is difficult to explain, but may relate to the spread of antibiotic resistant clones.^46 ]n
Scotland, data on the molecular characterisation of penicillin resistance and multidrug
resistant pneumococcal isolates are needed to investigate further.
If the observed increase in the prevalence of non-susceptible pneumococcal isolates
continues to occur in Scotland, the choice of empiric therapy may be limited for the
elderly and those with high-risk conditions who are at greatest risk of death and
complications from pneumococcal disease. In the US, the increase in the prevalence
of antibiotic resistant pneumococcal disease has led to changes in recommended
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empiric treatment regimens for pneumococcal meningitis, pneumonia and otitis
media.535,538,547,548 ^ clear clinical outcome of non-susceptible pneumococci
causing both invasive and non-invasive pneumococcal disease is yet to be fully
established but some evidence from the US reveals that patients infected with
penicillin non-susceptible pneumococcal strains have poor medical outcomes.6,8,300
Treatment failures associated with antibiotic resistant pneumococci in cases with
meningitis and acute otitis media have also been reported, 535,549,550 however, their
relationships to pneumococcal pneumonia is less certain and difficult to establish.267
The clinical impact of resistant pneumococcal disease is difficult to determine due to
variations in underlying medical conditions, the degree of resistance and the site of
infection.' 0 The current prevalence of antibiotic non-susceptibility and lack of a high
incidence of clinical failures in Scotland suggest that many antibiotics currently in use
may still be appropriate, if used correctly.
Although there have been no apparent outbreaks of pneumococcal disease in Scottish
nursing homes in the study period, unrecognised clusters of pneumococcal disease can
occur. 140 Outbreaks of pneumococcal disease due to antibiotic susceptible and non-
susceptible pneumococci have been reported in overcrowded
environments.140,143,230,287,551 Several factors including host susceptibility,
crowding, colonisation with a virulent strain and low PPV utilisation may contribute
to outbreaks. These data have important implications for the use of PPV in residents
of long-term institutions and the use of PCV for children attending day-care centres to
prevent outbreaks of antibiotic resistant pneumococcal disease.
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It has been proposed that the observed increase in the diagnostic rate of IPD in the
study period should result in selective antibiotic use thereby reducing inappropriate
antibiotic use and possible exposure to antibiotic selective pressure and limiting the
spread of pneumococcal resistance. However, it is also possible that the increase
in the incidence of IPD between 1988 and 1999 in Scotland may, in itself, be due to
the reduced antibiotic sensitivity of pneumococci.
The current study suggests that, at present, the level of antibiotic resistant
pneumococcal disease in Scotland is low compared with some other countries in
Europe and North America. Nevertheless, the pattern of antibiotic resistance increased
in the study period, highlighting the need for the constant surveillance of antibiotic
resistance in pneumococci. Additional studies are required to determine the clinical,
economic and epidemiological impact of antibiotic resistant pneumococcal disease.
5.2.3. Relative contribution of pneumococci to invasive bacterial disease
Bacterial meningitis and other invasive bacterial disease are leading causes of
morbidity and mortality in the UK.205,236,552 ancj other countries. 188,490,553 These
diseases are most frequently caused by pneumococci, meningococci, H. influenzae,
GBS and L. monocytogenes with the exception of Escherichia coli and
Staphylococcus aureus in the UK^Ol and US. 1^8,490 Before the widespread use of
Hib conjugate vaccine in Europe and US, between 50% and 75% of bacterial
meningitis or other invasive bacterial disease was due to Hib in children under 5 years
ofage.490,553
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Significant changes in the epidemiology of invasive bacterial disease occurred
between 1983-91 and 1992-99, before and after the widespread use of Hib conjugate
vaccine in Scotland. These include: (1) the incidence of bacterial meningitis due to
pneumococci and GBS was stable; (2) pneumococci were the predominant cause of
INMD in both periods; (3) the incidence of INMD caused by pneumococci,
meningococci and GBS increased by 56%, 27% and 55% respectively; (4) decreases
in the incidence of bacterial meningitis by 50% and INMD by 50% due to L.
monocytogenes were detected; (5) dramatic reductions in the proportions of bacterial
meningitis by 92% and INMD by 56% due to H. influenzae were documented. Such
data together with an understanding of pathogenic agents, pathogen-specific
epidemiological trends and at-risk populations are essential in prioritising treatments
and preventive interventions and in developing suitable clinical recommendations.
At present, polysaccharide or conjugate vaccines are available for the prevention of
disease due to pneumococcal, meningococcal and H. influenzae infections.554,555
Thus, many cases of invasive bacterial disease caused by these pathogens in Scotland
could be prevented with use of these existing vaccines. A 50% decrease in bacterial
meningitis due to these five pathogens occurred between 1983-91 and 1992-99, before
and after the routine use of Hib conjugate vaccine in Scotland. This suggests that a
similar result might be achieved if effective conjugate vaccines against pneumococci
are available for use in the future. The successful development of GBS conjugate
vaccines is another potential prospect for the prevention of invasive bacterial disease
since GBS is the principal cause of neonatal sepsis and meningitis.556
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The proportion of bacterial meningitis and INMD caused by pneumococci,
meningococci, H. influenzae, GBS and L. monocytogenes varied in both developed
and developing countries.557,558 Case-fatality rates of bacterial meningitis ranged
from 5% to 40%, with 9% to 30% of survivors sustaining neurological deficits,
depending on the infecting pathogen. 188,559,560 bas been reported that
pneumococcal meningitis is associated with higher rates of case-fatality ^ 88 and
disability than meningococcal or H. influenzae meningitis.1,559
The pneumococcus was the second most common cause of bacterial meningitis
between 1983-91 and 1992-99, accounting for 22.4% and 36.3% of total cases of
bacterial meningitis and INMD respectively between 1992 and 1999, highlighting the
increasing importance of pneumococci as a cause of bacterial meningitis in Scotland.
Surveillance data from Europe^l and US188 also showed that the pneumococcus
was the predominant cause of bacterial meningitis and other invasive bacterial
disease. Approximately 48% of cases of bacterial meningitis were caused by
pneumococci in the US^ anci about 30% in Malawi.562 in the present study, most
cases of INMD were due to the pneumococcus, 57% in 1983-91 and 69% in 1992-99,
demonstrating the importance of preventing disease associated with this pathogen.
Similar to previous studies in the UK.^63 and US, 188 changes in age-specific disease
trends occurred as a result of the routine Hib conjugate vaccination of infants and
young children. These data have important implications for current age-based
preventive and treatment guidelines.
Pneumococci caused 24% of INMD and 26% of bacterial meningitis in age groups,
less than 1 year and 1-4 years between 1992 and 1999 in Scotland. US multistate
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pneumococcal surveillance data found that approximately 50% of bacterial meningitis
was due to pneumococci in age group 1-23 months. 188 j^e incidence of bacterial
meningitis due to pneumococci (12/105 persons) was higher than GBS (8/105 persons),
H. influenzae (3/105 persons) and L. monocytogenes (1/105 persons) but lower than
meningococci (23/1 (T persons) in children less than one year of age in Scotland
between 1992 and 1999. The proportion of cases caused by pneumococci increased
nearly 2-fold in the age group less than one year between 1983-91 and 1992-99, but
no significant increase was observed in the elderly, 65 years and above. In keeping
with previous studies,92,188 the proportion of INMD caused by the pneumococcus
was substantially higher than other pathogens in age groups, 45 years and above or 65
years and above. US data show that the incidence of invasive bacterial disease caused
by pneumococci in the elderly, (65 years and above), was three-fold higher than GBS,
10-fold higher than H. influenzae and 20-fold higher than meningococci or L.
monocytogenes in 1995.188 In Scotland, the corresponding difference was nine-fold,
19-fold and over 41-fold between 1992 and 1999. These data identify the
pneumococcus as one of the leading causes of invasive bacterial disease in Scotland.
The routine use of meningococcal group C conjugate vaccine since November 1999
has been shown to reduce group C meningococcal disease by 92% to 97% in the
targeted age groups in England.393 -ppis vaccine should therefore impact significantly
on the epidemiology of invasive bacterial disease and bacterial meningitis, in
particular. Thus, it appears that a programme of pneumococcal conjugate vaccination
together with the successful development of vaccines for group B meningococcus and
GBS could further reduce the burden of invasive bacterial disease in the UK.
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5.3. Implications for vaccine prevention policy and strategies
5.3.1. Invasive pneumococcal disease
Current evidence shows that a relatively small numbers of serotypes cause most
disease; less than 11 serotypes in young children and less than 23 serotypes in
adultsA27,69 most prevalent serotypes are 14, 9, 19, 6, 23, 1, 3, 4, 7, 8 and 18,
accounting for between 82-94% of total invasive isolates in all age groups in
Scotland. Thus, if an 11-valent PCV includes all these serotypes, the vaccine could
potentially cover over 80% of invasive pneumococcal disease in young children,
adults and the elderly. Seroepidemiological studies reported that these serotypes were
the most commonly associated with IPD in US, Europe, New Zealand and
Australia^,72,511 ^ut ranging orcjer of these serotypes differed among developed
countries. For example, serotype 14 caused less than 3% of IPD in Spain compared
with 13% in Denmark, 17% in US, 22% in Finland and 29% in Belgium.69 Since the
selection of serotypes included in a PCV is limited, the formulation of vaccine would
need to be based on the predominant serotypes causing disease targeted for prevention
in one geographical location.
In Scotland, the most common serotypes were 14, 6, 19, 23 and 9 in the age group less
than 2 years; 14, 6, 23, 19, and 18 in those 5 years and less; 1,9, 14, 7 and 4 in those
5-64 years and 14, 19, 3, 9, and 23 in those 65 years and above. Serotype 14 was the
predominant cause of IPD in all age groups; this is also shown in other studies.69,72
Serotype 1 was the main cause of IPD in age group 5-64 years, accounting for 13.2%
of IPD. Serotype 1 was also associated with outbreaks of pneumococcal disease in
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adults. 138,144,564,565 has been reported that the risk of IPD caused by serotype 3
increased in the elderly.5 H In this study serotype 3 was the third leading cause of
IPD in the elderly. In accordance with previous findings,^ 11 serotype 14 was the most
important serotype in children aged 5 years and less, accounting for 29% to 32% of
IPD in Scotland. These data highlight the variation in contribution of different
serotypes to age specific disease incidence and outbreak involvement.
There is evidence to show temporal variations of the important pneumococcal
serotypes associated with disease.566 Earlier data from US show that serotype 12 was
the most frequent cause of bacteraemia in patients with pneumonia^ and associated
with outbreaks in both children567 and adults.568 jhis serotype was not a common
cause of IPD in Scotland. The relative importance of the 11 most prevalent serotypes
varied between 1993 and 1999 in the study. Although serotypes 1, 2 and 3 were
predominant causes of bacteraemia during 1950 and 1970,73,74 they represented less
than 5% cases of IPD between 1979 and 1994.68 However, recent US data indicate
that serotypes 1, 3 and 6A are important invasive pathogens, where serotype 1
accounted for 27% of IPD from blood isolates.569 7he potential risk of a shift in
serotype distribution raises the possibility of needing to change the components of
pneumococcal vaccines, over time, in some geographical locations. This also has
important implications for the long-term effectiveness of PCV.
The present study found that serotypes 14, 9, 19 and 6 were the most prevalent causes
of IPD in Scotland. Serotypes 6, 14, 18 and 23 were most frequently associated with
IPD in the US and other parts of Europe.69,72 Worldwide data on pneumococcal
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serotype distribution indicate that serotypes 1 and 5 were those most associated with
disease in Asia and Africa,69,72,503 serotypes 4, 19 and 23 in North America and
Europe^ 1 and serotypes 14, 6 and 19 in all geographical locations.69 Therefore, the
formulation of 9-valent PCV has included serotypes 1 and 5 with the intention of
global use.316 Variations in historical and geographical distribution of pneumococcal
serotypes may be due to differences in socio-economic conditions, practice of blood
culture sampling for diagnosis, use of pneumococcal vaccine and antibiotics,
immunocompromised status and genetic susceptibility of populations;570,571 but
they remain unclear. Such differences impose a major challenge for developing a
conjugate vaccine which is suitable for all geographical locations.
The 23-valent and previous 14-valent PPVs included 97% and over 83% of the
serotypes responsible for invasive disease respectively in Scotland. Coverage of PPV
was similar to other parts of the UK (91-97%), 103,235,572 Sweden (89-97%),502
Italy (84%),573 Finland (95%),'498 Denmark (92%),75 the US (above 85%),319,363
and Canada (above 90%)574 for older children and adults. Coverage of PPVs for
invasive disease causing serotypes was lower in some Asian countries, between 63%
and 75% coverage.575,576 These data indicate that the vast majority of serotypes
causing IPD in Scotland and most other developed countries were included in the
formulation of PPVs. In addition, PPV provides broader coverage of disease-causing
serotypes than PCVs. If the current 23-valent PPV is indeed 50% to 80% effective
against IPD, as estimated by retrospective studies,M2 greater use of this vaccine in
high-risk adults would prevent a significant proportion of IPD in Scotland.
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Studies have shown that coverage of 7-valent PCV vaccine in young children was
about 69-79% in the UK?7,179 an(j between 83% and 86% in the US^8 for serotypes
associated with IPD. In some parts of Europe, coverage of 7-valent PCV ranged from
53% to 83 % in children.539 jbe 7-valent PCV related serotypes accounted for 70%
of invasive isolates in Africa and 46% in Asia.^77 Vaccine coverage in Scotland was
above 80% with the 7- and 9-valent PCVs and above 90% with the 11-valent PCV in
children less than two years of age. However, coverage of 7-, 9- and/or 11 -valent
PCVs was substantially lower in age group 5 years and above: 50-57% with 7-valent,
62-63% with 9-valent and 75-76% with 11-valent conjugate vaccines. PPV and PCVs
coverage varied from year to year, between 1993 and 1999; the most prevalent
serotypes also varied in a similar fashion. This has important implications for the
potential effectiveness of pneumococcal vaccine and highlights the need for constant
surveillance on pneumococcal serotype distribution.
The most prevalent non-conjugate vaccine serotypes were 8, 11, 12 and 22,
accounting for 15.6% and 12.4% of isolates in age group 5-64 years and 65 years and
above respectively. The inclusion of these serotypes in the 11-valent conjugate
vaccine could increase the coverage of conjugate vaccine to above 80% in these two
age groups. In the US, the introduction and routine use of a 7-valent PCV has been
documented to reduce the incidence of IPD by 87.3%, 58.1% and 62.4% in children
aged less than 1 year, less than 2 years and less than 5 years respectively.532 Similar
results may be achievable if PCV is included in the routine childhood immunisation
programme in the UK. The role of PCV against IPD in the elderly and adults with
high-risk conditions has yet to be established. At present, PPV offers the potential for
prevention of disease in high-risk adults before the availability of new more effective
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vaccines. A combination schedule of PCV and PPV may induce good immune
responses for serotypes included in the PCV and offer a broad coverage to other
serotypes in the PPV. Thus, the optimal schedule for immunisation with PCV
followed by PPV needs to be investigated.
5.3.2. Non-invasive pneumococcal disease
A reduction in otitis media, lower and upper respiratory infection and acquisition of
nasopharyngeal carriage has been documented with pneumococcal conjugate
vaccination. Serotype distribution of non-invasive pneumococcal isolates may not be
the same as invasive isolates. Understanding serotype distribution and antibiotic
resistance patterns in non-invasive pneumococcal isolates would provide important
information for vaccine strategies and an estimation of the potential impact of PCVs
in the future.
The 11 most common serotypes associated with non-invasive disease were 23, 9, 6,
19, 14, 3, 15, 11, 33, 7 and 10 (in descending order) in Scotland. In common with
other reports in the UK.76,572,578 an(j other developed and developing
countries,78,575 serotypes 23, 9, 6 and 19 were the predominant causes of non¬
invasive pneumococcal disease. Although serotype 1 was one of the important
pathogens for IPD in Scotland and other countries,577 it was not a common cause of
NIPD. This supports the evidence that this serotype is not usually carried in the
nasopharynx.579
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Data on pneumococcal serotypes causing lower respiratory tract infection in young
children are less established because of the difficulties in obtaining adequate samples
for culture.580 Over 85% of non-invasive disease was due to 7-, 9- and 11-valent
PCVs related serotypes in children aged 5 years and less. Coverage of 7-, 9-, and 11-
valent PCVs was lower for older age groups than the age groups less than 2 years and
5 years and less as in other studies.77,78 Serotypes in all conjugate vaccine
formulations were responsible for over 80% of non-invasive disease in children aged
less than two years. The serotypes in the 7-, 9- and 11-valent PCV accounted for most
invasive and non-invasive disease in children in most parts of the world. Thus, PCV
targeted towards young children would not require more than 11 serotypes. The
prevalence of non-conjugate vaccines serotypes 15, 11, 33 and 10 were more common
in older age groups in Scotland, indicating that conjugate vaccine formulations for
adult age groups would ideally require different serotype compositions for the
prevention ofNIPD in Scotland.
The prevalence of nasopharyngeal carriage with both vaccine serotypes and non¬
invasive serotypes was reported to be higher in young children than in adults.51>53
PCVs have been shown to reduce nasopharyngeal carriage of vaccine serotypes, not
only in the vaccine recipients but also in their siblings.309,406 Since there is an
association between carriage and the spread of disease, children may be a major
source of pneumococci and pneumococcal disease in the community. One US study
also shows that exposure to children is a risk factor for IPD in adults.'53 Thus,
universal vaccination of young children may extend protection from pneumococcal
disease to non-vaccinated individuals by herd immunity.
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In the present study, the findings of a similar serotype distribution in both invasive
and non-invasive disease, regardless of the site of clinical isolates, is consistent with
serotypes colonising non-sterile sites and having the potential to cause invasive
disease. Data from Papua New Guinea suggest that serotypes causing upper
respiratory tract infection (URTI) could be used to obtain a conservative estimate of
susceptibility to invasive pneumococci.60 Since serotypes associated with NIPD
reflect closely those associated with IPD, immunisation would be expected to reduce
the risk of both forms of pneumococcal disease. However, this extrapolation is limited
to serotypes 1 and 5, important causes of invasive disease and serotype 3, an
important cause of otitis media, because they are not usually carried in the
nasopharynx.577 Although the efficacy of 7-valent PCV is lower in non-invasive
disease compared with invasive disease, the annual number of cases of non-invasive
pneumococcal disease such as otitis media, pneumonia and upper and lower
respiratory infections is substantially higher than invasive disease. Therefore, wider
use of PCV may reduce significantly the burden of non-invasive disease caused by
pneumococci in Scotland. The impact of PCVs on NIPD needs further evaluation.
Although the efficacy of PCVs has yet to be determined in adults, they induce higher
antibody responses than PPV in adults, the elderly and persons with
immunocompromised conditions.409,581 Thjs suggests that they may offer better
protection in adults with high-risk conditions. In Scotland, the coverage of PCVs was
less optimal for both invasive and non-invasive isolates in older age groups,
suggesting additional serotypes may need to be included in the PCV for use in adults.
However, the possibility of serious adverse events and poorer immunogenicity, due to
the inclusion of a large number of serotypes attached to a carrier protein, has raised
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concerns.582 Careful evaluation is also needed to determine the potential benefits and
cost-effectiveness of PCV in adults compared with the current 23-valent PPV. Further
studies are required to investigate these issues.
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5.3.3. Control of antibiotic resistance
Local knowledge of the site of infection and serotype distribution can inform
antibiotic treatment decisions and preventive measures. Serotypes 6, 9, 14, 19 and 23
(in descending order) were responsible for most cases of invasive penicillin and
erythromycin non-susceptible pneumococcal disease in this study; this is similar to
findings in other countries.267 The two high-level resistant invasive isolates from
blood were due to serotype 14. In addition, approximately 75% of invasive
erythromycin non-susceptible isolates were due to this serotype in Scotland. There
were no invasive isolates from CSF which were non-susceptible to penicillin and
other antibiotics. A recent Scottish study492 an(j us data383 indicated that serotype 3
was associated with higher mortality. Nevertheless, IPD and NIPD associated with
serotype 3 were uniformly susceptible to penicillin and other antibiotics in the study
period.
It has been observed that pneumococci carried in the upper respiratory tract are more
often resistant to antibiotics than invasive strains.43,578 Although their rank orders
differed, the same serotypes (23, 9, 6, 19 and 14) were most frequently associated
with antibiotic resistance among non-invasive isolates, accounting for over 95% of
total isolates. These five serotypes are most commonly carried in the
nasopharynx. 10,33 As the duration of nasopharyngeal colonisation with these
serotypes is longer than with other serotypes,384 they have higher exposure to
antibiotics thereby putting selective pressure on those populations of carried
pneumococci. The fact that most resistance is found in these five serotypes also
suggests that other pneumococcal serotypes may have more limited ability to acquire
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resistance genes from the environment. At present, resistance is rare or has not been
detected in serotypes more frequently found in adults.336
In England and Wales, similar serotypes (23F, 6B, 19A, 19C, 19F and 23F) were
identified as the most common cause of antibiotic resistance.235 Erythromycin
resistance was associated with serotypes 3, 5, 9, 14, 19 and 22 in 1990 and serotypes
3, 6, 14, 15, 19 and 23 in 1995.235 Serotypes 6, 9, and 23 were most frequently
associated with penicillin resistance in other UK studies.272,273,275 Elsewhere, the
most prevalent penicillin resistant pneumococci are; serotypes 9 and 23 in
Canada,374,585 14^ 19 an(j 23 in South Africa, Spain and Hungary237 ancj 53, 9V,
14, 19F and 23F in the US. 195,536 Serotype 14 was reported to have caused an
outbreak ofmultidrug resistant meningitis in a day-care centre 147 ancj serotypes 23F,
6A and 6B were more likely to be resistant to penicillin in the US. 195 There is also
evidence to show that penicillin resistant serotypes were more likely to be resistant to
other antibiotics.269,536 Overall, these data suggest that the pattern of penicillin and
erythromycin non-susceptible pneumococcal serotypes was similar in most
geographical locations. Nevertheless, serotype 35B in the US,386 serotype 15 in
Spain387 ancj serotypes 10, 13 and 16 in Kenya266,588 have been reported to be
associated with penicillin resistance. The appearance of new resistant strains has also
been reported in the US in recent years.389,590 Thus, it is important to monitor the
emergence of penicillin resistant strains, their genetic profiles and their frequency and
distribution in both adults and young children in the UK using the precise molecular
methods currently available.
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The 23-valent and previous 14-valent PPVs covered over 98% of invasive isolates
resistant to penicillin and erythromycin. Over 99% non-invasive isolates associated
with penicillin and erythromycin resistant strains were also included in the 23-valent
PPV. More than 94% of penicillin and erythromycin non-susceptible invasive and
non-invasive pneumococci were present in the formulation of 7-, 9- and 11-valent
PCVs. Thus, the formulation of PPVs and PCVs includes the principal serotypes
associated with penicillin and other antibiotic non-susceptible pneumococci in
Scotland and in other countries.
The ability of PCVs to interrupt transmission of carriage associated with antibiotic
resistant serotypes309 suggests that these vaccines have the potential to reduce
antibiotic resistant pneumococcal disease and the use of antibiotics. In addition, as
antibiotic resistance in pneumococci is largely restricted to those serotypes causing a
significant proportion of IPD, PCV would offer most benefit to populations with a
high prevalence of antibiotic resistance.406 Furthermore, the effects of PCV on
antibiotic resistant pneumococci have implications for the choice of antibiotics for
empiric treatment in children with febrile illness if a child is known to have received
PCV. The introduction and widespread use of PCV, together with Hib conjugate
vaccine, would dramatically reduce the incidence of occult bacteraemia in young
children. Changes in strategies for the management of a febrile child may be required
after introduction of universal infant immunisation with PCV. However, concerns
have been raised as to the possible emergence of antibiotic resistant non-conjugate
vaccine serotypes due to serotype replacement.^ 1
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5.4. Strategies to improve polysaccharide vaccine coverage
Despite the DoH recommendations,'- the vaccine is underused among high-risk
patients in the UK as in other developed countries. The overall vaccine coverage
was estimated to be 13% among patients recommended to receive the vaccine by the
UK Departments of Health. A substantially higher coverage of PPV (88%) was noted
in splenectomised patients. The elderly and persons in nursing homes or other long-
term care institutions are not currently included in the general recommendations.
Nevertheless, 22% of all elderly (aged 65 years and above) and 11% of elderly home
residents received the vaccine. This suggests that elderly persons are more likely to
receive the vaccine than other high-risk patients, with the exception of splenectomised
patients.
Poor coverage of PPV in high-risk patients may relate to uncertainty regarding the
benefits of vaccination, inadequate knowledge of risk and of the impact of
pneumococcal disease.462 js likely that these factors may affect the use of vaccine
by GPs in the UK. The majority of GPs and HDs in the present survey support the use
of PPV in high-risk groups and recognise the safety and effectiveness of the vaccine.
The US studies have also indicated that physicians in both general practice and
hospital settings have adequate knowledge of PPV target groups and its usefulness but
they have failed to act on this in clinical practice.487,592 jn addition, in the present
study, the majority of GPs considered that the responsibility for pneumococcal
polysaccharide vaccination lay with them. Nevertheless, the vaccine was underused
among recommended persons in Scotland. However, there was a substantial increase
in the distribution of PPV in the whole of Scotland and among the 53 CMR practices
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in recent years (since 1996). This has also been reported in some developed
countries. This pattern of increase in vaccine distribution coincided with the
national recommendations issued in 1992^93 ancj 1995458 a review of
pneumococcal polysaccharide vaccination polices in North America and Europe also
suggests that the presence of recommendations is strongly related to the level of
vaccine use and distribution. 15
Previous UK surveys^,14 show that coverage of PPV was less than 15% in patients
with indications for the vaccine. Current coverage of PPV was very similar to that
seen for influenza vaccine coverage in the late 1980s in the UK. Although the target
patients for pneumococcal polysaccharide vaccination are almost the same as those
for influenza vaccine,458 there was a remarkable difference in coverage of influenza
vaccine and PPV. 13,594 similar findings are also documented in the US and other
developed countries. 5,595,596 There was over 1.5-fold difference in coverage of
PPV among patients recommended for vaccination in the DoH guidelines, between
the data from the survey and an estimated figure based on the total number of patients
with vaccine indications and the total number of vaccine distributed in the CMR
practices. These data suggest that not all vaccines actually dispensed were used in
current target groups. The total number of high-risk patients recommended for PPV,
according to the DoH criteria, in the whole of Scotland was about 420,000 patients. If
all elderly aged 65 and above were included in the vaccine recommendations, this
number would increase 3-fold, to about 1,200,000. This indicates that a policy to
extend pneumococcal polysaccharide vaccination to all elderly would elevate costs
significantly, although the use of PPV in high-risk groups - especially the elderly -
178
may yet be economically justifiable.441,597 -phe increased risk of IPD in the elderly
documented in the present study results (section: 5.2.1) and previous studies (Table
4), together with a substantial body of evidence of PPV effectiveness against IPD in
the elderly from the retrospective studies (Table 9), also support the administration of
PPV to all elderly aged 65 years and above. Although there is absence of data on the
effectiveness of PPV in the prevention of pneumococcal pneumonia in the elderly
from the meta-analyses and RCTs, Fedson598 has argued that clinicians do not need
to know whether the vaccine is clinically - or cost-effective in preventing
pneumococcal pneumonia. The decision to use PPV in the elderly or patients with
high-risk conditions should be based on the demonstrated risk and effectiveness of
PPV against IPD in these at-risk groups.
UK studies have shown that influenza vaccine was three-fold more likely to be
recommended than PPV.599,600 jt js a|so dear from the survey that among both GPs
and HDs acceptance of influenza vaccine was higher than PPV. Unlike influenza
vaccination, PPV may be given opportunistically at any time of year. At present,
many opportunities have been missed to offer PPV during annual influenza
vaccination. It appears that the protective benefits of pneumococcal polysaccharide
vaccination have been largely undervalued by GPs. The lower levels of PPV coverage
in high-risk patients, compared with influenza vaccine coverage may, in part, relate to
this. GPs and HDs in the survey had suboptimal knowledge of vaccine safety and
effectiveness for patients who are elderly, immunocompromised or have other
underlying medical conditions. In addition, the study findings also showed that HDs
were less likely than GPs to know whether PPV was safe and effective in high-risk
patients. Since many patients come into contact with HDs during their hospitalisations
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and outpatient visits, this lack of knowledge about PPV could lead to missed
opportunities for vaccination in hospital settings. Thus, there is a need for an
education programme on adult vaccine preventable diseases in medical training.
Further problems are indicated by US studies which found that adult vaccination was
a low priority among physicians. 138,551
The factors related to poor use of PPV in single-handed and rural practices are
difficult to determine from our survey. Reasons may include greater workload or other
factors which require further investigation. To determine whether this might be due to
a disproportionate number of high-risk patients such as those with chronic heart and
lung conditions in urban areas, further data on the number of patients with chronic
heart disease and chronic obstructive pulmonary/lung disease in both urban and rural
areas from the CMR system, ISD, were extracted. If the patient population in urban
practices had higher proportions of such individuals, it might be expected that GPs
would have a greater knowledge of PPV for such conditions. The data showed that
there was a difference in the proportion of patients with chronic heart disease
(rural=25/l,000 population; urban=21/1000 population) and chronic pulmonary
disease (rural=57/1000 population; urban 42/1000 population) in rural versus urban
areas. Thus, it appears that differences in the use of PPV in rural and urban area GPs
are unlikely to relate to the proportion of such patients in the survey but may partly
relate to the higher prevalence of policies on PPV among urban or group practices.
Epidemiological studies have shown that more than two-thirds of persons with serious
pneumococcal disease had previous hospitalisation in the preceding 3-5 years.601
Studies in the US have consistently reported that hospital-based influenza and
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pneumococcal polysaccharide vaccination programmes during outpatient visits or at
hospital discharge are effective means of increasing coverage of the vaccine, 480,602
and should be considered as a complementary strategy to a primary care based
vaccination programme in the UK. Only 2% of patients in Scotland, with vaccine
indications, had ever received PPV in the hospital setting. This suggests that very little
effort has been made to improve coverage of PPV by health care workers in hospital.
Moreover, as persons with chronic medical conditions are more likely to use other
health care services and long-term care institutions, the initiation of pneumococcal
polysaccharide vaccination programmes in nursing homes and other medical care
facilities could improve the coverage of PPV in high-risk patients. The results also
indicated that vaccination programmes organised by nursing staff were considered to
be an effective strategy for improving coverage of PPV. Use of standard order for
nurses would ease the administration of adult vaccines in hospital settings and long-
term care facilities.603
While about half of nursing homes expressed the view that the presence of systematic
immunisation records would increase vaccine coverage, only 6% of homes reported
having such records. This finding has implications for the use of PPV because of
misconceptions about the risk of adverse reactions following revaccination.604 Jhus,
lack of systematic recording for PPV may inhibit the vaccination. US studies have
reported that the determination ofPPV status of patients is difficultJ 42,551 However,
as a second dose of PPV does not appear to be associated with serious adverse
effects,338,384 js recommended that PPV should be given to patients with unknown
vaccination history,while improvements in systematic recording of adult
immunisation may not only increase vaccine coverage, but also inform the timely
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revaccination of some high-risk patients. Indeed, there is evidence to show that the
level of antibody and protection by PPV may decline over time.604 Thus, compliance
with the DoH guidelines for revaccination of certain high-risk patients at the
appropriate interval may lower the risk of IPD in the recommended groups.
The most common reasons for non-receipt of PPV included lack of awareness and
failure to receive a recommendation from a GP in Scotland. It has been found that
77% and 15% of PPV recommended patients had not received the vaccine due to
these two reasons respectively.^ Most reported reasons for receiving PPV were
recommendations from GPs and other members of primary health care teams in the
present surveys. Previous studies from the UK and US revealed that 85% of PPV
recipients were immunised on the basis of advice from health care workers. 14,603
These data highlight the pivotal role of health care workers in determining coverage
of PPV. Previous studies have also shown that lack of awareness of the vaccine and
the risk of disease are the most important reasons for not receiving the
vaccine.605.608 Surveys in the UK and US showed that between 73% and 91% of
vaccine recipients were immunised due to physician advice. 14,551 jn common with
previous findings,1609 difficulty in obtaining consent on behalf of mentally
incompetent patients was indicated to be one of the important barriers to
pneumococcal polysaccharide vaccination in nursing home residents. A Canadian
study has indicated that obtaining consent for vaccination on admission for current
and future years can increase the coverage of PPV.610
The nursing home survey showed that the main factors in non-receipt of PPV included
refusal of vaccine by residents or family members, or no specific reason. In addition,
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there was an association between the deprivation category of high-risk patients and
the coverage of PPV. However, no relationship was observed between deprivation
category status and the coverage of recommended vaccines or antibiotic prophylaxis
in splenectomised patients. Data from the US also indicates a relationship between
low socio-economic status and poor vaccine coverage in children^! 1 and adults.606
These data suggest that although strategies to improve vaccine acceptance behaviours
may particularly need to focus on persons in lower socio-economic status, efforts are
equally necessary for those in higher socio-economic status. GPs and HDs in the
survey felt that a public health campaign on awareness of pneumococcal vaccine
could increase the coverage of vaccine. A UK study has demonstrated that an
organised public campaign of pneumococcal polysaccharide vaccination can increase
coverage of vaccine, from 4.5% to 19.5% among high-risk patients and use of vaccine
among GPs, from 17% to 89%.^ Education programmes aimed at both health care
professionals (doctors, nurses and pharmacists) and patients, improved practice
guidelines and effective methods to identify high-risk patients such as
letter/postcard/chart/computer reminders may help increase the likelihood of vaccine
uptake.603
Differences in the existence of influenza and pneumococcal polysaccharide
vaccination policies and vaccine coverage highlight the need for improved guidelines
and policies from the UK Departments of Health. At present, there is no set target for
pneumococcal polysaccharide vaccination in the UK. In the US, a national objective
has been set to achieve over 90% coverage of PPV in all elderly, residents of long-
term care facilities and other high-risk persons by the year 2010.612
Recommendations that provide the potential way to enhance vaccine coverage in
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adults have been issued in the US recently.1603 GPs and HDs in the survey reported
that clear immunisation guidelines were essential in improving PPV coverage. The
current chronic disease-based pneumococcal polysaccharide vaccination policy is not
well defined and requires clarifications of specific indications for vaccination such as
chronic lung or heart disease, which are yet unclear. Age-based strategies are more
successful in increasing vaccine coverage than patient-selection strategies based on
medical conditions.596 Nevertheless, the coverage ofPPV was lower in the age group
less than 65 years compared with the age group 65 years and above, suggesting that
greater attention is required to vaccinate the non-elderly with chronic medical
conditions. Although PPV is recommended two weeks prior to elective
splenectomy,458,613 adherence to this guideline was poor among GPs and other
clinicians. As PPV is likely to induce better antibody responses if given before
splenectomy,^^ improved guideline adherence is needed to ensure that elective
splenectomised patients receive the vaccine at the appropriate time.
At present, there are no payment mechanisms for pneumococcal polysaccharide
vaccination in Scotland. Over 80% of GPs and HDs suggested that financial support
and incentive payments for PPV could increase its use, suggesting that lack of
financial support may discourage the utilisation of PPV among GPs in Scotland. If
funding were made available and targets established for adult vaccination similar to
those for childhood vaccination, coverage of PPV might improve. The adoption of
universal use of influenza vaccine by the UK Departments of Health^68 jn a]| elderly
with fees payable to GPs has been an important step toward improving the coverage
of influenza vaccine. A gradual increase in the coverage of influenza vaccine, from
45% in 1988-89615, to 67% in 1991-92616, to 77% in 1995-96617 and to 89% in
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1998-99495 in the elderly and persons in long-term care facilities, may relate to
payment for influenza vaccination in the UK. Consideration should be given to
extending this scheme to cover combined influenza and PPV targets. The extent to
which financial incentives and disincentives impact on adult vaccination coverage
should be investigated to assess how far improved vaccine coverage could be
achieved with reimbursement policies. Establishing appropriate guidelines, audit and
feedback on performance may have a positive impact on improving coverage of PPV
in the future.
Additional studies in understanding the factors associated with the reasons for receipt
and non-receipt of vaccine among high-risk patients and clinicians' vaccine
preventable behaviours would aid in developing appropriate vaccination strategies.
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6. CONCLUSIONS
This study has confirmed the substantial and increasing disease burden from
pneumococcal disease and the rise in prevalence of antibiotic non-susceptibility
among pneumococci in Scotland. Although the use of PPV has increased in Scotland,
its use in recommended high-risk groups remains low.
The risk of IPD is highest in young children and the elderly. The incidence of
pneumococcal bacteraemia was high in these two groups, but this was not observed
for pneumococcal meningitis in the elderly. Males had a higher incidence of both
bacteraemia and meningitis than females. The peak activity of IPD was observed
during winter periods and corresponded with the pattern of influenza activity. There
was a 3-fold increase in the prevalence of antibiotic non-susceptibility for penicillin
between 1992 and 1999 and for erythromycin between 1994 and 1999. The observed
regional difference in the prevalence of antibiotic non-susceptibility correlated weakly
with the rate of penicillin prescription in Scotland. A statistically significant
correlation was noted between the annual prevalence of penicillin non-susceptibility
and the rate of penicillin prescription for age groups, 5 years and less and 65 years and
above but not for the age group 5-64 years.
The pneumococcus was the second leading cause of bacterial meningitis and the first
cause of INMD in 1992-99, the period after the routine use of Hib conjugate vaccine
in Scotland. The proportion of cases of bacterial meningitis due to pneumococci
increased nearly 2-fold in the age group less than one year from the period 1983-91 to
1992-99, but no significant increase was recorded for the elderly aged 65 years and
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above. Over 82% of cases of INMD in the elderly were due to pneumococci between
1983 and 1999.
The present data and those from other parts of the UK indicate that the formulation of
all current pneumococcal vaccines includes the predominant serotypes associated with
IPD and NIPD. Nearly all serotypes associated with invasive and non-invasive
antibiotic resistant pneumococcal disease were also included in the formulation of
PPVs and PCVs. Serotypes in the 23-valent and previous 14-valent PPVs accounted
for a significant proportion of disease in all age groups. Coverage of PCVs was
substantially higher in young children but lower in those above 5 years of age. The
annual pattern of the most prevalent serotypes varied between 1993 and 1999. In
addition, coverage of PCVs fluctuated markedly from year to year, but this was not
observed for PPVs. This highlights the critical importance of monitoring serotype
distribution to track changes overtime, both before and after full PCV implementation
in the UK.
Overall, these data indicate that the availability of PCV for young children and the
increased use of PPV in the elderly and adults with high-risk conditions would reduce
significantly the morbidity and mortality associated with antibiotic susceptible and
non-susceptible pneumococcal disease in Scotland. In addition, guidelines for
clinicians to use antibiotics judiciously, an education programme aimed at the public
on the implications of their unnecessary use in the emergence of resistant
pneumococci and the availability of pneumococcal vaccines for disease prevention are
important in containing resistance.
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Although PPV is recommended by DoH for preventing IPD in high-risk groups, the
majority of these individuals have not received the vaccine in Scotland. No single
factor was documented to account for the low use of PPV. Nevertheless, in recent
years, the distribution and use of the vaccine have been improved in Scotland. The
majority of GPs and HDs had adequate knowledge with regard to pneumococcal
polysaccharide vaccination. Thus, it appears that they may have failed to utilise this
knowledge in clinical practice. Most respondents in the surveys also felt that GPs
should take the responsibility for providing pneumococcal polysaccharide
vaccination. Nearly all patients who received PPV in the present study were
vaccinated in general practice. Recommendations from GPs and community nurses
were the principal reason for the receipt of PPV. These data highlight the important
role of GPs and other members of the primary care team in improving coverage of
PPV.
Intensified efforts are required to improve PPV coverage in patients with an indication
for the vaccine. The extension of universal targeting of PPV to all elderly, as with the
influenza vaccine, is worthy of consideration since this would offer efficiencies in
terms of cost benefits and simpler logistics for delivering two preventive measures in
one routine surgery visit. This also offers the opportunity to vaccinate at the time of
annual influenza vaccination, which has been recognised as the most efficient strategy
to delivery PPV. Unlike influenza vaccine, PPV generally lasts for 5 to 10 years. This,
together with the results from this study, highlights the need for improved systematic
immunisation records in adults. Accurate vaccination status is particularly relevant for
some high-risk patients for whom timely revaccination could be important. In
Scotland, accurate detailed information on the immunisation status of children for
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vaccines recommended through the routine immunisation schedule are available
through the Standard Immunisation Recall System and the Grampian Immunisation
Recall System. Such system should also be introduced for PPV and other vaccines
recommended for adults.
Clear national recommendations, reimbursement policies, identification of vaccine
eligible patients through computer systems or during routine consultation and
organised education and national campaign of vaccination were identified as the
important strategies to improve the coverage of PPV. At present, there is no national
coverage target for PPV in the UK. Such an objective, together with more specific
vaccination policies and clear recommendations for the indication of vaccine in high-
risk adults, is probably the most effective way to increase coverage of PPV. The most
common reason for non-receipt of PPV was refusal by patients or family members, or
no specific reason. Thus, clinicians in both general practice and hospital settings
should ensure that their patients are aware of the risk of pneumococcal disease and the
benefits of vaccination.
The results from the present study should provide important data for developing
appropriate strategies for vaccine policy and delivery of PPV for the prevention of
pneumococcal disease in Scotland. Since vaccination against pneumocooci is the
major means available to prevent pneumococcal disease, use of PPV and PCV in
high-risk groups can yield significant public health benefits. Improved continual
surveillance of pneumococci is an essential component of public health efforts to
inform the development of appropriate vaccination strategies to prevent antibiotic
susceptible and non-susceptible pneumococcal disease.
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7. RECOMMENDATIONS
At present, information on serotype and antibiotic susceptibility level is included in
less than 5% of laboratory reports reported to SCIEH, although data gained by the
SMPRL from its own sources and local laboratory sources results in a dataset
containing approximately 70% serotype and antibiotic susceptibility information. The
establishment of SMPRL in 1992 has clearly enhanced the data on serotypes
distribution and antibiotic susceptibility in Scotland but this still needs to improve in
order to inform vaccine policy and to monitor the impact of pneumococcal conjugate
vaccination programme. In order to address this issue, enhanced pneumococcal
surveillance was established in November 1999, in a collaboration between SCIEH
and SMPRL in Scotland. Confirmation of pneumococci, serotyping and antibiotic
susceptibility are performed for all isolates submitted to SMPRL from all diagnostic
laboratories in Scotland. A single national database has now been established by
combining pneumococcal case information or isolates received at SCIEH and SMPRL
on a regular monthly basis. In addition, information on demographic characteristics,
clinical presentations, underlying medical conditions and outcome of illness in
individual cases are now being followed up actively by a surveillance co-ordinator.
However, population-based and active pneumococcal surveillance require to be
extended to determine the accurate burden of disease and antibiotic resistance. In
addition, there is a need for complementary data on pneumococcal isolates associated
with important non-invasive disease such as otitis media and pneumonia in Scotland.
Local knowledge of pneumococcal isolates causing both invasive and non-invasive
disease can provide important strategic data for future vaccination policies and other
preventive measures. It is also important to know precisely how diagnostic
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laboratories select samples for serotyping and antibiotic susceptibility testing. This
would help to assess sources of potential bias in relation to accurate determination of
the disease burden, serotype distribution and the prevelance of antibiotic non-
susceptibility in Scotland.
Since PCV offers serotype specific protection, a reduction in carriage of these
serotypes could mean than their ecological niche may be replaced with non-vaccine
serotypes.^-5^ Replacement of vaccine serotypes with non-vaccine serotypes309 an(j
an increase in otitis media due to non-vaccine serotypes^ have been reported. To
date, there has been no increase in IPD associated with non-vaccine serotypes. In
addition, capsular switching promoting virulence of pneumococcus has also been
detected.618 This raises theoretical concerns that the virulence and capsular type of
pneumococci may change in response to conjugate vaccine,591 posing a potential
threat to vaccinated persons who are protected against carriage of vaccine type.432
This presents a potential public health problem. Although all pneumococcal isolates
received at SMPRL were serotyped, the population-based genetics of pneumococcus
is poorly understood in Scotland. The detection of capsule switching through genetic
recombination, (i.e the transfer of genetic determinants that specify pneumococcal
capsular polysaccharide), is possible using MLST.507 This technique can provide
clear evidence for a history of recombination in pneumococci.507 The availability of
MLST in Scotland in the future is important for the management and understanding of
antibiotic resistance, the selection of appropriate serotypes for vaccine formulation
and the long-term epidemiology of pneumococcal disease.
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Studies in the US have reported important developments in the understanding of 1PD
linked to several demographic and epidemiological factors.6>8,129,132,133,
137,140,300 These include (i) the increased risk of 1PD in both smokers and HIV-
infected persons (ii) the increased occurrence of antibiotic resistance in persons with
higher socio-economic status (iii) the poor medical outcomes in persons infected with
antibiotic resistant pneumococci and (iv) the increase in reports of outbreaks of
pneumococcal disease in long-term care facilities. These new epidemiological
associations have implications for prevention of pneumococcal disease in the US, in
particular for correct targeting of polysaccharide and conjugate vaccines in high-risk
groups.2»91 Thus, there is a clear need to update the accurate epidemiological features
of pneumococcal disease and to identify the distribution of risk factors in the Scottish
population.
In order to investigate the current epidemiological features of IPD in Scotland, a
record linkage study has been established. This method used data on cases of
laboratory confirmed IPD which were linked to the data from both Scottish Morbidity
Records and mortality records from the General Register Office for Scotland. These
data were used to examine the incidence of disease, antibiotic resistance, serotype
distribution, predisposing factors (underlying medical conditions and socio-economic
status), clinical presentation, diagnosis, resource use and outcome of IPD. Such record
linkage is a powerful epidemiological tool for ascertaining the burden of IPD in
Scotland more accurately than previously reported and will allow a detailed study of
associations between patients and the epidemiological behaviour of pneumococci to
be carried out. In the future, this methodology should be proposed as an essential part
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of routine surveillance for IPD, including monitoring the effects of vaccination on its
epidemiology.
The use of reminder systems such as postcards, letters or telephone calls can help in
improving vaccination coverage among high-risk patients. Since the majority of
hospitalised patients have recognised indications for PPV, interventions to improve
the coverage of PPV should be introduced in hospital care settings to complement the
current primary care based vaccination in the UK. A greater understanding of the
reasons for vaccination and issues relating to vaccine safety and effectiveness among
high-risk patients are key to increasing coverage of PPV. Thus, organised education
and vaccination campaigns for PPV are necessary for promoting awareness among the
public and for changing clinical practice, knowledge and attitudes of health care
professionals.
Clinicians, particularly those in primary care, should make greater efforts to ensure
that their patients understand the risks of disease and the benefits of vaccination. The
implementation of a standing order for nurses to administer PPV, the presence of a
vaccination policy with appropriate targets set and the introduction of an age-related
vaccination policy should also enhance vaccine delivery and coverage among patients
for whom PPV is recommended. Such interventions should narrow the gap between
the policy and practice of pneumococcal polysaccharide vaccination in the UK.
Although the results suggest areas for improving coverage of PPV, further research
into the factors associated with clinicians' and patients' preventive behaviours on
utilisation of PPV would identify additional barriers for acceptance of vaccination.
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national health service in scotland Edinburgh EH5 3SQ
Scotland Tel: (0131)552 6255 ext. 2843
+44 131 552 6255 (international)
Information & Statistics Division GTN; 7167
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Clifton 1 louse Our Reference MB/IS
Clifton Place
GLASGOW oate 11 February 2000
G3 7LN
Dear Mr Kyaw
VACCINATION STATUS IN ASPLENIC INDIVIDUALS: AN AUDIT OF PNEUMOCOCCAL,
HAEMOPHILLUS INFLUENZAE AND NEISSERIA MENINGITIS VACCINE UPTAKE IN
SCOTLAND
Thank you for your letter of 7 February 2000 in which you clarified the issues raised by the Privacy
Advisory Committee. 1 can confirm that the data you requested can now be released to you. As you
require details of those who have died we will provide the information using the linked SMR01 to GROS
deaths dataset. A member of the Record Linkage Team will be in touch with you in the near future.
Yours sincerely
Dr Marion Bain
Consultant in Public Health Medicine
c.c. James Boyd, Record Linkage Team




























PNEUMOCOCCAL DISEASE AND ASPLENIC PATIENTS
I write to confirm permission for access to Argyll and Clyde residents for the project on
pneumococcal disease in Scotland as described in your letter of 27 October 1999.




DEPUTY DIRECTOR OF PUBLIC HEALTH
DEPARTMENT OF PUBLIC HEALTH
J:\LMR\LETTERS\Nov99Uoncs30.doc -
Ross House, Hawkhead Road, Paisley PA2 7BN
Tel: 0141 842 7200 Fax: 0141 848 1414






















HAEMOPHILUS INFLUENZAE AND NEISSERIA MENINGITIS VACCINE
UPTAKESAMONGASPLENIC INDIVIDUALS INSCOTLAND
Thank you for your letter of 27 October regarding the above which I received on 10
November. I confirm that I am in agreement to your accessing details of asplenic Ayrshire
and Arran patients registered at ISD during the period 1998 - 1998/99. The release of this














Thanks for your letter of 27th October, which arrived in Shetland on 10th November. I
am happy that ISD should release details of asplenic Shetlanders to you.
Yours sincerely,
Dr Norman Waugh
ACTING DIRECTOR OF PUBLIC HEALTH
BOARD HEADQUARTERS, Brevik House, Lerwick, Shetland ZE1 OTG




Department of Public Health Tel No: (01463) 704886 Direct Dial













AUDIT OF ASPLENIC PATIENTS
I am happy to give permission for details of all asplenic patients resident in Highland to be
released from ISD to yourselves for the purposes of the audit project you outlined in your recent
letter of 27 October.
I look forward to seeing the findings of this.
Yours sincerely
Dr Ken Oates
Consultant in Public Health Medicine
Assynt House - Beechwood Park - Inverness IV2 3HG • Tel (01463) 717123 • Fax (01463) 235189 f~\
















Vaccination Status in Asplenic Individuals: An Audit of Hospital and Primary Care Aspienic
Register Database in Scotland
We have recently been contacted by Moe Hein Kyaw, a Research Student at SCIEH, who has written
on your behalf requesting the Health Board to release named patient data to SCIEH to facilitate an
audit of vaccination status. I enclose copies of the correspondence.
Grampian Health Board currently holds a register of asplenic patients and I would be happy to release
anonymised data from the register, but this would not provide all the data requested by SCIEH. The
register currently holds no information on the hyposplenic population in Grampian. It would not be
able to provide detailed information on reason for splenectomy nor whether it was performed as an
elective or emergency procedure. Although some information is held on the use of antibiotic
prophylaxis, we do not know the current status of individual patients. Additionally no detailed
information is held on pneumococcal or other infections in this group of patients.
Following consideration of this request, I confirm the Health Board is prepared to release patient and
GP details to allow SCIEH to contact the GP to request data for the audit. However in order to
comply with best practice, the data will only be released on the following basis:
♦ It is to be used only for the purpose stated in the letter, i.e. to allow audit of compliance with
current guidelines issued by the Department of Health and British Committee for Standards in
Haematology for the specific purpose of informing the planning of future service provision
♦ The data will be released into the care of the Caldicot guardian ofSCIEH (yourself)
If you find these terms acceptable, please confirm this in writing and I will then arrange for the data to




Date 7 September, 1999
Dr Norman Waugh
Acting Director of Public Health
cc. Moe Hein Kyaw, SCIEH
Anne-Marie Noble, Health Information Developer/Data Protection, GHB
Stephen Conaty, Locum Consultant in Public Health Medicine, GHB
Helen Howie, Senior Registrar in Public Health Medicine, GHB
Your Ref:
Our Ref: HB/JMM















Thank you for your note. I am happy to agree to the release of details of aspienic patients




Director of Public Health
Dalian House, PO Box 15327,350 St Vincent Street, Glasgow G3 8YU
Switchboard: 0141-201 4444 Textphone: 0141-201 4400











RE: Vaccination Status in Asplenic Individuals: an Audit of Pneumococcal,
Haemophilus Influenzae and Neisseria Meningitidis Vaccine Uptake in Scotland
I refer to your letter of 27lh October, which Dr McWhirter, Director of Public Health passed
on to the Forth Valley Ethics of Research Committee and which was discussed by that
Committee on 9 December 1999.
The Committee agreed that this is an audit exercise and that a full submission for ethical
approval is not required.
Yours sincerely
Dr A J Holiiday
Secretary to Ethics of Research Committee
c.c. Dr M McWhirter
33 Spiffa!Sfreef, Sfirlmg, FK81DX
Telephone: 01786 -457251




























AUDIT OF VACCINE UPTAKES AMONG ASPLENIC INDIVIDUALS IN
SCOTLAND
I have now discussed this proposed audit with the Chairman of our Local Ethics
Committee who considers that the proposal does not require to be submitted for
ethical approval. I understand that Dr Jim Chalmers, Information & Statistics
Division, can provide the details of asplenic patients registered at ISD from 1988-
1998/9, I am happy that he releases the relevant information to you.
Kind regards. /
J a-fr/lrt*t A
Yours sincerely 1 " '
DR LESLEY MACDONALD
Director of Public Health
S
o /
DUMFRIES and GALLOWAY HEALTH BOARD
GRIERSON HOUSE, THE CRICHTON,
BANKEND ROAD, DUMFRIES. DG1 4ZG
DEPARTMENT OF PUBLIC HEALTH MEDICINE
Tel: Dumfries (01387) 272700
Fax: 01387 252375
ur Ref. DC/JS Your Ref. Enquiries to:
Direct Dial (01387) 272725










Vaccine Uptake in Asplenic Patients
1 hereby authorise 1SD to provide you with details of asplenic patients registered in
Dumfries and Galloway from 1988 onwards.
Yours sincerely.
DR DEREK COX
Director of Public Health





Tel Direct Dial: 01896 82 5560










AUDIT OF PNEUMOCOCCAL, HAEMOPHILUS INFLUENZA AND
NEISSERIA MENINGITIDIS VACCINE UPTAKES AMONG ASPLENIC
INDIVIDUALS IN SCOTLAND
Thank you for your letter of 27 October 1999 about this audit proposal where you
have requested written permission from me for release of asplenic patient details to
SC1EH.
Please accept this letter as permission for I.S.D. to release such patient details to you.
1 look forward to seeing a full copy of the result after the completion of this audit.







Director of Public Health
Chief Administrative Medical Officer
Bord Slainte nan Eilean Siar
Western Isles Health Board
Ar Faklhlc:










Vaccination Status in Asplenic Individuals
Thank you for your letter of 27th October on this subject.
I am content for you to be sent the names of asplenic patients in the
Western Isles for the purpose of this study.It seems a very interesting
project and will act as an aide-memoire for general practitioners so that
any patients who have slipped through the net will then be vaccinated.
You may be interested to know that we are funding a special programme
this winter by paying general practitioners to vaccinate as many as





Dr. A. Michael George
Director of Public Health
Dr. A. Michael MacDhedrsa
Stiuiriche Slainte Phoblach
Health Board Offices, 37 South Beach Street,
Stornoway, isle of Lewis HS1 2BB
Tel: 01851 702997 Fax: 01851 706720
Oifisean Bord na Slainte, 37 Mol a Deas,
Stedrnabhagh, Eilean Leodhais HS1 2B8
Fon: 01851 702997 Facs: 01851 706720
E-mail: wihb@sol.co.uk Post Deaiain: wihb@sol.co.uk
b. Random sample selection method for surveys 1 and 2
The SPSS statistical package was used for random sample selection in these surveys.
A detailed method, SPSS random select function, is described below.
SPSS random select function
This function allows selecting a random sample based on an exact number of cases.
1. Specify a user-specific number of cases.
2. Specify the number of cases from which to generate the sample. This second
number should be less than or equal to the total number of cases in the data file. If the
number exceeds the total number of cases in the data file, the sample will contain
proportionally fewer cases than requested number.
3. Syntax.
4. Sample requested from the total number of cases.
Example: the selection of 10 patients from every CMR practice in survey 2
Create an SPSS file for each CMR practice, containing a record for every patient with
one or more of the specified conditions/illnesses.
Use SPSS aggregated function to count the number of these patients in each practice
(eg. Practice 1 had 466 patients, Practice 2 had 155 patients etc.).
Open File A and selected only patients in Practice 1
Use SPSS random select function (as stated above) to randomly select 10 patients






Pneumococcal polysaccharide vaccine has been available for use since 1979. However, the
usage of this vaccine remains low among recommended individuals and the reasons are
poorly understood. This survey is to identify the relevant factors which may affect the use and
administration ofpneumococcal vaccine in primary and hospital care.
Adult pneumococcal polysaccharide immunisation: a survey of general practitioners'/
hospital doctors' knowledge, attitudes and practices towards pneumococcal
polysaccharide vaccine
(Please tick as appropriate)
Strongly Agree Disagree Strongly Don!
Agree Disagree Kno\
1. The vaccine should be targeted
to patients with:
a. chronic pulmonary disease □ □ □ □ □
b. chronic heart disease □ □ □ □ □
c. chronic renal disease □ □ □ □ □
d. chronic liver disease □ □ □ □ □
e. immunodeficiency & immuno
suppression □ □ □ □ □
f. Diabetes mellitus □ □ □ □ □
g. asplenia & severe splenic dysfunction □ □ □ □ □
h. all older people aged >65 years □ □ □ □ □
i. all older people (>65 years) who are
residents of long stay facilities □ □ □ □ □
j. others (please specify):
2. The vaccine has proven safe and effective in preventing invasivepneumococcal disease in:
a. young adults
b. older people (>65 years)











































5. Pneumococcal immunisation policies in my practice/hospital include:
Written policies with target d
Written policies without target □
Verbal agreement on use among partners n
No policy □
Others (please specify):
6. If the vaccine is proven effective and safe, the primary responsibility for its use should lie with:





The Department of Health d
Others (please specify):
7. My knowledge of pneumococcal vaccine comes from: (please tick more than one if necessary)
Own review of medical literature d Past experience d
Discussion with colleagues d The Department of Health d
Further medical education d Local Health Board guidelines d
Advice ofmanufacturer d
Others (please specify):
8. Which of the following do you think would help to improve pneumococcal vaccine coverage in
in primary care? (please tick more than one if necessary)
A clear immunisation policy d
Financial support for vaccinations d
Further education on immunisation d
Nurse assistant d
Computerised systems to identify high risk patients d
Conclusive evidence of vaccine efficacy d




Surveyofinfl enzaa dpneumococcalvaccineptak intheCMRpractices,Scotland
GeneralPracticeLocation: GeneralPractitioner:










































































































Vaccineshouldbet rg tpatientswith(pl aseti kappropriate):d High-riskconditionsPneumococcalvaccine
Influenzavaccine
Chronicpulmonarydisease Chronicheartdisease Chronicre aldis ase Chronicliverdisease Immunodeficiency& immunosuppression Diabetesm llitus Splenicdisorders Allelderly>65yearsofag Longstaycareeld rly residents>65yearofage Others(pleasespecify) Immunisationpoliciesi yra iceinclude(ple stickappropriat ): PolicyPneumococcalvaccine
Influenzavaccine
Writtenpoliciesw thtarget Writtenpolicieswi houttarg Verbalagreementonus amongpartners Nop licy Others(pleasespecify)
Ifthevaccineisproveneffe tivendaf ,t rimaryresponsibilityritussh uldli with:(pleasetickmorh nonifnecessary) CategoryPneumococcalva cine
Influenzavaccine
Thepati nt Hospitalphys ci ns Generalpractitioners HealthBo rds TheDepartmentofHealth Others(pleasespecify)
Survey 3 questionnaire
Surveyof Influenzaand PneumococclVacci ationiNursi gHomes
Questionnaire
•Thenumberofgen ralpracticeslo kingaftr sident •Thenumberofresid nts •Theexistenceofsystematicimmunisationcards (notmedicalornursingr cords)
c
YesQNo[
Thenumbervaccinated:- Influenzavaccine(2000-01) Pneumococcalva cinewithinlast5years Bothvaccines
Factorswhichcouldimpr veveragefbotvaccin s(ti kailt tpply)
Factors
Influenzaand pneumococcalvaccine









Writtenpoliciesw ths ttarg t Writtenpolicieswithoutstarg Verbalagreementmongpartn rs Nop licy Others(pleasespecify)













PLEASE CIRCLE THE RELEVANT ANSWERS
Is the patient currently on your list?





Please fill in the rest of the form only if this patient is on your list and has had a splenectomy
(or) hyposplenic condition.
What was the date of the operation?
What was the reason for the splenectomy?
/
Was it performed as an elective or emergency procedure?
What were the other underlying medical conditions.
































What was the date
of the most recent
vaccination? / / / / / / / /
Does this patient take long-term prophylaxis with an antibiotic? YES NO
Has this patient been admitted to hospital for any infection since YES NO
developing asplenia?
PLEASE RETURN THE ORIGINAL QUESTIONNAIRE and NOT A PHOTOCOPY
Scottish Centre for Infection & Environmental Health, Clifton House, Clifton Place, Glasgow, G3 7LN
Summary of record linkage study results
Invasive pneumococcal disease in Scotland in 2000: use of record linkage to explore
associations between patients and disease in relation to future vaccination policy
Mae H Kyaw'-2, Peter Christie', Stuart Clarke3, Jim Chalmers'', lan G Janes', Harry Campbell2
Background
• The pneumococcus is an important cause of death and
hospitalisation in Scotland, and incurs large health care costs.
• A 7-valent pneumococcal conjugate vaccine has gained licensure
in the UK and is expected to be considered for the routine childhood
immunisation schedule.
• The vaccine only covers most of the more common serotypes, but
may have to be tailored for specific age groups and geographical
locations.
• Knowledge of local disease epidemiology can provide important
strategic data for deciding appropriate vaccination polices and other
preventive interventions.
Methods
• Enhanced pneumococcal surveillance was established in November
1999 in Scotland, in a collaboration between SCIEH and SMPRL.
• Isolates submitted to SMPRL were confirmed as pneumococci by
antigen testing. Coagglutination testing was used for serogrouping/
typing and the E-test method for antibiotic susceptibility.
• Data on cases of invasive pneumococcal disease (IPD) reported to
SCIEH and to SMPRL in 2000 were linked to Scottish hospital
discharge records (SMR01) and to death certificate data recorded
by the General Register Office in Scotland (GRO).
• Record linkage was carried by probability matching using date of
birth, sex, name and other identifiers.
• This methodology will provide an ongoing active system for
monitoring ofany future effects of vaccination on the epidemiological
features of IPD.
Results
559 cases of IPD recorded in 2000. 348 (62.2%) were successfully
linked toSMROl and GRO records. 364(65.1%) were serogrouped.
Antibiotic susceptibility was measured in 350 cases (62.6%) for




Case-fatality rate by antibiotic susceptibility
Penicillin Ciprofloxacin
Antibiotic
(Minimal inhibitory concentrations (MIC) break points);-
Susceptible Intermediate Resistant
Penicillin: 0.06pg/ml 0.1-1 pg/ml >2 pg/ml
Erythromycin: <0.5pg/ml l-2pg/m! >4 pg/ml
Ciprofloxacin: < 1 pg/ml - >1.1 pg/ml
Intermediate and resistance isolates were defined as
non-susceptible.
• Higher mortality in resistant infections
• No deaths in erythromycin resistant cases
Graph 3.




The Carstairs Deprivation Index is categorised into scores 1 to 7,
with 1 being the most affluent and 7 being themost socio-economically
deprived.
• No deprivation related difference
• Higher rates of ciprofloxacin resistance in less affluent groups
Graph 4.
Incidence and case-fatality rate of invasive pneumococcal
disease by age group in Scotland, 2000
Clinical presentations (leading diagnosis)







<1 y 1 y 2-4 y 5-17 y 18-49 y 50-64 y 65 y and
. above
Peak incidence in the young and the elderly
Peak case-fatality in < 1 years and > 50 years Meningitis 11%
Scottish Centre for Infection
and Environmental Health
Clifton House. Clifton Place, Glasgow G3 7LN
Tel: 0141 300 1100 Fax: 0141 300 1170 SCOTLAND
Invasive pneumococcal disease in Scotland in 2000: use of record linkage to explore
associations between patients and disease in relation to future vaccination policy
Moe H Kyaw' % Peter Christie', Stuart Clarke3, Jim Chalmers4, lan G Jones', Harry Campbell2
Graph 5.
Duration of hospitalisation relation to penicillin susceptibility
55 58
L m
11-30 days 31 days and above
Days
Graph 7.
• Antibiotic resistance is associated with longer
hospital stay
Serogroup distribution in age group less than 5 years
L——J|
L.IL.I1 _. 11 _
3 4 6 9 14 15 18 19 23 24
Serogroup
Serogroup distribution in age group 5-64 years
Frequency, prevalence (20y) and case-fatality rate by high-risk conditions
Cases (no.), prevalence (%) & case-fatality rate (%)














1 2 3 4 6 7 9 12 14 15 16 17 18 19 20 22 23 31 33 35
Serogroup
Serogroup distribution in age group 65 years and above
Higher case-fatality in coronary artery disease/CHD, hepatic/
alcohol abuse and renal disease
1 3 4 6 7 8 9 10 11 12 14 15 16 17 18 19 20 22 23 24 33 41
Serogroup
• Predominant serogroups:
Serogroup 14 in all age groups
Serogroup 6,18,19,23, in < 5 years
Serogroup 1,8,9.12 in 5-64 years
Serogroup 9,3,19,23 in >65 years
Graph 8.
Case-fatality rate associated with most common serogroups
1 9 14
Serogroup
• Serogroup 3 has higher case-fatality rate
• Serogroup 14 has lowercase-fatality rate but is more common
Scottish Centre for Infection
and Environmental Health
Clifton House. Chiton Place. Glasgow G3 7LN
Tel: 0141 300 1100 Fax: 0141 300 1170
NHS
SCOTLAND
Invasive pneumococcal disease in Scotland in 2000: use of record linkage to explore
associations between patients and disease in relation to future vaccination policy
Moe H Kyaw'-2, Peter Christie', Stuart Clarke3, Jim Chalmers4, Ian G Jones', Harry Campbell2
Vaccine related serogroup by age group
<5 years 5-64 years 65 years and above
Age group
• Incomplete vaccine serotype coverage for > ? years by
7-11 valent conjugate vaccines
Conclusions
• The risk of IPD is highest in young children, the elderly and persons
with certain underlying medical conditions
• Conjugate vaccines cover the majority of serogroups causing IPD
und antibiotic resistance in young children but coverage is lower in
older age groups
• The routine use of conjugate and polysaccharide pneumococcal
vaccines would prevent the majority of IPD. including those
associated with antibiotic resistant strains
• This methodology provides u unique opportunity to investigate
associations between patients und the epidemiological features of
pneumococci
• It cun be used as ongoing active long-term surveillance programme
for monitoring the impact of vaccination on pneumococci
Vaccine coverage for penicillin (n=19), erythromycin (n=32) and
ciprofloxacin (n=100) non-susceptible isolates
11-valent 14-valent
Ciprofloxacin resistant strains better covered by 23-valent
polysaccharide
Graph 11.
Vaccine related serogroups in Five leading risk conditions for invasive
pneumococcal disease
fj]lM.n
Diabetes Central nervous Coronary artery Non- Chronic lung
system disorder disease haematological disease
malignancy
Risk conditions for IPD
• Poorer coverage by conjugate vaccines in second highest risk group
(chronic lung disease) although inadequate microbiological
diagnosis may distort serotype coverage
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h. Glossary
Definitions
Serotype: The pneumococcus has 90 serotypes and 45 serogroups (section: 1.1.1).
Although serogroups and types are differed, the term "serotype" was used consistently
in the study.
Antibiotic non-susceptibility: The cut off point for antibiotic susceptibity is divided
into three levels, sensitive, intermediate resistant and high-level resistant. The term
"antibiotic non-susceptibity" refers to the latter two categories for this study.
Invasive disease: This includes cases where the pneumococcus is isolated from
normally sterile body sites such as cerebrospinal fluid, blood or joint fluid.
Invasive non-meningitic bacterial disease: This includes cases where the
pneumococcus, meningococcus, Group B streptococcus, Haemophilus influenzae or
Listeria monocytogenes are isolated from blood or other normally sterile sites but not
from cerebrospinal fluid.
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Serotypes/groups distribution and antimicrobial resistance of
invasive pneumococcal isolates: implications for vaccine
strategies
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SUMMARY
Based on the invasive pneumococcal isolates referred to reference laboratories in Scotland in
1988-99, we identified the distribution of serotypes/groups and their antimicrobial resistance
patterns in order to evaluate the coverage of polysaccharide and the new pneumococcal
conjugate vaccines. A total of 5659 invasive isolates were included. Of these, 5124 (90-5%)
were blood isolates, 308 (5-5%) were CSF isolates, 143 (2-5%) were blood and CSF and 84
(1-5%) were other normally sterile isolates. The most prevalent 11 serotypes/groups were 14, 9,
19, 6, 23, 1, 3, 4, 7, 8 and 18, in numerical order. These accounted for 84% of total
serotypes/groups.
The serotypes/groups included in the 23 and 14-valent polysaccharide vaccines accounted for
96% and 88% of all isolates. Both vaccines accounted for 98% of penicillin non-susceptible
and 100% of erythromycin non-susceptible isolates. The 7, 9, and 11-valent conjugate vaccines
covered 61, 68 and 80% of invasive isolates respectively. The coverage of these vaccines was
substantially higher in youngest age group with 84, 86 and 93% of invasive isolates in children
< 2 years included in the 7, 9 and 11-valent conjugate vaccines compared with 58, 64 and 77%
in adults > 65 years of age.
The serotype/group distribution of invasive isolates in Scotland varied from year to year
over the period 1993-9. The coverage of the 23-valent vaccine remained above 95% in each
year but the coverage of the 7, 9 and 11-valent conjugate vaccines showed more marked
fluctuation with coverage as low as 53, 60 and 75% in some years. Continued surveillance of
invasive pneumococcal isolates is required to inform the development of appropriate vaccine
strategies to prevent pneumococcal disease in Scotland.
INTRODUCTION
Despite the availability of effective antibiotics, in¬
vasive pneumococcal disease remains a serious public
health problem worldwide. Streptococcus pneumoniae
is a leading cause of bacteraemia and meningitis [1,2]
particularly among the very young and elderly and
* Author for correspondence: Clifton House, Clifton Place,
Glasgow, G3 7LN.
those with chronic medical conditions [3]. The current
23-valent polysaccharide pneumococcal vaccine
covers at least 90 and 88% of serotypes/groups
causing invasive pneumococcal disease in the UK [4]
and US [5, 6] respectively. However, this vaccine is
poorly immunogenic in children < 2 years old, the
age group with the highest burden of invasive
pneumococcal disease [7]. Therefore, new 7 to 11-
valent conjugate pneumococcal vaccines are now
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being developed and evaluated [8]. In addition,
conjugate pneumococcal vaccines may have a future
role in protecting the elderly and adults with con¬
ditions placing them at increased risk of pneumo¬
coccal disease.
The effectiveness of polysaccharide and conjugate
vaccines is dependent on the distribution of vaccine
serotypes in the population being immunized [9].
Therefore, knowledge of the distribution of pneu¬
mococcal serotypes/groups within a defined popu¬
lation is important in developing rational vaccine
policy for the future use of conjugate pneumococcal
vaccines in the prevention of invasive pneumococcal
disease. This paper reviews population based data on
Streptococcus pneumoniae isolates identified from
sterile body site specimens in Scotland during the
period 1988-99 and examines the seroepidemiological
characteristics of invasive pneumococcal disease.
METHODS AND MATERIALS
Background
The data for this study were obtained from Scottish
Centre for Infection and Environmental Health
(SCIEH) and Scottish Meningococcus and Pneumo-
coccus Reference Laboratory (SMPRL). SCIEH
serves as a national surveillance centre for monitor¬
ing infectious diseases and environmental hazards.
Reports from laboratories throughout Scotland are
received by SCIEH on a weekly basis. SMPRL is
the national reference laboratory for pneumococcal
disease. It has been established to enhance national
surveillance for these diseases and has excellent links
with microbiology laboratories throughout Scotland.
It acts as a national centre for serotyping and anti¬
biotic sensitivity testing of pneumococcal isolates.
Laboratory records of Streptococcus pneumoniae
reported to SCIEH (1988-1998/9) and the pneumo¬
coccal isolates received routinely by SMPRL (1993—
1998/9) from all diagnostic laboratories in Scotland
have been combined in a single database.
Study data
Only invasive isolates (blood, cerebrospinal fluid
(CSF) and other normally sterile sites) were included
in this study. Duplicate records in SCIEH and
SMPRL datasets were excluded. The Danish system
ofnomenclature was used for reporting pneumococcal
serotypes/groups in both data bases. Isolates that had
values of minimal inhibitory concentration (MIC)
< 0-06/ig/ml, between 0T2 and 1-0/tg/ml and
2-0 /ig/ml or higher were defined as sensitive, in¬
termediate, and high level penicillin resistance re¬
spectively. Isolates with MICs of intermediate and
resistant levels were described as non-susceptible.
Pneumococcal isolates that had erythromycin level of
< 1 /Ag/ml and > 1 /tg/ml were recorded as sensitive
and resistant respectively. The MICs were determined
on the receipt of organism with the use of standard
agar dilution MIC method in 1992-3 and the E-test
method (Cambridge Diagnostics, Cambridge UK)
since 1994.
Statistical analysis
Data analysis of pneumococcal isolates, serotypes/
groups, specimen type, vaccine serotypes/groups and
antimicrobial resistance were performed on the com¬
bined study dataset using SPSS version 8. 95%
confidence intervals were calculated for the coverage
of vaccines in different age groups during 1993-9.
RESULTS
A total of 17628 Streptococcus pneumoniae cases were
recorded in the SCIEH and SMPRL databases over
the study period. After removal of duplicate records,
10150 cases remained. Of these, only 5659 cases were
from blood, CSF and other sterile site specimens and
were included in the study. Of the 5659 invasive
isolates, 5124 (90-5%) were blood isolates, 308 (5 5 %) 4
were CSF isolates, 143 (2-5%) were isolated from
both blood and CSF, and 84 (1 -5 %) were other sterile
site isolates (Table 1). A high proportion, 2499
(44-2 %) were from elderly > 65 years old and only
661 (11-7%) were from children < 5 years old. 2601
(46%) were from females, 2886 (51 %) from males
and 172 (3%) sex unknown were included. The
median and mean age of patients was 63 and 54 years
old respectively. Information on serotypes/groups
was available for 1531 isolates. Of these, only 105
(6-9%) isolates had their serotype/group reported
during 1988-92. However, a high proportion, 1426
(93-1 %) isolates had their serotype/group recorded in
1993-99 due to the establishment of SMPRL in
1992/3. The distribution among the 15 Health Boards
in Scotland of isolates whose serotypes/groups were
determined was as follows: Greater Glasgow, 428;
Lothian, 400; Lanarkshire, 235; Grampian, 120;
Ayrshire and Arran, 88; Argyll and Clyde, 60; Forth
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Table 1. Number ofpneumococcal isolates from sterile sites
No. of isolates (%)
Blood
Year Total Blood CSF* +CSF Otherst
1988 296 248 23 23 2
1989 350 305 25 20 0
1990 343 300 28 14 1
1991 390 358 17 15 0
1992 441 403 27 10 1
1993 536 482 27 19 8
1994 622 560 38 14 10
1995 599 551 27 13 8
1996 617 563 34 7 13
1997 615 586 19 2 8
1998 646 590 32 5 19
1999} 204 178 11 1 14
Total 5659(100) 5124(90-5) 308 (5-5) 143 (2-5) 84(1-
* CSF, cerebrospinal fluid.
t Bone marrow, pleural aspirate, lung aspirate, pericardial fluid, bronchial aspirate.
J Data only available up to Aug. 1999.
Valley, 53; Tayside, 51; Highland, 44; Borders, 20;
Fife, 13; Dumfries and Galloway, 12; Western Isles,
4; Orkney and Shetland, 0; and unknown area, 3.
Serotypes/groups distribution 1988/9
Most prevalent 11 serotypes/groups
The leading 11 serotypes/groups were identified
among different age groups (Table 2). In all age
groups, these serotypes/groups accounted for over
80% of all invasive pneumococcal isolates.
Overall, type 14 was the most prevalent serotype,
accounting for about 10-32% of invasive isolates.
Serotype 1 was the most prevalent in the age group
5-64 years accounting for 13% of invasive pneumo¬
coccal isolates.
Annual pattern ofmost prevalent serotypes/groups
The prevalence of individual serotypes/groups fluc¬
tuated from year to year of the period 1993-9 (Table
3). This shows an increase in serotype 14 and a decline
in serotype 3 in recent years.
Prevalence of vaccine-related serotypes/groups
Coverage by 23-vaIent and 14-valent polysaccharide
vaccines
The current 23-valent and previous 14-valent vaccines
covered 96 and 88% of reported pneumococcal
serotypes/groups isolated in all age groups in the
study period. The reported coverage in individual age
groups is shown in Table 4.
Coverage bv 7, 9 and I I-valent conjugate
pneumococcal vaccines
The 7-valent conjugate vaccine includes serotypes 4,
6B, 9V, 14, 18C, 19F and 23F [8], Serotypes 1 and 5
are added in the 9-valent vaccine and 1, 3, 5, 7F in the
11-valent vaccine [10]. These 7, 9 and 11-valent
conjugate vaccines covered 61, 68 and 80% of
reported pneumococcal serotypes/groups isolated in
all groups respectively. Coverage was substantially
higher in the < 2 years than in older age groups
(Table 4).
Coverage of invasive serotypes/groups with 23-valent
polysaccharide and the 7-, 9- and 11-valent conjugate
vaccines: annual fluctuation over the period 1993-9
The 23-valent polysaccharide vaccine covered > 90%
of invasive isolates in all ages. However, the annual
coverage of the 7, 9 and 11-valent conjugate vaccine
showed substantial annual variation. Coverage was
59-97, 64-97 and 77-100% for 7, 9 and 11-valent
conjugate vaccine in < 2 years age group, 42-69,
47-75 and 57-88% for 7, 9 and 11-valent conjugate
vaccine in > 65 years age group and 53-73, 60-76 and
75-82% for 7, 9 and 11-valent conjugate vaccine for
all ages (Table 5).
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Table 2. Most prevalent {11) pneumococcal serotypes/groups in different
age groups
Serotypes/ No. of Serotypes/ No. of
groups isolates (%) groups isolates (%)
< 2 years > 65 years
14 69 (31-8) 14 83(14-5)
6 38(17-5) 19 61 (10-6)
19 22(10-1) 3 56 (9-8)
23 22(10-1) 9 53 (9-2)
9 14 (6-5) 23 47(8-2)
18 10 (4-6) 4 41 (7-2)
7 8 (3-7) 6 41 (7-2)
4 7 (3-2) 1 35(61)
3 6 (2-8) 8 26 (4-5)
1 5 (2-3) 22 19(3-3)
8 2 (0-9) 7 18 (3-1)
Total* 203 (93-5) Total* 480 (83-8)
Totalt 217(100) Totalt 573 (100)
< 5 years All ages
14 72 (29-3) 14 254(16-6)
6 40(16-3) 9 144 (9-4)
23 24 (9-8) 19 140 (9-4)
19 23 (9-3) 6 133(8-7)
18 18(7-3) 23 126 (8-2)
9 16(6-5) I 114(7-4)
7 10(4-1) 3 104 (6-8)
1 9 (3-7) 4 94(6-1)
4 8 (3-3) 7 70 (4-6)
3 6 (2-4) 8 64 (4-2)
8 2 (0-8) 18 40 (2-6)
Total* 228 (92-7) Total* 1283 (83-8)















* Total for top 11 serotypes/groups.
t Overall total.
Most prevalent serotypes/groups not included in the
new 11-valent conjugate vaccine
Serotypes/group 8, 11, 12 and 22 were the most
common nor-vaccine serotypes/groups, accounting
for 178 (12 %) of invasive isolates in all ages (Table 6).
A higher proportion of them was recorded in those
^ 5 years of age.
Penicillin/erythromycin susceptibility
The distribution of serotypes/groups that were peni¬
cillin and erythromycin susceptible and non-suscep¬
tible is shown in Table 7. The prevalence of high level
penicillin resistance is very low. Only two blood
isolates were shown to have penicillin resistance. Both
were serotype 14.
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Table 3. Most prevalent (11) serotypes/groups: annual variation (1993-9)
No. of isolates
Serotypes/ —
groups 1993 1994 1995 1996 1997 1998 1999 Total
1 15 22 16 23 11 11 7 105
3 11 16 15 14 20 9 6 91
4 13 9 20 12 10 10 11 85
6 22 17 17 24 13 18 17 128
7 8 12 14 4 13 9 3 63
8 10 12 6 6 11 7 8 60
9 19 11 19 21 12 30 24 136
14 21 31 26 35 29 52 50 244
18 4 10 5 3 3 8 1 34
19 21 20 18 15 15 23 20 132
23 14 23 13 17 14 13 26 120
Others 30 46 32 32 30 27 31 228
Total* COV") 183 169 174 151 190 173 1198
Totalf 188 229 201 206 181 217 204 1426
* A total of top 11 serotypes/groups in each year,
f All total serotypes/groups in each year.
Table 4. Vaccine coverage ofpneumococcal serotypes/groups in different
age groups
No. of vaccine related isolates (%)
Vaccines < 2 years 5 years 5-64 years ^ 65 years All ages
23-valent NAf 244 (99-2) 475 (95) 550 (96) 1476 (96-4)
14-valent NA 232 (94-3) 427 (85-4) 481 (83-9) 1354 (88-4)
1J -valent* 201 (92-6) 226 (91-9) 379 (75-8) 440 (76-8) 1221 (79-8)
9-valent* 187 (86-2) 210(85-4) 313 (62-6) 366 (63-9) 1047(68-4)
7-valent* 182 (83-9) 201 (81-7) 247 (49-4) 331 (57-8) 931 (60-8)
Total 217(100) 246 (100) 500 (100) 573 (100) 1531 (100)
* Pneumococcal conjugate vaccine,
t NA, not applicable.
Erythromycin resistant serotypes included types 4,
6, 9,14, 19 and 23. Of these, serotype 14 accounted for
81/108 (75%) of isolates. The most prevalent sero¬
types associated with penicillin intermediate resistance
were types 6, 9, 14, 19 and 23, accounting for 97/105
(92%) of isolates.
Vaccine coverage of antibiotic susceptible and non-
susceptible invasive pneumococcal isolates
The 23- and 14-valent polysaccharide vaccine pro¬
vided 97-100% and 86-98 % coverage of all penicillin
susceptible and non-susceptible isolates respectively.
The conjugate pneumococcal vaccines covered
58-79% and 94—100% of susceptible and non-
susceptible isolates (Table 8). A similar pattern was
noted for erythromycin sensitive and resistant isolates
(Table 8).
DISCUSSION
There are very few contemporary data on the
distribution of invasive pneumococcal serotypes/
groups in the UK. This study reports seroepidemio-
logical characteristics of invasive pneumococcal iso¬
lates referred to reference laboratories in Scotland
over the period 1988-99. The 7, 9 and 11-valent
conjugate vaccines are now undergoing clinical trials
in both developed and developing countries [8],
Earlier data on safety and immunogenicity of
conjugate vaccines are encouraging among infants,
and young children, [11-16] adults, [17, 18] and those
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with medical conditions which compromise immune
function [19-24]. The result of the first large-scale
clinical trial from Southern California showed that
the 7-valent conjugate vaccines had 100% efficacy in
prevention of invasive pneumococcal infections in
infants and children caused by the vaccine serotypes/
groups [25], This suggests that the 7-valent conjugate
vaccine may soon be licensed for use in infants and
children in developed countries. It has been proposed
that pneumococcal conjugate vaccines may also have
an important role in preventing pneumococcal disease
in the elderly [26].
Therefore, an understanding of the serotype dis¬
tribution of pneumococcal isolates will be crucial in
developing appropriate immunization policy for dif¬
ferent age groups in Scotland. This study reports on
the coverage of serotypes/groups in the current
polysaccharide and the new conjugate pneumococcal
vaccines in Scotland.
Serotypes/groups distributions
We found that the most prevalent serotypes (14, 9, 19,
6, 23, 1, 3, 4, 7, 8 and 18) accounted for over 82-94%
of total serotypes/groups in all age groups. Inclusion
of these serotypes/groups in the new 11-valent
conjugate vaccine will therefore cover > 80% of
invasive pneumococcal serotypes/groups in children,
adults and the elderly. This is similar to previous
findings from the US [27, 28], Europe [29-31], New
Zealand [32] and Australia [33]. In contrast, data from
Africa and Asia showed that serotypes 1 and 5 were
the predominant invasive isolates [9, 34].
The major serotypes/groups in different age groups
included serotypes/groups 14, 6, 19, 23 and 9 in
< 2 years, 14, 6, 23, 19 and 18 in ^5 years, 1,9, 14,
7 and 4 in 5-64 years old and 14, 19, 3, 9 and 23 in >
65 years old. In common with some other studies, our
data indicate that type 14 was the most common
infectious serotype in all age groups [9, 35].
Among the age group 5-64 years, serotype 1 was the
main cause of invasive disease, accounting for about
13% of cases. Earlier reports from US have ob¬
served that serogroup 12 is the most frequent cause
of bacteraemia in patients with pneumonia [36] and
associated with outbreaks in both children [37] and
adults [38]. In addition, surveillance data from the US
and Europe indicate that a shift of serotypes dis¬
tribution can occur over time [39]. Types 1-3 were the
most prevalent isolates in bacteraemic cases at the
beginning of the century, accounting for c. 70% of
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Table 6. Common prevalent serotypes/groups in Scotland not included in
the new 11-valent conjugate vaccine
Serotypes/
groups < 2 years ^ 5 years 5-64 years > 65 years All ages
8 2 2 29 26 64
11 0 1 13 14 33
12 3 3 18 12 35
22 3 6 18 19 46
Total* 8 (3-7) 12(4-9) 78(15-6) 71 (12-4) 178 (11-6)
Totalf 217 (100) 246(100) 500(100) 573 (100) 1531(100)
* Total, percentages given in parentheses for nonvaccine serotypes in the 11-valent
vaccine.
t Overall total, percentages given in parentheses.
invasive isolates [40,41]. However, since 1979, these
isolates have been very much less common (< 5%)
[42], and serotypes 6, 14,18 and 23 are more frequently
isolated in the US [43] and Europe [30, 31, 44],
This suggests that continued surveillance systems
are essential to monitor the stability of pneumococcal
serotypes/groups distribution in Scotland. Review of
serotype data from sterile site specimens from 16
countries showed that serotypes/groups 14, 6 and 19
were consistently found in all geographic locations [9].
However, the important invasive serotypes in children
< 5 years of age varied, with serotype 18 most
prevalent in developed countries, type 23 in Europe
and serotypes 1 and 5 in developing countries. These
differences in serotypes/groups distribution impose a
challenge for designing a conjugate vaccine with
appropriate serotypes distribution for all locations.
The 23- and 14-valent pneumococcal polysaccharide
vaccines
The increase in antibiotic resistant pneumococcal [45]
and the high burden of invasive pneumococcal disease
among high-risk groups has been documented con¬
sistently [10]. Pneumococcal polysaccharide vaccines
have been estimated by case-control and indirect
cohort studies, to be 50-80% effective in reducing
invasive pneumococcal disease in the elderly and in
adults with chronic medical conditions [46]. We have
found that the 23-valent and (previous) 14-valent
polysaccharide vaccines covered 97% and >83%
respectively of invasive isolates. This is similar to
published data from other parts of UK, Europe and
North America ; 91-97% in England and Wales, and
Scotland [35, 47, 48], 89-97% in Sweden [49], > 85%
in the US [5,27], >90% in Canada [50], 95% in
Finland [31] and 92% in Denmark [30] for older
children and adults.
Limited data are available on serotypes/groups
distribution in Asia and Africa where mortality rates
from pneumococcal disease are high. The available
data from Asian countries show a large variation in
the proportion of invasive pneumococcal isolates
covered by the 23-valent vaccine: 75% in Bangladesh,
70-5% in Korea [51] and 62-9% in Taiwan [52],
Conjugate vaccines
Conjugate pneumococcal vaccines are undergoing
phase I, II, and III clinical trials in the US, South
Africa, Israel, Gambia, Finland and Philippines
[8, 53]. Based on serological data, pneumococcal
conjugate vaccines appear to produce a more immuno¬
genic response in infants, the elderly, and immuno¬
compromised individuals than pneumococcal poly¬
saccharide vaccines [26]. In addition, findings from
South Africa [54] Gambia [55] and Israel [56] reveal
that conjugate vaccines reduce nasopharyngeal car¬
riage of vaccine serotypes. Therefore, it may be
possible to achieve herd immunity by widespread use
of conjugate vaccines in the future. Data from the US
suggest that the serotypes included in the current 7-
valent conjugate vaccine could prevent 86% and 83 %
of pneumococcal bacteraemia and meningitis in
children < 6 years old [43]. A previous survey in
England and Wales [4,48] noted that about 73%
of isolates found in children < 2 years old were
included in the 9-valent conjugate vaccines. We
found a higher coverage of > 90 % with the 11-valent
conjugate vaccine and > 80% with the 7-9
valent conjugate vaccines for children < 2 years of
age. The 11-valent vaccine also covers serogroups
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Table 7. Penicillin and erythromycin susceptible and non-susceptible invasive pneumococcal serotypes/groups
Penicillin susceptibility Erythromycin susceptibility
MIC




CSF Blood Others Total MIC groups CSF Blood Others Total
3 90 4 97 I 2 74 5 81
— 6 — 6 2 — 6 — 6
7 67 6 80 3 8 56 5 69
7 69 3 79 4 6 53 3 62
— 1 — 1 5 — 2 — 2
17 66 3 86 6 13 63 4 80
5 51 1 57 7 5 43 1 49
8 45 1 54 8 7 38 1 46
8 83 1 92 S 9 7 88 81 176
— 9 1 10 10 — 8 — 8
3 23 1 27 11 2 20 — 22
5 24 — 29 12 4 21 — 25
— 2 — 2 13 — 1 — 1
25 151 9 185 14 5 83 8 96
1 14 1 16 15 1 12 — 13
1 5 — 6 16 1 4 — 5
1 3 — 4 17 1 3 — 4
10 23 — 33 18 7 18 — 25
11 89 3 103 19 9 79 5 93
— 15 — 15 20 — 14 — 14
— 1 — 1 21 — 1 — 1
5 28 — 33 22 5 22 — 27
14 65 5 84 23 10 62 6 78
2 3 — 5 24 1 3 — 4
— — 1 1 27 — — 1 1
— 4 — 4 29 — 4 — 4
1 6 — 7 31 1 5 — 6
1 9 — 10 38 1 6 — 7
— 3 1 4 34 — 3 1 4
— 3 — 3 35 — 2 — 2
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* S, sensitive isolates; I, intermediate isolates; R, resistant isolates.
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Table 8. Penicillin and erythromycin susceptible and non-susceptible pneumococcal serotypes/groups covered by
the vaccines. No. (%) of vaccine-related isolates
Vaccines
Penicillin* Erythromycin
S 1 R Total S R Total
23 1100 (97-3) 104 (99-0) 2(100) 1206 (96-6) 910(96-3) 108 (100) 1018(96-7)
14 985 (86-3) 103 (98-1) 2(100) 1090 (87-3) 813 (86-0) 108 (100) 921 (87-5)
lit 897 (78-6) 102 (97-1) 2(100) 1001 (80-2) 738 (78-1) 108 (100) 846 (80-3)
9f 760 (66-6) 99 (94-3) 2(100) 861 (69) 620 (65-6) 108 (100) 728 (69-1)
7t 662 (58-0) 97 (97-4) 2(100) 761 (61) 537 (56-8) 108 (100) 645 (61-3)
* S, sensitive isolates; I, intermediate isolates; R, resistant isolates (non-susceptible isolates = intermediate and resistant
isolates).
t Pneumococcal conjugate vaccine.
3, 19 and 23 that were mainly responsible for otitis
media in US, Canadian and European children [57].
Therefore, it is unlikely that pneumococcal con¬
jugate vaccines for children need to include >11
serotypes. However, a substantially lower coverage
was observed, (about 50-57 % with 7-valent, 62-63 %
with 9-valent and 75-76% with 11-valent conjugate
vaccines) in those above 5 years (including elderly
> 65 years). In addition coverage in this age group
fluctuated from year to year, over the period 1993-9.
Serotypes/groups 8, 11, 12 and 22 were the most
common invasive isolates not present in the 11-valent
vaccine, accounting for 15-6 and 12-4% of isolates in
5-64 years old and > 65 years old respectively. In¬
cluding these serotypes/groups in the 11-valent could
increase the vaccine coverage to > 80% of invasive
isolates in these age groups. However, a larger number
of serotypes attached to a carrier protein could lead
to poorer immunogenicity and possibly promote
serious local reactions [58], Further research is
required on this issue. Furthermore, concerns about
the replacement of vaccine serotypes by serotypes not
in the vaccine have been expressed [55] and are now
under investigation [54],
Drug susceptible pneumococcal isolates
Pneumococcal isolates that are resistant to penicillin
and other antimicrobial drugs have been detected on
all continents [59, 60]. Serogroups 6, 19 and 23 have
been most associated with drug resistance [59, 61].
In the present study, serotypes/groups 6, 14, 19 and
23 were the most commonly associated with in¬
termediate resistance and serotype 14 with penicillin
and erythromycin resistant isolates. A previous survey
from England and Wales identified similar serotypes/
groups (23F, 6B, 19A, 19C, 19F and 23F) associated
with intermediate or high penicillin resistance. Re¬
sistance to erythromycinwasassociated with serotypes/
groups (3, 5, 9, 14, 19 and 22) in 1990 and with
serotypes/groups (3, 6, 14, 15, 19 and 23) in 1995 [48].
Other UK studies also indicated that type 23, 9 and 6
were most commonly associated with penicillin re¬
sistance [62-64].
The commonest serotypes/groups associated with
penicillin resistance in other countries included 9, 23
in Canada [50, 65], 6, 14, 19 and 23 in South Africa,
Spain and Hungary [45] and 6B, 9V, 14, 19F and 23F
in the US [66], In general, these data suggest that the
main serotypes patterns associated with lack of
susceptibility to penicillin and erythromycin are
similar in most geographical areas. However, recently,
type 15 in Spain and type 10 [67] and 16 and 13 in
Kenya [68, 69] have been found to be associated with
penicillin resistance.
Our data show that the 23-valent vaccine covers
99% of invasive isolates which were found to be
non-susceptible to penicillin or resistant to erythro¬
mycin. The 11-valent conjugate vaccine covered
> 78%, and 7- and 9-valent covered > 56% of non-
susceptible and resistant invasive isolates for both
drugs. Therefore, a greater use of 23-valent or the new
11-valent conjugate vaccine could possibly reduce the
majority of penicillin non-susceptible and erythro¬
mycin resistant invasive pneumococcal isolates.
The data presented in this study should be helpful
in predicting the potential impact of pneumococcal
vaccines on invasive pneumococcal disease. There is a
need for complementary data on isolates associated
with important non-invasive pneumococcal disease
such as otitis media in order to inform future policies
on the prevention of pneumococcal disease in
Scotland.
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SUMMARY
A review of the epidemiology of invasive pneumococcal disease in Scotland was carried out
using data from laboratory-based systems during the period 1988-99. This comprised 5456
(90-8%) isolates of Streptococcus pneumoniae from blood, 467 (7-8%) from cerebrospinal fluid
(CSF) and 84 (1-4%) from other sterile sites. The mean annual incidence of invasive disease
was 9-8/10r' population (9-0/105 for bacteraemia and 0-8/105 for meningitis). Invasive disease
was highest in children < 2 years of age and in the elderly > 65 years (44-9/10° and 28-4/10°
population in these age groups respectively). The highest incidence of pneumococcal meningitis,
11-8/10° persons occurred in children < 2 years of age. Males had a higher incidence of
pneumococcal bacteraemia and meningitis than females (male:female = 1-2:1 for bacteraemia
(RR = 1-17, 95% CI 1-11, 1-24) and 1-5:1 for meningitis (RR = 1-41, 95% CI 1-18, 1-70)).
Pneumococcal disease was highest in winter periods and coincided with influenza activity. The
proportion of penicillin and erythromycin non-susceptible isolates increased from 4-2% in 1992
to 12-6% in 1999 and from 5-6% in 1994 to 16-3% in 1999 respectively. Our data confirm the
substantial and increasing disease burden from pneumococcal disease and rise in prevalence of
antibiotic non-susceptibility among pneumococci in Scotland. Continued surveillance of groups
at increased risk for pneumococcal disease and the antibiotic susceptibility and serotype
distribution of isolates are important to develop appropriate policies for the prevention of
pneumococcal disease in Scotland.
INTRODUCTION
Streptococcus pneumoniae is one of the leading causes
ofbacteraemia andmeningitis in the United Kingdom.
The incidence of invasive pneumococcal disease is
greatest in young children, the elderly and persons
with underlying medical conditions which place them
at increased risk [1], Despite the use of appropriate
antimicrobial agents, case fatality rates of 12 38%
* Author for correspondence: Scottish Centre for Infection and
Environmental Health. Clifton House. Clifton Place, Glasgow, G3
7LN.
have been documented in high-risk groups [2-4] and
the emergence of antimicrobial resistant pneumococci
has been noted globally [5], Although it is not
consistently documented [6], there is strong evidence
that penicillin resistant invasive pneumococcal strains
are associated with increased morbidity and mortality
rates [2, 4], These data clearly highlight the clinical
impact and economic burden of pneumococcal disease
and the need to prevent it by vaccination.
This paper reports on all invasive pneumococcal
isolates referred to reference laboratories in Scotland
during the period 1988-99 and examines the epidemio-
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logical characteristics of invasive pneumococcal dis¬
ease. These data should inform future vaccination
policy in Scotland.
Background and study data
Analyses were performed on a combined dataset from
the Scottish Centre for Infection and Environmental
Health (SCIEH) and Scottish Meningococcus and
Pneumococcus Reference Laboratory (SMPRL). De¬
tailed background information was given in a previous
report [7] which documented the serotypes/groups
distribution and coverage of polysaccharide and
conjugate vaccines in different age groups. Infor¬
mation on antibiotic prescriptions for penicillin and
erythromycin in Scotland between 1992 and 1999 was
obtained from the Primary Care Unit, Information
and Statistics Division of the NHS in Scotland.
Pneumococcal isolates that had minimal inhibitory
concentration (MIC) values to penicillin < 0-06 pg/
ml, between 0-12 and 1 •()//,g/ml and 2-0 /xg/ml or
higher were defined as susceptible, intermediate
resistant and resistant respectively. The latter two
categories were considered non-susceptible to peni¬
cillin. For erythromycin a single breakpoint con¬
centration (1 //g/ml) was used to differentiate between
susceptible and resistant isolates. MICs were de¬
termined by a standard agar dilution method (incor¬
porating the antibiotic into agar) from 1992-3 and by
the E-test (Cambridge Diagnostics, Cambridge UK)
since 1994. A weekly review of laboratory reports is
conducted by SCIEH to ensure the accuracy of
records of pneumococcal disease. This showed in 1999
over 90% completeness for both reporting and
organism submission for invasive pneumococcal dis¬
ease. Between 1988 and 1999, the number of labora¬
tories reporting pneumococcal infections to SCIEH
and SMPRL increased from 29 to 33 and this increase
occurred after 1994. The corresponding denominator
population for reporting over this period rose from
5093 000 to 5 512000 [8], The mid-point year (1993)
population was used to calculate the age specific
incidence rate.
Statistical analysis
Pearson correlation coefficients were used to deter¬
mine associations between variables using SPSS
version 8. Relative risk and corresponding 95%
confidence intervals and the ;y2 test for trends were
calculated using the CIA programme (Gardner SB,
Winter PD, Gardner MJ: London, 1991).
RESULTS
A total of 17781 S. pneumoniae cases were identified
in SCIEH and SMPRL databases. After removal of
duplicate records. 10498 cases remained. Of these
6007 were invasive isolates; 5456 (90-8%) were from
blood, 467 (7-8%) from CSF and 84 (1-4%) from
other sterile sites.
Invasive pneumococcal isolates by age and sex
Of the 6007 invasive isolates, 2675 (44-5%), were from
the elderly (> 65 years of age) and 734 (12-2%) were
from children <5 years of age, 2186 (36-4%) were
from 6-64 age group and for 412 (6-9%) the age was
unknown. The age range of patients was 0-99 years
(median = 63, mean = 54). There were 2758 (45-9%)
isolates from females and 3077 (51-2%) from males.
Sex was not recorded in 172 (2-9%) records. Both the
frequency and incidence of pneumococcal bacterae-
mia and meningitis were higher in males than females.
The overall incidence in males and females was 9-4
and 8-1 /10° population (male:female = 1-2:1) (RR =
1-17, 95% CI Ml, 1-4) for bacteraemia and 0-9 and
0-6/10" population (male:female = 1-5:1) (RR =
1-41, 95% CI MS, 1-70) for meningitis.
Annual incidence
The mean annual incidence of invasive pneumococcal
disease was 9-8/10" population from 1988 to 1999 and
a gradual increase was observed over the study period.
This was due to an increase in reported bacteraemia
from 248 in 1988 to 510 in 1999. No increase in
meningitis was noted. Bacteraemia increased in
children ^ 5 years of age (26 in 1988 to 66 in 1999),
and the elderly (114 in 1988 to 245 in 1999). In the last
6 years, the incidence of invasive pneumococcal
disease has been relatively stable (Fig. 1). The annual
incidences of bacteraemia and meningitis were higher
in males than females during the period 1988-99
(except for years 1993 and 1996 for meningitis and
1994 for bacteraemia).
Age specific incidence of disease
Figure 2 shows that the incidence of invasive disease
was highest in infants under 2 years of age and the
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Fig. 2. Incidence of pneumococcal bacteraemia and meningitis per 100000 by age group, 1988-99.
elderly (44-9 and 28-4/10® population respectively).
The rate for bacteraemia was 9/10r> population in all
ages but reached 33-1 /10° population in the youngest
patients and 27-5/10'' population in the oldest. The
rise in bacteraemia in the study period was particularly
marked in infants (16-9 in 1988 to 47-4/105 population
in 1998) and the elderly (14-5 in 1988 to 31-2/10"
population in 1999).
The rate of meningi tis was 0-8/10" population in all
ages. The highest incidence (11-8/105 population) was
in infants but this was significantly lower (0-4/10"
population) in the 2-4 years age group. There was no
increase in pneumococcal meningitis over the study
period 1988-99 (Fig. I).
Seasonal variation
A significant seasonal variation in pneumococcal
disease was observed. Data aggregated in 3-month
periods over the study period showed that the number
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ug. 4. Penicillin (1992-9) and erythromycin (1994-9) non-susceptible pnemnocoeci in Scotland.
of cases peaked in the first 3 months of the year. This
pattern was similar to that for influenza activity
reported to SCIEH (Fig. 3).
(P — 0-0015). Only 2 cases of penicillin-resistant
pneumococci were reported (in 1998).
Antimicrobial susceptibility
Of the 6007 invasive isolates, 1248 and 1053 were
tested for penicillin and erythromycin MIC levels
respectively and the great majority of them (87 % and
95%) were fully susceptible to these antibiotics.
Penicillin non-susceptible isolates increased from 1
(4-2%) in 1992 to 21 (12-6%) in 1999 (f for trend =
11-52, P = 0-0007) (Fig. 4) and erythromycin resistant
isolates from 7 (5-6%) in 1994 to 27 (16-3%) in 1999
Antimicrobial susceptibility and antibiotic
prescriptions
Scotland is divided geographically into 15 health
board areas for administrative purposes. There was
some geographical variation in penicillin and erythro¬
mycin non-susceptibility patterns of pneumococci
(Table 1). A statistically significant correlation was
recorded for penicillin prescription rate and the
incidence of non-susceptible isolates in each health
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board (Pearson correlation, r = 0-52, P = 0-047). No
correlation was documented for erythromycin pre¬
scription rate and the incidence of erythromycin
non-susceptible isolates (r — 0-39, P = 0-157).
DISCUSSION
Contemporary population based data on the age and
sex specific incidence of pneumococcal bacteraemia
and meningitis in the United Kingdom are scarce. This
may in part reflect a poor understanding of the public
health burden of invasive pneumococcal disease.
This study reports on invasive pneumococcal disease
throughout Scotland in the years 1988-99 and is based
on a large database of high quality data on pneumo¬
coccal isolates reported to SCIEH and SMPRL.
Because acceptance criteria for the diagnosis of pneu¬
mococcal infections differ widely we included only
laboratory confirmed cases of S. pneumoniae recovered
from blood, CSF and other sterile sites.
The reported incidence of invasive pneumococcal
disease varies widely between countries. Nevetheless,
it is universally recognized that the elderly and young
children are most at risk of bacteraemia [9], and those
under 2 years, of meningitis [10, II]. A higher
incidence of invasive disease has been reported in
native populations in New Zealand [12], Alaska (US)
[13], Apache (US) [14], Navajo (US) [15] and Ab¬
original (Australia) [16] compared with other popu¬
lation groups in the respective countries. Similarly
high rates have been found in young children in
Gambia [17, 18], Israel [19] and Chile [20]. Our data
show a greater incidence of invasive pneumococcal
disease in males (51 %) than females (46%). This is
consistent with previous studies from the United
Kingdom [3], United States [21], Europe [22, 23], and
Australian Aboriginals [16].
We found a twofold increase in incidence of invasive
disease in Scotland over the period 1988-99 which is
similar to that reported in most studies from the
United States and Sweden [24, 25] but is different
from Finland in the last decade [22]. In contrast to the
twofold annual increase in bacteraemia, there was no
increase in pneumococcal meningitis during the study
period. The increase in bacteraemia may be an artifact
due to an increase in the number of blood cultures
taken rather than in disease incidence [26, 27] and
changing referral practices by diagnostic laboratories
may also have had an influence. Furthermore in¬
creased clinical awareness and patterns of investiga¬
tions may also have affected the earlier rise in
incidence. However, the participation of an additional
four diagnostic laboratories from 1994 onwards is
unlikely to explain most of the observed increase in
disease incidence since a clear increased trend was
established prior to that year.
Our data may still represent an underestimate of
invasive disease since most febrile patients are not
routinely tested by blood culture. Blood cultures also
lack sensitivity for confirmation of pneumococcal
disease [28] as only 10-20% of blood cultures are
reported positive [29]. Although lung aspirates are
more sensitive than blood cultures, the technique is
not suitable for routine use [30] and may cause
adverse effects [31]. Recently, a PGR method to detect
pneumococcal DNA in blood has been shown to
improve the diagnosis of bacteraemia [32]. The lack of
a reliable diagnostic method may therefore contribute
to an underestimate of the burden of pneumococcal
disease [30]. Moreover, prior to antibiotic treatment
blood culture confounds the diagnosis as a study
demonstrated that only 5 % of blood cultures were
positive in those who had prior antibiotics compared
with 19% in those who did not receive them [33].
The prevalence of invasive disease was clearly
related to season in the present study with the highest
reported cases in January March each year which
coincided with the period of peak influenza activity.
Previous studies in the United Kingdom [3, 34],
United States [35] and Israel [19] have also shown that
pneumococci are isolated more frequently during the
winter period. This seasonal increase may be influ¬
enced by the coincident circulation of other res¬
piratory viruses as winter is associated with increased
respiratory virus activity which has been cited as a risk
factor for developing pneumococcal disease [35, 36].
About 50-80% of pneumococcal pneumonia is
thought to be associated with prior occurrence of
some form of viral respiratory illness [36].
In the present study, the proportion of both
penicillin and erythromycin non-susceptible isolates
increased by threefold. A gradual increase in the
prevalence of drug resistance in S. pneumoniae has
been documented worldwide [37. 38]. From 1990 to
1998, the PHLS Communicable Disease Surveillance
Centre in England and Wales noted an increase from
< 1 % to 3-6-7-4% for penicillin resistant isolates and
of 5 % to 11 % for erythromycin resistant isolates [39].
In the United States, the level of drug resistant
pneumococci increased from 14% in 1993/4 [40] to
25% in 1998 [41]. Increased awareness of invasive
disease and improved detection of resistant isolates by
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laboratories may also have contributed to this
increase.
Penicillin resistance in isolates has serious implica¬
tions for the management of invasive pneumococcal
disease, particularly for meningitis. The clinical failure
of third line generation antibiotics (cefotaxime/
ceftriaxone or other cephalosporins) effective against
penicillin-resistant strains has been documented [42,
43], Experience in the United States demonstrates that
outbreaks of pneumococcal meningitis with multi¬
drug resistant strains (serotype 14) can occur [44] and,
indeed, invasive pneumococcal disease with penicillin-
resistant strains has been associated with increased
mortality rates [4] and longer periods of hospitaliza¬
tion [2],
Seroepidemiology data in the United Kingdom
shows that the current 23-valent polysaccharide
pneumococcal vaccine includes the majority of sero-
types/groups that show resistance to many antibiotics
[7, 45], Thus, the increased use of these vaccines may
serve to prevent invasive disease due to antimicrobial
resistant strains in high-risk individuals. Seven to 11 -
valeht pneumococcal conjugate vaccines have been
reported to reduce nasopharyngeal carriage, par¬
ticularly associated with drug resistant serotypes, in
vaccinated children [46], Our previous report showed
that 7 to 11-valent conjugate vaccines cover > 94%
of penicillin and 100% of erythromycin non-sus¬
ceptible pneumococcal isolates in Scotland [7], There¬
fore, the widespread use of conjugate vaccines has the
potential to reduce the transmission of drug-resistant
pneumococci. A 7-valent conjugate pneumococcal
vaccine has been licensed for use in children in the
United States. The decision on use of this new vaccine
in the UK is expected soon.
We found variation in antibiotic non-susceptibility
in different geographic locations in Scotland. The
reasons for this may be complex but mobility of the
population probably contributed to these differences
[41, 47, 48], Others have shown that the frequency of
antibiotic resistant invasive pneumococcal isolates
varies within and between countries [37, 38] with
reported rates within the United States of 7-25% to
penicillin and 6-15% to erythromycin [2, 49-51], It
has been suggested that variation in antibiotic use
influences the prevalence of resistant strains of
pneumococci in different locations [52], Other factors
such as differences in populations and different study
methods may also play a part. Antibiotic prescription
data indicated geographical variation in prescription
rates for penicillin and erythromycin and a significant
correlation with frequencies of antibiotic resistant
strains of pneumococci was recorded for penicillin
only, not erythromycin.
In conclusion, our data confirm the substantial and
increasing public health burden from pneumococcal
disease and the concomitant rise in antibiotic non-
susceptibility among pneumococci in Scotland. It is
clear that this burden cannot be eliminated by the
utilization of antibiotics alone. Polysaccharide or new
conjugate pneumococcal vaccines in high-risk indivi¬
duals remain the most effective preventive measure to
reduce disease and control the spread of resistant
isolates. Continued surveillance of the incidence of
pneumococcal disease, serotypes/groups distribution
and antibiotic susceptibility continue to be essential to
inform policy and decision making to reduce the
burden to the public health.
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SUMMARY
We reviewed laboratory data on non-invasive pneumococcal isolates reported from all
diagnostic laboratories in Scotland during the period 1988-99. Of 4491 isolates from
hospitalized patients, 654 (64-7%) were from sputum, 79 (7-8%) from the nasopharynx and
278 (27-5%) from other superficial sites. The serogroups included in the 23-valent
polysaccharide vaccine caused 96-9% of all non-invasive disease in all age groups. The 7-, 9-,
and 11-valent conjugated vaccine serogroups were responsible for 87-94%, 85-93%,
74-81 % and 75-84% of non-invasive disease respectively in age groups < 2 years, < 5 years,
> 65 years and all ages. The coverage of non-susceptible penicillin and erythromycin non¬
invasive isolates was > 99% and > 95% with the 23-valent polysaccharide and 7-11-valent
conjugate vaccines respectively. The eight most common serogroups were 23, 9, 6, 19, 14, 3, 15
and 11 (in descending order). The serogroups associated with antimicrobial resistance in non¬
invasive disease were similar to those found in invasive disease. The finding of a similar
serogroup distribution in both invasive and non-invasive disease (regardless of the site of
clinical isolate), is consistent with serogroups colonizing non-sterile sites and having the
potential to invade. The availability of conjugated vaccines reinforces the importance of
systematic surveillance to determine accurately and regularly the coverage of pneumococcal
serogroups and types causing both invasive and non-invasive disease.
INTRODUCTION
The pneumococcus is a major pathogen in the young
and the elderly and in those with underlying chronic
medical disorders [1]. In addition, it is a leading cause
of non-invasive diseases such as community-acquired
pneumonia [2] and otitis media [3], and can be
associated with considerable morbidity and economic
burden [4]. It poses an important public health
problem in the UK.
Although there are 90 known serotypes of pneu-
mococci, the majority of pneumococcal disease is
* Author tor correspondence: Scottish Centre for Infection and
Environmental Health, Clifton House, Clifton Place, Glasgow,
G3 7LN.
associated with fewer than 11 serotypes in infants and
children and fewer than 23 serotypes in adults [5-7].
Colonization with pneumococcal serogroups 6, 14, 19
and 23 is most common in young children and adults
[8-10]. These serogroups are also the dominant cause
of disease and antibiotic resistance worldwide [11-14].
The available evidence shows that pneumococcal
conjugated vaccines induce mucosal immunity [15].
Studies in South Africa and Israel showed a reduction
in carriage of vaccine-related pneumococcal serotypes,
especially antibiotic resistant strains [16, 17], Thus,
widespread use of pneumococcal conjugate vaccine
could limit the spread of pneumococci and decrease
the prevalence of antibiotic resistant strains.
Knowledge of the coverage of non-invasive sero-
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groups for 7-11-valent conjugated vaccines and the
23-valent pneumococcal polysaccharide vaccine in
various age groups and from different clinical sites is
important for vaccine formulation and recommenda¬
tions for usage. In addition, data on the distribution
of pneumococcal serogroups isolated from non-sterile
site specimens may help to determine which sero¬
groups are important in the development of invasive
disease. We report here the prevalence of the major
serogroups causing non-invasive disease and the
coverage of polysaccharide and conjugated vaccines
for non-invasive pneumococcal serogroups from pop¬
ulation-based laboratory surveillance in Scotland,
during the period 1988-99.
METHODS
Data from this study were obtained from the Scottish
Centre for Infection and Environmental Health
(SCIEH) and the Scottish Meningococcus and Pneu-
mococcus Reference Laboratory (SMPRL). Both
organizations provide the national surveillance and
monitoring for diseases caused by these organisms in
Scotland (estimated 5 million population). The es¬
tablishment of SMPRL in 1992 has improved the data
on both invasive and non-invasive pneumococcal
disease, particularly for serogroup/type distribution
and antimicrobial resistance in Scotland. Although
SMPRL encourages all diagnostic laboratories to
send isolates from body fluid of patients with
suspected pneumococcal infection, it is likely that
some laboratories may refer isolates thought to be
antimicrobial resistant. Enhanced pneumococcal sur¬
veillance is currently underway in Scotland and will
improve population-based data on this disease before
and after the implementation of any pneumococcal
conjugate vaccine strategy. Detailed background
information and methods of this study have been
described in a previous report [18). This earlier study
evaluated the prevalence of antibiotic resistance,
serogroup/type distribution, and coverage of poly¬
saccharide and conjugate pneumococcal vaccines
related-serotypes/groups for invasive isolates. This
report encompasses isolates from non-sterile sites
from patients who were admitted to hospital mainly
with acute respiratory infections and who were diag¬
nosed as having pneumococcal infection. Serogroup-
ing and serotyping of pneumococcal isolates were
performed by coagglutination testing [19], using
antisera obtained from the Statens Serum Institut
(Copenhagen, Denmark). Isolates included those
from sputum, nasopharynx, ear, eye, urine and other
non-sterile sites. Antimicrobial susceptibility testing
against penicillin and erythromycin was performed on
selected isolates using the E-test method (Cambridge
Diagnostics, Cambridge, UK). Isolates showing mini¬
mum inhibitory concentrations (MICs) of < 0-06 fig/
ml, 0-1—1 //g/ml and ^ 2/u.g/m\ were considered
sensitive, intermediate and highly resistant respect¬
ively, to penicillin. Erythromycin sensitivity and
resistance were defined by MICs of < 1 /tg/ml and
> 1 /xg/ml respectively. Intermediate resistant and
highly resistant isolates were considered as non-
susceptible isolates. Multiple isolates from the same
patient were excluded from the study. Laboratory
reports included demographic and limited clinical
information. Data analysis was performed using SPSS
version 10.
RESULTS
There was a total of 4491 non-invasive isolates in
1988-99. Of these, 1262 (28-1 %) were from females,
1692 (37-7%) from males and in 1537 (34'2%) cases,
the patient gender was unknown. Serological in¬
formation was available for 1011 (22-5%) isolates. Of
these serogrouped/typed isolates, 654 (64-7%) isolates
were from sputum, 79 (7-8%) from the nasopharynx
and 278 (27-5%) from other non-invasive sites.
Serogroup/type information was available for 186
(18-4%) isolates from those aged less than 2 years, 209
(20-7%) isolates from those aged 5 years or less, and
375 (37-1 %) isolates from those aged 65 years or
more. Of the 1011 isolates with serological infor¬
mation, 524 had specific serotype information and 833
had serogroup information (Table 1).
Patient ages ranged from 1 year to 99 years, with a
mean and median age of 36 years and 35 years respect¬
ively. Susceptibility to penicillin and erythromycin
was tested in 60-4% (611/1011) and 50% (505/1011)
of all isolates which were serogrouped/typed. The
prevalence of non-susceptible isolates was 373/611
(61%) for penicillin in 1992-9 and 70/505 (14%)
for erythromycin in 1994-9 for the isolates for which
there was serogroup/type information.
Potential vaccine coverage in different age groups
Serogroups contained in the 23-valent vaccine accoun¬
ted for 99% of non-invasive isolates in age groups
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Table 1. Distribution of pneumococcal serotypes and serogroups
No. Percent No. Percent
Serogroups Serotypes (cont.)
Groups Types
23 224 26-9 27 3 0-6
9 166 19-9 29 3 0-6
6 150 18 4 2 0-4
19 138 16-6 20 2 0-4
15 36 4-3 22A 2 0-4
11 35 4-2 34 2 0-4
33 18 2-2 42 2 0-4
7 15 1-8 5 1 0-2
10 15 1-8 16F 1 0-2
18 13 1-6 24F 1 0-2
17 6 0-7 37 1 0-2
12 5 0-6 Total 524 100
16 5 0-6
22 3 0-4 Serogroups/types
24 3 0-4 Groups/types
41 1 01 23 224 22-2






Serotypes 19 138 13-6
Types 14 69 6-8
23F 77 14-7 3 54 5-3
23A 12 2-3 15 36 3-6
19F 57 10-9 11 35 3-5
19A 18 3-4 33 18 1-8
14 69 13-2 7 15 1-5
6A 32 61 10 15 1-5
6B 30 5-7 8 13 1-3
9V 36 6-9 18 13 1-3
9N 13 2-5 1 12 1-2
15B 16 3-1 35 9 0-9
15C 6 1-1 17 6 0-6
15A 3 0-6 12 5 0-5
15F 3 0-6 16 5 0-5
11A 33 6-3 31 5 0-5
11C 1 0-2 22 3 0-3
33F 16 3-1 24 3 0-3
10A 14 2-7 27 3 0-3
8 13 2-5 29 3 0-3
1 12 2-3 4 2 0-2J
18C 12 2-3 20 2 0-2
7F 9 1-7 34 2 0-2
7C 1 0-2 42 2 0-2
35 7 1-3 5 1 0-1
17F 6 1-1 37 1 0-1
31 5 1 41 1 0-1
12F 3 0-6 Total 1011 100
< 2 years and ^ 5 years and 96% in age groups
> 65 years and all ages. The coverage of 7, 9 and
11-valent conjugate vaccine in these age groups was
87-94%, 85-93%, 74-81% and 75-84% of non¬
invasive isolates respectively. Overall, coverage of
7- to 11-valent conjugate vaccine serogroups was
between 85% and 94% for age groups <2 years
and ^ 5 years but their coverage reduced to 74-84%
in age groups ^ 65 years and all ages. Overall, the 23-
valent polysaccharide vaccine serogroups accounted
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Table 2. Coverage ofpneumococcal vaccines for penicillin and erythromycin susceptible and non-susceptible
isolates
Penicillin* Erythromycint
No. (%) of vaccine related serotype No. (%) of vaccine related serotype
Vaccine Sensitive Intermediate Resistant Total Sensitive Resistant Total
7-valent 158 (66-4) 347 (95-6) 10(100) 515 (84-3) 376 (86-4) 68 (97-1) 444 (87-9)
9-valent 166 (69-7) 348 (95-9) 10(100) 524 (85-8) 382 (87-8) 68 (97-1) 450 (89-1)
11-valent 194 (81-5) 353 (97-2) 10(100) 557 (91-2) 405 (93-1) 68 (97-1) 473 (93-7)
23-valent 228 (95-8) 360 (99-2) 10(100) 598 (97-9) 423 (97-2) 70 (100) 493 (97-6)
Overall 238 (100) 363 (100) 10(100) 611 (100) 435 (100) 70 (100) 505 (100)
* Sensitive MIC < 0-06/ig/ml, intermediate MIC 0T2-1-0/ig/ml, resistant MIC > 2 /tg/ml, f Sensitive MIC < 1 /rg/ml,
resistant MIC>1 /ig/ml (7-valent vaccine serotypes: 4, 6B, 9V, 14, 18C, 19F, 23F), (9-valent vaccine serotypes: 7-valent
vaccine serotypes with serotypes 1 and 5), (11-valent vaccine serotypes: 9-valent vaccine serotypes with serotypes 3 and 7F),
(23-valent vaccine serotypes: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and
33F).
Table 3. Penicillin and erythromycin susceptible and non-susceptible non-invasive pneumococcal
serogroupsj types
No. (%) of isolates
Penicillin Erythromycin
Serogroups/ Sensitive Intermediate Resistance Sensitive Resistance
types (MIC ^ 0 06) (MIC = (0-12-1-0)) (MIC 5* 2) Total (MIC < 1) (MIC > 1) Total
23 72 78 5 155 110 24 134
9 14 115 4 133 113 5 118
6 24 61 0 85 53 19 72
19 35 45 0 80 55 8 63
14 12 46 1 59 43 11 54
Others* 81 18 0 99 61 3 64
Totalt 157 (66) 345 (95) 10(100) 512(83-8) 374 (86) 67 (95-7) 441 (87-3)
TotalJ 238 (100) 363(100) 10(100) 611 (100) 435 (100) 70(100) 505 (100)
* Others (sensitive = serogroups/types 11, 15, 1, 7, 10, 31, 33, 16, 4, 5, 22, 24, 29, 34, 35, 42) (intermediate =
serogroups/types 8, 15, 7, 29, 1, 4, 18, 35) in descending order for penicillin. * Others (sensitive = serogroups/types 8, 15,
1, 7, 29, 31, 16, 4, 5, 18, 22, 24, 33, 34, 35, 42) (resistant = serogroups/types 4, 11, 15) in descending order for erythromycin.
Non-susceptible isolates = intermediate and resistant isolates,
t Total isolates for serogroups/types (23, 9, 6, 19, 14).
J Overall total isolates.
for 96-9% of non-invasive disease respectively in
all age groups.
Potential vaccine coverage for penicillin and
erythromycin non-susceptible isolates
7-9-, ll-valent vaccine
The 7-11-valent vaccine serogroups accounted for
> 95 % and > 97% of penicillin and erythromycin
non-susceptible non-invasive isolates respectively
(Table 2).
23-valent vaccine
The coverage for non-susceptible penicillin and ery¬
thromycin non-invasive isolates was > 99 % and
95% respectively with 23-valent vaccine (Table 2).
Most prevalent non-invasive pneumococcal
serogroups, 1988-99
The eight most prevalent pneumococcal serogroups
(in descending rank order) were 23, 9, 6, 19, 14, 3, 15
and 11. These eight serogroups were responsible for
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over 86-3% of non-invasive disease regardless of
specimen type.
Antibiotic susceptibility
Serogroups 23, 9, 6, 19 and 14 were associated with
the majority of penicillin and erythromycin non-
susceptibility (Table 3).
DISCUSSION
Our data indicate that the serogroups included in the
23-valent polysaccharide and 7-11-valent conjugated
pneumococcal vaccines caused the majority of non¬
invasive pneumococcal disease in all age groups in the
study period in Scotland. In addition, serogroups
associated with antibiotic resistance were found to be
very similar in both non-invasive and invasive disease
in Scotland [18]. In this study, data on coverage of
vaccines were based on serogroups, assuming that
there is cross-reactivity of serotype-specific protection
within a serogroup (e.g. 6A vs. 6B, 9A vs. 9V) [20].
However, since there are limited data on cross-
reactivity of vaccine serotypes within a serogroup [21],
our data may have overestimated the potential
coverage of vaccines for non-invasive disease. Peni¬
cillin resistant isolates are likely to be over-represented
in this as a result of selectively higher referral by
diagnostic laboratories. Also, only 60% and 50% of
the total serogrouped/typed isolates were tested for
penicillin and erythromycin susceptibility respectively
in the study period. For these two reasons, data on
antibiotic sensitivity should be interpreted with con¬
siderable caution.
Serogroups 23, 9, 6 and 19 were the predominant
causes of non-invasive pneumococcal diseases, in
keeping with earlier reports from the United Kingdom
[22-4] and from other developed and developing
countries [12,25], In common with other reports
[12, 26], the coverage of 7-9-valent conjugated vaccine
serogroups was lower for the elderly and the 'all age'
group than the age groups < 2 years and < 5 years.
The conjugated vaccine-related serogroups were the
cause of over 80% of non-invasive disease in children
under 2 years of age. Earlier studies [27, 28] reported
a higher nasopharyngeal carriage with both vaccine
serotypes and non-vaccine serotypes than in adults.
Since there is an association between carriage and the
spread of disease, children may be a major source of
pneumococci and pneumococcal disease in the com¬
munity. If so, universal vaccination of young children
may extend protection from pneumococcal disease to
non-vaccinated individuals by herd immunity.
The finding of a similar serogroup distribution in
both invasive and non-invasive disease (regardless of
the site of clinical isolate), is consistent with sero¬
groups colonizing non-sterile sites and having the
potential to cause invasive disease. Acquisition and
carriage of S1. pneumoniae is associated with the
development of both invasive and non-invasive dis¬
ease [28-30]. Data from Papua New Guinea suggest
that serogroups/types causing upper respiratory tract
infection (URTI) could be used to obtain a con¬
servative estimate of susceptibility to invasive pneu¬
mococci [31]. Therefore, targeting vaccination on
serogroups/types associated with non-invasive disease
could reduce the risk of invasive disease. The efficacy
of 7-valent pneumococcal conjugated vaccines in
preventing pneumonia and otitis media has been
documented: 73 % (95 % CI 38-88) against clinically
diagnosed pneumonia confirmed with chest radio¬
graph (pulmonary consolidation ^ 2-5 cm) in a US
study [32] and 57% (95% CI 44-67) against otitis
media caused by vaccine serotypes in a Finnish study
[33], Studies from Europe and the United States
reported that the estimated incidence rate of pneu¬
mococcal pneumonia was 5-9 per 1000 children under
5 years of age [34-36]. In addition, the incidence rate
of pneumococcal otitis media has been estimated at
0-56 episodes per child under 2 years of age [3, 37],
Therefore, it appears that pneumococcal conjugated
vaccination could reduce non-invasive disease caused
by S. pneumoniae significantly. Additional studies are
required to determine its efficacy in preventing disease
in adults, the elderly and in immunocompromised
patients.
Pneumococci carried in the upper respiratory tract
are more often resistant to antibiotics than invasive
strains [23, 38], Serogroups 23 and 9 were frequently
associated with penicillin and erythromycin non-
susceptibility in this study. Our previous study on
invasive pneumococcal isolates found that serotype 14
was the most common serotype. associated with
penicillin and erythromycin non-susceptibility [18]. In
accordance with data from other countries [11], we
found that serogroups 23, 9, 6, 19 and 14 were
responsible for ^ 95% of non-invasive pneumococcal
antibiotic resistance in Scotland. All these serogroups
are represented in the 7-valent conjugated vaccine.
Existing data suggest a reduction of antibiotic
resistant pneumococcal serotypes [17] and use of
antibiotics (5-3%) in pneumococcal conjugated vac-
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cine recipients [39]. Thus, widespread use of pneu¬
mococcal conjugated vaccine could prevent the spread
of antibiotic resistant pneumococcal isolates and
thereby reduce antibiotic consumption. However,
serotype exchange and capsular switching by pneu-
mococci leading to an increase in virulence has been
observed [40,41], It is possible that in the future,
conjugated vaccine-induced pressure could lead to
replacement of vaccine serotypes with non-vaccine
serotypes of increased virulence, leading to increased
disease and antibiotic resistance [42, 43], Thus, it will
be necessary to monitor the epidemiological, micro¬
biological and immunological characteristics of the
pneumococcal population worldwide. Our data high¬
light the importance of improved pneumococcal
surveillance in Scotland in order to inform effective
local public health strategies.
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The Changing Epidemiology of Bacterial
Meningitis and Invasive Non-meningitic Bacterial
Disease in Scotland During the Period 1983-99
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We reviewed population-based laboratory reports of invasive meningococcal, pneumococcal, Haemophilus influenzae, Group
B Streptococcus (GBS) and Listeria monocytogenes isolates in order to examine the changing epidemiology of meningitis and
invasive non-meningitic disease (INMD) caused by these 5 pathogens in the 2 periods before (1983-91) and after (1992-99)
routine use of H. influenzae type B conjugate vaccine (Hib) in Scotland. Ncissieria meningitidis was the most common cause
of meningitis, accounting for 39.2% of cases of meningitis in 1983-91 and 47% of cases in 1992-99, followed by H.
influenzae (31%), Streptococcus pneumoniae (22.4%), GBS (3.9%) and L. monocytogenes (3.5%) in 1983-91 and S.
pneumoniae (36.3%), H. influenzae (7.8%), GBS" (6.1%) and L. monocytogenes (2.8%) in 1992-99. The important
epidemiological features of meningitis and INMD caused by these 5 pathogens between 1983-91 and 1992-99 include:
1. The incidence of bacterial meningitis due to S. pneumoniae and GBS was stable;
2. S. pneumoniae was the predominant cause of INMD in both periods;
3. The incidences of INMD caused by N. meningitidis, GBS and S. pneumoniae increased, by 27'%, 55% and 56'%,
respectively;
4. Decreases in the incidences of bacterial meningitis (by 50%) and INMD (by 50%) due to L. monocytogenes were detected;
and
5. I'hcrc were dramatic reductions in the proportions of bacterial meningitis (by 92%) and INMD (by 56%) due to H.
influenzae in vaccinated and non-vaccinated individuals.
Continued surveillance is necessary to monitor the disease trend, population at risk, serotype distribution and antimicrobial
susceptibility in order to implement appropriate public health interventions against invasive bacterial disease.
At. //. Kyaw, Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7/.A, UK.
Tel: +44 141 300 11X4; Fax: +44 141 300 1170; E-mail: Moe.Kyaw@scich.csa.scot.nhs.uk
INTRODUCTION
Bacterial meningitis and invasive non-meningitic bacterial
disease (INMD) are important causes of morbidity and
mortality worldwide (1-6). Before the implementation of
universal Haemophilus influenzae type B (Hib) conjugate
vaccination in the US and Europe, Hib accounted for
50 75% of cases of meningitis or other bacterial invasive
disease in children aged < 5 y (2, 7, 8). The use of Hib
conjugate vaccines has dramatically reduced the incidence
of invasive Hib disease and has altered the epidemiology of
invasive bacterial disease. Surveillance data from the US
have shown that Streptococcus pneumoniae is now the
most common cause of bacterial meningitis or other bacte¬
rial invasive disease, followed by Ncissieria meningiditis,
Group B Streptococcus (GBS), Listeria monocytogenes and
H. influenzae (3). No similar review of invasive bacterial
disease has been carried out in the UK since the introduc¬
tion of Hib vaccination in October 1992. Polysaccharide or
conjugate vaccines are available to protect against some
serotypes/groups of H. influenzae, S. pneumoniae and N.
meningitidis. Therefore, a review of the epidemiology of
invasive bacterial disease is important in order to make
rational decisions concerning future prevention and control
strategies for bacterial meningitis and INMD in Scotland.
The aim of this study was to define the epidemiological
features of invasive bacterial disease between 1983 and 1999
and to examine the changing pattern of meningitis and
INMD between 1983-91 and 1992-99 using the available
population-based laboratory data.
MATERIALS AND METHODS
The study data were obtained from the Scottish Centre for Infec¬
tion and Environmental Health (SCIEH), which serves as a na¬
tional surveillance centre for infectious diseases and environmental
health hazards in Scotland. Laboratory records of cases of S.
pneumoniae, N. meningitidis. H. influenzae, GBS and L. monocy¬
togenes reported to the SCIEH during the period 1983-99 were
reviewed. We only included invasive isolates from blood, cere¬
brospinal fluid (CSF) and other sterile fluids (pleural fluid, ascitic
fluid, synovial fluid and tissue aspirates) in the study. Duplicate
isolates were excluded. Bacterial meningitis was defined by the
isolation of bacteria from CSF or blood and CSF. Isolates from
blood or other normally sterile sites but not from CSF were
regarded as INMD. although some of these may have been diag¬
nosed clinically as meningitis. Information on demographic charac¬
teristics (age, sex and geographic location) and the time when the
isolate was obtained were available from laboratory reports.
We determined the annual proportions of meningitis and INMD
due to the 5 pathogens between 1983 and 1999. Two time periods
(1983-91 and 1992-99) were chosen in order to examine the
changing patterns of meningitis and INMD in different age groups
before and after the routine use of Hib vaccine, which was intro-
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duced in October 1992. The 2 midpoint years (1987 and 1996) were
used to calculate the age-specific incidence rates for the 2 periods.
The number of laboratories reporting to the SC1EH has increased
during these 2 periods: from 29 to 33 for S. pneumoniae and N.
meningitidis, from 25 to 28 for GBS and H. influenzae and from 15
to 22 for L. monocytogenes. A consultant physician was responsi¬
ble for reviewing these laboratory data every week to ensure
completeness and reliability. Although all existing laboratories
have reported cases caused by these pathogens to the SCI EH
during the study period, the laboratory collection system relies on
the voluntary reporting of cases by these laboratories. Therefore,
invasive disease is likely to be under-reported, particularly as
identified from blood cultures. During the study period, the meth¬
ods of diagnosis for these pathogens (such as non-cultural diagno¬
sis using molecular methods) and the clinical practice of clinicians
taking blood/CSF cultures for these pathogens have also changed
substantially and may affect the results. Nevertheless, our large
population-based passive surveillance system provides data on the
relative importance of the 5 pathogens during the 2 time periods.
Information on antibiotic prescribing for the whole of Scotland
was obtained from the Information and Statistics Division (1SD)
of the Common Services Agency of the National Health Services
(NHS), Scotland.
Data analysis
Statistical analysis was performed using SPSS version 10. The %2
test was used to compare variables, p <0.05 was considered statis¬
tically significant.
RESULTS
A total of 12,108 invasive isolates were identified during the
study period, of which 2514 (20.8%) were obtained from
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CSF. The annual relative contributions of meningitis and
INMD due to N. meningitidis, S. pneumoniae, H. influen¬
zae, GBS and L. moncytogenes between 1983 and 1999 are
presented in Figs 1 and 2, respectively. The proportions
and incidences of meningitis and INMD caused by these 5
pathogens between 1983-91 and 1992-99 are shown in
Table I. Age-specific incidence rates for meningitis and
INMD varied with the pathogen (Tables II and III). Cases
of meningitis (n = 1317 vs. 1151) and INMD (« = 4822 vs.
4512) were more numerous in males than in females. All 5
pathogens showed some seasonal variations (Figs 3 and 4).
The overall changes in the incidences of bacteria] meningitis
and INMD caused by these 5 pathogens were a 50%
decrease (from 3.8 to 1.9 per 100,000 population) and a
30% increase (from 9.7 to 12.6 per 100,000 population),
respectively between 1983-91 and 1992 -99 (Table I). The
prescription of all antimicrobial agents in Scotland also
increased between the 2 periods (data not shown).
N. meningitidis
N. meningitidis was the most common cause of meningitis
and the third most common cause of INMD in 1983-91
and in 1992-99. The overall changes in the incidences of
meningitis and INMD due to N. meningitidis were a 40%
decrease (from 1.5 to 0.9 per 100,000 population) and a
27% increase (from 1.1 to 1.4 per 100,000 population),
respectively between these 2 periods (Table I). An increase
83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 93 99
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Fig. 2. Proportion of INMD
caused by the 5 pathogens dur¬
ing the period 1983-99.
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N. meningitidis 681 39.2 1.5 365 47 0.9 -40
S. pneumoniae 389 22.4 0.8 282 36.3 0.7 -12.5
H. influenzae 539 31 1.2 61 7.8 0.1 -91.7
GBS 68 3.9 0.1 47 6.1 0.1 0
L. monocytogenes 60 3.5 . 0.1 22 2.8 0.05 -50
Total 1,737 100 3.8 111 100 1.9 -50
Non-meningitic disease
N. meningitidis 507 11.4 1.1 555 10.8 1.4 + 27.3
S. pneumoniae 2,518 56.7 5.5 3,540 68.7 8.6 + 56.4
H. influenzae 732 16.5 1.6 . 280 5.4 0.7 -56.3
GBS 520 11.7 1.1 711 13.8 1.7 + 54.5
L. monocytogenes 167 3.7 0.4 64 1.3 0.2 -50
Total 4,444 100 9.7 5,150 100 12.6 + 29.9
in the proportion of cases of invasive meningococcal dis¬
ease was observed in all age groups except for the 15-44 y
age group for meningitis and the >45 y age group for
INMD (Tables .11 and III). .Most cases of meningococcal
meningitis (61%) and invasive non-meningitic meningococ¬
cal disease (54%) occurred in the <4 y age group (p <
0.0001 each). The proportions of meningitis and INMD
due to N. meningitidis were higher in the < 24 y age group.
A seasonal pattern of meningococcal meningitis and inva¬
sive non-meningitic meningococcal disease activity was ob¬
served, with peaks during the first and last 4 weeks of the
year (Figs 3 and 4). Of the 1046 CSF isolates, serogroup
information was available for only 150 (20%), with the
predominant serogroups being B (52%) and C (46%).
S. pneumoniae
S. pneumoniae was the most common cause of INMD and
the second most common cause of meningitis between
1983-91 and 1992-99. During these 2 periods, the inci¬
dence of meningitis caused by S. pneumoniae decreased by
12.5% (from 0.8 to 0.7 per 100.000 population) and that of
INMD increased by 56% (from 5.5 to 8.6 per 100.000
population) (Table L). An increase in invasive disease due
to S. pneumoniae was noted in all age groups except for the
5-14 y and 45-64 y age groups for meningitis and the
5-24 y age group for INMD (Table II and Table III).
Those aged < 5 y showed the greatest increases in the
proportions of cases of meningitis and INMD due to S.
pneumoniae between the periods 1983-91 and 1992-99.
Cases of pneumococcal meningitis were more numerous in
the age groups < 1 y (/; < 0.0001) and >45 y (p <0.0001)
compared with other age groups during the period 1983—
99. The risk of invasive non-meningitic pneumococcal dis¬
ease was highest in the elderly, accounting for 49.2% of
cases of other invasive pneumococcal disease in 1983- 99. A
seasonal trend of pneumococcal meningitis and invasive
non-meningitic pneumococcal disease activity was noted
(Figs 3 and 4). The peak number of cases occurred in the
first and last 4 weeks of the year for INMD. The seasonal
pattern of pneumococcal meningitis was less distinctive.
Data on serogroups were recorded for 5.3% (320/6058) of
invasive non-meningitic pneumococcal isolates and for
8.5% (57/671) of pneumococcal meningitis isolates. Of
these, 11-valent pneumococcal conjugate vaccine serotypes/
groups 14, 3, 4, 1, 9, 6, 19, 18, 7, 23 and 5 (in descending
order) accounted for 80.6% (304/377) of all serolyped/
grouped invasive isolates. The 7- and 9-valent pneumococ¬
cal conjugate vaccine serotypes/groups caused 54.6%
(206/304) and 63.7% (240/304) of all cases of invasive
disease, respectively.
H. influenzae
H. influenzae was the second most common cause of bacte¬
rial meningitis and INMD in 1983-91, accounting for 539
(31%) and 732 (17%) cases, respectively (Table I). As a
result of the routine Hib vaccination programme, the over¬
all reductions in the incidences of meningitis and INMD
due to H. influenzae were 92% (from 1.2 to 0.1 per 100,000
population) and 56% (from 1.6 to 0.7 per 100,000 popula¬
tion), respectively for all age groups between 1983-91 and
1992-99 (Table I). During the second study period, 11.
influenzae was the third most common cause of meningitis
and the fourth most common cause of INMD. The relative
proportions of meningitis and INMD due to H. influenzae
















































































































































































































































































































































































































































































































































































































































Fig. 3. Seasonal pattern of
meningitis caused by the 5
pathogens over 4-\veek blocks
of the year during the period
1983-99.
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Fig. 4. Seasonal pattern of
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decreased in all age groups except for the 45—64 y age group
for meningitis and the > 65 y age group foi INMD (Tables
II and III). A marked reduction in cases of meningitis and
INMD due to H. influenzae was seen in children and adults
who had not received Hib vaccine as well as in the vaccinated
group aged <4 y. A biphasic seasonal pattern of II.
influenzae meningitis and invasive nou-meuiugitic II. influen¬
zae was observed (Figs 3 and 4). Serotype information was
available for 787 (48.8%) cases of invasive disease between
1983 and 99: serotype B was responsible for 99.7% (367/368)
of cases ofmeningitis and 99.5% (417/419) of cases of INMD.
GBS
Between 1983-91 and 1992-99, the overall incidence ofGBS
meningitis remained the same but there was a 55% increase
(from 1.1 to 1.7 per 100,000 population) in the incidence of
INMD caused by GBS (Tabic I). Marked increases in the
proportions of cases of meningitis (/; < 0.0001) and INMD
(p < 0.0001) caused by GBS were seen in the < 1 y age group
compared to other age groups between these 2 periods (Table
II and Table III). Children aged < 1 y had the highest risks
of GBS meningitis and non-memngitic disease, accounting
for 84.1% and 36.5% of all cases, respectively in 1983-99.
The second highest proportion of cases of bacterial meningi¬
tis and INMD due to GBS occurred in the 15-44 y age
group. Seasonal variations in GBS meningitis and INMD
disease activity were recorded throughout the study period
(Figs 3 and 4).
L. monocytogenes
Overall reductions in the incidences ofmeningitis (50%; from
0.1 10 0.05 per 100,000 population) and INMD (50%; from
0.4 to 0.2 per 100,000 population) due to L.. monocytogenes
were documented between 1983-91 and 1992 99 (Table I).
A decline in the number of cases of meningitis and INMD
caused by L. monocytogenes was noted in all age groups
except for the 5 14 y age group for meningitis and the 5- 14
y and > 65 y age groups for INMD (Tables II and III). A
marked decline in the number of cases of Listeria meningitis
(from 17 to 4) and invasive non meningitic listeria! disease
(from 35 to 5) in children aged < 1 y was noted between
1983-91 and 1992-99. The greatest increase in the propor¬
tion of cases of bacterial meningitis and INMD caused by
L. monocytogenes was noted in the > 65 y age group. A
seasonal variation in iislerial meningitis and invasive non-
meningitic iistcrial disease activity was recorded (Figs 3 and
4). Serotyping was performed for 17/82 (20.7%) of the CSF
isolates and for 33/73 (45.2%) of other invasive isolates.
Serotypes 4, 4b, 1 and 1/2 caused all serotyped cases of
listcrial meningitis and invasive non-mcningitic listeria! dis¬
ease.
DISCUSSION
Despite the availability of antibiotics and the advances made
in producing effective vaccines for S. pneumoniae, H. influ¬
enzae type B and N. meningitidis, bacterial meningitis
continues to have a case fatality rate of 5-40%, with 9-30%
of cases who survive showing neurological deficits (3, 9, 10).
Studies in the US have also shown a 56.4% reduction in the
incidence of bacterial meningitis and a 43.7% increase in the
incidence of invasive bacterial disease caused by these 5
pathogens in 1995 compared with 1986 (3, 7). The increased
number of blood cultures obtained from patients with febrile
illness could be responsible for the increase in the number
of cases of INMD.
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In this study, conducted between 1983-91 and 1992-99,
the most important findings were:
1. The incidence of bacterial meningitis due to S. pneumo¬
niae and GBS was stable;
2. S. pneumoniae was the predominant cause of INMD in
both periods;
3. The incidences of INMD caused by N. meningitidis,
GBS and S. pneumoniae increased, by 27%, 55% and
56%, respectively;
4. Decreases in the incidences of bacterial meningitis (by
50%). and INMD (by 50%) due to L, monocytogenes
were detected; and
5. There were dramatic reductions in the proportions of
bacterial meningitis (by 92%) and INMD (by 56%) due
to H. influenzae in vaccinated and non-vaccinated
individuals.
Changes in age-specific disease trends as a result of
vaccination against Hib were identified as in previous re¬
ports from the US and UK (3, II). This has important
implications for current age-based preventive and treatment
guidelines.
N. meningitidis was the commonest cause of bacterial
meningitis in the present study. The US studies reported
that N. meningitidis was the leading cause of bacterial
meningitis in the < 5 y (12) and 2-18 y (3) age groups. Our
results indicated that N. meningitidis was the predominant
cause of meningitis in the age group 5-24 y. In common
with other reports (2, 3, 13), we found that the risks of
meningococcal meningitis and invasive non-meningitic
meningococcal disease were highest in infants and young
children aged 1-4 y. Implementation of serogroup C
meningococcal conjugate vaccine into the UK primary
immunization schedule has been reported to reduce the
incidence of serogroup C disease by 92-97% in vaccinated
groups (14). This may also have a substantial impact on the
current distribution of mcningoccal serogroups as well as a
shift in the distribution of disease in the > 18 y age group
that is not currently targeted for vaccination. In the present
study, at least 52% of cases of meningococcal disease were
due to serogroup B. This highlights the importance of
developing an effective vaccine against serogroup B in
order to further reduce the burden of bacterial meningitis.
S. pneumoniae was the second most frequent cause of
meningitis in Scotland. Data from other developed coun¬
tries showed that S. pneumoniae was the predominant
cause of bacterial meningitis and invasive disease in the US
(3) and the second most frequent cause of bacterial menin¬
gitis in Italy (15). In the US, 20-26% of cases of invasive
pneumococcal disease occurred in children aged < 5 y (3,
16). In the present study, 32.6% of cases of pneumococcal
meningitis and 10.3% of cases of other invasive pneumo¬
coccal disease occurred in children aged < 5 y. Our previ¬
ous report (17) showed that the prevalence of penicillin and
erythromycin non-susceptible pncumococci has increased,
from 4.2% in 1992 to 12.6% in 1999 and from 5.6% in 1994
to 16.3% in 1999. respectively. As a 7-valent pneumococcal
conjugate vaccine has been shown to prevent 97.4% of
cases of invasive disease and to reduce nasopharyngeal
carriage of vaccine serotypes in infants and young children,
which is particularly associated with drug resistance (18,
19), the future routine use of conjugate vaccine in the UK
could have a substantial impact on the incidence of invasive
pneumococcal disease and on drug resistance in this age
group. Consistent with other reports (20), the proportion of
INMD caused by S. pneumoniae was higher in the age
groups > 45 y and > 65 y. As the serotypes/serogroups in
the 23-valent polysaccharide vaccine covered > 90% of the
older age groups in Scotland (21), greater use of this
vaccine might reduce the burden of invasive pneumcoccal
disease in the elderly. However, coverage of pneumococcal
polysaccharide vaccine was low among recommended pa¬
tients: 4-15% in the UK (22, 23). We found that < 65% of
disease-causing serotypes were covered by the 7- and 9-va-
lent conjugate vaccines in all age groups, indicating a need
for a conjugate vaccine with > 9 serotypes for the older age
groups. As yet, the efficacy of conjugate vaccines has not
defined in adults and other high-risk groups and requires
further research.
The dramatic decline in invasive H. influenzae disease
after routine Hib vaccination documented in the present
study was similar to that reported in other UK studies (2,
11). Our findings also showed similar reductions in the
proportions of cases of meningitis and INMD due to H.
influenzae. Data from this study and the previous report
(24) clearly indicate that important progress has been
achieved in reducing Hib invasive disease in children aged
< 5 y in a country with universal Hib vaccination. Hib
vaccine coverage was > 95% in target groups in Scotland
and has been reported to have 97% effectiveness in children
aged 5-71 months (with an estimated vaccine failure rate
of 2.2 per 100,000 in vaccine recipients) (25). Our study also
showed marked reductions in H. influenzae meningitis and
INMD in those who were not targeted for Hib vaccination,
indicating a clear herd immunity effect as observed in other
studies in the US (26, 27) and UK (28). Although we did
not find a notable increase in the occurrence of invasive H.
influenzae disease among children aged > 5 y, such findings
have recently been reported in the US (28, 29). Our study
confirmed that serotype B remains the dominant cause of
invasive H. influenzae disease. Complete ascertainment of
serotype information is necessary in order to monitor the
effectiveness of the vaccination programme and any possi¬
ble future increase in non-type B H. influenzae disease
despite universal Hib immunization of in'fants in the future.
GBS is the most common cause of meningitis and INMD
in neonates (3, 7, 30), with a case fatality rale of 4-6% (31,
32). The current study showed that the majority of cases of
GBS meningitis and 1NMD occurred in children aged < 1
y. The major route of GBS transmission in infants is from
their mothers, who are colonized with GBS in the genital
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tract (33). Chemoprophylaxis of pregnant women with risk
factors for GBS is effective in reducing the incidence of
GBS disease in infants (34). The increased use of prophy¬
lactic intrapartum antibiotics has been suggested to have
reduced early-onset neonatal GBS disease by 65% over the
period 1993-98 in the US (35). In agreement with Cana¬
dian (36) and US (37-39) studies, the present study found
a higher proportion of cases of INMD due tu GBS in
adults during the period 1983-99. This may in part reflect
the increased practice of blood culture collection for sus¬
pected cases and an increase in the prevalence of individu¬
als with diabetes, cirrhosis, renal failure, stroke and breast
cancer, all of whom are at increased risk of GBS disease
(40). These data highlight the need for continued surveil¬
lance for GBS disease and for strategies to provide antimi¬
crobial agents for selected women in Scotland. The
development of conjugate GBS vaccines is now underway
and could reduce the burden of disease and the need for
antimicrobial agents as prophylactics in the future (41, 42).
Pregnant women, neonates, the elderly and the immuno¬
compromised are at increased risk of invasive listeria! infec¬
tion (43). The majority of cases of listerial meningitis and
invasive non-meningitic listerial disease occurred in children
aged < 1 y and in adults aged > 65 y in the present study.
In common with US surveillance data (3, 7), we found that
L. moncytogenes caused 11-17% of cases of bacterial
meningitis in the > 65 y age group and was the second
most common cause of bacterial meningitis, after Pneumo-
eoceus. Evidence suggests that most listerial infections are
caused by contaminated food (44). The 44% reduction in
cases of invasive L. monocytogenes in the US (45) and the
proportional decline in meningitis (12.2%; from 3.3% to
2.9%) and INMD (62.9%; from 3.5% to 1.3%) caused by L.
monocytogenes in this report may be due to tight regula¬
tions on contaminated loods and dietary recommendations
for high-risk individuals issued by the UK Departments of
Health and the Centers for Disease Control in the US (46,
47), indicating that these preventive measures are effective.
In line with previous published data (48), serotypes 4, 4b, 1
and 1/2 were responsible for almost all cases of meningitis
and INMD. Therefore, they should be considered as the
main candidate antigens for the development of any vac¬
cine against this pathogen.
Certain limitations exist in our surveillance data. As only
C'SF isolates were regarded as meningitis, cases without
CSF cultures which were blood culture-positive but with a
clinical diagnosis of meningitis were classified as INMD. As
a result of culture-negative cases and under-reporting, our
data may underestimate the true incidence rate of disease
caused by these 5 pathogens. The increased use of non-cul¬
ture diagnostic methods and an increase in the number of
reporting laboratories are also likely to have influenced the
study results. However, the increase in the number of
reporting laboratories for the major pathogens, namely
Pncumococci, Meningococci, GBS and H. influenzae, was
relatively small. Although an additional 7 laboratories re¬
ported L.. monocytogenes, the number of cases due to this
pathogen was small. In addition, cases of L. moncytogenes
decreased over the study period. These data suggest that
the increase in the number of laboratories reporting to the
SCIEH during the study period is not likely to represent a
primary explanation for the reported findings. Further¬
more, pathogens that were not included in the study can
cause meningitis and INMD. However, based on previous
reports (49 — 51) meningitis and INMD due to other bacte¬
rial pathogens are much less common and should not have
a major impact on the burden of disease.
CONCLUSIONS
Routine vaccination against H. influenzae type B and judi¬
cious use of antimicrobial agents has changed the epidemio¬
logical characteristics of bacterial meningitis and INMD in
Scotland as assessed by routine surveillance data. The
current widespread use of meningococcal Group C conju¬
gate vaccine, the implementation of S. pneumoniae conju¬
gate vaccines into the routine childhood immunization
schedule and the successful development of meningococcal
Group B or multivalent bacterial conjugate vaccines in the
future could lead to major progress in the prevention and
control of bacterial meningitis and INMD. In order to
inform appropriate immunization policies and clinical prac¬
tice, continuous surveillance of invasive bacterial disease is
necessary to enable assessment of the changing pattern of
disease incidence and determination of the populations at
risk of disease, serotype distributions and antimicrobial
susceptibilities.
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Prevalence of Penicillin Non-susceptible Invasive
Pneumococcal Disease in the Elderly in
Scotland, 1992-99
MOE H. KYAW'-2, IAN G. JONES2 and HARRY CAMPBELL1
From the 'Public Health Sciences. University of Edinburgh. Edinburgh. UK. -Scottish Centre for Infection and
Environmental Health. Glasgow. UK
Penicillin resistance nf Pneumococci is a problem in several Earopean countries. Therefore, we examined 510 invasive
pneumococcal isolates, collected between 1992 and 1999 via a national network of diagnostic laboratories covering the entire
population of Scxitland, for penicillin susceptibility, in order to determine the prevalence, site of infection and scrogroup/type
distribution or penicillin-resistant Pneumococci in the elderly ( > 65 y). Of the 510 isolates, 91.6% (n = 467) were from blood,
4.7% (n = 24) from other sterile sites and 3.7% (n— 19) from cerebrospinal fluid. The prevalence of penicillin non-susceptible
isolates during the study period was 9%. An increase in the proportion of Pneumococci non-susceptible to penicillin was
detected from 1996 onwards, from 10.8% in 1996 to 14.3% in 1999. There were 2 isolates with high-level penicillin resistance,
both of which were of serotype 14, accounting for 4.3% (2/46) of all non-susceptible isolates. Penicillin non-susceptible
isolates belonged to the following serogroups: 14 (32.6%); 9 (30.4%); 6 (19.6%); 23 (10.9%); and 19 (6.5%). The leading
non-susceptible serotype/group varied according to the specimen type: serotype 14 for blood and serogroup 9 for all other
sterile sites. Current polysaccharide and new 7-, 9- and ll-valent conjugate vaccine formulations included the serogroups
responsible for all the penicillin non-susceptible isolates detected. Therefore vaccination represents the most effective strategy
for decreasing the burden of drug resistance. Constant surveillance of the patterns of antibiotic non-susceptible isolates, the
site of infection and the serogroup/type are necessary in order to select antibiotic therapy and establish vaccination policy for
the prevention of invasive pneumococcal disease.
M.H. Kvuie, Scottish Centre for Infection and Environmental Health, Clifton House, Clifton Place, Glasgow G3 7LN. UK.
Tel.: +44 141 300 1184: Fax: +44 141 300 1170; E-mail: moe.kyute@fcieh.csajcot.nlts.uk
INTRODUCTION
Pneumococci are responsible for a substantial burden of
disease in the elderly, resulting in hospitalization, disease
complications and death. The incidence rate of invasive
pneumococcal disease is estimated to be between 45 and 90
per 100,000 persons aged >65 y (1). Compared with other
age groups, the case-fatality rate of pneumococcal disease is
higher in the elderly, being 20-40% (2—4). The prevalence
of Pneumococci resistant to penicillin and other antibiotics
is increasing globally (5) and this complicates the treatment
of invasive pneumococcal disease, particularly meningitis
(6).
The rate of drug-resistant isolates varies with the geo¬
graphic location (7) and the age of the patient, being more
common in children than adults (8). Although extensive
data exist concerning rates of drug resistance in young
children, little is known about the level of drug resistance in
the elderly in Scotland and most other parts of the world.
Data from the US indicate that the prevalence of drug-re¬
sistant Pneumococci in the elderly was s 15'% in 1995-96
and has been increasing in recent years (9). In some parts of
the US. up to 40% of invasive isolates have shown reduced
susceptibility to penicillin. Therefore, we decide to review
laboratory reports of penicillin non-susceptible invasive
pneumococcal disease collected via a national network of
diagnostic laboratories covering the entire population of
Scotland during the period 1992-99. in order to estimate
the magnitude of this problem in the elderly population.
• 20(12 Taylor & I'rancis. ISSN (H)36-554K
METHODS AND MATERIALS
Isolates from patients with pneumococcal disease tested for peni¬
cillin susceptibility were identified from laboratory reports received
at the Scottish Centre for Infection and Environmental Health
(SCIEH) and the Scottish Meningococcus and Pneumococcus Ref¬
erence Laboratory (SMPRL). The SMPRL provides a national
service for culture confirmation, serogrouping/typing and antimi¬
crobial susceptibility of Pneumococci and Meningococci to all 32
diagnostic laboratories in Scotland. It was established in 1992 for
the purpose of monitoring the epidemiological characteristics of
pneumococcal and meningococcal disease in Scotland. All diagnos¬
tic laboratories in Scotland are encouraged to send all invasive
pneumococcal isolates to the SMPRL for serotyping and antibiotic
susceptibility testing. However, the referral pattern is likely to vary
among participating laboratories. Therefore, enhanced pneumo¬
coccal surveillance was established in November 1999 with the aim
of producing an improved pneumococcal dataset for the periods
before and after the introduction of conjugate vaccine in the UK.
In this study we only included isolates from sterile samples, such
as blood, cerebrospinal fluid (CSF). joint and pleural fluids. Dupli¬
cate isolates from the same patient were excluded from the study.
Pneumococci isolated from these sterile sites were regarded as
evidence of invasive disease. During the study period, the elderly
population (>. 65 y) of Scotland comprised a: 15.3% (784.141/
5.120.000) of the entire population (10).
A latex agglutination test was used to identify Pneumococci (II).
Serotying was done on the basis of capsular swelling with type-spe¬
cific antisera obtained from the Statens Serum Institut (Copen¬
hagen. Denmark). Penicillin susceptibility testing was performed
using the E-lest (Cambridge Diagnostics. Cambridge. UK). The
breakpoints lor penicillin susceptibility were defined in accordance
with the recommendations of the NCCI.S (12). Penicillin sensitiv¬
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isolates had MICs of £0.06. 0.1-1 and >2 MS.ml. respectively.
Intermediately and high-level resistant isolates were considered as
non-susceptible isolates.
Data concerning the annual doses of penicillin dispensed in
Scotland between 1992 and 1999 were obtained from the Primary
Care Unit. Information and Statistics Division. National Health
Service. Scotland. The SPSS software program (Version 10) was
used for data analysis. Pearson correlation was used to determine
the association between the annual prevalence of penicillin-resis¬
tant isolates and the number of penicillin doses dispensed in
Scotland between 1992 and 1999. The 1996 mid-year population
figure was used to calculate the overall incidence rate of invasive
disease. Annual rates of antibiotic prescriptions per 100 population
were calculated for penicillin, erythromycin and all antibiotics for
1992-99.
RESULTS
Between 1992 and 1999, 510 invasive isolates were tested
for penicillin susceptibility from the .elderly: 46.3% (n —
236) were from males. 53.5% (a = 273) from females and in
0.2% (a = 1) the gender was unknown. The mean age of the
subjects was 77 y (range 65-98 y). Of the 510 isolates,
91.6% (a = 467) were from blood. 4.7% (a = 24) from other
sterile sites and 3.7% (a = 19) from CSF (Table I). There
was a steady increase in the number of blood cultures
during the study period. The ratio of positive blood to
positive CSF cultures increased from 23:1 in 1992 to 67:1 in
1999. The overall incidence of invasive pneumococcal dis¬
ease was 11.3 per 100,000 population during 1992-99
(range 8.6-12.6).
Proportion ofpenicillin non-susceptible isolates
The prevalence of penicillin non-susceptible isolates ranged
from 2.6% to 14.7% during 1992-99 (Fig. 1). There was no
increase in the prevalence of penicillin non-susceptible iso¬
lates between 1992 and 1995, in contrast to the increasing
proportion of these isolates found from 1996 onwards. A
similar trend was also observed for the age groups <5 y
and 5-64 y. Overall, the rate of non-susceptible isolates in
the elderly during 1992-99 was 8.6%, which was similar to
that in the age group 5-64 y (7.3%) but substantially higher
than that in the age group < 5 y (3.7%). The annual
prevalence of non-susceptible isolates in the elderly was
consistently higher than that in the age group < 5 y. The
annua! rate of non-susceptible isolates in the elderly was
also higher than that in the age group 5-64 y, except for
the years 1996 and 1998. Rates of antibiotic prescriptions
per 100 population ranged from 230-272 for penicillin.
51-79 for erythromycin and 365-485 for all antibiotics
during 1992-99.
There was a significant correlation between the preva¬
lence of penicillin non-susceptible isolates and the rates of
penicillin, erythromycin and all antibiotic prescriptions dis¬
pensed in Scotland between 1992 and 1999 for the age
groups < 5 y (y> = 0.004. 0.002 and 0.009, respectively) and
> 65 y (/) = 0.021. 0.026 and 0.013. respectively). A statisti¬
cally significant correlation was noted between penicillin
non-susceptibility and the prescription rate for ery¬
thromycin (y; = ().OI3). but not for penicillin (yj = 0.153) or
all antibiotics {p = 0.056). in the age group 5-64 y.
Non -susceptible serogroups <types
The distribution of penicillin non-susceptible serogroups,
types by specimen type is shown in Table I. The most
common serogroups/types were 14 (32.6%: 15/46). 9
(30.4%; 14/46). 6 (19.6%; 19/46). 23 (10.9%; 5/46) and 19
(6.5%; 3/46). These 5 serogroups/types accounted for all the
non-susceptible isolates. Serotype 14 was responsible for
high-level resistance, accounting for 4.3% (2/46) of non-sus¬
ceptible isolates. The main non-susceptible serogroup/type
also varied with the source of the specimen; serotype 14
from blood and serogroup 9 from other sterile sites. There
were no non-susceptible isolates from CSF (Table I).
Vaccine coverage
The coverage of 7-11-valent conjugate vaccine and the
23-valent polysaccharide vaccine were both 100% for peni¬
cillin non-susceptible pneumococcal isolates (Table II).
DISCUSSION
An increase in the prevalence of penicillin non-susceptible
Pneumococci has been detected in the Scottish elderly in
recent years. Although not consistent, an increase in the
rate of non-susceptibility in the age groups <5 y and 5-64
y was also observed after 1996. Although the reason for
this is not clearly understood, the introduction of a new
blood culture system (BacTAlert) in 1996 and the increase
in blood cultures taken from febrile patients may be partly
responsible (13). A 3-fold increase in the ratio of positive
blood to positive CSF cultures during the study period
would tend to support these explanations. However, our
findings are likely to be biased owing to the voluntary
referral for testing of penicillin susceptibility and variations
in referring invasive pneumococcal isolates to the SMPRL
among diagnostic laboratories in Scotland.
It is also possible that non-susceptible isolates were more
likely to be submitted if they were from patients with
treatment failure. In addition, the primary laboratory may
be more likely to refer for confirmation non-susceptible
isolates which have already been tested for susceptibility.
The prevalence of penicillin non-susceptible isolates was
lower in subjects aged <5 y than in those aged > 65 y.
This suggests that the reporting of invasive isolates is likely
to be affected by age. Thus these data should be interpreted
with caution. Nevertheless, they indicate the extent of
penicillin non-susceptible pneumococcal disease among the
elderly. US data show that penicillin-resistant Pneumococci
are increasing in prevalence (9) and are more often likely to
be resistant to other antibiotics (14). This rise in non-sus¬
ceptible isolates limits the choice of empirical therapy in the
elderly, who are at the greatest risk of death and the
complications of pneumococcal disease. Although the clini-
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Table I. Distribution ofpenicillin mm -susceptible isolates in the elderly in Scotland. IW2 99
No. ol" isolates




2 4 - - 4
3 42 - - 42
4 35 - - 35







9 35 10 - 451
10 7 - - 7
11 10 - - ioL
12 10 - - 10
13 2 - - 2f
14 58 12 2 72'
15 7 - - 7
17 1 - - 1
18 3 - - 3
19 46 2 - 48
20 10 - - 10
21 1 - - 1
22 14 - - 14
23 33 < 37
24 1 4 1
31 3 J : 3
33 4 - _ 4
34 2 - 2
35 1 - - 1
38 4 - - 4
41 1 - - 1
42 1 - - 1
































•' Isolates from pleural aspirate, pericardial lluid. lung aspirate, bronchial aspirate and bone marrow.
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Fig. I. Prevalence of penicillin non-susceptible pneumococcal iso¬
lates in the elderly in Scotland. 1992-99.
cal outcomes of non-susceptible pneumococcal disease
have not been fully characterized, recent US data reveal
that high-level penicillin-resistant invasive pneumococcal
disease (MIC >2.0 nig/ml) is associated with increased
mortality (15). Patients infected with penicillin non-sus¬
ceptible Pneumococci (mainly intermediately resistant) are
also reported to have worse medical outcomes (16) and a
longer duration of hospitalization (3.7 d) compared to
patients infected with penicillin- susceptible Pneumococci
(4). These data highlight the need to minimize the impact
of drug-resistant Pneumococci in Scotland. Improved
surveillance for drug resistance, promotion of the judi¬
cious use of antibiotics and improved use of pneumococ¬
cal vaccine are key strategies in order to limit the spread
of drug resistance (17). In the present study, the annual
prevalence of penicillin non-susceptible isolates) tiid not
correlate with the annual number of doooG of penicillin
dispensed in Srnflaiujt The observed development of an
increased rate of non-susceptible isolates is difficult to
determine and may relate to the spread of drug-resistant
clones (18). Studies on the molecular characterization of
penicillin-resistant and multidrug-resistant pneumococcal
isolates in Scotland are necessary to establish this.
Data on the prevalence of resistance, site of infection
and serogroup/type distribution can inform antibiotic
treatment decisions. Treatment failures have been ob¬
served in patients with penicillin-resistant strains (MIC 2:
0.12 mg/ml) causing meningitis (19, 20). In the present
study, no isolates from CSF were non-susceptible to peni¬
cillin. Previous data indicate that serotype 3 is associated
with a high case-fatality rate (21). We found that
serotype 3 was the third most common serotype isolated
from blood specimens. Nevertheless, these isolates were
uniformly susceptible to penicillin. Serogroups 6. 9. 14.
19 and 23 accounted for all cases of penicillin non-sus¬
ceptibility in Scotland. The 2 high-level resistant isolates
were found to be serotype 14. In the US. serotype 14 was
reported to have caused an outbreak of multidrug-resis¬
tant meningitis in crowded facilities (22) and serotypes
23F, 6A and 6B were more likely to be resistant to peni¬
cillin (23). Studies have shown that these 5 serogroups
are most commonly carried in the nasopharynx (24). Our
data showed that the current formulations of polysaccha¬
ride and conjugate pneumococcal vaccines include all
these penicillin non-susceptible serogroups and this high¬
lights the importance of vaccination for the prevention of
pneumococcal disease. New pneumococcal conjugate vac¬
cines have been shown to reduce not only disease (25)
but also nasopharyngeal carriage, particularly that associ¬
ated with drug-resistant Pneumococci (26). Thus, the use
of conjugate pneumococcal vaccine in the elderly is likely
to affect the transmission and spread of drug-resistant
Pneumococci in institutional settings such as nursing
homes and geriatric wards. In addition, there is strong
evidence that polysaccharide vaccine is 50-80% effective
at preventing invasive disease (27). The increased use of
this vaccine could prevent^ only pneumococcal disease
hut nlsn anrihimir resist a nrtf (28). Nevertheless, uptake of
this vaccine in the elderly is low (29, 30) and should be
increased in the UK and other developed countries.
CONCLUSION
Our data show an increase in the proportion of penicillin
non-susceptible Pneumococci among the elderly. It is
likely that this will result in increases in morbidity and
mortality due to invasive pneumococcal disease in this
age group. Vaccination is the most effective measure to
prevent pneumococcal disease resistant to penicillin and
other antimicrobial agents. Current polysaccharide and
conjugate pneumococcal vaccines cover the serogroups re¬
sponsible for penicillin non-susceptibility in the elderly in
Scotland. Constant surveillance of the patterns of antibi¬
otic non-susceptible isolates and the site of infection is
necessary in order to select optimal antibiotic therapy for
the management of invasive pneumococcal disease.
Table II. Penicillin non-susceptible pneumococcal isolates covered hy the vaccines
Vaccine Sensitive; n (%) Intermediate: n (%) Resistant: n (%) Total; n (%)
7-valent 255/464 (54.6) 44.44 (100) 2 2 (100) 301/510 (59.0)
9-vaient 286/464 (61.6) 44/44 (KM)) 2/2 (100) 332/510 (65.1)
1l-valent 351/464 (75.6) 44 44 (100) 2/2 (100) 397/510 (77.8)
23-valenl 445/464 (95.9) 44 44 (100) 2/2 (100) 491-510 (96.3)
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Pneumococcal vaccination: opinion of general
practitioners and hospital doctors in Scotland,
1999-2000
MH Kyaw, JC Bramley, J Chalmers, IG Jones, H Campbell
Summary: A cross sectional survey by postal questionnaire was carried out to examine
general practitioners' (GPs) and hospital doctors' (HDs) knowledge, attitudes and
practice (KAP) ivith regard to pneumococcal vaccination in primary and hospital care
in Scotland. Most GPs and HDs considered patients with chronic medical conditions,
as recommended by the Department ofHealth (DoH), to be candidates for pneumococcal
vaccination. Although the DoH does not currently recommend the vaccine for ail the
elderly, 47% of GPs and 46% ofHDs reported that the vaccine should be given to this
group. GPs (61-85%) and HDs (48-55%) indicated that they considered the vaccine
to be safe and effective. The acceptance of pneumococcal vaccine was much lower than
for influenza vaccine however, and 79% ofHDs and 17% of GPs had never used the
vaccine. Documented policies (with or -without set targets) for pneumococcal vaccine
existed in only 14% of general practice and 3% of hospital settings. Over 70% of
respondents indicated that GPs should take responsibility for pneumococcal vaccination.
The main sources ofknowledge about pneumococcal vaccines were stated to be discussion
with colleagues, review of medical literature, past experience, and the DoH
recommendations. A clear immunisation policy and financial support for vaccination
were identified as important strategies to improve pneumococcal vaccine coverage.
Strategies directed toward these factors could enhance vaccine delivery and coverage of
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Introduction
Pneumococcal disease is an important cause of
hospitalisation and death in the United Kingdom (UK)
and presents a significant public health problem'. The
current 23-valent polysaccharide vaccine is safe, and
is effective in preventing 50-80% of invasive
pneumococcal disease2-3. This vaccine has, in addition,,
been shown to be cost-effective in the United States
and Europe including the UK4'6. However,
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polysaccharide vaccine is ineffective in two year olds,
the age group with the highest incidence of invasive
and mucosal disease. This has led to the development
of conjugate vaccines, one of which has been shown
to be highly efficacious in preventing invasive disease
(97.4%, 95% CI, 82.7-99.9) in infants7. It is under
review for European licensure.
In the UK, pneumococcal polysaccharide vaccine
is currently recommended for individuals aged two
years and above with splenic dysfunction, chronic
heart, lung, liver, and renal diseases, diabetes mellitus
or immunocompromising conditions8. However,
surveys in England have shown that only 4-15%, and
0.5% of people with these indications, had received
the vaccine in primary and hospital care
respectively9-10. it is clear that acceptance of
pneumococcal vaccine among general practitioners
(GPs) and hospital doctors (HDs) is low. We therefore
conducted a survey of GPs and HDs in Scotland to
examine their KAP in relation to pneumococcal
vaccination in order to identify the barriers that may
affect vaccine use.
Methods
in September 1999, a total of 800 GPs and HDs
practising in Scotland were identified for the survey.
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The Information and Statistics Division (ISD) of the
Common Services Agency, Edinburgh, supplied the
names of 400 GPs selected at random from a national
register, together with associated demographic
characteristics. The HDs were chosen by asking each
of 30 NHS hospitals, selected to be representative of
Scotland, to supply details (names, specialties,
positions and corresponding addresses) of 25 medical
doctors selected non-systematically from personal
records. Four hundred doctors from 16 hospitals were
surveyed. The study design and questionnaire was
modified from that of Berk and colleagues11. A pilot
study was conducted among 12 GPs and 12 HDs
during October 1999 after which the questionnaire was
amended as necessary. In November 1999, the revised
questionnaire was sent to the 800 GPs and HDs with
a reminder questionnaire sent to those who did not
respond after six weeks. Participants were questioned
about the target groups for vaccine, vaccine
effectiveness, practice and policies, the source of their
knowledge, and any initiatives in place to increase the
use of pneumococcal vaccine in their setting.
Data analysis
Data analysis was performed using SPSS version 10.
The chi-squared test was used to determine the
significance of association between the variables for
KAP of pneumococcal vaccination.
TABLE I Characteristics of questionnaire respondents
General practitioners (n=286) Number (56)
Patient population
mean number of patients per practice 5127
mean number of registered elderly patients 386







Hospital doctors (n=198) Number (56)
Grades
Consultant 39 (20)
Specialist Registrar 39 (20)
Registrar 42 (21)
Senior Registrar 40 (20)
House Officer 38 (19)
Specialties
Cardiology 18 (9)
Respiratory medicine 20 (10)




Accident and Emergency 27 (13)
Geriatric/ Elderly medicine 21 (II)
General medicine 24 (12)
Results
Of the 800 questionnaires, 504 (63%) were returned.
Of these, 20 were unanswered because the intended
recipient had moved or did not want to participate.
Of the 484 (60%) completed questionnaires, 286 (59%)
were from GPs and '198 (41%) were from HDs. Table 1
displays the characteristics of respondents by
healthcare setting.
Pneumococcal vaccine: knowledge of target
groups
The respondents' views on pneumococcal vaccination
in various high-risk conditions are shown in Table 2.
Splenic dysfunction was the conditionmost frequently
agreed or strongly agreed to be an indication for
pneumococcal vaccination by both GPs (99%) and HDs
(81%). Vaccination of all elderly was least frequently
considered as an indication by either GPs (47%) or HDs
(46%). GPs were more likely than HDs to agree or
strongly agree about the need for the vaccine in the
high-risk conditions currently recommended for
vaccination by the DoH. Compared to GPs, HDs were
more likely to be uncertain whether the risk condition
cited was an indication for vaccine recommendation.
Pneumococcal vaccine: knowledge of safety and
effectiveness
A significant proportion of respondents did not know
about pneumococcal vaccine safety and effectiveness for
the patient categories given (Table 3). The proportion
was much higher fgr HDs than GPs.
Pneumococcal vaccine: use
Themajority of HDs (79%) had never used the vaccine
compared with only 17% of GPs (figure 1). A statistical
significance was not found for particular specialities
or grades of HDs in their use of vaccine. General
practice location and type were associated with
vaccine use among GPs, with higher use by GPs in
urban areas than rural areas (rural = 35/40 (88%)
versus urban = 199/242 (82%), p = 0.55) and by group
practices rather than single practices (group practices
= 199/235 (85%) versus single practices = 35/47 (74%),
p = 0.089).
FIGURE I Use of pneumococcal vaccine among
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TABLE 2 Views of respondents on indications for pneumococcal vaccination in various high risk patient groups by level
of agreement (%)* (GPs: n=286, HDs: n=l98)
Strongly Strongly Don't
Risk conditions Respondent agree Agree Disagree disagree know
Splenic dysfunction" GPs 80 19 0 1 0
HDs 67 14 2 1 16
Chronic pulmonary disease* GPs 59 36 1 1 2
HDs 34 40 5 1 20
Immunocompromised* GPs 51 33 5 1 8
HDs 36 32 6 22
Chronic heart disease* GPs 39 39 II 1 9
HDs 21 40 II 1 27
Chronic renal disease* GPs 36 40 10 1 13
HDs 20 35 10 1 33
Diabetes mellitus* GPs 36 40 10 1 13
HDs 14 38 15 1 32
Chronic liver disease* GPs 30 39 13 1 16
HDs 17 39 1 1 I 31
Elderly (>65 years) GPs 15 34 28 5 16
(residents of long stay facility) HDs 13 39 18 3 25
All elderly >65 years GPs 16 31 32 8 12
HDs 10 36 22 4 27
* Not all categories add up to 100% due to incompete forms
# Currently recommended by che UK Departments of Health
TABLE 3 Views of respondents on the safety and effectiveness of pneumococcal vaccine in preventing invasive
pneumococcal disease by patient group (%)* (GPs: n=286, HDs: n=l98)
Strongly Strongly Don't
Risk conditions Respondent agree Agree Disagree disagree know
Immunocompromised adults GPs 28 46 5 2 18
HDs 17 38 4 1 38
Adults with chronic heart/pulmonary GPs 25 60 3 1 11
/renal/liver/diabetic disease HDs 13 40 4 1 42
Elderly (>65 years) GPs 20 45 1 1 2 20
HDs 12 36 6 2 43
Young adults GPs 22 39 7 4 28
HDs 16 34 7 3 40
Pneumococcal vaccine attitudes and
practice
If an elderly patient specifically requested a vaccine
to protect them against pneumonia, 53% of GPs and
41% of HDs answered they would use both influenza
and pneumococcal vaccines. Influenza vaccine alone
would be recommended by 40% of GPs and 36% of
FIGURE 2 Response to elderly patients' requests for a
vaccine against pneumonia (GPs: n=277, HDs: n=l72)
100 —I
I I I
Influenza Pneumococcal Both Neither
vaccine vaccine
Vaccine given
HDs (figure 2). GPs in urban areas were more likely
to offer both influenza and pneumococcal vaccines
(rural = 21/117 (18%) versus urban = 125/141 (89%),
p = 0.0001), and those in rural areas were more likely
to use influenza vaccine alone (rural = 96/117 (82%)
versus urban = 16/141 (11%), p = 0.0001). Practice
type was also related to use of vaccine. GPs in group
FIGURE 3 Reported pneumococcal vaccination policies
(GPs: n=276, HDs: n=l65)
100 -i
| | I I
Documented Documented Verbal No policy Dont know
policy with policy without agreement
set target set target among partners
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TABLE 4 Sources of knowledge about pneumococcal
vaccine among respondents (GPs: n=562, HDs: n=368)
TABLE 5 Suggested strategies for improving
pneumococcal vaccine coverage
Source* GPs HDs
Discussion with colleagues 43 27
Own review of medical literature 38 33
Past experience 27 26
Department of Health 27 32
Health Boards 22 27
Further medical education 22 28
Advice from manufacture 14 5















* can answer more than one source
practices were more likely to recommend influenza
vaccine alone (group practices = 99/216 (46%) versus
single practice = 13/42 (31%), p = 0.075) or both
influenza and pneumococcal vaccine (group
practices = 117/216 (54%) versus single practices =
29/42 (69%), p = 0.075) than those in single practices.
Pneumococcal vaccination policies
Figure 3 shows the policies for pneumococcal
vaccination in the respondents' settings. There was
no pneumococcal vaccination policy in the clinical
setting of 70% of HDs and 43 % of GPs. Only 3% of
GPs had a policy which included a set target. Very
few HDs (3%) knew of a documented policy which
existed in their clinical area, and none of these carried
a set target.
Policies for pneumococcal vaccination were
associated with general practice type and location,
with GPs in urban areas (rural = 25/41 (61%) versus
urban = 113/226 (50%), p = 0.19) and group practices
(group practices = 124/229 (54%) versus single
practices = 23/47 (49%), p = 0.51) more likely to have
some form of pneumococcal vaccination policy than
those in rural and single practices. No association was
found in HDs' grades or specialties (data not shown).
Pneumococcal vaccination responsibilities
Figure 4 summarises the respondents' views on the
primary responsibility for pneumococcal vaccination.
Over 70% of GPs and HDs felt that the primary
responsibility for pneumococcal vaccination lay with
general practitioners, followed by the DoH and the
Health Boards (HBs) and Health authorities (HAs).
FIGURE 4 Views on the primary responsibility for
pneumococcal vaccination (GPs: n=478, HDs: n=356)
Source* GPs HDs
A clear immunisation policy 87 80
Financial support for vaccination 72 54
Computerised systems to identify high 49 47
risk patients
Vaccine awareness public health campaign 46 46
Further education on immunisation 32 44
Conclusive evidence of vaccine efficacy 22 30
Provision of a nurse assistant 18 16






* can answer more than one source
Pneumococcal vaccine: source of knowledge
Discussion with colleagues, personal review of
medical literature and past experience were the main
sources for pneumococcal vaccine information among
GPs and HDs. Consultants and specialist registrars
mostly acquired information about pneumococcal
vaccine from past experience and further education
compared with HDs in other grades who stated other
categories (see table 4).
Pneumococcal vaccine: strategies to improve the
coverage
Eighty-seven percent of GPs and 80% of HDs believed
that a clear vaccination policy would increase the
coverage of vaccine in high-risk individuals. Financial
support for pneumococcal vaccination was considered
to be an important element in improving the vaccine
coverage by both GPs (72%) and HDs (53%). Over
45% of both GPs and HDs considered that public
health campaigns on pneumococcal vaccination and
a computerised system to identify persons with
definite indications for the vaccine would raise the
vaccine coverage (table 5).
Discussion
Although pneumococcal polysaccharide vaccine has
been licensed in the UK since 1979, information about
the use of vaccine among GPs and HDs has not been
available. To our knowledge, our data represent the
first survey of the knowledge and reported
pneumococcal vaccination practices of GPs and HDs
in the UK. The sampling methods adopted and the
good response rate from GPs and HDs suggest that
these results may be representative of the GPs and
HDs throughout Scotland.
Pneumococcal vaccine: knowledge and use
Our findings indicate that the majority of GPs and HDs
support the use of vaccine in high-risk groups and
recognise the safety and effectiveness of the vaccine.
Surveys from the United States have also showed that
physicians in general practice and hospital settings
have adequate knowledge of pneumococcal vaccine
target groups and its usefulness, but that they have
failed to act on this in clinical practice'1"12. Compared
to GPs, HDs were less likely to know whether the
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vaccine was safe and effective in high-risk patients.
Since many high-risk persons come into contact with
HDs during their hospitalisations and out-patient
visits, this lack of knowledge about pneumococcal
vaccine could lead to missed opportunities for
vaccination in hospital care.
It is clear from the survey that among both GPs
and HDs acceptance of influenza vaccine was
higher than of pneumococcal vaccine. Poor
acceptance and low use of pneumococcal vaccine
among GPs and HDs may have been influenced by a
poor understanding of the burden of pneumococcal
disease together with the inconclusive evidence from
randomised trials of its efficacy in the elderly15. The
factors accounting for poor use of pneumococcal
vaccine in single practices and practices located in
rural areas are not fully understood. Whether this
is a result of greater workload or other factors is
difficult to determine and requires further
investigation.
As a result of this finding, further data on the
number of patients with chronic heart disease and
chronic obstructive pulmonary/lung disease in
urban and rural areas were sought from the
Continuous Morbidity Recording (CMR) system, ISD.
The CMR system includes 53 general practices, more
than 5% of the population of Scotland. The data
from the CMR are considered to be representative of
Scottish population in term of sex, age and
geographic locations. The CMR data showed that
there was a difference in the portion of patients with
chronic heart disease (rural = 25/1,000 population
versus urban = 21/1,000 population) and chronic
pulmonary disease (rural = 57/1,000 population
versus urban = 42/1,000 population) in rural versus
urban areas (data obtained from Matthew Armstrong,
ISD on 30/Jan/2001). This suggests that differences
in KAP of pneumococcal vaccination in rural and
urban area GPs are unlikely to be related to the
proportion of such patients.
Evidence from the UK and North America suggests
that acceptance of pneumococcal vaccination in high-
risk persons increases when primary and secondary
health care teams offer the vaccine9'10'16'17. A recent
American survey found that the lack of a doctor's
recommendation was the predominant reason for not
receiving pneumococcal vaccine'8. It is therefore important
to educate all members of primary and secondary care
teams regarding vaccine effectiveness and side effects,
and the benefits of pneumococcal vaccination in high-
risk persons. Although there is a considerable doubt on
its efficacy in immunocompromised individuals19,
vaccination may be the most effective measure in this
group with the highest incidence of invasive disease.
Incorporating teaching on prevention of pneumococcal
disease and an adult (as opposed to only childhood)
vaccination programme in undergraduate and
postgraduate medical training could not only increase
the levels of knowledge and understanding of vaccination
but also alter the attitudes and behaviour of doctors
towards pneumococcal vaccination in the future.
Pneumococcal vaccine: source of information
and policies
It appears that there is a need for more attention to
be given to the promotion of recommendations on
pneumococcal vaccination by the DoH and HBs/
HAs since most GPs and HDs acquire this
information from their own review of the medical
literature. In addition, many practices and hospital
care settings lacked clear pneumococcal vaccination
policies. A review of pneumococcal vaccination
policies in 21 countries suggests that specific
recommendations and action by the health officials
would play an important role in improving the use
of pneumococcal vaccine15. Establishing
appropriate guidelines, audit and feedback on
performance may have a positive impact on
improving coverage of pneumococcal vaccine in the
future.
Pneumococcal vaccination: responsibilities and
strategies
Since the target groups for influenza and
pneumococcal vaccines overlap, offering
pneumococcal vaccine to eligible persons when they
attend for annual influenza vaccination could achieve
a similar coverage for both (45%)20. This strategy has
been strongly recommended by the DoH8. Our
findings show that both GPs and HDs consider that
the primary responsibility of pneumococcal
vaccination should lie with GPs although a minority
thought that this should be the DoH or ITB/HA
function. It is clear that collaboration and support
from the DoH and HBs/HAs to GPs will be important
in overcoming existing barriers.
HDs, nurses and pharmacists all play a vital role
in improving the coverage of pneumococcal vaccine.
Studies from the United States have shown that
hospital-based pneumococcal vaccination
programmnes during admissions or out-patient visits
are an effective strategy for vaccinating high-risk
persons21-2. Surveys have shown that 56-88% of
pneumococcal vaccine eligible persons had previous
hospital admissions22'25. Therefore, hospital based
vaccination is a complementary strategy which should
be considered in the UK.
About 85% of GPs and HDs suggested that
financial support and incentive payments for
pneumococcal vaccine could improve its use. At
present, there is no payment mechanism for GPs
regarding pneumococcal vaccination in Scotland. This
clearly discourages the use of this vaccine by GPs. If
funding were made available to establish target
payments for adult vaccination as for childhood
vaccination then the vaccine coverage would be likely
to increase. The recent adoption of universal influenza
vaccination in all elderly 65 years of age and above
with a related payment scheme has been important
step forward to improve the coverage of influenza
vaccine2". Considera tion should be given to extending
this scheme to cover combined influenza and
pneumococcal vaccine targets.
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The need to identify and target eligible persons
for pneumococcal vaccine with a computerised
system was commented on by the majority of GPs
and HDs. Studies from the United States have shown
that a reminder system (with use of computer, chart
and letter), standing orders for nurses and walk-in
clinic produced an improvement in influenza and
pneumococcal vaccines administration in the primary
care and hospital care16-27'38.
One American report highlighted that the lack of
public awareness of indications for the vaccine was
the major reason for not receiving the vaccine'8. Most
respondents in the present survey also felt that a
public health campaign on pneumococcal vaccine
awareness was important in improving the coverage
of vaccine. One British report showed that such
campaigns in general practices increased
pneumococcal vaccine coverage from 4% to 33%".
Similar findings have been reported from the United
States and Belgium2''"3'.
In the present survey most GPs and HDs suggested
that clear guidelines were essential to improve the
coverage of vaccine. The current chronic disease-
based pneumococcal vaccination policy needs to-be
made more precise so that specific indications of
vaccination are given. In the United States, a specific
objective has been set up to reach 80% coverage among
high-risk persons by the year 2010'8. A pneumococcal
vaccination target does not yet exist in the United
Kingdom.
American surveys showed that the majority of
physicians believed pneumococcal vaccine should be
given to elderly patients"-12. Our study found less
support for vaccination of all elderly aged 65 years
and above among GPs and HDs. In contrast to the
American age-based policy, pneumococcal vaccination
is not currently recommended for all elderly by the
British DoH". Economic studies have consistently
shown that pneumococcal vaccination is cost effective
or cost saving in the elderly32. Therefore, its routine
use in the elderly should be reconsidered in the United
Kingdom.
Our survey indicates that the majority of GPs and
HDs have sufficient understanding and knowledge of
pneumococcal vaccination. Compared to GPs, HDs
were more likely to be uncertain about indications,
safety and effectiveness of vaccine. No single factor
appears to account for the low use of pneumococcal
vaccine among GPs and HDs. The main barriers to
improving the vaccine coverage are reported to be lack
of clear immunisation policies and of financial support
for adult vaccination. The results of this survey should
provide relevant data to inform the development of
future policies aiming to increase the coverage of
pneumococcal vaccination among those recommended
for vaccination in primary and hospital care settings.
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Abstract
A national survey was carried out to determine the coverage of influenza and pneumococcal vaccines, policies, reasons for receipt,
non-receipt of vaccine and strategies to improve vaccine coverage in Scottish nursing homes. Of the 550 nursing homes, 72% (394)
participated in the study. Overall coverage was 85% for influenza vaccine in 2001-2002 season and 11% for pneumococcal vaccine in
the last 5-year period. Only 6% (23/394) of homes were reported to have a systematic immunization record. The most frequently stated
reasons for improved coverage ofboth vaccines were clear immunization policies (76%), awareness and education for staff and residents
(68%), and consent on behalf of the incompetent residents (66%). The presence of vaccination policies was higher for influenza vaccine
than pneumococcal vaccine expressed as verbal agreement (27% versus 3%), written policies with set target (24% versus 5%) and written
policies without set target (17% versus 2%). Advice from the members of the community health care team was the principal reason for
the receipt of both vaccines. The predominant reasons for non-receipt of vaccine were refusal by residents and family members (both
vaccines) and lack of advice from general practitioners (pneumococcal vaccine). The substantial disparity in coverage of influenza and
pneumococcal vaccine reflects the lack ofnational recommendations and policies for reimbursements for pneumococcal vaccination. These
data suggest that greater efforts are needed to improve prevention behaviors of health care professionals and the public, organized vaccine
delivery strategies and systematic vaccination documents to increase influenza and pneumococcal vaccination rates in nursing homes and
other long-term care facilities. © 2002 Elsevier Science Ltd. All rights reserved.
Keywords: Scottish nursing homes; Influenza and pneumococcal vaccination; Policies
1. Introduction
The elderly are at-risk of influenza and pneumococcal
disease. Most elderly living in nursing homes have chronic
medical conditions [1], and therefore have higher risk of
complications and mortality from influenza and pneumococ¬
cal disease than the elderly living in the community [2-4],
Outbreaks of influenza and pneumococcal disease have been
well documented in nursing homes [5-7]. In addition, data
from the US shows that the prevalence of drug resistant
pneumococci is increasing in the elderly [8]. Drug resistant
pneumococcal strain (serotype 23) has been reported as a
cause of an outbreak of pneumococcal disease in a nursing
home with low vaccine coverage [6],
Susceptibility to infection and transmission of influenza
and pneumococcal disease can be prevented by vaccina¬
*
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tion [9,10]. Studies show that the estimated effectiveness
of influenza vaccine is 43-55% against pneumonia [9] and
>42% against influenza-like illness [11] among elderly nurs¬
ing home residents. Pneumococcal vaccine is 61-75% ef¬
fective in preventing bacteraemia or meningitis in the el¬
derly [12,13]. The administration of both vaccines is also
considered cost-effective in the elderly [14—16]. Despite this
evidence, influenza and pneumococcal vaccines are under¬
used in the UK [17,18]. Influenza vaccination is currently
targeted to all elderly (aged 65 years and above) and resi¬
dents in long-term care facilities. However, pneumococcal
vaccination is not yet recommended for these groups in the
UK [19]. There are limited data on coverage and polices
of influenza and pneumococcal vaccinations in UK nursing
homes. In addition, little is known of the reasons for receipt
and non-receipt of these vaccines in elderly nursing home
residents. We therefore report national coverage of and poli¬
cies for influenza and pneumococcal vaccines together with
the factors which may be associated with the use and re¬
ceipt of both vaccines in Scottish nursing homes. These data
0264-410X/02/S - see front matter © 2002 Elsevier Science Ltd. All rights reserved.
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could help to develop strategies to improve coverage of in¬
fluenza and pneumococcal vaccines in nursing homes and
other long-term care facilities.
2. Methods
A list of nursing homes and their addresses was obtained
from the Information and Statistics Division (ISD) of the
Common Services Agency of the National Health Service
(NHS), Scotland. In 2001, there were 550 licensed nursing
homes in the whole of Scotland, which provided nursing
care primarily to the elderly population. A postal question¬
naire was sent to each nursing home on 12 June 2001 with
a request for it to be completed by the nurse in charge or
care manager. A reminder was posted to non-respondents
on 2 August 2001. The questionnaire requested information
on the number of residents, the number of general prac¬
tices looking after residents, the existence of immunization
record, the number of residents receiving influenza vaccine
or pneumococcal vaccine or both vaccines, vaccination poli¬
cies, the factors associated with improved vaccine coverage
and the reasons for receipt and non-receipt of vaccine, se¬
lected from a number of key reasons defined in a pilot study.
Information was requested as aggregated format. Therefore,
data are completely anonymous and do not identify individ¬
ual elderly living in each nursing home. Information was
entered in DataEase version 4.5 and data analyses were car¬
ried out in SPSS version 10 and Stata (Stata Corporation,
version 6.0, 1999, College Station, Texas). Since the data are
non-normally distributed, non-parametric tests were applied.
Mann-Whitney tests were used to compare median coverage
where the covariate binary and Kruskal-Wallis tests were
used when the covariate had more than two levels.
3. Results
Of the 550 nursing homes, 394 homes (72%) responded
to the questionnaire. The mean size of home was 46 res¬
idents. The number of general practices looking after res¬
idents ranged from 1 to 24 practices per nursing home
(mean = 5). A systematic immunization record, which was
defined as complete documentation of immunization history,
existed in 6% (23/394) of nursing homes.
No significant differences in median influenza vaccina¬
tion rates were found for the following covariates: areas of
Scotland by Health Boards (P = 0.37), the presence of sys¬
tematic immunization record (P = 0.47), the number of
GPs per home (<5 GPs = 88% versus >5 GPs = 89%,
P = 0.69). Similar results were obtained for the pneumo¬
coccal vaccine (P = 0.37, 0.55 and <5 GPs = 0% versus
>5 GPs = 0%, P = 0.10, respectively). The number of res¬
idents was found to significantly affect the median cover¬
age of influenza vaccination (<30 residents = 89% versus
31-50 residents = 90% versus >51 residents = 85%, P =
0.007) although this association was not observed in pneu¬
mococcal vaccination rates (P = 0.71). Nursing home with
a pneumococcal vaccine policy had significantly higher me¬
dian coverage rates of this vaccine than those who did not
(P = 0.007). However, the presence of an influenza vacci¬
nation policy appeared to have no association with influenza
vaccine coverage (P = 0.54).
4. Vaccine coverage
Although 394 returned the questionnaire, information
on vaccine coverage of influenza and pneumococcal vac¬
cinations was provided by 328 homes and 142 homes,
respectively. Thus, vaccine coverage was calculated based
on the appropriate denominators. Overall vaccine coverage
was 85% for enfluenza vaccine in 2001-2002 season and
11% for pneumococcal vaccine in the last 5 years among
13,700 residents. Coverage of influenza and pneumococcal
vaccines in residents by nursing home is shown in Table 1.
Coverage of influenza vaccine was >70% of residents in
85% of nursing homes. The majority of nursing homes
(74%) had less than 5% pneumococcal vaccine coverage
among their residents.
5. Factors suggested for improving vaccine coverage
The most frequently reported reasons for improving cov¬
erage of both vaccines were a clear immunization policy
Table 1
Influenza and pneumococcal vaccine coverage among nursing homes
which provided information on vaccination
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(76%), awareness and education for staff and residents
(68%) and consent on behalf of the incompetent residents
(66%) (Fig. 1). Other reported factors associated with vac¬
cinations were organized vaccine programs by nursing staff,
active promotion of vaccine, annual review of vaccination
status and improved immunization records.
6. Vaccination policies
Of the respondents (394 homes), 68% (n = 260), 10%
(n = 42) and 10% (n = 42) of nursing homes had one form
of vaccination policies for influenza, pneumococcal or both
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Fig. 4. Main reasons for non-receipt of influenza and pneumococcal vaccine.
vaccination was higher than pneumococcal vaccination: ver¬
bal agreement (27% versus 3%), written policies with set
target (24% versus 5%) and written policies without set tar¬
get (17% versus 2%) (Fig. 2). Over 70% of nursing homes
did not provide information on pneumococcal vaccination
policies.
7. Main reasons for receipt and non-receipt of vaccine
The most reported reasons for receipt of influenza vaccine
were advice from community doctors and nurses (72%),
nursing home policies and guidelines (57%) and efficacy
against respiratory infection (54%) (Fig. 3). Similar reasons
were indicated for receiving pneumococcal vaccine (20, 12
and 13%, respectively).
The most common reasons for non-receipt of influenza
vaccine were refusal by residents (73%), and family
members (41%) (Fig. 4). The predominant reasons for
non-receipt of pneumococcal vaccine were that it was not
recommended by their GPs (19%) and refusals by residents
(15%).
8. Discussion
Overall, coverage of influenza and pneumococcal vaccine
was 85 and 11%, respectively of residents in the present
study. No differences in the average number of residents and
the presence of immunization policies were documented be¬
tween nursing homes that took part and did not take part in
the survey. This suggests that our results appear to reflect all
nursing homes throughout Scotland. Previous surveys in the
UK [20] and US [21] showed an increased trend in cover¬
age of influenza vaccine in the elderly over time. In the UK,
coverage of influenza vaccine in the elderly nursing home
residents was 45% in 1988-1989 [2], 67% in 1991-1992
[22], 77% in 1995 [23] and 89% in 1998-1999 [20], The
rate of influenza vaccination in the present study exceeded
the target level of 65% among recommended groups in Scot¬
land [24]. Nevertheless, about 8% of nursing homes failed
to achieve 60-69% coverage of influenza vaccine. The ob¬
served high coverage of influenza vaccine is likely to be
due to growing awareness of vaccination and changes in
national vaccination recommendations and reimbursement
policies by the UK Department of Health. Influenza vaccine
coverage of above 80% can reduce the transmission of in¬
fluenza virus in nursing homes by indirect protection (herd
immunity) [5,25,26], Therefore, nursing homes with high
vaccine coverage are not only less likely to have outbreaks
than those with low vaccine coverage but also more likely
to reduce influenza morbidity and mortality. We found that
74% of nursing homes had optimal influenza vaccine cover¬
age of between 80 and 100% of residents. Since the records
of influenza and pneumococcal vaccinations were based on
nursing home medical/nursing records rather than patient
GP records, our results are likely to underestimate the cov¬
erage of these vaccines.
To our knowledge, this is the first national survey on cov¬
erage ofpneumococcal vaccine in nursing home residents in
the UK. Coverage of pneumococcal vaccine was very low
(11%) in the present study. Pneumococcal vaccine coverage
was higher in US nursing homes (38%) [27] and in Cana¬
dian long-term care facilities (71%) [28] in 1999. Although
nursing homes have closed and high-risk populations, which
provide ideal conditions for spread of pneumococci, out¬
breaks of pneumococcal disease have been rarely reported
in UK nursing homes. The UK epidemiological studies have
shown that the incidence of invasive pneumococcal disease
in the elderly, aged 65 years and above, is 21-36 per 100,000
persons [29,30], but rates vary •substantially in Europe and
North America, ranging from 25 to 90 per 100,000 persons
[31]. Case-fatality rates range from 18 to 40% [32-34]. Cur¬
rent 23-valent polysaccharide vaccine included stereotypes
caused all reported outbreaks [7,35]. Studies indicate that
outbreaks of pneumococcal disease are likely to occur in
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nursing homes with low vaccine coverage [3,6,36], These
data highlight the importance of pneumococcal vaccination
in the elderly nursing home residents in the UK. Therefore,
re-evaluation of current vaccination policies is needed in the
UK.
Our data show that there was a substantial disparity in the
coverage of influenza and pneumococcal vaccine. Previous
studies in the US and UK indicate that low coverage of
pneumococcal vaccine may reflect uncertainty of vaccine
effectiveness, misconception about adverse reactions, lack of
reimbursements and policies and unclear recommendations
[37,38]. In Scotland, GP payment mechanisms similar to
influenza vaccination are not yet in place for pneumococcal
vaccine and may influence its administration to the elderly
and other high-risk groups.
9. Reasons for receipt and non-receipt of vaccines
In common with previous surveys [3,39,40], we found that
recommendations from community doctors and nurses were
the principal reason for being vaccinated. However, in com¬
parison with influenza vaccination, pneumococcal vaccina¬
tion was more than three-fold less likely to be recommended.
Surveys from the UK and US highlighted that between 73
and 91% of nursing homes provided pneumococcal vaccine
based on physician discretion [3,40], Polices for vaccination
was reported to be an important factor for receiving influenza
and pneumococcal vaccine. Similar to our previous study
in general practices and hospital care settings [18,38], the
presence of vaccination policies was reported to be an effec¬
tive means for increasing pneumococcal vaccination rates in
nursing homes. In keeping with other reports [3,41], nurs¬
ing homes in Scotland are less likely to have policies on
pneumococcal vaccination than influenza vaccination. We
also found that the perceived efficacy of vaccine was an im¬
portant reason for receipt of vaccines. Influenza vaccination
behavior in high-risk patients also showed similar findings
[39]. The predominant reason for not receiving influenza or
pneumococcal vaccine was due to refusal of vaccine by resi¬
dents or family members or no specific reason in the present
study. Therefore, greater emphasis is needed in increasing
awareness of risk of disease and the benefits of vaccination
in nursing home residents and their family members.
10. Strategies for vaccination
The extension of pneumococcal vaccination policy to
residents of long-term care facilities offers the opportunity
to vaccinate at the time of annual influenza vaccination.
This can undoubtedly enhance the use of pneumococcal
vaccine in this at-risk group. In the US, a national objective
has been set to achieve coverage of influenza and pneumo¬
coccal vaccine in over 90% for residents of long-term care
facilities and other high-risk groups for the year 2010 [42],
There is no clear set target for pneumococcal vaccination in
the UK. In the present study, only 6% of nursing homes had
systematic vaccination records despite half of them express¬
ing the view that these would improve vaccine coverage.
Surveys have shown that the determination of pneumococ¬
cal vaccination status in individual long-term care residents
is difficult and represents a major barrier for pneumococcal
vaccination because of misconceptions about the risk of
adverse reactions following revaccination [3,43]. The avail¬
able evidence indicates that second dose of pneumococcal
vaccine does not appear to be associated with serious ad¬
verse reactions [44,45]. Thus, pneumococcal vaccine could
be given to patients with unknown vaccination history
[10,46], Studies in US nursing homes identified that vacci¬
nation was low priority among physicians [3,36]. Improved
knowledge of adult vaccination in health care professionals
may reduce missed opportunities for vaccination during
consultations.
Difficulty in obtaining consent on behalf of incompe¬
tent residents was stated to be one of the important barri¬
ers to increased influenza and pneumococcal vaccination
rates and this has been noted by others [47]. Data from
Canada indicate that obtaining consent for vaccination on
admission for current and future years is associated with
higher influenza and pneumococcal vaccination rates [28].
Our findings also showed that vaccination programs or¬
ganized by nursing staff were considered as an effective
strategy for enhancing coverage of influenza and pneu¬
mococcal vaccine. It has been documented that organized
vaccination programs are the most important strategy to
improve influenza and pneumococcal vaccination rates
[48]. Standing orders for nurses could allow for the eas¬
ier administration of vaccines in long-term care facilities
[49].
11. Conclusions
Our results highlight a large gap between influenza and
pneumococcal vaccination rates in nursing homes. This is
mainly due to lack of national recommendations and reim¬
bursement policies for pneumococcal vaccination. Changes
in attitudes, knowledge and practice of healthcare profes¬
sionals and public together with the implementation of orga¬
nized vaccine delivery strategies and systematic vaccination
records are crucial in improving vaccination rates in nursing
home residents and other long-term care facilities. Further
studies in understanding of patients and clinicians vaccine
preventable behaviors would aid in increasing coverage of
these vaccines in high-risk patients.
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SUMMARY
A survey of the coverage, distribution and the factors associated with use of influenza and
pneumococcal vaccines among general practitioners (GPs) in primary care and in hospital
settings was carried out in 53 general practices in Scotland taking part in the 'Continuous
Morbidity Recording' (CMR) programme. The annual vaccine distribution increased
substantially among 53 general practices from 1993 to 1999 and in Scotland as a whole from
1984 to 1999. From the questionnaire, overall coverage was 43% (95% CI 38-48) for influenza
vaccine in the 2000-1 season and 13% (95% CI 9-16) for pneumococcal vaccine in the last
5 year period, in high-risk patients recommended for these vaccines by the Department of
Health (DoH). Influenza vaccine coverage was highest in the elderly (65 years of age and above)
at 62% (95% CI 59-74). Although pneumococcal vaccination is not currently recommended for
all elderly, coverage of this vaccine was also higher in this group (22%, 95% CI 16-29). In the
majority of patients (influenza vaccine, 98% and pneumococcal vaccine, 94%), vaccination was
carried out in general practice. Only 2% of patients had received pneumococcal vaccination in
a hospital setting. The level of influenza and pneumococcal vaccination varied with the level of
deprivation. Most GPs considered that the responsibility for influenza and pneumococcal
vaccination lay with them. Forty-five percent of GPs reported having a written policy with set
target for influenza vaccination and 11 % for pneumococcal vaccination.
INTRODUCTION
Influenza and pneumococci are important causes of
hospitalization and deaths in the United Kingdom [1],
Influenza and pneumococcal vaccination reduces hos¬
pitalization and death in the elderly and persons with
chronic medical conditions [2-4]. Influenza vaccine is
effective in preventing at least 50% of severe respirat¬
ory illnesses, hospitalizations and deaths in the elderly
and those living in long stay facilities [4, 5], The cur¬
rent 23-vaIent pneumococcal polysaccharide vaccine
covers over 88 % of serotypes which cause disease in
the United Kingdom [6, 7] and is reported to be 50-
* Author for correspondence: Clifton House, Clifton Place,
Glasgow G3 7LN.
80 % effective against invasive pneumococcal disease
[8], Both vaccines are currently recommended for per¬
sons at increased risk of influenza and pneumococcal
disease and may be administered simultaneously at
different sites [9]. Annual vaccination is required for
influenza vaccine but not for pneumococcal vaccine
which lasts for 5-10 years.
Information on the actual use of these vaccines in
primary care and hospital settings is poor but limited
evidence suggests that influenza vaccine and pneumo¬
coccal vaccines are underused in the United Kingdom.
Estimated coverage for influenza vaccine has been
reported to be 20-45 % and 4-15 % for pneumococcal
vaccine among at-risk patients [10-12], Only 0-5% of
immunizations for influenza or pneumococcal vaccine
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were given in hospital settings [11, 13]. No studies
have compared their distribution patterns, use and
coverage among high-risk individuals in the primary
care and hospital settings. We therefore report on the
distribution of influenza and pneumococcal vaccines
in 53 general practices in Scotland. We also examine
views on vaccine indications, policies and responsibili¬
ties for vaccination among GPs and use of influenza
and pneumococcal vaccines in primary care and hos¬
pital care. Since the CMR practices record diagnostic
codes, it is possible to identify all patients meeting
high-risk criteria and therefore be able to measure
vaccination rates in these groups.
Data from this study should aid in the development
of appropriate vaccination strategies and policies for
improving coverage of influenza and pneumococcal
vaccines among at-risk patients.
METHODS
The practice data were collected from 53 general
practices which contribute to the 'Continuous Mor¬
bidity Recording' (CMR) system (which include more
than 5% of the population of Scotland). Information
obtained from CMR system is considered to be
representative of the Scottish population in terms of
sex, age, deprivation and rural/urban mix and
geographic locations [14] and became part of the
national 'core data set' on 1 April 1998. The CMR
system requires at least one diagnosis to be recorded
at each face-to-face contact between a GP and patient.
The diagnoses are Read coded and all data are
internally linked to build up a continuous record for
each patient. The number of high-risk patients
registered in the CMR practices was determined by
searching for the specific diagnosis codes for chronic
medical conditions. Data on the number of high-risk
patients were based on persons rather than GP
consultations, to ensure that patients who had more
than one high-risk condition for influenza or pneumo¬
coccal vaccine were not counted more than once.
Information on the number of doses of influenza
and pneumococcal vaccines distributed obtained from
prescribing returns from the Primary Care Unit,
Information and Statistics Division (1SD), NHS in
Scotland. Data were examined for the whole of
Scotland during 1984-99 and for the CMR practices
during 1993-9. Based on the total number of high-risk
patients and the total number of influenza and
pneumococcal vaccine doses distributed in the CMR
practices, we estimated the likely overall coverage of
this vaccine in all high-risk patients and in patients
who are recommended for vaccination by the De¬
partment of Health (DoH).
Using computer generated random selection, ten
high-risk patients were selected from each of the 53
CMR practices. As the CMR system is completely
anonymous, we do not know the names of the
patients, but we supplied other details (date of birth,
sex and postcode) of these patients which allowed GPs
to identify them and their medical records. A
questionnaire was sent to each GP asking them to
review the medical records to identify whether these
individuals had been vaccinated with influenza and/or
pneumococcal vaccines in either a primary care or
hospital setting. In addition, information on their
views on vaccine indications, policies and responsibili¬
ties for vaccination programme was also requested.
Each GP was offered a set fee for establishing and
recording the vaccination status of their patients, to
compensate for their time taken to review the (10)
records and to answer the questionnaire.
We were able to check data on coverage of
pneumococcal vaccine based on vaccine distribution
statistics. We then made an estimate of total numbers
of high-risk patients or required immunizations for
influenza and pneumococci in Scotland based on the
total numbers of high-risk patients registered in the
CMR practices. We used the Carstairs Deprivation
Scores [15] to determine whether deprivation status of
the patient's area of residence was associated with the
coverage of these vaccines. This measurement is based
on postcode sector which is assigned a deprivation
category, ranging from 1 to 7, 1 being the most
affluent and 7 being the most deprived.
The annual number of influenza vaccine doses
prescribed was calculated as the number of doses
dispensed per 1000 population [16], Pneumococcal
vaccine use is presented as the number of doses
dispensed per 10000 population as in the previous
report [17], Data analyses were carried out using
SPSS version 10. x~ test for trend was used to
determine the association between vaccine coverage
and deprivation index. 95% confidence intervals and
X2 tests for trends were calculated for vaccine coverage
using the CIA programme (Gardner SB, Winter PD,
Gardner MJ: London 1991).
RESULTS
A substantial increase in the annual distribution of
both influenza and pneumococcal vaccines occurred
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Table 1. Number of influenza and pneumococcal vaccine dispensed in the
53 CMR* practices, 1993-9
Influenza vaccine Pneumococcal vaccine
No. of dose Dose distributed per No. of dose Dose distributed per
Year dispensed 1000 population dispensed 10000 population
1993 22180 72-2 58 1-9
1994 22618 73-6 237 7-7
1995 26813 87-3 768 25-0
1996 24955 81-2 196 6-4
1997 32624 106-2 1000 32-6
1998 33151 107-9 2092 68-1
1999 34106 111-0 1538 50-1




:g. 1. («) Annual numbers of doses of influenza vaccine distributed per 1000 population in Scotland. 1984-99. (b) Annual
irnbers of pneumococcal vaccine distibuted per 10000 population in Scotland. 1984-99.
ver the period 1984-99 in Scotland and in 1993-9 in
ic CMR practices (Fig. 1, Table 1). Of the 53
uestionnaires sent out to CPs within the CMR
practices, 45 (84-9%) were returned and completed.
The selected patients fell into eight categories; chronic
pulmonary, heart, liver, renal disease, or diabetic
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Fig. 2. Views on agreement of influenza and pneumococcal vaccine indications.
mellitus, asplenic disorders, the elderly (65 years of
age and above) and the elderly (75 years of age and
above) (Table 2).
Influenza vaccine
Distribution and coverage of vaccine among high-risk
patients
Between 1984 and 1999, influenza vaccine distribution
increased from 2 to 94 doses per 1000 population in
Scotland, a 47-fold increase (Fig. la). The vaccine
distribution substantially increased after 1991-2 and
1996-7. This improvement appears to be correlated
with the official Department of Health (DoH) recom¬
mendations issued in 1992 and 1996. The distribution
of influenza vaccine also increased in the CMR
practices, from 72-2 to 111 per 1000 population, a 1-5
fold increase over the period 1993-9 (Table 1). Using
patient-based data from the questionnaire, the overall
coverage of influenza vaccine was 43 % among high-
risk patients recommended by the DoH. Coverage
of influenza vaccine differed significantly in each
category of patients, with higher coverage in the
elderly and patients with chronic renal disease (67%)
and lower coverage in patients with asplenic disorders
(17%) and chronic pulmonary disease (35%) com¬
pared with other high-risk conditions (Table 2a).
Views on vaccine indications
Most GPs agreed that influenza vaccination should be
targeted to the elderly and patients with chronic
medical conditions. Nevertheless, patients with as¬
plenic disorders and chronic liver disease were less
likely to be considered as indications for influenza
vaccination than other conditions (Fig. 2).
Vaccination policies
Figure 3 shows influenza vaccination policies among
GPs. Forty-five percent of GPs indicated that they
had written a policy with set target. Only 4 % of GPs
reported that they did not have any form of influenza
vaccination policy.
Vaccination responsibility
GPs views on the primary responsibility for influenza
vaccination are presented in Figure 4. Fifty-three
percent ofGPs thought that the primary responsibility
for influenza vaccination should lie with GPs and
40% thought it should lie with the patient.
Pneumococcal vaccine
Distribution and coverage of vaccine among high-risk
patients
There was no pneumococcal vaccine distribution until
1991. Annual distribution rates for pneumococcal
vaccine increased from 0 to 63 doses per 10000
population during the period 1991-9 for the whole of
Scotland (Fig. 1 b). The vaccine distribution was very
low, 1-7 doses per 10000 population during the
period 1992-6. A substantial growth occurred after
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Fig. 3. Influenza and pneumococcal vaccination policies in primary care.
□ Influenza vaccine
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The patient Hospital General Health boards The Department Others
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Fig. 4. Views on primary responsibility of influenza and pneumococcal vaccination.
1996, from 30 doses per 10000 population in 1997 to
63 doses per 10000 population in 1999. The im¬
provement of vaccine distribution coincided with the
DoH recommendations for pneumococcal vaccina¬
tion in at-risk patients, issued in 1996. In the CMR
practices, the levels of pneumococcal vaccine dis¬
tribution rose from 1-9 doses to 50-1-68-1 doses per
10000 population during the period 1993-1998/9, a
26 36 fold increase (Table 1). The overall coverage
of pneumococcal vaccine in the last 5 year period
was 13% among patients who met DoH indications
for the vaccine from the questionnaire survey. Cover¬
age of pneumococcal vaccine was 0 22% among
patients in the eight risk categories, with lower
coverage in patients with chronic renal disease (0%)
and chronic pulmonary disease (10%) and the higher
level coverage in the elderly (22%) (Table 2b).
Views on vaccine indications
Figure 2 indicates views on pneumococcal vaccine
indications among GPs. Patients with asplenic con¬
ditions (76%), and chronic pulmonary disease (70%)
were more likely to be considered as indications for
pneumococcal vaccination than other conditions.
Only 13% of GPs felt that pneumococcal vaccination
was indicated for all elderly (including those living in
long-term care facilities).
Vaccinal ion policies
Pneumococcal vaccination policies among GPs are
shown in Figure 3. Eleven percent of GPs reported
that they had a pneumococcal vaccination policy with
or without a set target. A majority of GPs (45%)
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Table 3. Number ofpatients indicated for influenza and pneumococcal vaccine and the estimated influenza and
pneumococcal vaccine coverage in the CMR practices and the whole of Scotland, 1993-9
High-risk conditions No. of patients*
(a) Estimated number of high-risk patients in the CMR practices
Chronic liver disease 265
Chronic pulmonary disease 13696
Chronic renal disease 318
Diabetes 3991
Chronic heart disease 6684
Immunosuppression/inimunodeficiency 41
Asplenia 125
Elderly 65 years of age and abovef 45495
Elderly 75 years of age and above 20150
(b) Estimated vaccine coverage based on the number of high-risk patients registered in the CMR practices and vaccine
prescription data
Pneumococcal vaccine coverage. 1993-9
Conditions recommend by the DoH
All conditions (including all elderly)
Influenza vaccine coverage, 1999-2000
Conditions recommend by the DoH
(including the elderly aged 75 years
and above but not include those 65
years of age and above)





(c) Estimated number of required influenza and pneumococcal vaccinations in Scotland
Estimated number of high-risk patients
(= Number of required influenza Influenza vaccine (rate
and pneumococcal vaccinations) per 1000 population)
All high-risk conditions
418646 81
1202787 (including the elderly 234-9
aged 65 years and above)
760948 (including the elderly 148-6
aged 75 years and above)
Without chronic liver disease
414229 80
1198370 (including the elderly 234
aged 65 years and above)
756531 (including the elderly 147-7
aged 75 years and above)
* Patients are based on person (patients with two high-risk conditions = 1374, three high-risk conditions = 78 and four high-
risk conditions = 2).
DoH recommendations for pneumococcal vaccination include all listed high-risk conditions except the elderly.
DoH recommendations for influenza vaccine is recommended for all listed high-risk conditions (except chronic liver
diseases), with persons with living in long-term care facilities (f vaccination extend to all the elderly 65 years and above since
September 2000).
reported that they had verbal agreement on its use
among partners.
Vaccination responsibility
Figure 4 shows GPs' views on the primary responsi¬
bility for pneumococcal vaccination. Most GPs (55 %)
believed that the responsibility for pneumococ¬
cal vaccination should be taken by GPs. The re¬
sponsibility of vaccination was not related to use
of vaccine (105/255 (41%) vs. 73/158 (46%), P =
0-368) for influenza vaccine) and (28/263 (1 1 %)
vs. 24/151 (16%), P = 0-126 for pneumococcal
vaccine).
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Table 4. Level of influenza and pneumococcal
vaccine coverage relation to socioeconomic statuses
Deprivation* category No (%) Yes (%) Total
Influenza vaccine
1 10(4-4) 9(5-1) 19
2 26 (11-6) 24(13-7) 50
3 56 (24-9) 55 (31-4) 111
4 86 (38-2) 59 (33-7) 145
5 14(6-2) 12(6-9) 26
6 26 (11-6) 14(8) 40
7 7(3-1) 2(1-1) 9
P = 0-2293 225 (100) 175 (100) 400
(y2 for trend = 1 -445)
Pneumococcal vaccine
1 15(4-3) 4(8) 19
2 43 (12-3) 7(14) 50
3 90 (25-6) 22 (44) 112
4 132 (37-6) 13(26) 145
5 24 (6-8) 2(4) 26
6 38 (10-8) 2(4) 40
7 9 (2-6) -(0) 9
P = 0-0109 351(100) 50 (100) 401
(y2 for trend = 6-483)
* 1 being the most affluent and 7 being the most deprived.
Estimated number of high-risk patients, vaccine
coverage based on vaccine prescription data in the
CMR practices, the total required immunisations
A total estimated number of high-risk patients and the
elderly population in the 53 CMR practices are given
in Table 3a. The estimated influenza vaccine coverage
in 2000-1 season and the estimate cumulative pneumo¬
coccal vaccine coverage in 1993-9 based on vaccine
prescription data in the CMR practices show in Table
3b. The estimated number of people (with and without
the elderly) recommended for vaccination and the
projected total number of required immunizations for
influenza and pneumococcal vaccines are displayed in
Table 3c.
Place of vaccination
Most patients were vaccinated in general practice:
accounting for 98-9% of influenza vaccine coverage
and 94-2% of pneumococcal vaccine coverage. Very
few patients had received these vaccines at home:
1-1% of influenza vaccine coverage and 3-8% of
pneumococcal vaccine coverage. Only 2% of patients
who received pneumococcal vaccine, were vaccinated
in hospital care setting.
Socioeconomic status in relation to vaccine coverage
The level of influenza and pneumococcal vaccination
varied with the level of deprivation (Table 4).
However, the association between deprivation index
and vaccination was noted for pneumococcal vaccine
{P = 0-0109, x2 for trend = 6-483) only, not influenza
vaccine {P = 0-23, y2 f°r trend = 1 -45).
DISCUSSION
We found that patient-based data from the ques¬
tionnaire, an estimated 43 % and 13 % of at-risk
patients defined by the DoH guidelines received
influenza vaccine in 2000-1 season and pneumococcal
vaccine in the last 5 year period respectively. Since
the CMR practices were selected to represent a fair
cross-section of Scottish general practices and as there
is no evidence to suggest GPs in the CMR practices
may have different influenza and pneumococcal
immunization characteristics compared to other GPs,
our results should be reasonably representative of the
whole of Scotland. Data on coverage of primary
immunization coverage at 2 years old were the same in
the CMR practices as in Scotland as a whole.
Although influenza and pneumococcal vaccines cover¬
age remains less than optimal, the annual vaccine
distribution has increased substantially in the CMR
practices and in Scotland as a whole in the last 3 years.
Vaccine distribution
Data on distribution of influenza [16, 18] and
pneumococcal vaccine [17] in other developed coun¬
tries have shown a similar pattern of increased vaccine
distribution in recent years. We found that the increase
in influenza and pneumococcal vaccine distribution
appeared to be related to vaccination recommen¬
dations in 1992 and 1996. Reports on influenza [18]
and pneumococcal [17] vaccination policies in Europe
and North America also suggest that the presence of
recommendations is strongly correlated with the levels
of influenza and pneumococcal vaccine use and
distribution. For patients recommended for vacci¬
nation by the DoH advice, there was over one and a
half fold difference in coverage of pneumococcal
vaccine, between the data from the survey and an
estimated figure based on the total number of vaccines
distributed in the CMR practices. These data suggest
that not all total number of vaccines actually
dispensed were used in current target groups. Our
estimate shows that the number of required influenza
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vaccinations per 1000 population is 81 if persons with
chronic medical conditions are considered. This rises
to 234-9 if all the elderly, 65 years of age and above are
also included. The latter rate is substantially higher
than that reported from a previous study in Wales
(148 per 1000 population) [19] and the influenza
vaccine distribution rate from prescription data in
Scotland.
Influenza vaccine coverage
Influenza vaccine coverage in the present survey was
similar to previous United Kingdom studies, which
reported vaccine coverage of 17-41 % in patients with
underlying medical conditions [13, 20] and 43—48 % in
the elderly [12, 20]. Coverage of influenza vaccine
(also pneumococcal vaccine) was particularly low in
patients with chronic pulmonary disease and asplenic
conditions among the vaccine recommended groups
and those aged < 64 years compared with ^ 65 years
of age. This might have been influenced by the small
number of patients included in each of the high-risk
categories and the higher number of patients with
chronic pulmonary disease in age group < 64 years. It
is likely that the elderly (^65 years) may have a
higher number of GP visits than those =% 64 years of
age, leading to 4-6 fold higher influenza and pneumo¬
coccal vaccine coverage. Although the levels of
influenza vaccine coverage have increased in the
elderly, coverage of the vaccine remains suboptimal
for other high-risk conditions. It has been recom¬
mended that to achieve herd immunity particularly in
nursing homes, influenza coverage should exceed
80% [21]. Recently, the United Kingdom has adopted
influenza vaccination policy for all elderly 65 years of
age and above with fees payable to GPs [22], This may
encourage influenza vaccine use among GPs and could
achieve high vaccination coverage in the future. Vac¬
cination has shown to be associated with cost saving
of $75 per elderly per year [23], Thus vaccination
is the most effective intervention to reduce the impact
of influenza in at-risk groups.
Pneumococcal vaccine coverage
As in the surveys from England [10, 11], the overall
coverage of pneumococcal vaccine in the last 5 year
period appears low at 13% among recommended
patients. This is very similar to influenza vaccine
coverage in the late 1980s. Although target groups for
influenza and pneumococcal vaccines overlap con¬
siderably, there was a remarkable difference in
coverage of influenza and pne umococcal vaccine in the
present survey. This indicates that many opportunities
have been missed for pneumococcal vaccination
during annual influenza vaccination. Many studies
have reported that the incidence and case-fatality rates
ofpneumococcal disease are substantially higher in the
elderly and high-risk groups [24, 25]. In addition,
drug resistant pneumococci are increasing in the
United Kingdom [26, 27], Nevertheless, we found
that over 70% of high-risk patients had not received
pneumococcal vaccine. Studies have reported that low
coverage of pneumococcal vaccine may be due to lack
of advice from GPs [11, 28, 29], This may be due to
uncertainty regarding the benefits of pneumococcal
vaccination, inadequate knowledge of risk and the
impact of pneumococcal disease [30]. It appears that
these factors are likely to influence the use of vaccine
among GPs. Although the current United Kingdom
policy does not advise GPs to vaccinate all elderly
aged 65 years, vaccination coverage in this group is
high relative to other high-risk conditions.
Vaccination strategies
In the present survey, GPs were more likely to target
influenza vaccination than pneumococcal vaccination
to at-risk patients, particularly the elderly. This may
explain the lower levels of pneumococcal vaccine
coverage in the elderly and other at-risk groups
compared with influenza vaccine coverage. It appears
that the protective benefits of pneumococcal vac¬
cination have been largely unrecognized by GPs. Our
data also suggest the need for education of adult
vaccine preventable diseases in medical training.
Variations of influenza and pneumococcal vaccination
policies among GPs and disparities in coverage of
both vaccines among various high-risk groups empha¬
size the need for improved guidelines and policies by
the DoH. We also found that receipt of pneumococcal
vaccine varied with level of deprivation in the area of
residence. Therefore, improved strategies to increase
vaccine-seeking behaviours are required to increase
the coverage of these vaccines in all segments of
population. Since lack of awareness on vaccine and
the risk of disease are the principal reasons for not
receiving the vaccines, particularly pneumococcal
vaccine [28, 31-33], education of health care workers
454 M. H. Kyaw and others
(doctors, nurses and pharmacists) and patients,
improved practice guidelines, and effective methods to
identify high-risk patients such as letter/postcard/
chart/computer reminder would help to enhance
coverage of these vaccines [29]. Since coverage of both
vaccines was lower in those aged < 64 years compared
with > 65 years, attention should be paid to vaccinate
the non-elderly with chronic medical conditions. A
study from England has demonstrated that an
organized public campaign of pneumococcal vac¬
cination can increase coverage of vaccine, from 4-5 %
to 19-5% among at-risk patients and use of vaccine
among GPs, from 17% to 89% [10]. The majority of
patients accept influenza or pneumococcal vaccine
when offered by a health care workers [29]. This
emphasizes the critical role of heath care workers in
increasing coverage of influenza and pneumococcal
vaccines.
Although most GPs considered that the responsi¬
bility for influenza and pneumococcal vaccinations
should lie with them, coverage of these vaccines
remained inadequate. Vaccine cost may partially be
responsible for low pneumococcal vaccine coverage
among high-risk groups. At present, there are no
payment mechanisms for pneumococcal vaccination
in Scotland. The extent to which financial incentives
and disincentives impact on adult vaccination cover¬
age should be evaluated to assess to what extent
improved vaccine coverage could be achieved with
reimbursement policies. In addition, understanding of
the factors involved in the reasons for receipt and
non-receipt of pneumococcal vaccine among at-risk
patients could be helpful in informing vaccination
strategies. Given the current coverage of influenza and
pneumococcal vaccine, primary care based influenza
and pneumococcal vaccination alone may not be
feasible to achieve optimal vaccine coverage among
high-risk persons. Evidence from the United Kingdom
and United States suggests that a majority ofhigh-risk
patients had a previous hospitalization in the last
5 years [34], Therefore,- hospital-based influenza and
pneumococcal vaccination programmes have the
potential to be an effective strategy to deliver the
vaccines to those who have greatest need of them. In
the present study, only 2% of patients had received
pneumococcal vaccination in the hospital care setting,
suggesting that very little effort has been made to
improve coverage of these vaccines by health care
workers in hospitals. In addition, most GPs did not
have a written policy with a set target especially for
pneumococcal vaccination. It appears that a clear
vaccination policy and financial support for vac¬
cination are necessary to achieve a higher coverage of
influenza and pneumococcal vaccine among high-risk
individuals [35],
In conclusion, although coverage of influenza and
pneumococcal vaccines was suboptimal, the number
of these vaccines distributed and reported coverage in
general practice in the recent years has improved
substantially. Since influenza and pneumococcal vac¬
cination has been reported to be effective, improved
coverage of these vaccines among at-risk patients can
yield significant public health benefits. A clear
vaccination policy, organized education and national
campaign of influenza and pneumococcal vaccination
could improve coverage of these vaccines. Clinicians
in both general practice and hospital settings should
ensure that their patients are aware of the risk of
influenza and pneumococcal disease and benefit for
both vaccines.
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A survey of vaccine coverage and antibiotic prophylaxis
in splenectomised patients in Scotland
M H Kyaw, E M Holmes, J Chalmers, I G Jones, H Campbell
J Clin Pathol 2002;55:472-474
Aims: To determine the coverage of vaccine and antibiotic
prophylaxis in splenectomised patients in Scotland.
Methods: Patients who had undergone splenectomy
between 1 January 1988 and 31 December 1998 were
identified. A questionnaire was sent to general practition¬
ers to validate vaccine and antibiotic status for these
patients.
Results: A total of 974 living splenectomised patients
were identified during the study period. Information on
vaccine and antibiotic status was available for 708 (73%)
and 770 (79%) of living patients, respectively. Coverage
of pneumococcal vaccine (88%) was higher than that of
Haemophilus influenza type b (Hib) conjugate vaccine
(70%) or meningococcal vaccine (51%). Only 47% of
patients received all three vaccines. A higher coverage
was also documented for pneumococcal vaccine (28%)
than Hib (19%) and meningococcal vaccine (14%) before
elective splenectomy. Only 13% received all three
vaccines before splenectomy. Coverage of influenza
vaccine increased significantly, from 76% in the 1997/
1998 season to 96% in the 2000/2001 season.
Antibiotic prophylaxis was received by 67% of all
patients. The current recommendation, comprising pneu¬
mococcal and Hib vaccination and antibiotic prophylaxis,
was received by only 52% of the patients. There was no
association between the coverage of vaccine and
socioeconomic status.
Conclusion: Further improvement in coverage of recom¬
mended vaccines and antibiotic prophylaxis is still needed
to reduce the risk of serious infection in this high risk group.
Patients without spleens are at a significantly increasedrisk of serious infection with encapsulated bacteria,especially Streptococcus pneumoniae, Haemophilus i fluenzae
type b (Hib), and Neisseria meningitidis.' Antibiotics and
polysaccharide pneumococcal, meningococcal, influenza, and
Hib conjugate vaccines are available for the prevention of
postsplenectomy infection and are recommended for all
splenectomised patients by the Department of Health (DoH)
and the British Committee for Standards in Haematology
(BCSH), with the exception of meningococcal polysaccharide
vaccine/1 Because the adherence to preventive measures has
been reported to be low,"' we conducted this study to
determine the coverage of appropriate vaccination and
antibiotic prophylaxis in splenectomised patients in Scotland
during an 11 year period from 1988 to 1998.
"Patients without spleens are at a significantly increased
risk of serious infection with encapsulated bacteria"
METHODS
Patients who underwent splenectomy from 1 January 1988 to
31 December 1998 were identified using the Scottish Morbid¬
ity Record (SMR01), which is collected at discharge from all
episodes of hospital inpatient or day case care. It records
information on demography, number of hospital admissions,
and the clinical nature of the patient treatment episode.
SMR01 records were linked to General Register Office
(Scotland) death registrations using probability matching to
exclude patients who had died because their medical records
would not be available to general practitioners. A question¬
naire was sent to general practitioners of living patients
requesting details of elective or emergency splenectomy, anti¬
biotic prescribing, and vaccination with pneumococcal,
meningococcal, Hib, and influenza vaccines. A reminder was
sent to those who did not respond after six weeks. The
Carstairs deprivation score" was used to determine the depri¬
vation index values of the patients' areas of residence and the
coverage of these vaccines. Data analysis was performed on
SPSS version 10 and Stata (Stala Corporation, version 6, 1999;
College Station, Texas, USA) for Fisher's exact test.
RESULTS
There were 974 living patients who had undergone splenec¬
tomy during the study period. Information on vaccination
status was available for 708 (73%) of those patients. A higher
coverage was documented for pneumococcal vaccine (622 of
708, 88%) and Hib vaccine (468 of 664, 70%) than for menin¬
gococcal vaccine (317 of 619, 51%) (table 1). All three vaccines
were received by 47% (269 of 576) of the patients. Vaccination
status before elective splenectomy was recorded for 541 (56%)
of the patients. Coverage of pneumococcal vaccine (153 of 541,
28%) was higher than that of Hib (83 of 435, 19%) or menin¬
gococcal vaccine (48 of 335, 14%) for elective splenectomy. All
three vaccines were received by 13% (38 of 291) of the
patients. An increasing trend in coverage of influenza vaccine
was noted between 1997 and 2000: from 76% in the 1997/1998
season to 96% in the 2000/2001 season. Of the 770 (79%)
patients in whom antibiotic status was recorded, 518 (67%)
received antibiotic prophylaxis. Coverage was 35% (201 of
571) for all three vaccines and antibiotic prophylaxis and 52%
(333 of 634) for pneumococcal and Hib vaccines and antibiotic
prophylaxis.
There were no significant trends in the deprivation index
values for coverage of vaccine with (p = 0.12) or without
(p = 0.14) antibiotic prophylaxis for the combination of
pneumococcal and Hib vaccine. Similar findings were re¬
corded for the combination of pneumococcal, meningococcal,
and Hib vaccine with (p = 0.07) or without (p = 0.08)
antibiotic prophylaxis. In addition, no association was
documented for influenza vaccine coverage and the value of
the deprivation index (Fisher's exact test, p = 0.46).
Abbreviations: BCSH, British Committee for Standards in
Haematology; DoH, Department of Health; Hib, Haemophilus influenza
type b; SMR, Scottish Morbidity Record
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Table 1 Vaccine and aniibiotic coverage in splenectomised patients
Vaccine coverage
DoH and BCSH
recommendations Vaccine or antibiotic prophylaxis Timing of vaccination N %
Yes Pneumococcal All cases (before or after surgery) 622/708 88
Two weeks before elective surgery 153/541 28
Yes Hib All cases (before or after surgery) 468/664 70
Two weeks before elective surgery 83/435 19
No Meningococcal All cases (before or after surgery) 317/619 51
Two weeks before elective operation 48/335 14
Yes Influenza All cases (before or after surgery)
Season 1997-8 16/21 76
Season 1998-9 24/27 89
Season 1999-2000 82/89 92
Season 2000-2001 329/342 96
Yes Antibiotic prophylaxis - 518/770 67
Yes Pneumococcal and Hib All cases (before or after surgery) 439/641 68
Two weeks before elective surgery 80/406 20
No Pneumococcal and meningococcal All cases (before or after surgery) 305/602 51
Two weeks before elective surgery 44/313 14
No Hib and meningococcal All cases (before or after surgery) 276/588 47
Two weeks before elective surgery 40/305 13
No Pneumococcal, meningococcal and Hib All cases (before or after surgery) 269/576 47
Two weeks before elective surgery 38/291 13
Yes Pneumococcal and Hib vaccine and antibiotic All cases (before or after surgery) for vaccines and after 333/634 52
prophylaxis surgery for antibiotic prophylaxis
No Pneumococcal, meningococcal, and Hib vaccine All cases (before or after surgery) for vaccines and after 201/571 35
and antibiotic prophylaxis surgery for antibiotic prophylaxis
BCSH, British Committee for Standards in Haematology; DoH, Department of Health; Hib, Haemophilus influenza type b.
DISCUSSION
Optimal management comprising pneumococcal and Hib vac¬
cines and antibiotic prophylaxis was received by 52% of the
patients. Annual influenza vaccination uptake increased sub¬
stantially during 1997 and 2000 and reached over 96% cover¬
age in the 2000/2001 season. A review of studies of
postsplenectomy infection between 1952 and 1987, before the
availability of Hib conjugate vaccine, found that most cases of
postsplenectomy infection are caused by 5 pneumoniae (57% of
cases), followed by H influenzae (6%), N meningitidis (4%), and
Escherichia coli (4%), with a 32-77% case fatality rate.' The
widespread use of Hib conjugate vaccine appears to influence
the prevalence of causative organisms of postsplenectomy
infection. Passive surveillance data in the UK, based on 77
cases of postsplenectomy infection between 1994 and 1998,
showed that S pneumoniae and N meningitidis accounted for
87% and 3% of cases, respectively.7 The remaining 10% of cases
were caused by Listeria monocytogenes, E coli, Klebsiella sp, Salmo¬
nella typhimurium, and others.
The coverage of vaccine was higher in this large survey
compared with previous UK studies, which reported 35.5%) in
1986-90 for pneumococcal vaccine" and 10% in 1992-96 for
Hib and meningococcal vaccines.5 A recent study in England
showed that the coverage of pneumococcal, meningococcal,
and Hib vaccine was 79%), 51%), and 40%, respectively."
However, in our present study, it is possible that vaccine cover¬
age was lower among splenectomy patients who had died, and
that our results are biased.
In Scotland, the guidelines for the management of
postsplenectomy infection are based on the DoH and BCSH
recommendations. As with other vaccinations and preventive
measures, general practitioners are responsible for ensuring
that these patients receive appropriate preventive measures.
However, there is a need for a national splenectomy register to
identify those patients who have not received vaccines or anti¬
biotic prophylaxis in Scotland. This could also be used to gen¬
erate a regular reminder to general practitioners regarding
their patients' prophylaxis status. Our data also suggest that
most general practitioners and other clinicians follow recom¬
mendations for pneumococcal and influenza vaccines but not
for other vaccines. Although the administration of bacterial
vaccines is recommended for at least two weeks before elective
splenectomy,2' compliance with this schedule was subopti-
mal. It appears that compliance with current recommenda¬
tions for the timing of vaccination with regard to splenectomy
was poor among clinicians. Although the effectiveness of
pneumococcal, meningococcal, and Hib vaccines in asplenic
patients is uncertain, the increased susceptibility to serious
infection and the documented safety and potential benefits of
these vaccines justify their use in these patients. As yet,
meningococcal polysaccharide vaccine is not included in the
general recommendations, the vaccine is likely to offer
benefits to these patients and thus should be considered.
New conjugate vaccines may offer better protection against
these organisms. Meningococcal group C conjugate vaccine
has recently been recommended for routine immunisation in
Take home messages
• Coverage of pneumococcal vaccine (88%) was higher
than that of Haemophilus influenza type b (Hib)
conjugate vaccine (70%) or meningococcal vaccine
(5 1%) and only 47% of patients received all three vac¬
cines
• A higher coverage was also documented for pneumo¬
coccal vaccine (28%) than Hib (19%) and meningococ¬
cal vaccine (14%) before elective splenectomy and only
13% of patients received all three vaccines before
splenectomy
• Coverage of influenza vaccine increased from 76% in
the 1997/1998 season to 96% in the 2000/2001
season
• Antibiotic prophylaxis was received by 67% of all
patients and only 52% of patients received pneumococ¬
cal and Hib vaccination and antibiotic prophylaxis (the
current recommendation)
• Thus, it is apparent that further improvement in coverage
of recommended vaccines and antibiotic prophylaxis is




asplenic patients." The decision to use pneumococcal conju¬
gate vaccine is expected soon. Although our study found no
significant correlation between the coverage of the combina¬
tion of pneumococcal polysaccharide and Hib vaccine or the
combination of pneumococcal, meningococcal, and Hib
vaccine, with or without antibiotic prophylaxis, studies in the
USA have highlighted low socioeconomic status in relation to
poor coverage of childhood10 and adult vaccines."
"As yet, meningococcal polysaccharide vaccine is not
included in the general recommendations, the vaccine is
likely to offer benefits to these patients and thus should be
considered"
Although current guidelines recommend life long antibiotic
use in these patients,' only 67% of patients in our study had
received antibiotic prophylaxis. We do not know how many of
these patients had discontinued the prophylactic regimen or
were taking macrolides (those allergic to penicillin). The rapid
emergence of drug resistant pneumococcus complicates this
preventive measure and highlights the need for the improved
use of pneumococcal polysaccharide vaccine, which covers
most drug resistant serotypes. Our survey indicates a high
degree of coverage for pneumococcal and influenza vaccine
but suboptimal coverage for Hib and meningococcal vaccine
and antibiotic prophylaxis despite the existence of national
guidelines and the risk of serious infection in these patients.
Efforts to increase the coverage of recommended vaccines and
antibiotic prophylaxis should continue.
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A review was carried out on 774 invasive meningococcal isolates reported to the active meningococcal
surveillance system in Scotland from 1994 to 1999. This showed that serogroups B (51.7%) and C (39.2%)
caused the majority of disease. The six common PorB proteins (4, 1, 15, 2B, 12, and 21) and PorA proteins
(serosubtypes) (P1.4, PI.15, PI.9, PI.14, PI.7, and PI.16) accounted for 50 and 51% of all group B isolates,
respectively, during the study period.
Neisseria meningitidis is the most common cause of bacterial
meningitis in the United Kingdom and throughout the world
(27). The organism has at least 13 serogroups, 20 serotypes, 10
serosubtypes, and 13 immunotypes (19, 25). Of the five differ¬
ent structural classes of outer membrane proteins (OMPs),
class 2 or 3 OMP (PorB) is expressed by all meningococci and
defines the serotype (14). Class 1 protein (PorA) is generally
present in most meningococci and determines the serosubtype
(2).
Worldwide, serogroups A, B, C, Y, and W135 are the most
common causes of disease (19), and their distributions differ
with age, time, and geographic location (23, 25). Although
polysaccharide and conjugate meningococcal vaccines are
available for the prevention of serogroup A, C, Y, and W135
disease, there is no effective vaccine against group B menin¬
gococcal disease. Since group B polysaccharide is poorly im¬
munogenic and has cross-reactivity with human neonatal neu¬
ral tissue (13), a vaccine against group B disease has been
developed based on OMPs. These vaccines have been shown to
be safe and immunogenic in infants (8, 17) and adults (18).
Studies have suggested that OMP vaccines need to include
multiple OMPs due to the diversity of the prevalence of OMPs
in group B strains. Therefore, the identification of the impor¬
tant OMPs associated with group B isolates would aid in se¬
lecting appropriate OMPs for vaccine formulation. We herein
examine the characteristics of invasive meningococcal isolates
and identify the distribution of group B serotypes and serosub-
types reported to the population-based surveillance system in
Scotland from 1994 to 1999.
The estimated population under surveillance was 5.1 million
in the study period. A case of invasive meningococcal disease
(IMD) was defined when N. meningitidis was isolated from a
normally sterile site such as blood, cerebrospinal fluid, or joint
fluid. Serogrouping was performed for all invasive isolates.
Latex agglutination and coagglutination tests were used for the
serogrouping of N. meningitidis (7, 12). Serotyping and sero-
subtyping were carried out by a whole-cell enzyme-linked im¬
munosorbent assay (1, 14). The full set of meningococcal
monoclonal antibodies available from the National Institute of
Biological Standards and Control (http://www.nibsc.ac.uk) was
used for the immunotyping of the disease strains. The set is the
same as that used by the other major meningococcal reference
laboratories, including the Meningococcal Reference Unit at
Manchester Public Health Laboratory, Manchester, United
TABLE 1. Annual cases of meningococcal disease by age group and serogroup in Scotland, 1994 to 1999
No. of cases by serogroup in indicated yr
Age group 1994 1995 1996 1997 1998 1999 1994 to 1999
B C Others B C Others B C Others B C Others B C Others B C Others B C Others
<1 yr 19 4 0 15 2 5 22 3 5 20 2 2 23 6 1 21 3 1 120 20 14
1 yr 14 7 0 8 2 2 7 1 1 4 5 2 11 3 1 7 8 1 51 26 7
2 to 4 yr 15 5 0 12 3 3 13 4 3 8 7 5 4 6 0 14 9 0 66 34 11
5 to 17 yr 9 8 1 12 13 3 15 11 4 11 14 3 9 36 3 14 24 0 70 106 14
18 to 34 yr 2 1 0 7 3 3 9 11 4 14 15 1 5 10 2 14 25 1 51 65 11
35 to 49 yr 4 1 0 0 2 2 1 6 0 1 5 1 2 3 2 2 4 1 10 21 6
50 to 64 yr 4 0 0 4 4 0 3 2 0 1 2 1 0 3 0 7 2 0 19 13 1
a65 yr 1 2 0 2 1 0 3 3 1 0 2 2 0 5 2 7 5 2 13 18 7
All ages 68 28 1 60 30 18 73 41 18 59 52 17 54 72 11 86 80 6 400 303 71
* Corresponding author. Mailing address: Scottish Centre for Infec¬
tion and Environmental Health, Clifton House, Clifton Place, Glas¬
gow, G3 7LN, United Kingdom. Phone: 0141-300-1184. Fax: 0141-300-
1170. E-mail: Moe.Kyaw@scieh.csa.scot.nhs.uk.
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Kingdom. Data analysis was performed with SPSS version 10
(SPSS INc., Chicago, 111.).
There were 774 cases of IMD in all: 400 cases (51.7%) were
caused by group B strains, 303 cases (39.2%) by group C
strains, 11 cases (1.4%) by group Y strains, 7 cases (0.9%) by
group W135 strains, 7 cases (0.9%) by other strains (including
those of groups Y, Z, 29E, and X), and 46 cases (5.9%) by
nongroupable strains. The proportion of cases of IMD due to
group C strains increased significantly from 1994 to 1999, but
the incidence of group B disease was relatively stable (Table 1).
The majority of cases of IMD occurred in patients aged 5 to 17
years and <1 year. There was also an increase in the number
of cases of IMD in patients aged 5 to 17 and 18 to 34 years
during the study period.
Cases of IMD caused by group B strains were more preva¬
lent in patients aged <1 year (30%), while those caused by
group C strains were more prevalent in patients aged 5 to 17
years (35%) and 18 to 34 years (21%). The incidence of both
group B IMD and group C IMD was highest in patients aged
<1 and 1 year (33.3 and 14.5 cases per 10,000 persons for
group B disease and 5.6 and 7.4 cases per 10,000 persons for
group C disease, respectively).
The distribution of group B meningococcal serotypes and
subtypes was substantially diverse and varied annually (Tables
2 and 3). Of the 212 isolates (53%) with serotype information,
serotypes 4, 1, 15, 2B, 14, and 21 (in descending order of
prevalence) accounted for 50% of the total isolates from 1994
to 1999. The predominant serotype was 4. The six most prev-
TABLE 2. Annual distribution of PorB group B meningococci, 1994 to 1999
Yr Serotype No. of cases % Yr Serotype No. of cases %
1994 4 15 22.1 TY 31 52.5
15 12 17.6 NT 28 47.5
2B 11 16.2 All 59 100
1 5 7.4
21 4 5.9
14 3 4.4 1998 4 14 25.9
2A 1 1.5 1 7 14
4,15 1 1.5 15 4 7.4
4,21 1 1.5 2A 1 1.9
2B 1 1.9
TY" 53 77.9 21 1 1.9
NT6 15 22.1
All" 68 100 TY 28 51.9
NT 26 48.1
All 54 100
1995 4 10 16.7
15 9 15
1 3 5 1999 4 18 20.9
2B 3 5 1 10 11.6
21 2 3.3 14 2 2.3
14 1 1.7 15 2 2.3
2A 1 1.2
TY 28 46.7 2B 1 1.2
NT 32 53.3 21 1 1.2
All 60 100 4,21 1 1.2
1.2
1996 4 19 26
41.91 4 5.5 TY 36
14 3 4.1 NT 50 58.1
22 3 4.1 All 86 100
2B 3 4.1
2A 2 2.7
15 2 2.7 1994 to 1999 4 93 23.3
1 36 9
TY 36 49.3 15 32 8
NT 37 50.7 2B 20 5
All 73 100 14 10 2.5
21 9 2.3
2A 5 1.3
1997 4 17 28.8 22 3 0.8
1 7 11.9 4,21 3 0.8
15 3 5.1 4,15 1 0.3
2B 1 1.7
14 1 1.7 TY 212 53
21 1 1.7 NT 188 47
4,21 1 1.7 All 400 100
" TY, total serotypeable isolates.
b NT, nontypeable isolates.
£' All serotypeable and nonserotypeable isolates.
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TABLE 3. Annual distribution of PorA group B meningococci, 1994 to 1999
Yr Serosubtype No. of cases % Yr Serosubtype No. of cases %
1994 P1.7 11 16.2 P1.3 1 1.7
PI.4 10 14.7 PI.10 1 1.7
PI.10 8 11.8 PI.12 1 1.7
PI.15 6 8.8 PI.19 1 1.7
PI.14 4 5.9
PI.16 4 5.9 TY 34 57.6
PI.2 3 4.4 NT 25 42.4
P1.9 3 4.4 All 59 100
PI. 1,7 2 2.9
PI.2,5 2 2.9
1998 P1.4 13 24.1
TY" 53 77.9 P1.9 5 9.3
NT6 15 22.1 PI.15 5 9.3
All" 68 100 PI.16 4 7.4
PI.5 3 5.6
PI.14 3 5.6
1995 PI.4 10 16.6 Pl.l 1 1.9
PI.16 7 11.7 P1.3 1 1.9
P1.9 6 10
PI.15 5 8.3 TY 35 64.8
PI.7 5 8.3 NT 19 35.2
P1.10 3 5 All 54 100
P1.2 3 5
PI.14 2 3.3
P1.3 1 1.7 1999 PI.4 12 14
P1.6 1 1.7 P1.9 9 10.5
PI.13 1 1.7 PI.15 9 10.5
PI.14 8 9.3
TY 44 73.3 PI.3 4 4.7
NT 16 26.7 PI.5 3 3.5
All 60 100 PI.12 1 1.2
PI.13 1 1.2
PI.16 1 1.2
1996 PI.4 19 26 Pl.7,16 1 1.2
PI.15 7 9.6
PI.14 4 5.5 TY 49 57
PI .9 3 4.1 NT 37 43
PI.10 3 4.1 All 86 100
P1.3 2 2.7
PI.16 2 2.7
Pl.2,5 2 2.7 1994 to 1999 PI.4 72 18
PI.12 1 1.4 PI.15 38 9.5
PI.13 1 1.4 PI.9 28 7
P1.5 1 1.4 PI.14 25 6.3
PI.6 1 1.4 P1.7 20 5
PI.16 20 5
TY 46 63 PI.10 15 3.8
NT 27 37 PI.5 11 2.8
All 73 100 P1.2 11 2.8
PI.3 9 2.3
Pl.l,7 3 0.7
1997 P1.4 8 13.6 PI.13 3 0.7
PI.15 6 10.2 PI.12 3 0.7
P1.5 4 6.8 P1.6 2 0.5
PI.14 4 6.8 PI.19 1 0.3
P1.7 3 5.1
PI.9 2 3.4 TY 261 65.3
PI.16 2 3.4 NT 139 34.7
P1.2 1 1.7 All 400 100
" TY, total serotypeable isolates.
b NT, nonscrotypeable isolates.
' All serotypeable and nonserotypeable isolates.
alent serosubtypes expressed by group B were PI.4, PI.15,
PI.9, PI.14, P1.7, and PI.16, accounting for 51% of all isolates
(Table 3). The predominant serosubtype was PI.4.
Although a shift in the age distribution of group B disease
has been detected recently in older children and adults in the
United States (20) and Canada (11), we did not observe this in
the present study. The incidence of both group B and C disease
in infants in Scotland was significantly higher than that in the
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United States (20). In many countries, an increase in the prev¬
alence of group B meningococcal disease was reported to par¬
allel the high prevalence of serotype 4 (3), which was associ¬
ated with the majority of disease in New Zealand from 1991 to
1999 (86% of cases) (16), in Canada from 1987 to 1995 (4, 15),
in Spain from 1987 to 1992 (53% of cases) (5), and in other
European countries from 1992 to 1995 or 1996 (10). In the
United States (13, 14), serotypes 15, 14, 10, 1, and 2a ac¬
counted for 67% of all serotypeable isolates between 1992 and
1998 (24). A multivalent PorB vaccine composed of the six
most common serotypes in Scotland accounted for 40 to 74%
of all serosubtypes (86 to 100% of serotypeable isolates) in the
study period.
Studies show that an increased incidence of group B disease
has been associated with hypervirulenl strains (9, 21). In de¬
veloped countries, group B was associated with PI.4 in The
Netherlands (22) and New Zealand (16) and with PI.7,16 in
Norway (26). Surveillance of meningococcal disease in Europe
showed that most group B isolates expressed PI.7,16, P1.4,
P1.5, PI.2, and Pl.2.5 in most European countries (10). We
found that 18% of cases were associated with P1.4. The six
most prevalent serosubtypes in Scotland were responsible for
42 to 58% of all group B isolates (72 to 86% of serosubtypeable
isolates) from 1994 to 1999. In the United States, six serosub¬
types (PI.7,16, PI.19,15, PI.7,1, Pl.5,2, P1.22a,14, and P1.14)
were found in 54% of serosubtypeable group B isolates from
1992 to 1998 (24).
Although the serosubtypes (PI.7,16, Pl.5,2, PI.19,15, PI.7,
P1.5, and PI.1213) in the current hexavalent PorA OMP vac¬
cine were associated with a majority of group B disease in The
Netherlands, these serosubtypes accounted for only 9% of
total isolates in Scotland. Wide diversity of PorA proteins and
geographic differences in their prevalence pose major chal¬
lenges to designing an effective group B vaccine for global use.
Studies have shown that antibodies directed against immu-
nodominance variable region of OMPs produced a broader
protective immune response (6). Therefore, data on the char¬
acteristics of variable region in OMPs are needed in Scotland.
Continued enhanced surveillance of the distribution of sero-
groups, serotypes, serosubtypes, the emergence of new clones
of virulent meningococci, and the extent of cross-reactivity
among the different OMPs could assist control strategies for
epidemic outbreaks, the implementation of immunization pol¬
icies, and the design of a vaccine for the prevention of menin¬
gococcal disease.
We thank microbiologists, Consultants in Public Health Medicine,
and the staff of the Scottish Centre for Infection and Environmental
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SUMMARY
We examined the serological characteristics of 774 invasive meningococcal isolates collected
through an active laboratory-based surveillance system in Scotland from 1994 to 1999. Of
these, 72-73 % of isolates were tested for susceptibility to several antimicrobial agents.
Meningococci with high-level resistance to sulphadiazine had a prevalence of 10% and
incidence of 0-22 per 100000 population. High-level resistance to penicillin and other antibiotics
was not detected. The prevalence of moderate penicillin resistant meningococci was 8-3%.
There was no increase in moderate penicillin resistant meningococcal isolates during the study
period, but there were temporal and geographic variations. The estimated incidence of
moderate penicillin resistant meningococci was 0-15 per 100000 population. High and low
incidence of moderate penicillin resistant meningococci appeared to correlate with the number
of doses of penicillin prescribed in some geographic locations. The majority of moderate
penicillin resistant isolates belonged to serogroups B (52-2%) and C (39-2%). However, the
prevalence of moderate penicillin resistance in serogroup W135 was substantially higher
(51-7%) than serogroups B (7-8%) and C (7-6%). Serogroup W135 accounted for a higher
proportion of moderate penicillin resistance (8-7%) than disease (1 %). There was no
predominant penicillin resistant serotype/subtype within any serogroup. Constant surveillance
is necessary to monitor the emergence and spread of resistance and to guide appropriate public
health interventions in preventing drug resistant meningococci.
INTRODUCTION
Neisseria meningitidis is an important cause of
bacterial meningitis and septicaemia in the United
Kingdom and worldwide [1, 2]. Despite the avail¬
ability of effective antimicrobial agents, 10-20% case-
fatality and 20% neurological sequelae ratios have
been documented [3, 4], Invasive meningococcal iso¬
lates that are resistant to penicillin have been detected
in the United Kingdom, Europe and North America
[5J. Surveys in the United Kingdom have shown
* Author for correspondence.
that the prevalence of moderately resistant penicillin
meningococcal isolates is increasing: 1-3% in 1986/7,
8% in 1991 [6, 7] and 11 % in 1995 [8]. A substantial
increase has also been detected in Spain: from 0-4 % in
1985 to 46% in 1990 [9], and to 67% in 1996 [10]. In
addition, meningococcal strains with high-level re¬
sistance to penicillin, through /7-lactamase production,
have been reported [11-13]. At present, high-level
resistant isolates are extremely rare in the United
Kingdom and elsewhere.
The failure of standard treatment in a patient with
meningococcal disease caused by a penicillin resistant
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strain (minimal inhibitory concentration (MIC) of
0-64 pg/ml) has been reported [14]. Since penicillin is
the drug of first choice for the treatment of meningo¬
coccal disease, the emergence and spread of penicillin
resistant meningococcal strains in the United King¬
dom and other countries represents a major challenge.
Little is known about the distribution of meningo¬
coccal serogroup, type and subtype in relation to
penicillin resistance. Here, we examine the prevalence
and seroepidemiology of penicillin resistant invasive
meningococcal isolates reported to the active popula¬
tion-based surveillance system in Scotland during the
period 1994—9.
METHODS
There has been an active population-based surveil¬
lance system for meningococcal disease in Scotland
since the 1970s. However, the Scottish Meningococcus
and Pneumococcus Reference Laboratory (SMPRL)
was established in 1993 as the national service for the
laboratory confirmation of meningococcal and pneu¬
mococcal disease and to monitor the epidemiological
characteristics of these diseases, providing serotyping
and antimicrobial susceptibility testing. We report on
invasive meningococcal isolates submitted to the
SMPRL from all diagnostic laboratories in Scotland
for serological characterisation and antimicrobial
susceptibility testing. Isolates from blood, cerebro¬
spinal fluid (CSF), joint fluid and other sterile sites
were regarded as invasive isolates.
Meningococcal isolates with a MIC level of
< 0-06 pg/ml, 0-1-1 pg/ml, and > 2 pg/ml were
regarded as susceptible, moderately and highly resis¬
tant to penicillin respectively. Meningococci were con¬
sidered susceptible, moderately and highly resistant to
sulphadiazine when their MICs were < 16 pg/ml, 32-
64 pg/ml and 5= 128 pg/ml respectively. Isolates with
MICs of < 1 pg/ml and > 2 pg/ml were indicated as
susceptible and resistant to ciprofloxacin, cefotaxime,
ceftriaxone and rifampicin respectively. During the
study period, the E-test (Cambridge Diagnostics,
Cambridge, UK) was used to determine the antimicro¬
bial susceptibility level. The E-test has been proven to
be a reliable method for evaluating the antimicrobial
susceptibility levels of meningococci [15].
For the purpose of health service administration,
Scotland (population 5-1 million) is divided into 15
health boards. The prevalence of antimicrobial re¬
sistant meningococci per 100000 population was
calculated based on the estimated population of
Scotland for the mid point year, 1997 [16]. In¬
formation on the number of doses of penicillin
prescribed in the whole of Scotland between 1994 and
1999 was obtained from the Information and Statistics
Division (ISD) of Common Services Agency, Edin¬
burgh, Scotland. These data were used to calculate the
number of penicillin doses prescribed per 100000
population and the number of penicillin resistant
isolates in different geographical locations.
Statistical analysis
Data analyses were performed using SPSS version 10
and Stata (Stata Corporation, version 6.0, 1999,
College Station, Texas). In comparisons between
variables a P-value of < 0-05 was regarded as
statistically significant.
RESULTS
A total of 774 invasive meningococcal isolates were
received by SMPRL during the period 1994-9. Of
these, antimicrobial susceptibility testing was per¬
formed for: 568 (73-4%) isolates for penicillin and
sulphadiazine, 567 (73-3 %) isolates for rifampicin,
563 (72-7%) isolates for ciprofloxacin and ceftriaxone,
and 561 (72-5%) isolates for cefotaxine (Table 1). Of
the 774 invasive isolates, serogroup B caused 400
(51-7%) cases of invasive disease, followed by group
C with 303 (39-1 %) cases, non-typeable group (NG)
with 46 (5-9%) cases, W135 with 7 (1 %) cases and
other serogroups with 18 (2-3%) cases in 1994-9.
Antimicrobial resistant meningococci
The prevalence of antimicrobial resistance in invasive
meningococcal infections in Scotland is shown in
Table 1. The only drug to which any isolate was highly
resistant was sulphadiazine (57 isolates, 10%). Forty-
seven isolates (8-3 %), 44 isolates (7-7%) and 1 isolate
(0-2%) were moderately resistant to penicillin, sul¬
phadiazine or ciprofloxacin respectively.
The estimated incidence of moderately resistant
meningococci per 100000 population was 0-15. The
rate of sulphadiazine resistance was 0-14 per 100000
population for moderately resistant isolates and 0-22
for highly resistant isolates.
Moderate resistance to penicillin by meningococcal
serogroup
All isolates classed as moderately resistant to penicillin
belonged to meningococcal serogroups B, C and
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Table 1. Prevalence of antimicrobial resistant invasive N. meningitidis infection in Scotland, 1994-9
No. (%) of isolates Rate per 100000 population
Susceptible Intermediate Resistant Total Intermediate Resistant Total
Penicillin* 521 (91-9) 46 (8-1) 0(0) 567 (100) 0-15 0 0-15
Sulphadiazinef 467 (82-3) 44 (7-7) 57 (10) 568 (100) 0-14 0-22 0-37
Ciprofloxacin:": 562 (99-8) 0(0) 0(0) 563ft (100) 0003 0 0-003
Cefotaxime)? 561 (100) 0(0) 0(0) 561 (100) 0 0 0
Ceftriaxone^ 563 (100) 0(0) 0(0) 563 (100) 0 0 0
Rifampicin** 567 (100) 0(0) 0(0) 567 (100) 0 0 0
* MICs: susceptible < 0-06 pg/ml; intermediate resistant, 0-1-1-0 pg/ml; resistant Js 2 gg/ml.
f MICs: susceptible < 0-16 pg/ml; intermediate resistant, 32-64 pg/ml; resistant > 128 pg/ml.
t MICs: susceptible ^ 1 pg/ml; resistant 3* 2 pg/ml.
§ MICs: susceptible ^ 1 pg/ml; resistant > 2 pg/ml.
1 MICs: susceptible < 1 pg/ml; resistant > 2 pg/ml.
** MICs: susceptible ^ 1 pg/ml; resistant 3= 2 pg/ml.
ft included one isolate with MIC — 1-5 pg/ml.
Table 2. Prevalence of disease and moderate penicillin resistance in
invasive N. meningitidis isolates by serogroups, 1994-9
Year B C W135 Others Total
1994
No. total tested 62 27 0 1 90
No. resistant 1 0 0 0 1
Resistant% 1-6 - - - 1-1
1995
No. total tested 36 19 1 1 57
No. resistant 11 4 0 0 15
Resistant % 17-5 21-1 - - 26-3
1996
No. total tested 59 38 0 3 100
No. resistant 2 5 0 0 7
Resistant % 3-4 13-2 - - 7
1997
No. total tested 46 40 2 3 91
No. resistant 2 3 1 0 6
Resistant% 4-3 7-5 50 - 6-6
1998
No. total tested 42 60 2 6 110
No. resistant 3 4 2 0 9
Resistant % 7-1 6-7 100 — 8-2
1999
No. total tested 60 53 2 5 120
No. resistant 5 2 1 0 8
Resistant % 8-3 3-8 50 - 6-7
1994-9
No. total tested 305 237 7 19 568
No. resistant 24 18 4 0 46
Resistant% 7-8 7-6 57-1 - 8-1
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Fig. 1. Distribution of meningococcal serogroups in invasive disease and penicillin resistance, 1994-9.
Table 3. Temporal and geographic distribution of relatively penicillin resistant invasive N. meningitidis isolates
and pattern ofpenicillin prescribing in Scotland, 1994-9




Total Incidence No. of doses Rate per 10
Location* 1994 1995 1996 1997 1998 1999 1994-9 ratet, 1994-9 prescribed population
AC _ 2 1 1 2 1 7 0-27 62,770.675 2-4 x 10 '
AA — 1 2 — - I 4 0-18 50,728.780 2-2 x 10"
BR — — — — — — — — 13,329,784 2-1 x 10*
DG — — — - — 1 1 0-11 19,005,257 2-1 x 10*
FF — — — - 1 — 1 0-05 49,252,019 2-3 x 10*
FV — 1 — — 1 1 3 0-18 35.266,571 2-1 x 10*
GR — 1 — 1 - — 2 0-06 69.884,948 2-2 x 10*
GG 1 2 3 1 — 2 9 0-17 151,186.546 2-8 x 10*
LN - 3 1 2 3 1 10 0-30 93,133.697 2-8 x 10*
LO — 1 — 1 — 1 3 0-06 106,646.135 2-3 x 10*
OR — — — - _ — — — 2,277,914 l-9x 10*
SH — — — — 1 — 1 0-72 2,766,403 2-0 x 10*
TY — 2 — - - - 2 0-08 55,193.772 2-3 x 10*
WI — — — - — — — — 3,148.540 1-8 x 10*
HI — 2 — 1 — 3 0-24 26,958.029 2-1 x 10*
Scotland 1 (2-2) 15 (32-6) 7(15-2) 6(13-0) 9(19-6) 8(17-4) 46(100) 0-15 741.549,070 2-4 x 10*
* AC. Argyll & Clyde: AA, Ayrshire & Arran; BR, Borders; DC, Dumfries & Galloway; FF. Fife; FV, Forth Valley; GG,
Greater Glasgow; GR, Grampian; HI, Highland; LN. Lanarkshire; LO. Lothian; OR, Orkney: SH, Shetland; TY.Tayside;
WI. Western isley.
t Incidence rate per 100000 population.
W135 (Table 2). During 1994-9, as a whole, serogroup
B was the predominant cause of invasive disease
(51-7%) and of moderate resistance to penicillin
(52-2%) (Fig. I). This was followed by serogroup C,
which accounted for 39-1 % of invasive disease and of
isolates with moderate resistance to penicillin. The
proportion of isolates moderately resistant to peni¬
cillin and belonging to serogroup W135 (8-7%) was
marked higher than the proportion of invasive disease
due to serogroup W135 (1%) (Fig. 1). Indeed, the
prevalence of moderate penicillin resistance in sero¬
group W135 was substantially higher (51-7%) than in
serogroups B (7-8%) (p = 0 0001) and C (7-6%) (P =
0-0001) (Table 2). Although an increasing trend for
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moderate penicillin resistance caused by serogroup B
was not consistent during the period 1994-9, a clear
increase was noted from 3-4% in 1996 to 8-5-9-5% in
1998/9 (Table. 2). In contrast, the proportion of
group C isolates which were moderately penicillin
resistant decreased from 21-1% in 1995 to 3-8% in
1999. On the other hand, invasive meningococcal
disease caused by serogroup C increased from 28-9%
in 1994 to 52-6% in 1998 and to 46-5 % in 1999. There
was no increase in group B invasive meningococcal
disease in the study period. No apparent change in the
incidence of group W135 meningococcal disease or
moderate penicillin resistance was noted between 1994
and 1999.
Temporal and geographic distribution of moderately
penicillin resistant meningococci and the pattern of
penicillin prescribing
Table 3 shows the temporal and geographic dis¬
tribution of moderately penicillin resistant meningo¬
cocci and pattern of penicillin prescribing in Scotland.
There was no association between moderately peni¬
cillin resistant isolates and penicillin prescription rate
across all health boards (Pearson correlation, r =
0-129, p = 0-646).
Serotype and subtype distribution of isolates in
relation to moderately penicillin resistant invasive
isolates
The serotype and subtype of invasive isolates mod¬
erately resistant to penicillin were diverse (Table 4).
Twenty-four serotypes/subtypes in group B, 18 sero-
types/subtypes in group C and 4 serotypes/subtypes
in groupW135 were found to havemoderate resistance
to penicillin. A higher proportion of isolates moder¬
ately resistant to penicillin had the serotype/subtype
4:PI.4, NT:PI. 16, NT:P1.9 or 4:P1.15 in group B,
and 2a:P1.2, 2a:P1.5 or 2b:P1.16 in group C. Three
serogroup W135 isolates moderately resistant to
penicillin were serotypes/subtypes NT:P1.3,6, NT:
PI.3, PI.6, and NT:P1.6, P1.3. The incidence of
disease or resistance was higher in type and subtype
4:P.14, NT:P1.9 and NT:P1.16 of group B and type
and subtype 2a:PI.2 and 2a:PI.5 of group C.
DISCUSSION
Our study shows a low prevalence of invasive
meningococcal isolates resistant to penicillin and other
third generation antibiotics in Scotland between 1994
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and 1999. Ten percent of isolates were highly resistant
to suiphadiazine but no high level resistance was
found to any other antimicrobial agents. High-level
resistance to sulphadiazinc could be due to the
common use of suiphadiazine as chemoprophylaxis in
close contacts of index patients during the 1950s to
1970s. However, isolates with resistance to penicillin,
ciprofloxacin, ceflotaxime, ceftriaxone and rifampicin
are of particular concern because they are generally
used to treat patients with meningococcal meningitis
and their close contacts. The failure to find any
evidence of high level resistance to these antibiotics in
the present study suggests that current antimicrobial
agents remain effective in treating meningococcal
disease. These data on antimicrobial resistance of
meningococci are essential to inform guidelines on
therapy for patients with meningococcal disease.
The annual incidence of moderately penicillin
resistant meningococci was 0-15 per 100000 popu
lation. US data reported an incidence of 0 04 per
100000 population for moderate penicillin resistant
meningococci in 1991 [17]. The prevalence ofmeningo¬
cocci moderately resistant to penicillin was 8'3% and
no evidence of an increase in moderate penicillin resis
tant isolates was observed during the study period.
Previous studies have reported that the prevalence of
penicillin resistant meningococci was 6% in Belgium
in 1998 [18] and <2% in the Netherlands [19].
A higher resistance rate was documented in England
and Wales [8] and Spain [10]. Similar to our data,
the US studies [17,20] reported no overall increase
in penicillin resistant meningococci during 1980s and
1990s. In contrast, a trend of increased resistance to
penicillin among meningococci has been documented
in England and Wales [6-8] and Spain [10, 21, 22],
The reason for geographic variation in prevalence
ofmeningococcal isolates resistant to penicillin is not
clear, but may be due to difference in MIC testing
method. Similar to other meningeal bacterial patho¬
gens such as Streptococcus pneumoniae, mcningo
coccal disease jsquires treatment with antimicrobial
agents. In addition, the rates of asymptomic carriage
of meningococci and pneumococci are also similar in
the population. However, the prevalence of penicillin
resistance has been shown to increase globally for
Streptococcus pneumoniae [23], and not for the
meningococcus. Further studies arc needed to address
this issue. In common with evidence from Spain,
geographic difference in the incidence of moderately
penicillin resistant meningococci has been noted in the
present study [22]. Although there was no statistical
association, the areas with higher incidences of peni¬
cillin resistant meningococci tended to have higher
penicillin prescribing rates. One study in Iceland noted
that antimicrobial use was significantly related to
nasopharyngeal colonisation with penicillin resistant
pneumococci in children [24]. However, one survey
from England suggested that an association between a
high rate of antibiotic prescribing and a high incidence
rate of meningococcal disease in some geographic
locations might in part, be confounded by increased
general practitioner consultation rates for lower res
piratory infection [25], Nevertheless it has been widely
accepted that the selective pressure imposed by wide¬
spread use of antibiotics is likely to be responsible
for the emergence and maintenance of antibiotic
resistance [26],
Mechanisms leading to resistance are similar in
gonococci and pneumococci [5], Studies have also
shown that the development of penicillin resistance in
meningococci is due to altered forms of the penicillin
binding protein (PBP) gene resulting in reduced
affinity for the antibiotics [22, 27, 28], In addition, the
emergence of penicillin resistant meningococci has
been shown to occur by recruitment of a PBP gene
from closely related species such as Neisseriaflavescens
[28]. It appears that antibiotic pressure combined with
decreased affinities of penicillin binding proteins has
been the primary factors for the development of
resistant strains. Therefore, guidelines to limit the
excessive usage of antibiotics will be helpful in
controlling the emergence of resistance.
In England and Wales, meningococcal serogroups
B and C were shown to be responsible for moderate
penicillin resistance in 1985-9 [29]. We noted that
serogroup B was associated with a higher proportion
of penicillin resistance than group C. and W135. This
is consistent with previous reports in the US [17] and
Spain [22]. In the present study, the prevalence of
moderate penicillin resistance in meningococcal cero
group W135 was 57-1 %. In addition, the proportion
of resistant isolates contributed by scrogroup W135
(8-7%) was substantially higher than the proportion
of invasive disease caused by this serogroup in 1994-9.
Recently, meningococcal serogroup W135 cases have
been reported among pilgrims who had travelled to
the Hajj in Mecca and their close contacts [30,31].
Our data and this evidence confirm recent UK
guidance on the advisability of offering all pilgrims
the quadrivalent polysaccharide vaccine before tra
veling to Mecca.
Although meningococcal disease caused by sero¬
group C increased during the study period, there was
no increase in the prevalence of penicillin resistance
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among serogroup C penicillin resistant isolates. One
study in Spain also failed to show an associated
increase in the prevalence of serogroup C penicillin
resistance with an increase in serogroup C disease [32].
Similarly, we did not find any correlation between
serogroup C meningococcal disease and penicillin
resistant isolates.
In the United Kingdom, widespread use ofmeningo¬
coccal group C conjugate vaccine in November 1999
resulted in a rapid decline of group C disease in age-
groups targeted for vaccination, with preliminary
data showing a short-term efficacy of 97% for
teenagers and 92% for toddlers [33]. In the present
study, a higher proportion of meningococcal disease
and penicillin moderately resistant isolates was caused
by serogroup B. Our data reinforce the additional
need for a vaccine against serogroup B meningococcal
disease.
Our study shows a wide range of serotypes/
subtypes in different serogroups amongpenicillin resis¬
tant isolates. Although group B serotypes/subtypes
4:P1.4 (16-7%) and NT:P1.16 (12-5%), group C
serotypes/subtypes 2a:P1.2 (15-8%) and 2a:P1.5
(15-8%) were associated with a high proportion of
moderate penicillin resistance, there was no clearly
dominant serotype/subtype that was associated with
penicillin resistance in a specific serogroup. Studies in
Spain have shown conflicting results. One study found
that group B serotype/subtype 4: PI. 15 was associated
with 51-4% of penicillin resistance and group C and
non-serogroupable serotype type 2b were associated
with 86% and 87% of penicillin resistance respec¬
tively [22]. However, an examination of 16 penicillin
G-resistant strains in Spain failed to find a serotype
specific association for penicillin resistant isolates [34].
We found that serogroups/types/subtypes B: 4:P. 14,
B: NT:PI.9, B:NT:P1.16, C:2a:P1.2 and C:2a:P1.5
were associated with a higher proportion of resistance
as well as disease. Due to the limited number of
resistant isolates, caution should be taken in the
interpretation of these data.
Our results show that at present the prevalence of
penicillin resistant meningococci is low in Scotland,
with marked geographic and temporal variations. The
clinical importance of meningococci moderately re¬
sistant to penicillin is not clear, but meningococci with
high-level resistance would have serious implications
for patients with invasive disease. Since the prevalence
of penicillin resistant meningococci could change
rapidly, surveillance must be conducted continuously
to detect any possible emergence of resistant meningo¬
cocci. Further understanding of meningococcal sero-
epidemiology and of the molecular characteristics of
disease and penicillin resistance is critical for develop¬
ing appropriate vaccines to control the disease and
antibiotic resistance. Development ofgroup B mening¬
ococcal vaccine will be critical in adding to the success
of group C conjugate vaccination in the United
Kingdom, as vaccination is the most effective method
to control the spread of disease and the emergence of
resistance.
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KINGDOMWITH PNEUMOCOCCAL VACCINES
M.H. Kyaw, Research Fellow, Scottish Centre for Infection and Environmental Health and Department of Public
Health Sciences, University of Edinburgh; H. Campbell, Senior Lecturer, Department of Public Health Sciences,
University ofEdinburgh; I.G.Jones, Director, Scottish Centre for Infection and Environmental Health, Glasgow
INTRODUCTION
Disease caused by Streptococcus pneumoniae (the
pneumococcus) is an important cause of avoidable
morbidity and mortality in the UK.1 It particularly affects
very young children, the elderly and individuals with
chronic systemic illnesses, including heart, lung and kidney
disease, diabetes, immunosuppression, asplenia and
alcoholism. These groups are predisposed to serious
infections, including pneumonia, bacteraemia and
meningitis. A recent paper has identified cigarette smoking
as the strongest independent risk factor for invasive
pneumococcal disease among immunocompetent, non-
elderly adults.2 The risk of invasive pneumococcal disease
is particularly high in human immunodeficiency virus (HIV)
infected persons, and is estimated to be 100- to 300-fold
greater.3 The A 23-valent polysaccharide vaccine is licensed
for use in the UK, and a new 7-valent conjugate vaccine
has recently obtained a licence in the US. This paper
reviews the epidemiology of S.pneumoniae and the scope
for disease prevention using polysaccharide or conjugate
vaccines.
THE EPIDEMIOLOGY OF PNEUMOCOCCAL DISEASE
Pneumococcal disease is a major single cause ofpotentially
vaccine preventable bacterial disease in the UK and other
countries. Since it is not reportable, its precise incidence
is unknown. Evidence suggests that 36-50% ofcommunity-
acquired pneumonias are due to S. pneumoniae,4,5 The
estimated annual incidences ofpneumococcal pneumonia,
bacteraemia and meningitis are 100 per 100,000, seven
per 100,000 and 0.4 per 100,000 respectively in the UK,4-6
with corresponding case fatality rates of 5%, 20% and 30%.7
Pneumococcal otitis media is also common in children
under the age of five, among whom it has an estimated
annual incidence of40,000 per 100,000.8,9 The prevalence
of penicillin and erythromycin resistant pneumococcal
isolates has increased from <1% to 3.6-7.4% and from 5%
toll% respectively during 1990/91 to 1997/98.'° The
increasing incidence of pneumococcal disease - largely
due to the rise in numbers of elderly people, the global
HIV pandemic, and multidrug resistant epidemic
underscores the importance of pneumococcal infection
as a significant public health problem.
Since S. pneumoniae was first isolated in 1880, this
capsulated Gram-positive bacterium has been found to
have at least 90 serotypes. The mucosal epithelium of the
nasopharynx is the primary site of colonisation with risk
of carriage depending on age, overcrowding and daycare,
centre attendance, breast feeding, season, smoking and prior
antibiotic therapy." The reported carriage rate is up to
60% in pre-school children, 25-35% in high school
students, 18-29% in adults with children in household
and 6% in adults without children in household.12 The
carriage rates in children in developing countries are two-
or three-fold higher than in children in developed
countries.13 Nasopharyngeal colonisation is achieved by
interaction between pneumococcal surface proteins and
human epithelial cell receptors.14 It occurs at some point
in the first two years of life in most children.15 The
development of disease and spread of the pathogen are
associated with nasopharyngeal colonisation.16,17
The pneumococcus has three main surface layers; cell
membrane, cell wall and capsule.1" The polysaccharide
capsule protects this bacterium from phagocytosis." The
level ofpneumococcal virulence is based on the chemical
composition of the capsule and varies considerably among
the 90 known serotypes.20,21 Immunity to pneumococci
depends on the production ofserotype-specific protective
antibody in response to capsular polysaccharide.22, 23
Colonisation and development of antibody to relevant
polysaccharide have been observed in military personnel
and family members of persons with pneumonia.24,2'
Pneumococcal serotypes vary with age, source of
specimens, geographic locations and time.26"29 Between
five and eight serogroups are responsible for at least 75%
of invasive pneumococcal disease in children, and around
ten or 11 in older children and adults in both developed
and less developed countries.3" Serogroups 4, 6, 9, 14, 18,
19 and 23 in young children, and 4, 6, 9, 12, 14, 19 and 23
in older children/adults, are more often associated with
invasive disease in developed countries.3" Types 1 and 5
are the most common causes of invasive pneumococcal
disease in less developed countries.28 In Scotland the most
prevalent 11 serotypes and serogroups were, in numerical
order, 14,9,19, 6, 23,1, 3, 4,7, 8 and 18, and these accounted
for 84% of the total.31 In addition, the prevalent serotypes
causing mucosal and invasive infections are different. The
data from the US showed that types 3, 19A and 23F, types
4, 9V, 14 and 18C, and type 6B were more frequently
isolated from middle ear fluid, blood and cerebrospinal
fluid (CSF) respectively.27 Since the effectiveness of
immunisation depends on the distribution of vaccine
serotypes in the population being immunised,28 a
knowledge of the distribution of serogroups and serotypes
is vital for vaccine policy in the prevention of invasive
pneumococcal disease.
In 1967 the first isolate resistant to penicillin was
reported from Australia, and the first multidrug-resistant
pneumococci (resistant to three or more antimicrobial
agents) from South Africa in 1977.32,33 Studies using
molecular techniques have shown that the spread of only
a few resistant clones account for the vast majority of
resistant pathogens.34 Evidence indicates that modern
transport and the movement of people are responsible for
the worldwide distribution of resistant mutants.35
Pneumococcal serogroups 6, 9, 19 and 23 are the major
causes of drug resistance world-wide, accounting for 80%
of all pneumococcal resistant isolates.36,37 Nasopharyngeal
colonisation with these strains is common in children and
may play a major role in their spread.17,38,39 Prior antibiotic
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use and daycare attendance correlate with increased
antibiotic resistance in children under the age of five.40,41
Geographic variation in the prevalence of drug resistance
has been observed in Europe, North America, Asia and
South Africa.42 The highest penicillin resistance rates were
reported from Hungary (58%)43 and some countries in
Asia (>70%).44
The high level penicillin resistance (minimal inhibitory
concentration,MIC >2 mg/ml) in Scotland was very low,
with only two serotype 14 (0.02%) blood isolates tested
possessing this.31 Penicillin intermediate resistance (MIC
between 0.12 and 1 .Omg/ml) accounted for 8% of isolates,
most of which were serotype 14. In the US and other
European countries, the most prevalent penicillin resistant
serotypes are 23F, followed by 6, 14, and 19.45 Studies
from the US showed that a large proportion of penicillin
resistant strains were also resistant to other antibiotics.46,47
The molecular epidemiology of penicillin resistant
pneumococci in 15 countries found that the 23F and 9V
clones are responsible for global spread of drug resistant
pneumococcal isolates.48
PNEUMOCOCCAL POLYSACCHARIDE VACCINE
Although a 14-valent pneumococcal polysaccharide
vaccine was first licensed in the UK in 1979 and the 23-
valent vaccine in 1989, the UK's Joint Committee on
Vaccination and Immunisation (JCVI) did not recommend
its use in vulnerable groups until 1992. The current 23-
valent vaccine includes serotypes 1,2, 3, 4, 5, 6B, 7F, 8, 9N,
9V, 10A, 11A, 12F, 14,15B, 17F, 18C, 19A, 19F,20,22F,23F
and 33F and accounts for over 95% of invasive disease in
the UK40 and 88% in the US.50 The current 23-valent poly¬
saccharide covers above 95% ofinvasive disease in Scotland.31
The polysaccharide vaccine is effective in preventing
70—80% ofinvasive pneumococcal disease.51,52 Based on
this effectiveness, economic analysis from the US and
Europe (including the UK) has suggested that
pneumococcal vaccination would be a cost effective strategy
for preventing invasive disease in the elderly.53,54 In addition,
the most frequently encountered global drug resistant isolates
(6B, 9V, 14,19A, 19F, 23F) ofinvasive pneumococcal disease
are included in this vaccine.42 Therefore, the increased use
of polysaccharide vaccine may reduce the incidence of
antibiotic susceptible and non-susceptible invasive
pneumococcal disease. A single dose of the vaccine is
currently recommended for those aged two years or older
in whom pneumococcal infection is likely to be more
common or more serious, including those with chronic
cardiac disease, chronic pulmonary disease, chronic liver
disease, chronic renal disease, diabetes mellitus, splenic
dysfunction and immunodeficiency states.55 The uptake
ofvaccine was estimated to be 5% in 1995 and 15% in 1998
among recommended groups in the UK.56, 57 Re-
immunisation should be considered for persons at highest
risk ofpneumococcal disease, including those with asplenia,
splenic dysfunction or the nephrotic syndrome. These
individuals may need booster doses after five or ten years
because of declining antibody levels.
Unfortunately, the current polysaccharide vaccine is
poorly immunogenic in children under the age of two, the
age group with the highest incidence ofinvasive and mucosal
disease, and as a consequence it is not recommended for
them. Moreover, the vaccine does not reduce carriage,
and antibody levels fall over time.58 Since polysaccharide
antigens are T-cell independent, the vaccine is unable to
induce immunological memory and protection is relatively
short-lived.59
Four systematic reviews or meta-analyses of randomised
controlled trials evaluating the effectiveness ofimmunisation
with pneumococcal polysaccharide vaccine have been
TABLE 1
Conclusions of four systematic reviews or meta-analyses on the efficacy of pneumococcal polysaccharide vaccine.
Reference Type of review Conclusion
Fine MJ et al.M Meta-analysis of nine trials
published up to 1991
Pneumococcal vaccination appears efficacious in reducing
bacteraemic pneumococcal pneumonia in low risk adults.
However, evidence from randomised controlled trials fails to
demonstrate vaccine efficacy for pneumococcal infection-related
or other medical outcomes in the heterogeneous group ofsubjects
currently labelled as high risk.
Watson L61 Systematic review and meta¬
analysis of 16 trials published
up to March 1999
For studies carried out in the West, there was no protective effect
found on mortality, all pneumonia or pneumococcal pneumonia,
although there was a protective trend for pneumococcal
bacteraemia, a surrogate outcome. In Third World studies, a
significant protective effect was found for the three clinical
outcomes.
Hutchison BG et al.52 Meta-analysis of 13 trials
published up to November 1996
Vaccination with pneumococcal polysaccharide vaccine can be
expected to reduce the risk of systemic infection due to
pneumococcal types included in the vaccine by 83% and systemic
infection due to all pneumococci by 73%. The vaccine was not less
efficacious for the elderly, institutionalised people, or those with
chronic disease.
Bandolier 62 Systematic review of nine trials
published up to 1999
Polysaccharide pneumococcal vaccines have yet to be shown to
work in the types of people given them in industrialised
countries. The only real evidence that they do comes from two
improperly randomised studies from the 1940s.
ProcRColl Physicians Edinb 2001; 31:124-133 125
carried out (Table l).52, 60,62 Unfortunately, these papers
reached differing conclusions, highlighting problems with
meta-analysis which have been the subject of debate in
journals.63 Trials included had insufficient power to detect
a number ofdifferent endpoints of relatively low incidence
using vaccines of different composition. Due to study
design problems in the published trials, expert reviewers
have considered evidence from other case control and
indirect cohort studies, and the current international
consensus is that the vaccine can be considered to be 50-
80% effective against invasive pneumococcal disease.51,64,65
Although data from case control and indirect cohort studies
have lower validity than those from randomised trials, it
has been suggested that they offer logistical, ethical and
statistical advantages in estimating the vaccine's effectiveness
in patients with various high risk conditions.66,67 Tables 2
and 3 present the summaries of randomised trials, case
control and indirect cohort studies conducted in the high
risk groups. The current consensus ofopinion from expert
reviewers supports the recommendations of the JCVI to
promote the uptake of pneumococcal polysaccharide
vaccine for the prevention of invasive disease in at risk
groups until the new conjugate vaccines become available
in the UK.
CONJUGATE VACCINE
To address the inherent problems of polysaccharide
vaccines, pneumococcal conjugate vaccines have been
developed by coupling the capsular polysaccharides of the
epidemiologically important serotypes to carrier proteins.
The latter include tetanus toxoid, diphtheria toxoid, CRJvI]97
(a non-toxic mutant ofdiphtheria toxin), pneumolysin or
meningococcal outer membrane protein complex.68 This
has the effect of rendering the antigen T-cell dependent,
leading to an anamnestic response to future infection.69
Although the threshold antibody level which confers
protection is unknown at present, pneumococcal conjugate
vaccines elicit higher antibody responses than
pneumococcal polysaccharide vaccines, induce mucosal
antibody and immunologic memory and are likely to have
a higher efficacy in preventing both invasive and non¬
invasive disease.70 The conjugate pneumococcal vaccine
contains 7 to 11 serotypes that cause the majority of
pneumococcal disease in young children.7' The 7-valent
conjugate vaccine includes serotypes 4, 6B, 9V, 14, 18C,
19F and 23F. In the 9-valent and 11-valent vaccines,
serotypes 1 and 5 and serotypes 1,5, 3, and 7F are added
respectively. In the US, the 7-valent vaccine would cover
above 80% of invasive and 65% of non-invasive
pneumococcal disease in children under six years of age.27
The coverage of9- to 11-valent vaccines covers serotypes
causing 76—93% of invasive disease in children in the US
and Europe.72 A substantially lower coverage, 65-68%, of
invasive isolates with 11-valent vaccine was observed in
adults in developed countries.30 In Scotland, the 7-, 9-
and 11-valent conjugate vaccines would cover 61%, 68%
and 80% of invasive pneumococcal isolates in all ages.31
Antibody responses to pneumococcal conjugate
vaccines vary with serotypes and vaccine formulations.71
Studies in developed and developing countries have
reported that the pneumococcal conjugate vaccines are
immunogenic in infants aged six to eight weeks.70,73
Antibody levels at seven months of age after a series of
three doses range from 0.5 to 4.29 mg/ml for the poor
immunogenic serotypes to 1.13 to 14.09 mg/ml for the
most immunogenic serotypes.70 It has been suggested that
antibody levels of0.3 mg/ml may afford protection against
invasive disease caused by serotypes 3, 4, 6A, 8,14,19F and
23F in children.74 Studies in patients with immuno¬
compromised disorders75,78 (HIV, Hodgkin's and sickle cell
diseases) and recurrent respiratory infections79,80 have shown
that pneumococcal conjugate vaccines are capable of
inducing higher antibody responses than the polysaccharide
vaccine.
The first available data from a large scale double blind
randomised controlled clinical trial in children have been
reported from the three year Northern California Kaiser
Permanente study among 37,000 children using Wyeth-
Lederle's 7-valent pneumococcal CRM])? conjugate
vaccine,81 and the results of the Finnish efficacy trial for
the prevention ofpneumococcal otitis media are expected
soon. Table 4 shows the vaccine efficacy in preventing
various types ofpneumococcal disease after immunisation
at two, four, six and 12 to 15 months ofage in the American
study. The vaccine also appears to be safe and immuno¬
genic. The adverse reactions to conjugate pneumococcal
vaccines are minimal and comparable to the 23-valent
polysaccharide vaccine and other routine paediatric
vaccines.71,82"84
The vaccine currently licensed in the US contains
serotypes which are associated with multidrug resistant
invasive strains.42 Studies in other countries have shown a
significant reduction in nasopharyngeal carriage in
vaccinated infants and children.85"87 Data from South Africa
showed a reduction of 50% in nasopharyngeal carriage in
vaccine serotypes in infants immunised at six, ten and 14
weeks.87 This suggests that universal childhood vaccination
with pneumococcal conjugate vaccine has the potential
to produce herd immunity and decrease the spread of
antibiotic resistant pneumococcal disease in children.
Nevertheless, studies in South Africa and the Gambia found
that colonisation with non-vaccine serotypes were
increased in vaccines compared to controls.85,87 Therefore,
continued surveillance data are essential to monitor the
long-term colonisation effects of widespread use of
conjugate vaccines in future.
Health economic studies in the US have concluded
that infant immunisation with pneumococcal conjugate
vaccine has the potential to be cost effective.88,89 If the
vaccine costs were less than the manufacturer's list price
of $58 for each dose, vaccination could even be cost
saving.88 The experience following the introduction of
Hib vaccine in 1992 could therefore be repeated with
pneumococcal conjugate vaccine (Figure 1).
The results of the US trial raise questions about the
use of conjugate vaccine in adults. Unfortunately, the
results are not directly applicable to older age groups for a
number of reasons and the effectiveness ofpneumococcal
conjugate vaccines in preventing pneumonia and other
respiratory infections, as well as their role in the elderly
and high risk adults, require further examination. One
problem is the more limited coverage of invasive disease
serotypes in adults than in children, as noted above. Eight
clinical studies of conjugate vaccines in adults have been
reported.58 Of these, six studies in younger adults showed
that the conjugate vaccine produced higher antibody
responses than the polysaccharide vaccine.68,78,83,90"92 In
contrast to these findings, two other studies in persons
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TABLE 4
Protective efficacy of 7-valent protein conjugate pneumococcal vaccine against invasive disease and otitis media.81
Analysis Per protocol
% (95% confidence interval)
Intention to treat
% (95% confidence interval)
For serotypes contained in the vaccine, fully 97-4 (82-7—99-9)
vaccinated, invasive disease
93-9 (79-6-98-5)
For all cases regardless of serotypes contained -
in the vaccine, invasive disease
89-1 (73-7-95-8)
Otitis media visits 8-9 (5-8—11-8) 7-8 (5-2-10-5)
Otitis media episodes 7-0 (4-1—9-7) 6-4 (3-9-8-7)
Frequent otitis (five episodes in six months/six in a year) 22-8 (6-7—36-2) 12-3 (0-23-2)
Ventilatory tube placement 20-1 (1-5-35-2) 20-3 (3-6-34-1)
aged 50 years and older did not show significant advantages
in antibody responses over polysaccharide vaccine with
the conjugate vaccine.68,83 Further studies are planned
using different formulations and different schedules to
assess the implications of conjugate vaccine for the
prevention of pneumococcal disease in adults.
AREAS FOR FURTHER RESEARCH
Many questions which remain unanswered on
pneumococcal immunisation need to be addressed. At
this stage we do not know whether to recommend the
polysaccharide or the conjugate vaccine for children over
the age of two, nor under what circumstances or criteria.
Will a course of conjugate vaccine require periodic
boosting with conjugate or polysaccharide vaccine? Does
the vaccine impair the immunological response to other
childhood vaccines when given in the UK's accelerated
immunisation schedule? Even more importantly, what effect
would mass infant immunisation have on carriage among
children and adults? Could this result in serotype
displacement and the emergence of invasive or mucosal
disease caused by serotypes not commonly associated with
infection? Would the potential elimination of carriage
result in ecological niches being filled with these other
virulent strains ofpneumococci or other organisms? Post-
vaccine carriage studies of the kind currently being
undertaken in relation to meningococcal C conjugate
vaccine will be necessary to resolve this. Some of these
questions are already the subject of current studies.
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Pneumococcal disease is a major cause of morbidity and mortality in infants and young children
worldwide. New pneumococcal conjugate vaccines include 7 to 11 serotypes, which are the most
common cause of paediatric disease in most parts of the world. The efficacy of a 7-valent
conjugate vaccine was 97.4% (95% CI, 82.7-99.9) against invasive pneumococcal disease, and
57% (95% CI, 44-67) against otitis media, caused by vaccine serotypes. Evidence shows that the
vaccine has the potential to prevent pneumonia. Pneumococcal conjugate vaccination has also been
shown to reduce nasopharyngeal carriage of vaccine serotypes (particularly serotypes associated
with antibiotic resistance). Thus widespread use of pneumococcal conjugate vaccine could
substantially reduce the burden of invasive disease and would have the potential to control the
global spread of antibiotic resistance in pneumococci.
Conclusion: It is important that these highly effective vaccines should be made available to
children in the developing countries. \
Key words: Conjugate vaccines, developing countries, disease prevention, pneumococcus
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The pneumococcus is a major cause of pneumonia,
bacteraemia, meningitis and otitis media in children
under 5 y of age. The World Health Organization
(WHO) has estimated that 1.2 million children under
5 y of age die annually as a result of pneumococcal
disease (1). More than 70% of pneumococcal disease in
children occurs before the age of 2 y (2-4). Data from
the US and Europe indicate that the estimated annual
incidence rates per 100000 young children are 700 for
pneumococcal pneumonia (5-8), 10 for pneumococcal
meningitis (9, 10), 20 to 140 for pneumococcal bacter¬
aemia (9, 10) and 40000 for pneumococcal otitis media
(11-13). The available 23-valent pneumococcal poly¬
saccharide vaccine has been shown to reduce invasive
bacterial infections by 50-70% in children older than
2y of age (14,15). However, the vaccine is poorly
immunogenic in children under 2 y, particularly against
serotypes 6A, 14, 18C, 19F and 23F (16, 17). Pneumo¬
coccal isolates resistant to penicillin and other anti¬
biotics are gradually increasing worldwide (18), with
the prevalence of resistant isolates as high as 80% (in
Asia) (19). This significant morbidity and mortality
together with the growing spread of (multi) drug-
resistant isolates emphasizes the clear need for effective
new vaccines against pneumococcal disease.
The spectacular success of the Haemophilus influen¬
zae type b (Hib) conjugate vaccine, which has almost
eradicated serious disease caused by Hib in countries
where universal vaccination has been introduced,
suggests that it may be possible to achieve a similar
outcome with an effective conjugate pneumococcal
vaccine. Linking a protein carrier to pneumococcal
polysaccharides has been shown to increase imrnuno-
genicity in both primary and booster doses in young
children by producing a vaccine that evokes a T cell-
dependent immune response (20, 21). The results from
ongoing multicentre clinical trials in developed and
less-developed countries suggest that pneumococcal
conjugate vaccines will be safe and immunogenic in
infants and children (22-28).
The current 7-valent conjugate vaccine (which
includes serotypes 4, 14, 6B, 19F, 18C, 23F and 9V)
covers 86% and 83% of pneumococcal serotypes that
cause pneumococcal bacteraemia and meningitis, re-
© 2001 Taylor & Francis. ISSN 0803-5253
474 MH Kyaw el al. ACTA P.EDIATR 90 (2001)
spectively, in the US (29). The 9- and 11-valent
conjugate vaccines, which include serotypes 1 and 5
and 1, 3, 5 and 7F, respectively, cover an estimated 73-
92% of invasive pneumococcal disease in the developed
countries (15). An extensive analysis of recent data
from Latin America, Europe and North America
indicates that the serogroups included in 9-valent and
11-valent conjugate vaccines cover 60% or more of all
pneumococcal isolates from pneumonia patients, both
young children and older children (30). The 7-valent
conjugate vaccine serotypes account for 65% of otitis
media in the US (29,31) and 56% of otitis media in
Israel (32). Furthermore, serogroups 3, 19, and 23,
which are major causes of otitis media in young
children in the US, Canada and Europe, are included
in the 11-valent conjugate vaccine (30).
Significant geographical variation in serotype dis¬
tribution of prevalent pneumococcal isolates that cause
invasive pneumococcal infections has been reported.
Serotypes 1 and 5 are the most common causes of
invasive pneumococcal disease among children less
than 2 y of age in Africa and Asia but not in Western
Europe and North America (33). Seroepidemiological
data indicate that the proportion of isolates which
belong to a serogroup contained in the 7 to 11-valent
conjugate vaccines covers only approximately 20-55%
of isolates from cases of meningitis in Asian countries
(30). Differences in serotype distribution and seroepi-
demiology of disease among regions and countries
could lead in the future to the development of
pneumococcal conjugate vaccines with different sero¬
type constituents.
Pneumococcal conjugate vaccines elicit higher anti¬
body responses than pneumococcal polysaccharide
vaccines (21). The threshold antibody level that confers
protection is unknown at present, although evidence
from Hib conjugates implies that pneumococcal con¬
jugate vaccines will have a higher efficacy than
polysaccharide vaccines in preventing both invasive
and non-invasive pneumococcal disease. The first
available data from a large-scale clinical trial in
Northern California, conducted among 37 868 children
using the 7-valent Pnc-CRM197 conjugate vaccine,
were shown to have 97.4% efficacy (95% CI, 82.7-
99.9) in preventing invasive pneumococcal disease
caused by vaccine serotypes after immunization at 2,
4, 6 and 12-15 mo of age (31). The reported serotype-
specific efficacy of pneumococcal conjugate vaccine
against otitis media was 57% (95% CI, 44-67) in the
Finnish study (34). The US trial found a reduction in
episodes of pneumonia in conjugate vaccine recipients:
efficacy of 11.4% (95% CI, 1.3-20.5) against clinical
pneumonia, 33.0% (95% CI, 7.3-51.5) against X-ray-
confirmed pneumonia, and 73.1% (95% CI, 38-88.3)
against consolidation (>2.5 cm on X-ray) (35). Pneu¬
mococcal conjugate vaccine appears to be safe and
immunogenic (36). Children with HIV infection
(37, 38), Hodgkin's disease (39) and sickle cell disease
(40,41) also show improved immune responses with
this vaccine compared with the pneumococcal poly¬
saccharide vaccine.
Pneumococcal serotypes (6B, 9V, 14, 19A (19F),
23F), which are closely associated with multidrug-
resistant strains associated with invasive disease in
children in many countries, are included in the 7-valent
vaccine (18). Studies from Gambia (42), Israel (25) and
South Africa (28) have shown a significant reduction in
nasopharyngeal carriage in vaccinated infants and
children. This suggests that widespread vaccine use
(coverage above 90%) may produce herd immunity by
reducing transmission of the pneumococcus and thus
risk of infection. Therefore, universal childhood vacci¬
nation with pneumococcal conjugate vaccine has the
potential to decrease the spread of pneumococcal
serogroups included in the vaccine (which includes
the major serogroups associated with antibiotic resis¬
tance). Reduced carriage of pneumococcal vaccine
serotypes, particularly resistant serotypes, has been
observed in vaccinees (25, 28). Nevertheless, replace¬
ment of vaccine serotypes by non-vaccine serotypes has
been reported (42,28). In a recent Finnish otitis media
trial, an increase in disease caused-by non-vaccine
serotypes was documented (34). It is uncertain whether
this indicates true serotype replacement, or the "un¬
masking" of less-prevalent serotypes due to elimination
of dominant serotypes by conjugate vaccine. Interest¬
ingly, a large-scale US study, so far, did not observe the
emergence of non-vaccine serotypes in place of the
vaccine serotypes (31).
In less-developed countries, the highest incidence of
invasive pneumococcal infections is in the first 6 mo of
life (4). Since any new pneumococcal conjugate vaccine
is likely to be introduced into the childhood immuniza¬
tion schedules at 2/4/6 or 2/3/4 mo of age, there will be a
need for complementary immunization strategies.
These include maternal immunization with 23-valent
polysaccharide vaccine, to protect infants under 6 mo of
age. The administration of pneumococcal polysacchar¬
ide vaccines during the third trimester of pregnancy has
been shown to be safe, and to produce infant/matemal
antibody responses in serum and breast milk (43-45).
Studies from the US and Papua New Guinea show that
. passively acquired pneumococcal antibodies could
prevent 30% of serious pneumococcal infections in
early infancy and childhood (43,46). Maternal immu¬
nization may therefore be a feasible strategy in reducing
infant morbidity and mortality from pneumococcal
infection in the less-developed countries and merits
further research. Current research priorities include
further evaluation of the reduction in nasopharyngeal
carriage associated with vaccination, seeking evidence
of replacement of vaccine serotypes by non-vaccine
serotypes and investigating the nature of herd immunity
associated with pneumococcal conjugate vaccines.
The new pneumococcal conjugate vaccines will be
expensive. The reported cost of a course of the recently
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licensed 7-valent vaccine in the US is currently more
than $230 (47). At a cost of US $58 per dose, universal
vaccination with pneumococcal conjugate vaccine
would cost society $80000 per life saved, $3200 per
case of pneumonia prevented, $160 per episode of otitis
media prevented, $280000 per meningitis case pre¬
vented and $15000 per bacteraemia case prevented
(47).With the increasing number of childhood vaccines,
it is possible that some health systems will respond by
seeking to give priority to some vaccines in order to
manage the escalating costs of healthcare, even in
developed countries. However, in the context of the
total costs of healthcare, the costs of childhood vaccines
remain small. Nevertheless, less-developed countries
will not be able to afford to include them in their routine
childhood immunization programmes. The situation
may be similar to Hib vaccines, where routine use in
less-developed countries remains extremely limited,
despite clear evidence of the (cost) effectiveness of
vaccination (48,49).
Pneumococcal conjugate vaccines have the potential
to save the lives ofmore than one million children under
5 y of age annually, worldwide. By eliminating naso¬
pharyngeal carriage in vaccinated children, they could
possibly control the global spread of antibiotic-resistant
isolates and the incidence of pneumococcal infections
among persons with HIV in Asia and Africa. Conse¬
quently, there is likely to be a strong public health case
for pneumococcal conjugate vaccines to be made
available for use in less-developed countries".' The
motivation of rich countries to invest in the control of
pneumococcal disease worldwide and the reduction of
global childhood mortality from pneumococcal disease
remains to be determined.
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Prevention through vaccination
Breaking the vicious circle
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The pneumococcus is an important cause ofbacteraemia, meningitis, pneumonia, otitismedia and sinusitis in children nd ad lts. It
is a major cause of morbidity and mortality, par¬
ticularly in young children and in adults with
underlying medical conditions.1 The burden of
pneumococcal disease is highest in infants and
young children.
The World Health Organisation has conservative¬
ly estimated that in developing countries alone,
each year, pneumococci are responsible for at
least 1.2 million deaths in children under five
years of age.2
Treatment for pneumococcal disease is becoming
more complex due to the global increase in inci¬
dence of drug-resistant pneumococci. The preva¬
lence of penicillin-resistant pneumococcal isolates
has been reported to be 43 per cent in South
Africa, 49 per cent in US, 53 per cent in France,
60 per cent in Spain, ond 79 per cent in Korea.3
Although the UK has a low level of penicillin-resist¬
ant pneumococci, an increase in penicillin-resist¬
ant invasive pneumococcal isolates from 4.2 per
cent in 1992 to 12.6 per cent in 1999 have been
documented recently."
Recent studies have shown that patients infected
with penicillin non-susceptible pneumococcal
strains have longer durations of hospital stay and
higher case-fatality rates than those infected with
penicillin susceptible strains.66 Therefore, effective
measures against pneumococcal disease are of
high public health priority.
Serotype distribution
The pneumococcus has at least 90 different
serotypes, according to antigenic differences in their
capsular polysaccharide.6 The polysaccharide cap¬
sule is the most important virulence factor and pro¬
tects the organism from phagocytosis. Worldwide
data on pneumococcal serotype distribution have
shown that most of pneumococcal disease is
caused by 23 serotypes in adults,6 and in children
80 per cent are caused by 7 serotypes.10
The five most common serotypes (6, 14, 18, 19,
and 23) are responsible for global antibiotic
resistance. Individual serotypes vary in their
immunological properties.9 This presents a major
challenge for developing effective vaccines.
Immunisation against pneumococcal disease has
been available in the UK since 1979. The current
23-valent polysaccharide vaccine covers approxi¬
mately 90 per cent of invasive pneumococcal iso¬
lates in the UK.'0 This vaccine has been reported to
be between 57 and 84 per cent effective against
invasive pneumococcal disease in immunocom¬
petent individuals but lower in patients with partic¬
ular underlying conditions." However, it does not
protect against non-invasive disease such as
pneumonia or otitis media and does not reduce
nasopharyngeal carriage.1
Immature immune response in children
Capsular polysaccharides are T-cell independent
antigens. Infants and young children do not have
mature T- and B-lymphocyte function to respond to
these antigens.12 In addition, these capsular poly¬
saccharides do not induce long-term immunolog¬
ical memory. Conjugate vaccines have been
developed in response to these problems.
Bacterial polysaccharides are linked to protein car¬
riers to convert them to T-cell-dependent antigens.
This results in induction of immunological memo¬
ry and maturation of immune response in infants,
the elderly and those with immunocompromised
conditions.7'13 Conjugate vaccines have proven
highly successful in reducing invasive
Haemophilus influenzae type b (Hib) and group C
meningococcal diseases.
Pneumococcal conjugate vaccine formulations
comprise the 7 to 11 serotypes which are respon¬
sible for most disease in children in most parts of
the world. A study in California conducted among
37,868 children has shown that pneumococcal
conjugate vaccine is highly efficacious in prevent¬
ing invasive disease with a lower efficacy against
otitis media and pneumonia.1" Otitis media as the
primary endpoint for determining vaccine efficacy
was also studied in 1662 Finnish children.
Preliminary data indicate an efficacy of 57 per
cent against vaccine serotypes.15 These results
suggest that the effect of pneumococcal conjugate





tis media is likely to be substantial if the vaccine
is introduced into the routine childhood immuni¬
sation schedule in the UK.
Hib conjugate vaccine has been shown to prevent
nasopharyngeal colonisation that results in
decrease of transmission and establishment of
herd immunity. Pneumococcal conjugate vaccina¬
tion has also been shown to reduce nasopharyn¬
geal colonisation.16 A recent trial in Finland
documented an increase in otitis media episodes
caused by non-vaccine serotypes in conjugate
vaccine recipients compared to placebo
recipients.15
The 7- to 11-valent conjugate vaccines also
include the five serotypes which are most often
associated with antibiotic resistance. A decrease
in antibiotic-resistant pneumococcal serotypes
has been identified in children vaccinated with
conjugate vaccine.16 In addition, siblings of chil¬
dren who received conjugate vaccine were less
likely to carry resistant serotypes than siblings of a
placebo group, indicating clear herd immunity
effect within families.'6
In the California trial, a reduction of 5.3 per cent in
antibiotic use was observed in pneumococcal
conjugate vaccine recipients." Thus pneumococ¬
cal conjugate vaccine has the potential to reduce
the prevalence of pneumococcal resistant strains
and the use of antibiotics. One US economic
analysis suggested that routine use of pneumo¬
coccal conjugate vaccine in infants and young
children is likely to be cost effective.'6
Safety of vaccination
Pneumococcal conjugate vaccine has also been
reported to be safe and immunogenic in the elder¬
ly, in patients with HIV, sickle cell disease,
Hodgkin's disease, bone marrow transplant and
recurrent respiratory infections, and in Alaska
Natives and American Indians in the US.19
Although efficacy has not yet been studied in these
high-risk groups and the elderly, its ability to pro¬
duce high-levels of antibody with immunological
memory suggests pneumococcal conjugate vac¬
cine could be beneficial in these groups. A 7-
valent pneumococcal conjugate vaccine has
recently been licensed by Wyeth Vaccines
throughout Europe. The same vaccine has been
approved throughout the US for over a year where
the routine immunisation schedule is 2, 4, 6
months for primary series and 12 to 15 months
for the booster dose.18
It appears that a significant burden of pneumo¬
coccal disease could be reduced by widespread
use of pneumococcal conjugate vaccine in young
children. Its potential use in high-risk adult groups
requires further research but also may be of con¬
siderable importance. Systematic surveillance is
necessary to monitor the distribution of pneumo¬
coccal serotypes before and after the routine use of
pneumococcal conjugate vaccine, to assure vac¬
cine formulations include the predominant
serotypes associated with disease and antimicro¬
bial resistance.
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